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SUMMARY
Sensitive, specific, reproducible ELISAs were developed and validated for cow’s milk 
B-lactoglobulin and a-casein specific IgG and IgA antibodies and B-lactoglobulin antigen. A 
novel method for the quantitation of cow’s milk B-lactoglobulin and a-casein specific IgG sera 
standards was developed. This involved affinity purification and nephelometry. These assays were 
applied to a number of studies investigating the physiological and pathological levels of these 
antibodies and antigens in various body fluids from adults and infants.
There was a large individual variation in the B-lactoglobulin and a-casein specific antibody 
levels and the B-lactoglobulin antigen levels in sera, breast milk and saliva samples in both 
atopic and non-atopic individuals. B-lactoglobulin IgG antibody levels were higher than the a- 
casein IgG antibody levels in all of the sera samples assayed. Explanations are offered for these 
differences.
A prospective study on 39 infants was performed to investigate the effect of parental atopy 
and of a maternal milk-free diet during late pregnancy and lactation, on the immune response 
to milk specific antigens and the allergy incidence in their infants. The presence of atopy had 
a significant influence on the allergy incidence of infants, with infants bom to atopic parents 
having a significantly higher allergy incidence than infants bom to non-atopic parents (p <0.001). 
Atopic mothers also showed a tendency to transfer higher quantities of antigenically intact B- 
lactoglobulin via the placenta and breast milk compared to non-atopic women, and in addition 
had a lower milk specific IgA antibody concentration in their breast milk. These factors could 
add to an underlying predisposition of allergy in infants, increasing the risk of allergy 
development later.
The strict removal of all milk and milk products from the diet significantly reduced the 
circulating B-lactoglobulin IgG antibody levels after a period of 7 weeks (p<0.05). In "at risk" 
infants it was demonstrated that a strict maternal milk-free diet during late pregnancy and 
lactation significantly reduced the allergy incidence up to 18 months postpartum (p <0.0005). 
A significant increase in IgG antibodies against B-lactoglobulin and a-casein was demonstrated 
in all infants on their first milk ingestion: this response was found to be higher in infants who 
developed allergy, but not significantly. The clinical implications of such a dietary regimen are 
discussed.
In an adult study undertaken to examine allergic disorders, both B-lactoglobulin and a- 
casein specific IgG4 antibody levels were significantly higher (p <0.001) compared with IgGl, 
IgG2 and IgG3 subclasses. A significantly higher a-casein IgG4 antibody level (p<0.05) was 
found in individuals suffering from food allergy compared with controls and atopy, not related
to food. A  positive correlation was found between the total IgE antibody levels and the fi- 
lactoglobulin and a-casein specific IgG4 antibody levels.
In a study investigating absorption o f antigens in normal adult subjects antigenieally intact 
B-lactoglobulin was absorbed across the gut wall in a biphasic pattern in 7/8 healthy adult 
subjects after a milk load. Levels o f G-lactoglobulin were found to peak at 30-90 mins and 
165-240 mins with a significant increase in antigenieally intact G-lactoglobulin with time 
(p<0.01). The levels o f G-lactoglobulin and a-casein specific IgG antibody levels were not 
influenced by the milk load. The significance o f the transfer o f milk antigens was discussed.
The data reported in this thesis offers more information regarding the immunological 
handling o f cow’s milk protein by atopic and non-atopic adults and infants born to such women.
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There is something fascinating about science. One gets such wholesale 
return of conjecture out of such a trifling investment of fact.
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GLOSSARY OF ABBREVIATIONS
a-la a-lactalbumin
a-cas a-casein
B-Lg B-Lactoglobulin
BSA Bovine serum albumin
ELISA Enzyme-linked immunosorbant assay
GALT Gut associated lymphoid tissue
HSA Human serum albumin
H Heavy chain
IgA Immunoglobulin A
IgD Immunoglobulin D
IgE Immunoglobulin E
IgG Immunoglobulin G
IgM Immunoglobulin M
j Joining chain
L Light chain
NA Not analysed
NHS Normal horse serum
NK Natural killer cells
NSB Non-specific binding
OPD Ortho-phenylene diamine
OV Ovalbumin
PBS Phosphate buffered saline
PBSGT Phosphate buffered saline + 0.1% gelatine + 0.05% Tween 20
PJ Peptijunior
RIA Radioimmunoassay
SC Secretory component
SD Standard deviation
SE Standard error
slgA Secretory IgA
SNHS 0.9% saline + 1% normal horse serum
STNITS 0.9% saline + 1% normal horse serum + 0.5% Tween 20
TMB 3,3’,5,5’ tetramethylbenzidine
UD Undetected
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CHAPTER 1
IN T R O D U C T IO N
1
1. INTRODUCTION
1.1 HISTORY OF IMMUNOLOGY
Observations relating to the study of immunology can be traced back to the earliest writings. 
Asthma and its treatment was reported by Chinese physicians. Both Hippocrates and Galen 
accurately described allergic reactions and other atopic states in their writings and even 
suggested that some of these might be the result of environmental factors. In more recent 
history there have been many important discoveries which have increased our knowledge of the 
immune system and our awareness of its involvement with the mechanism of disease and allergic 
disorders. Towards the end of the 19th century, Jenner reported the first successful attempt to 
prevent the development of smallpox by immunisation, when he injected the pus of a cowpox 
sore into a boy. In 1880 Pasteur developed 3 types of vaccines, living, heat-killed and attenuated 
and in 1881 Koch discovered delayed hypersensitivity to tuberculosis. Another important 
discovery was in 1883 when Metchnikoff described the role of phagocytosis in immunity which 
was later found to be enhanced by immunization, in 1895, by Denys and Leclef. In 1890, Von 
Behring had became aware of antibodies to diphtheria toxin in serum and also recognised the 
possibility of passive immunization. Complement was discovered in 1893 by Buchner, with 
Pfeiffer and Bordet elucidating its action with antibodies in the process of cell destruction by 
lysis. A further clarification of antigen-antibody interaction appeared in the work of Durham 
in the late eighteen hundreds, who discovered the agglutination of bacteria in response to 
specific antibodies (Roitt, 1989).
At the beginning of the 20th century immune response was considered to be of two kinds, 
humoral and cellular. Humoral immunity emphasized the antibodies synthesized by cells of the 
immune system after immunization by antigens. Cellular immunity was concerned with cells and 
their products, lymphokines, and the protection of an organism against antigenic material. Over 
the last 30 years immunology has emerged as an individual science drawing from, and 
contributing to many other biological and chemical disciplines.
1.2 THE IMMUNE SYSTEM
The principle function of the immune system is to protect animals from infectious organisms 
and from their toxic products. This system has evolved a powerful range of mechanisms to 
locate foreign cells, viruses or macromolecules, to neutralize these invaders and to eliminate 
them from the body. This surveillance is performed by proteins and cells that circulate 
throughout the body. Many different mechanisms contribute to the surveillance for foreign
substances within the body. They can be divided into two broad categories of immunity: innate 
and adaptive.
1.2.1 Innate Immunity.
Innate immunity is mediated by cells that respond non-specifically to foreign molecules, 
including such systems as phagocytosis by macrophages, secretion of lysozyme by lacrimal cells 
and cell lysis by natural killer cells. This type of immunity does not improve with repeated 
exposure to foreign molecules (Roitt, 1989).
The simplest way to avoid infection is to prevent the microorganism from gaining access to 
the body. The skin, in combination with the inhibitory effects of lactic acid, fatty acids and a 
low pH in sweat, forms the first line of defence. Mucous, secreted by the membranes lining the 
inner surfaces of the body, acts as a protective barrier by preventing viral penetration of cells. 
Finally, there are binding microbes, which are removed by mechanical stratagems such as ciliary 
movement, coughing and sneezing. The washing action and the bacterial components of the 
tears, saliva and urine are also of importance.
If an organism penetrates an epithelial surface it encounters phagocytic cells of the 
reticuloendothelial system. These cells are of several different types, but are all derived from 
the bone marrow stem cells. Their function is to engulf particles, including infectious agents, 
internalize and destroy them. The blood phagocytes include the neutrophil polymorph and blood 
monocyte. Both of these cells have the ability to migrate from the blood to the tissue in 
response to a suitable stimulus.
Natural killer (NK) cells are leucocytes capable of recognising cell surface changes on 
virally-infected cells. The NK cells can bind to these target cells and kill them. These cells are 
activated by interferons which are themselves components of the innate immune system. 
Interferons are produced by virally-infected cells, and sometimes by lymphocytes. They have an 
additional purpose of inducing a state of viral resistance in uninfected cells (Roitt, 1989).
The serum concentration of acute phase proteins can dramatically increase, and remain 
elevated throughout the infection. These proteins can coat bacteria, facilitating the binding of 
complement, which in turn enhances phagocytosis. This is known as opsonization. Complement 
is a group of about twenty serum proteins which interact with each other and with other 
components of the innate and adaptive immune system. The complement system is 
spontaneously activated by the surface of a number of microorganisms by the so-called 
alternative complement pathway. A further group of components cause direct lysis of bacterial 
cell membranes by the lytic pathway. The components of the innate immune system act in
3
concert with each other.
1.2.2 Adaptive Immunity
In contrast to non-adaptive immunity, adaptive immunity is mediated by cells called 
lymphocytes. These synthesize cell-surface receptors or secrete proteins, antibodies, that bind 
specifically to foreign material. Any molecule that binds to an antibody is called an antigen or 
immunogen. The basis of this advanced adaptive immune response is memory, specificity and 
recognition of non-self, and is under extremely complex genetic control. The specificity of the 
adaptive immune system is based on the specificity of the antibodies and lymphocytes. Each 
lymphocyte is only capable of recognizing one particular antigen. On binding, it induces them 
to proliferate, resulting in the production of sufficient cells to mount an adequate immune 
response (Harlow & Lane, 1988).
There are two distinct types of lymphocytes, B and T cells. The former proliferate and 
mature into antibody-producing cells; the latter are involved in the recognition and destruction 
of virally-infected cells. These lymphoid cells and the subsequently produced antibodies are the 
basis of this very complex adaptive immunity (Harlow & Lane, 1988).
1.2.3 Lymphoid Cells
These cells are produced in the primary lymphoid organs, the thymus and bone marrow. The 
secondary lymphoid organs and tissue contain mature B and T lymphocytes and accessory cells. 
Lymph nodes, present throughout the body, drain the tissue spaces. Cells from the lymph nodes 
respond to lymph born antigens, and lymphoid cells in the spleen respond well to blood-borne 
antigens. In the small intestine, unencapsulated masses of lymphoid tissue in the gut associated 
lymphoid tissue (Peyer’s patches) have great importance to oral antigen presentation (Walker, 
1987).
The lymphoid cells are produced at a high rate (109 cells/day) with the average human 
possessing 1012 cells. These cells represent about 20% of the total white blood cells present in 
the adult circulation. Although B and T cells appear to be similar, they can be distinguished 
from one another since they carry different cell surface proteins which act as "markers" and 
have differing functions in the immune response.
The T cells account for 75% of all lymphocytes in the peripheral blood. They are produced 
in the thymus and migrate to the different lymph nodes from there. They are generally involved 
in the recognition and destruction of virally infected cells. There are a number of sub­
populations, including suppressor, effector and killer T cells. Suppressor T cells can exert
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inhibitory effects on the synthesis of antibodies when interacting with B cells, whereas effector 
T cells produce lymphocytes of the opposite function. Killer T cells result in cell cytotoxicity 
(Roitt, 1989).
B cells represent about 5-15% of the circulating lymphoid pool. They are produced in the 
fetal liver and then marrow-derived cells of mammals. For their effective function it is essential 
for them to possess an efficient method of antigen recognition. This is thought to be mediated 
by antibody synthesis in the cell, which is also bound to the surface. The specificity of the 
antibody is determined by genetic characteristics of the specific lymphocyte (McCleod, 1984). 
Immunocompetent B cells are formed after passing through pre-B and immature B cell stages. 
Some class-switching can occur before contact with an antigen as a result of micro­
environmental factors (Harlow & Lane, 1988).
1.2.4 Lymphocyte Proliferation and Maturation
During their development, both T and B lymphocytes acquire specific receptors for an 
antigen which commit them to a single antigenic specificity for the rest of their life-span. The 
cells are activated when they bind their specific antigen in the presence of accessory cells, the 
resting "virgin" lymphocytes then proliferate and mature into effector cells. This clonal selection 
through antigen recognition results in expansion of specific clones which either terminally 
differentiate into effectors, or give rise to memory cells. The resting lymphocytes (in particular 
memory cells) recirculate through the body tissue and lymphoid organs, via the blood and the 
thoracic duct, thus providing surveillance of the body tissues for invading microorganisms (Roitt, 
1989). Following lymphocyte activation, distinctive differentiation features are observed at 
ultrastructural level.
1.2.5 Antibody Synthesis
After the injection of a foreign molecule into an animal an antibody response is initiated. 
Fig 1:1 illustrates the kinetics of the appearance of immunoglobulin (Ig) M and G from the 
activated B cells in the serum, following immunization with any given antigen.
Although the antibodies are synthesized by the B cells, there is co-operation between the 
B and T lymphocytes. The antigen on presentation to the B cell is degraded, and fragments 
appear on the cell surface bound to class II proteins. The antigen-antibody complex on the cell 
surface is internalised. The complex of class II protein and the antigen fragment is now a target 
for binding by helper T cells. This contact is fundamental to the regulation of antibody 
production. The B cell then begins to synthesize a cell-surface receptor for B cell growth factor
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(interleukin-4) and differentiation factors (interleukin-5) both produced by helper T cells. The 
B cell then divides into plasma cells and memory cells. The plasma cells are highly specialised 
to secrete large amounts of specific antibodies, the isotype depending on the surface antibody. 
These cells are terminally differentiated, and live for 3-4 days (Harlow & Lane, 1988).
For a compound to induce an antibody response, it must have an epitope that can bind to 
the surface antibody on the virgin B cell, and on degradation must generate a fragment that 
can bind simultaneously to both class II protein and T cell receptor. The failure to generate 
these complexes can be caused by three mechanisms. Firstly, some molecules are too small to 
bind to T cells and need to conjugate to a larger carrier protein before they can elicit an 
antibody response. Secondly, antibodies may not be produced if the genetic background of the 
animal does not provide class II proteins that can bind to the antigenic fragment. The third way 
in which B and T cell collaboration can fail is through "tolerance". If either the B or T cell 
expressing the correct receptor has been eliminated during maturation of the immune system, 
no response will be seen. If it is due to the lack of the appropriate B cell then tolerance can 
not be overcome. However, if it is due to lack of a T cell, then modifying the compound to 
create a binding site for T cell receptor will break tolerance (Kindred & Shreffler, 1972).
Genetic factors and feedback mechanisms, also have a vital influence on immune response. 
Although an antibody response is essential, it is necessary to limit antibody production to 
prevent the body being overwhelmed by activated cells, and the subsequently produced 
antibodies, after antigen stimulation. The process of catabolism, neutralization, blocking and 
diversion of an antigen to immunogenically inoffensive sites, is important in the prevention of 
primary sensitization. In addition, T cells not only can amplify the B cell response, but also 
suppress it (Roitt, 1989). It has been postulated that a crowding out of acceptor sites on the 
macrophage by T suppressor cells could be responsible for antigenic competition, in which one 
T dependent antigen can block the response to another (Roitt, 1989). Lastly, idiotypic 
determinants on an antibody may provoke an anti-idiotype response which would limit the 
proliferation of the clone producing that antibody. The immune response and its regulation is 
therefore very complex and still poorly understood. Fig 1:2 represents a simplified summary of 
the regulation of the immune response.
1.2.6 Immunoglobulin Structure
Ig antibodies, are a large family of glycoproteins found solely in the gamma globulin 
fraction of the blood, which share key structural and functional features. There are 5 distinct 
forms - IgG, IgM, IgA, IgD and IgE. Many of the structural features of the Ig are similar and
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it is easier to discuss them by considering an IgG molecule as a model. In 1959, Rodney Porter 
showed that IgG can be cleaved into three active 50 Kdal fragments by the proteolytic action 
of the enzyme papain, shown in Fig 1:3. Two of the fragments, Fab (antigen binding fragment), 
have the ability to bind antigens. The other fragment, called Fc (crystalline fragment), is unable 
to bind antigens but is essential in the immune regulation. The region between the F.b and Fc 
fragments is called the hinge, allowing lateral and rotational movement of the two antigen 
binding domains. In practice, this allows the binding domains freedom to interact with a large 
number of different antigen conformations.
The IgG molecule also consists of two kinds of polypeptide chain. These are bound by 
disulphide bonds which can be reduced by pepsin. These two chains are called light (L) and 
heavy (H) chains (Fig 1:3). The L and H chains are not uniform in structure, each containing 
a variable and constant region. The variable region is always at the amino terminal and is 
involved in antigen binding. IgG has two intrachain disulphide bonds in the L chain, one in the 
variable and one in the constant region. Similarly, there are four such bonds in the H chain.
There is a heterogeneity in both the L and H chains. There are two types of light chain 
structures: kappa and lambda. Kappa has a cysteine residue at the carboxy terminal, and lambda 
a serine residue preceded by a cysteine residue at the carboxy terminal. Only one type of L 
chain is present in any one IgG molecule (Roitt, 1989). Studies have found that there are 5 
distinct H chains which define the different classes of Ig - IgG, IgM, IgA, IgE and IgD. These 
different chains determine the function of the Ig. Table 1:1 describes the major physicochemical 
properties of the five Ig classes.
1.2.6.1 Immunoglobulin G (IgG)
This is the predominant Ig in normal serum, (12 mg/ml of serum) and accounts for 70-75% 
of the total Ig pool. IgG is a monomer with an approximate molecular weight of 146,000. This 
is the major Ig of the secondary immune response and has the unique ability to pass across 
the placenta to provide passive immunity to the neonate. IgG diffuses more readily than the 
other Ig into the extravascular body space. Here it carries out the major task of neutralizing 
bacterial toxins and binding to micro-organisms to enhance phagocytosis. The IgG also has the 
ability to activate complement by interaction with the Fc portion of the molecule. With respect 
to overall regulation of IgG levels in the body, the catabolic rate appears to depend directly 
upon the total IgG concentration, whereas synthesis is entirely governed by antigen stimulation 
(Roitt, 1989).
Pig-1*3 Diagrammatic view of structural arrangements of polypeptide chains 
of immunoglobulin molecule. The chains are held together by three 
disulphide bonds. Pepsin splits the molecule, leaving an Fc fragment 
(crystaliizable) and Fd parts of the heavy chains with attached light 
chains—the whole making Fab (or antigen binding) fragments. The N 
terminal ends of the light and heavy chains have variable sequences of 
amino-acids as shown by the broken line, There are also a number of 
intra-chain disulphide bonds which influence the shape of individual chains. 
The carbohydrate (Cbh) groups may be concerned with the catabolism of the 
molecule
Fc
FRAGMENT 
Sites for:
Complement Fixation 
Reactivity with 
Rheumatoid Factors 
Membrane Transmission 
Skin Fixation 
Macrophage Fixation 
Regulation of Catabolism
C bh- r-Cbh
LIGHT 
CHAIN  
(212 residues)
/A R IA BIE  REGION
Fab FRAGMENT 
(Antigen binding site)
W eir (1975).
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Table 1:1
Physical properties of major immunoglobulin classes.
W H O  Designation IgG IgA Ig M Ig D IgE
Sedimentation
coefficient 7 5 7 S, 95 , 116’* n)S 7 5 8S
Molecular weight 150,000 160,000 and 
polymers
900,000 185,000 200,000
Num ber of basic 
4-peptide units 1 I ,  2* 5 1 1
Heavy chains y a g <5 r.
Light chains k +  X k  +  A k +  A K +  A K + X K +  A
Molecular form ulaf 72K2'72^2 ( a 2 K 2 > l - 3
(a2" D l -.1
(a2/c2) 2S*
(a 2A2) 2S*
(/' 2* 2)5 
( ^ 2^ 2)5
6 2 X 2 ( 6 2 X 2  ?) k2k 2-s2A2
Valency for 
antigen binding
2 2 ,
(? polymers)
5( 10)
i
? 2
Concentration range 
in normal serum
8-16  mg/ml 1-4 -4  mg/ml 0-5-2  mg/ml 0- 0-4 mg/ml 17-450
n g/m lj
% total 
immunoglobulin 80 13 6 1 0-002
Carbohydrate content,
° // o 3 8 12 13 12
* D im er in external secretions carries secretory com ponent— S. 
f  IgA polym ers and lgM  contain J chain.
J  n g  =  t o -0 g.
R o itt (1989).
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There are four IgG subclasses which vary chemically because of small differences in the H 
chain. These subtypes are classified as IgG subclasses 1, 2, 3 and 4, on the basis of their 
concentration in normal serum. The greatest structural difference of the four subclasses reside 
in the hinge region, with the physicochemical properties shown in Table 1:2.
The difference in the hinge region is thought to influence complement binding. IgG4 having 
a short, inflexible hinge, hinders access of Clq and prevents complement activation by the 
classic pathway. Other structural differences include the point of attachment of the L chain to 
the H chain, and the Gm allotypes, which are regular minor differences in the gamma chain 
of the particular subclasses.
There is evidence that the antibodies to certain groups of antigens can be limited to one 
or some of the IgG subclasses. Antibodies to carbohydrates and dextran, are found to be 
exclusively IgG2 molecules and some food specific IgG molecules are reported to be restricted 
to the IgG4 subclass (Shakib et al, 1984).
1.2.6.2 Immunoglobulin A (IgA)
IgA represents 15-20% of the human serum Ig pool (3.5 mg/ml in serum). In man, more 
than 80% occurs in the serum as the basic four chain monomer, and the remaining as a dimer. 
Secretory IgA (slgA) exists mainly in a dimeric form and is the predominant Ig in seromucosal 
secretions, such as saliva, tracheobronchial secretions, colostrum, milk and genito-urmary 
secretions. This Ig, like IgM, contains a j (joining) chain. The binding of the j chain in 
polymeric molecules is via an additional C-terminal octapeptide with a penultimate cysteine 
residue, which is able to bind covalently (Roitt, 1989).
The slgA molecule also contains a secretory component which is thought to be wound 
around the slgA dimer attached by disulphide bonds to the constant region of the H chain. In 
contrast to the j chain, the secretory component (SC) is not synthesised by the plasma cells, but 
by epithelial cells. IgA held in the dimer configuration by a j chain and secreted by submucosal 
plasma cells, actively binds SC as it traverses epithelial cell layers. Bound SC may both facilitate 
transport of slgA into secretions as well as protect the Ig from proteolytic attack.
1.2.6.3 Immunoglobulin M (IgM)
IgM accounts for about 10% of the immunoglobulin pool (1.5 mg/ml in serum). This protein 
is largely confined to the intravascular pool, and is the predominant Ig produced in a primary 
immune reaction.
The molecule has a pentameric structure. The subunits are held together by disulphide
Table 1:2
Comparison of human IgG subclasses.
Ig G l IgG 2 IgG 3 IgG 4
% of total IgG  in normal serum 65 23 8 4
Electrophoretic mobility slow slow slow fast
Spontaneous aggregation - - H— 1—h —
G m  allotypes a,z,f,x n b,b3,b4,s,
t,c,g
Ga site reacting with rheumatoid factor* 
Combination with staphylococcal A
H— 1— h +  +  + — 4—1— h
protein +  +  + +  +  + — +  +  +
Cross placenta +  + + +  + ’ +  +
Complement fixation (C l pathway) 4—i— h +  + _j— |—j— |- ±
Binding to monocytes +  +  + + +  +  + +
Binding to heterologous skin +  + — +  + +  +
Blocking IgE binding - _ +
Antibody dominance A nti-R h An ti-cl ex tran 
Anti-levan
A nti-R h Anti 
Factor V I I I
* Other rheumatoid factors apparently react with G m  specific sites.
Roitt (1989).
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bonds between the constant regions of the H chain and a densely packed central region with 
radiating arms. Within the IgM molecule there is an abundance of oligosaccharide units 
associated with the gamma chain, in addition to a peptide chain, called the j chain. This is 
thought to assist the process of polymerization prior to secretion by the antibody-producing 
cell.
1.2.6.4 Immunoglobulin D (IgD)
IgD accounts for less than 1% of the total plasma Ig pool (0.03 mg/ml in serum), but it is 
known to be present in the membrane of many circulating B lymphocytes. The precise biological 
function of this class is not known, but it may play a role in antigen-triggered lymphocyte 
differentiation.
This Ig contains a high content of carbohydrate distributed in multiple oligosaccharide units 
and is more susceptible to proteolysis then the other Ig classes.
1.2.6.5 Immunoglobulin E (IgE)
This Ig is only present in trace amounts in the serum (5 x 10'5 mg/ml in serum) although 
it is found on the surface membrane of basophils and mast cells in all individuals. On binding 
antigen, the cells lyse, releasing mediators. This class may play a role in active immunity to 
helminthic parasites, but has recently been more commonly associated with immediate 
hypersensitivity diseases such as asthma and eczema. It has a large quantity of oligosaccharide 
units.
1.2.7 Development of the Immune System
The stage at which the fetus, neonate or infant possesses the ability to mount an immune 
response has great significance, not only regarding the ability of the individual to fight infection, 
but also the possible time of sensitization against environmental antigens. This has implications 
in the development of food allergy.
The majority of work into immune development has been performed on animals, but 
recently ontogeny in the human fetus has emerged. It has been established that precursors of 
B cells originate early in embryonic life in the yolk sac. B cells subsequently migrate through 
the spleen and liver to the bone marrow (Van Furth et al, 1965). Even earlier in fetal 
development, cells from the embryonic 3 rd and 4th pharyngeal pouches (eventually forming the 
throat) migrate into the chest to form the thymus. Cooper & Buckley (1982) suggested that 
thymic hormone may be able to influence the differentiation of cells that have not yet entered
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the gland, a stage previously believed to be essential for maturity.
Sterzl and Silverstein (1967) reported that there was an absence of an antibody response 
to antigens injected into the developing young that indicated a state of immunological 
immaturity during intrauterine life. It has been suggested that a competent immune system has 
developed in the human fetus by 7 months of gestation (Rothberg, 1969). However the 
synthesis of Ig and the presence of a mature reaction is said to be centred in the lymphoid 
tissue and occurs mainly after birth (Roitt, 1989).
Van Furth et al (1965) demonstrated the synthesis of IgM and IgG by the fetus as early as 
the 12th week of gestation, and antigen responses to antigens have been documented with T 
lymphocytes of fetal tissue at 15 to 16 weeks of gestation (Hayward, 1981). Evidence from 
Miller et al (1973) supported this theory of early development, when they reported plasma cells 
in the spleen at 10-12 weeks gestation, and IgG and IgE antibodies in the amniotic fluid at 13 
weeks gestation. Rothberg (1969) observed food specific IgG and IgM serum antibodies 
synthesized by the premature infant at 7 months, and suggested that after this time an increase 
in Ig is related to birth and not gestational age. Although immune competence in humans is 
probably not developed until soon after birth, the reported antibodies present before this time 
have great significance in the development of allergy.
1.3 FETO-MATERNAL RELATIONSHIP
The ability to reject grafts and to mount an antibody response is reasonably well developed 
by birth. Yet the Ig levels, except IgG, are low in the absence of an intrauterine infection. The 
transfer of antibodies, antigens and cells from the mother to the fetus and infant via the 
placenta and breast milk, respectively, is of great significance in the immunological outcome of 
the child.
1.3.1 Antibody Transfer
IgG is the only Ig class that is transferred across the placenta, and there is evidence that 
this is due to an active transport mechanism, which in humans develops between week 20-30 
of gestation. This is believed to be energy dependent (Harlow & Lane, 1988). Prior to 20 weeks 
of gestation, only small amounts of IgG are detectable and are believed to be of fetal origin 
(Cramer et al, 1974). After 30 weeks gestation, total IgG concentrations in the mother and fetus 
are similar, and at the physiological end of gestation, IgG levels in cord blood tend to be higher 
than paired maternal samples (Kohler & Farr, 1966; Carlsson et al, 1976 and Iikura et al, 1989). 
Fig 1:4 illustrates the changes in serum antibody levels in late fetal life and early childhood.
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Fig 1:4
Development of serum immunoglobulin levels.
Roitt (1989).
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The purpose of this antibody transfer is not clearly understood. It affords a degree of 
passive immunity for the first 3 months of the infant’s life which is believed to alter the immune 
response of the newborn infant by inhibiting the response to its specific antigen (Strobel, 1988). 
Maternal antibodies may also be able to enhance infant antibody production when present in 
small amounts (Levi et al, 1969 and Dawe et al, 1971). In addition, the passage of intact 
maternal cells via the placenta to the fetus has also been implicated (Mohr, 1972). Although 
the number of lymphocytes that traverse the placenta appears to be small, persisting for only 
short periods of time, they might play a role in passing information to the fetal cells or 
recruiting fetal cells during a response. They have also been implicated in graft-versus-host 
reactions (Roitt, 1989).
The passage of antibodies to the neonate via breast milk is well reported. The predominant 
antibody within this secretion is slgA (Hanson & Windberg, 1972), with lower levels of IgG and 
IgM. The levels of IgG and IgM are consistently low during the lactation period, 11-31 
mg/lOOml and 3.9-38.0 mg/lOOml respectively, over the first week of lactation, whereas the 
reported slgA levels are found to have a significantly higher concentration in colostrum, 
619mg/100ml which fall dramatically by the end of the first week of lactation to 57mg/100ml 
(Jatsyk et al, 1985). This dramatic decline in antibody concentrations during the first week of 
lactation appears to be compensated for by increases in milk volume (Carlsson et al, 1976). The 
observed antibody reduction is therefore a dilution effect (Cruz & Arevalo, 1985), with the 
infant receiving a relatively constant concentration of slgA antibodies for the first month of 
lactation (Hannart et al, 1991).
The slgA appear to block the adhesion of potential pathogens to mucosal epithelial cells, 
in addition to complexing with potential antigens to facilitate their clearance (Slade et al, 1987). 
The transferred slgA antibodies are against a wide variety of microorganisms, their products and 
potential harmless substances such as food proteins (Machtinger & Moss, 1986). An increased 
risk of food allergy development in infants has been reported to be associated with a lack of 
these slgA antibodies specific to food antigens in maternal breast milk, although the mechanism 
of this action is not clear (Hanson et al, 1977 and Machtinger & Moss, 1986).
In addition to antibodies there are also a variety of cells found in human colostrum and 
breast milk. Most of the cells are neutrophilic granulocytes and macrophages, with the 
percentage of each dependent on the amount of nursing. However the ability of breast milk 
lymphocytes to function as normal is doubted (Slade & Schwartz, 1987).
The benefit of transferred antibodies from the mother to the infant is believed to be 
significant in aiding prevention of infantile infection in addition to the prevention of allergy
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development (Carlsson et al, 1976; Hanson et al, 1977 and Machtinger & Moss, 1986).
1.3.2 Antigen Transfer
During gestation the developing fetal immune system has the protection of the maternal 
environment. The placenta provides a physical barrier, selectively preventing the passage of 
potentially damaging agents reaching the fetus. However there is a growing body of clinical 
evidence which suggests that there may be a passage of antigens across the placenta. The 
sharing of sensitization by the mother and fetus has been demonstrated for a number of 
diseases, (Catalano & Sever, 1971). Common allergens such as grass pollen, ragweed, molds and 
dust have also been implicated in shared sensitivities (Hashem, 1972). Van Asperen et al (1983) 
reported an analphylactic response by a child on the first ingestion of milk, strongly suggesting 
antigen transfer and sensitization.
Although the transfer of antigens via the placenta is controversial, there is much evidence 
demonstrating the presence of antigens in breast milk, in both individuals who have a genetic 
predisposition to allergy development (atopic), and those who do not (non-atopic). More than 
70 years ago Talbot (1918) suggested that eczema in a 3 week infant was due to chocolate 
eaten by the breast feeding mother. Jakobsson and Lindberg (1978) showed that infantile colic 
could often be relieved by removing cow’s milk from the mothers diet. More recently the direct 
quantitation of food antigens within breast milk has been performed by a number of individual 
groups. The presence of ovalbumin (OV) (Kilshaw & Cant, 1984), B-Iactoglobulin (B-Lg) 
(Axelsson et al,1986 and Machtinger & Moss, 1986) and gliadin (Troncone et al, 1987) in breast 
milk has been demonstrated by sensitive immunoassay in the range of 200pg-800ng/ml. The 
quantity found within the breast milk varies greatly depending on the specific food protein, the 
individual dietary intake and the assay used. From work performed on animals it has been 
observed that significantly less bovine serum albumin and bovine gamma globulin were present 
within the breast milk compared with OV and B-Lg. These differences could be explained by 
preferential clearance of antigens into maternal tissue other than mammary glands, or by the 
existence of specific transport mechanisms for certain proteins within the mammary gland 
(Telemo et al, 1986 and Harmatz et al, 1986).
The presence of antigens, including food antigens, within breast milk is not restricted to 
atopic individuals, and is therefore a natural occurrence. A possible explanation for the presence 
of antigens within breast milk, could be the development of oral tolerance. This is defined as 
the inability of an individual to produce a specific antibody in response to an ingested antigen. 
Since antibody titre to numerous dietary substances decreases with age and reaches a stable low
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level around the age of 40-50 for most individuals, it is possible that the eventual development 
of oral tolerance could be the result of continued antigen absorption (Rothberg & Farr, 1965 
and Andre et al, 1975). Indirect evidence however, indicates the possible disadvantage of this 
antigen transfer, when even exclusive breast feeding does not eliminate some infants from 
allergy development (Hattevig et al, 1989). It has therefore been speculated that the antigens 
may have the ability to sensitize the "at risk” infant, resulting in subsequent allergy development 
(Machtinger Sc Moss, 1986; Jakobsson & Lindberg, 1978 and Cant et al,1986). For the 
development of both sensitization and allergy development the transferred antigen must have 
transversed the infants mucosal epithelium.
1.4 INTESTINAL MUCOSAL BARRIER AND GUT CLOSURE
At birth, the newborn infant must be prepared to deal with the ingestion of food antigens 
and their fragments. These potentially active substances, if permitted to penetrate the mucosal 
epithelial barrier, could cause inflammatory and allergic reactions under adverse conditions, 
resulting in gastrointestinal or systemic disease states.
1.4.1 Non-Immunological Processes
It is now apparent that non-immunological processes working independently, and in concert 
with the local mucosal immune system, collectively comprise an effective barrier, "the mucosal 
barrier", to the attachment and penetration of antigens present in the intraluminal environment 
(Walker & Isselbacher, 1977).
Non-immunological factors include gastric function, with Kraft et al (1967) reporting that 
low gastric acidity represents an important factor in increased bovine serum albumin absorption. 
This is believed to be due to inadequate protein hydrolysis. Intestinal proteolysis in the small 
intestine also determines, to an extent, the composition of microbial surface factors, enterotoxins 
and antigens, and may contribute to their capacity to attach to and penetrate the microvillus 
surface (Walker, 1987). The extent of proteolysis depends not only on the individual protein, 
with OV > B-Lg > a-cas in proteolysis resistance (Husby et al, 1985b and Marcon-Genty et al, 
1989a & 1989b), but also on the intestinal enzyme composition.
Peristalsis is another important factor, increasing the flow rate through the intestine and 
therefore reducing the likelihood of antigen absorption. Thickness and composition of the 
mucosal coat, the composition of the membrane which changes as the epithelial cells migrate 
up the villus (Quaroni et al, 1980) and age (DeBoth et al, 1975) also play important roles in
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antigen exclusion.
1.4.2 Immunological Processes
The immunological components of the mucosal barrier consist predominantly of slgA 
antibodies. Walker & Isselbacher (1977) postulated that this immunoglobulin prevents the 
transport of microbes, antigens and toxins, by complexing with them in the lumen or within the 
mucosal coat, thereby impeding absorption. The concentration of slgA in saliva, stools and 
serum of newborn animals and humans is lower than in mature, immunocompetent individuals. 
It has been hypothesised that this transient deficiency, in part, accounts for the increased 
transport of antigens across the mucosal epithelium in newborn animals (Taylor et al, 1973).
Another important component of mucosal immunity is the access of intestinal antigens to 
the gut associated lymphoid tissue, especially the Peyer’s patches. This has been determined as 
a necessary first step in the slgA cycle, stimulating the local and distant immune system 
(Cunningham-Rundles, 1987). The presence of specialized cells overlaying the Peyer’s patch that 
have few microvilli, a poorly developed glycocalyx and an absence of lysosomal organelles have 
been demonstrated (Owen, 1977). These cells are called M (membranous epithelial) cells. They 
non-specifically endocytose antigens and then extrude them into the extracelluar space, where 
they are phagocytosed by lymphoid cells circulating through the Peyer’s patch (Owen, 1977).
1.4.3 Interaction Between Immunological and Non-Immunological Processes
Several recent observations have suggested that the local immune processes can augment 
the capacity of the non-immunological protective components of the mucosal barrier (Walker, 
1987). Examples of this interaction include the increased proteolysis due to the presence of 
immune complexes after immunization, the enhanced discharge of goblet cell mucin occurring 
in intestinal anaphylaxis and the role of cells in clearing immune complexes from the 
gastrointestinal tract at a faster rate compared with antigens alone (Walker, 1987). During the 
perinatal period in all mammalian species studied, the operational mucosal barrier to antigen 
uptake and transport remains immature for varying time periods. During this time excessive 
quantities of antigens may be transported across the intestinal epithelium into the systemic 
circulation. The purpose of this increased protein uptake in animals is related to the transfer 
of IgG antibodies from maternal milk. Passive immunity in ruminants is received exclusively 
from milk derived IgG antibodies, unlike humans, where transplacental antibody transfer is the 
major mode of transport (Walker & Isselbacher, 1977). In humans, the evidence for antibody 
transfer in the neonate has been harder to demonstrate than in animals, although Ogra et al
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(1979) have shown that infants fed human colostrum rich in IgA antibodies to polio virus have 
titres of anti-polio antibodies in their serum.
1.4.4 Gut Closure
The time when intestinal immunological and non-immunological host defence develops, 
intestinal epithelial cells mature functionally and morphologically, and the uptake of 
macromolecules decreases, is known as "closure", and is the result of maturational events in the 
gastrointestinal development. The process of closure in humans is more subtle than in other 
animals, and although the exact time is uncertain it is thought to have occurred by 3 months 
postpartum. Rapid closure in infants would seem of benefit in the prevention of excessive 
antigen, bacterial and toxin absorption. However the initiation and progression of this process 
is unclear (Cunningham-Rundles, 1987). Studies have observed that stimulation of closure has 
been implicated to colostrum, facilitating maturation of mucosal epithelial cells (Hansen, 1977). 
Udall and colleagues (1981) found that colostrum reduced the transfer of bovine serum albumin 
across the gut, compared to bottle feeding. Breast milk also offers the protection afforded by 
slgA antibodies.
1.4.5 Antigen Absorption by the Gut
Several clinical studies suggest that macromolecules can cross the mucosal barrier under 
normal physiological conditions in humans. Small quantities of food antigens, negligible 
nutritionally, but immunologically significant have been detected circulating within the sera of 
healthy individuals. Paganelli & Levinsky (1980) detected circulating B-Lg in subjects after a 
milk challenge, although this was not confirmed by Husby et al (1985b). However in the latter 
study Husby did observe OV absorption after egg ingestion. Antigen non-specific assays for 
immune complex detection have shown varying results. An increase of immune complexes in 
serum after food ingestion was reported by Gallagher et al (1983), but was not consistently 
found by others (Husby et al, 1985b).
The presence of food antigens suggests a natural antigen transfer across the gut wall. As 
previously described, the presence of specialized M cells facilitates antigen absorption. This 
process is believed to be important in the IgA-producing plasma cell cycle, facilitating local and 
systemic immune response. The formation of immune complexes and their subsequent uptake, 
has been implicated as another transport mechanism. Bockman & Winbom (1966) assumed that 
the formation of IgG immune complexes might trigger a chemotactic-mediated response 
resulting in enhanced penetration of all intraluminal macromolecules. However recent reports
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have suggested that receptors exist for IgG antibodies and IgG complexes on the epithelial 
surface, and may represent a facilitated transport for antigens (Walker, 1987).
Pinocytosis represents a more primitive absorptive process in the alimentary canal than M 
cell transport, and should therefore be greater in the immature gut than the mature gut. This 
theory of increased permeability in infants has been supported by a number of studies. During 
the immediate postpartum period, especially for premature and small-for-date infants, the 
elaborate local defence system is incompletely developed. It has been observed that although 
transfer of antigens does occur in small amounts in healthy infants, higher quantities have been 
found in these immature infants (Rothberg, 1969; Taylor et al, 1973 and Eastham et al, 1978). 
The implication of these studies is that the neonatal intestine absorbs ingested protein more 
readily than the mature gut, although the significance of the delayed gut closure is unknown.
1.5 ALLERGY
Originally, the term allergy was defined by Von Pirquet referring to a "stage of changed 
reactivity" in a host, occurring as a result of contact with an antigen. This reactivity could either 
be beneficial to the host as is the case in immunity, or detrimental as in anaphylaxis. Allergic 
reactions are not a recent phenomenon and were described in early Chinese writings, which 
accurately described asthma and its treatment. Hippocrates and Galen also described allergic 
reactions and other atopic states, suggesting some may be the result of environmental factors 
(Roitt, 1989). However, even with the dramatic advance in technology, allergic reactions, their 
causes and occurrence are poorly understood.
Allergic disorders are reported to be among the most common ailments afflicting humans, 
occurring in 10-20% of the adult population (Foucard, 1985). The systems most frequently 
affected by allergic disorders are the respiratory system and the skin, followed by the GI tract 
(Strobel, 1988). The pathogenic factors in allergenic diseases are primarily, but not exclusively, 
related to the organ systems where the allergens first elicit their effects.
It is well recognized that the risk of developing an immediate or delayed type food allergic 
disease is higher in children compared with adults. This implies that developmental factors 
operative during gestation and after birth, are likely to play an important, although as yet poorly 
defined role in the development in food allergic disease (Strobel, 1988).
1.5.1 Hypersensitive Reactions
Allergic diseases may be caused by one or more of the four basic immuno-pathological, 
hypersensitive reactions described by Coombs and Gell in 1975.
22
Type 1: Anaphylactic or Immediate Hypersensitivity Reaction. The antigen reacts with the 
IgE bound to the mast cells or circulating basophils through a specialized region of the Fc 
fragment. This leads to degranulation of the cell and the subsequent release of 
pharmacologically active substances (mediators) such as histamine, leukotrienes, serotonin and 
plasma kinins. These substances are responsible for increased capillary permeability, vasodilation, 
a fall in blood pressure, prolonged contraction of the smooth muscle and an increased migration 
of polymorphonuclear leucocytes into the tissue. The eosinophils at the site of invasion, can 
modulate the mast cell mediators by diffusing histamine with histaminase (Roitt,1989).
Although IgE is the predominant antibody in this reaction, IgG can also act as reagins, 
antibodies capable of acute anaphylaxis. The extent of their contribution to the allergic state 
in humans is not resolved (Shakib et al, 1984).
There are several physiological effects in atopic individuals of the released mediators, these 
include asthma, hay fever, urticaria, angioedema and atopic eczema (Strobel, 1988).
Type 2: Cytotoxic Reactions. In this reaction antibodies bind to antigens on the surface of 
cells and cause phagocytosis of the cell by opsonic or immune C3 adherence, non-phagocytotic 
extracelluar cytotoxicity by killer cells or complement-mediated lysis. The clearest example of 
this is autoimmune haemolytic anaemia, rhesus incompatibility, autoimmune disease and organ 
transplant rejection.
Type 3: Complex Mediated Reaction. This reaction develops when antigen-antibody 
complexes are formed in large quantities or when they cannot be cleared adequately. This 
causes activation of complement, resulting in a polymorphonuclear response leading to 
inflammation and extensive tissue damage. Macrophages and lymphocytes are also activated by 
the attachment of Fc regions of Ig. Hydrolytic enzymes released from the leucocytes contribute 
to vascular damage. An example of this is glomerular nephritis.
Type 4: Cell Mediated (delayed) Reaction. This reaction is mediated by T cells which are 
stimulated by macrophage bound antigens. This leads to a release of lymphokins which mediate 
a range of inflammatory responses. In the reaction against viral cells or transplants, the 
stimulated lymphocytes transform into blast-like cells capable of killing target cells possessing 
the bound sensitizing antigen. The symptoms take 1-2 days to manifest. This reaction occurs due 
to skin contact with drugs, viral invasion and transplant rejection.
1.6 FOOD ALLERGY
The idea of food allergy is not a new one. As far back as 1789 William Cullen defined 
idiosyncrasy as "any unusual response of the body to any substance in the external environment,
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including food". However during the last 20 years, many advances have been made in our 
understanding of food intolerance and allergy in both infants and adults. Despite many recent 
studies within the field of food allergy, there is still no agreement on its frequency. The main 
reasons for the discrepancy in the reported food allergy incidence are probably due to its 
definition, and the criteria for its diagnosis.
Kajosaari in 1982 reported an increasing incidence of allergic reactions during the past two 
decades. Whether this increased incidence is real is not known, as it has been reported that 
food allergy is often over diagnosed (Foucard, 1985). Despite this uncertainty, the incidence of 
true food allergy is usually quoted as between 2-5% (Roitt, 1989), with 0.3-20% of children 
reported to have suffered from symptoms caused by some form of food intolerance (Royal 
College of Physicians, 1984).
1.6.1 Types of Food Allergies.
There are four basic subcategories of food allergies based on the nature of the causative 
mechanism. Food allergy includes individuals with an immunological basis for their adverse 
reactions. Three of the afore mentioned hypersensitive reactions (Type 1, 2 and 4) are reported 
to occur with food (Taylor, 1985). Type 4 is only applicable to the handling of foods. Type 1 
anaphylaxis is of major interest due to acute reactions after ingestion of food. Food intolerance 
includes sensitivities caused by some genetic or drug induced deficiency. The classic example 
of this is lactose intolerance, caused by a deficiency of intestinal lactase. Idiosyncratic reactions 
to food have an unknown mechanism of action. Adverse reactions to food additives and coeliac 
disease are examples. Lastly Anaphylactoid reactions, these are often confused with true 
allergies due to the similarities in symptomology. The classic example is that of histamine 
poisoning due to ingestion of some cheeses or spoilt fish.
1.6.2 Symptoms of Food Allergy
Usually food allergy is accompanied by a number of different clinical symptoms including 
gastrointestinal, respiratory, dermatological and probably also behavioral. Gastrointestinal 
symptoms include nausea, vomiting, diarrhoea, abdominal pains, colic and laryngeal oedema. 
Dermatological symptoms include urticaria, atopic dermatitis, atopic eczema and contact 
dermatitis. Respiratory symptoms include asthma and rhinitis, and miscellaneous symptoms 
include migraines and arthritis. The most severe reaction associated with food allergies is 
anaphylactic shock which can be fatal (Foucard, 1985).
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1.6.3 Genetic Factors in Allergy Development
Genetic factors are reported to greatly influence the risk of infant allergy development. In 
a review Foucard (1985) identified two Swedish studies in which infants with two atopic parents 
had a 53-58% risk of developing allergic symptoms in infancy. With one atopic parent the risk 
amounted to 17-29% and with no direct family history of atopic disease, the risk for atopy was 
9-13%. Recently a gene has been identified on chromosome llql3 for atopy and atopic asthma, 
further substantiating the genetic background for atopy (Cookson et al, 1989).
1.6.4 Causes and Manifestations of Food Allergy
The majority of food allergies are believed to be due to the Type 1, IgE mediated reaction, 
although recently much interest is being given to the involvement of IgG antibodies and their 
subclasses. There are two main hypotheses to explain how certain predisposed or atopic 
individuals develop IgE antibodies and Type 1 hypersensitivity to food constituents, which are 
tolerated by the majority of people. Soothill and co-workers (Taylor et al, 1973) suggested that 
atopy was a consequence of over-stimulation by antigens during early life. In infants there is 
a relative IgA deficiency in the gut, resulting in an increased capacity to absorb macromolecules 
and leading to over-stimulation.
The alternative hypothesis by Jarrett (1977) suggested that normally antigen stimulation 
results in T-suppressor cell activation, which suppresses IgE synthesis. The atopic individual in 
this respect is considered to have a specific T-cell deficiency, resulting in IgE antibody 
production on antigen presentation. In this hypothesis a transient mucosal slgA deficiency 
should enhance the absorption of food antigens leading to a suppression rather than a 
stimulation of the IgE response. This has been reported in a number of studies (Juto & 
Bjorksten, 1980), and may help to explain the natural transfer of maternal dietary antigens via 
the breast milk.
Although the mechanism(s) of food allergy is at present obscure, it would appear that 
intestinal transport of antigens is a necessary initial step. It has been found that individuals 
with eczema have an increased absorption of polyethyleneglycol (PEG) from the intestinal tract 
(Jackson et al, 1981). It has also been observed that individuals with an IgA deficiency have 
higher titres of milk containing immune complexes, indicating an increased antigen transfer 
(Cunningham-Rundles et al, 1979). Many studies have observed higher antibody levels (Kletter 
et al, 1971; Burgin-Wolff et al, 1980; Campbell et al, 1987 and Peltonen et al, 1988;) immune 
complexes (Paganelli et al, 1979 and Bell & Porter, 1988) and a specific antibody class 
(Paganelli et al, 1983 and Husby et al, 1986c) in atopic individuals compared with non-atopic
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controls. However, whether the increased antigen transport was due to, or a cause of the atopic 
disease, is as yet far from certain. As with a number of multifactorial diseases it is hard to 
establish the contribution of each individual factor.
During periods of increased antigen absorption, such as the neonatal period, it has been 
suggested that susceptible infants may become sensitized to specific ingested proteins (Rothberg, 
1969). With later re-exposure, the much smaller quantities absorped could cause allergy. These 
symptoms could be propagated by further uptake of allergens across the disrupted mucosal 
surface. For this reason, the prevention of foreign protein absorption in neonates would seem 
advantageous in an attempt to reduce the risk of sensitisation to these foreign proteins, and 
possible allergy development.
1.6.5 Breast Feeding as a Protection Against Allergy
The unique role of breast milk in providing the optimum nutrition for healthy term infants 
during the first phase of life is undisputed. However, there is still controversy concerning the 
protective effect of breast milk, as opposed to cows milk formula, in the development of atopic 
diseases. During the past 50 years numerous studies have been performed in an attempt to 
elucidate a greater understanding of this subject.
Two critical reviews were recently published in which various studies on the protective effect 
of breast feeding on allergy development were compared (Zeiger, 1987 and Kramer, 1988). 
Kramer (1988) reviewed 36 original studies published between 1936 and 1986 to determine 
whether those studies which confirmed a protective effect of breast feeding in the development 
of atopy were better conducted compared with those that found no protective effect. He 
assessed biological and methodological aspects of cow’s milk exposure, outcome (atopic 
conditions) and statistical analysis of food allergy. He found that most of the studies had 
weaknesses in various areas, preventing their direct comparison. Kramer concluded that "the 
inconsistent findings, even among the better studies, prevents any firm inferences, although it 
seems likely that the results from the larger high-quality studies could be compatible with a very 
large protective effect".
Zeiger (1987) has discussed a large number of confounding variables and weaknesses in 
numerous studies. These include timing and control of solid food introduction, lack of blind 
assessments, failure to document compliance, lack of immunological documentation, differential 
environmental control measures in groups, high drop out rate, small sample size and a brief 
duration of breast feeding. Due to these variables, comparison of these studies is in many cases 
inappropriate. However his conclusions were in agreement with Kramer (1988).
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It has been found that breast feeding can reduce the allergy incidence during early 
childhood (Chandra et al, 1989), although this protection seems to be lost at 5 years (Poysa et 
al, 1989). This was supported by Aberg et al (1989), who reported a significantly lower 
cumulative incidence of allergic disease during the first three years of life in breast fed children 
with a double parental history of allergy compared with children having no or a single parental 
history of allergy. However at the age of 7, 10 and 14 years, the diet in infancy had no 
influence on the incidence of atopy, irrespective of parental history.
The results from these studies suggest that the effect of breast feeding is to delay the onset 
of allergic disease, and not to decrease the overall risk of becoming allergic during childhood.
1.6.6 Maternal Exclusion Diets
Exclusive breast feeding does not eliminate the risk of allergy development (Jakobsson & 
Lindberg, 1978). A possible explanation for the lack of conclusive evidence for the benefit of 
breast milk compared with infant formula feeding in the risk of allergic disease development, 
is that in non-randomized trials, atopic mothers are more inclined to breast feed their infants 
compared to non-atopic mothers. In addition to this, the possible influence of maternal dietary 
protein transfer to the infant via the placenta or breast milk is, in the majority of studies, not 
considered.
As previously discussed, food antigens are transferred to a breast fed infant via maternal 
milk. Many studies have observed sensitization of infants by these transferred food proteins 
(Van Aspern et al, 1983 and Lifschitz et al, 1988). It would therefore seem that elimination 
of the suspected protein from the mothers diet during pregnancy, lactation or both, could 
reduce the risk of allergy development. This is not a new concept. As early as 1918, Talbot 
observed, that on removing the suspected food from the mothers diet during breast feeding, the 
infants symptoms were eliminated.
Numerous studies have been performed regarding the value of maternal dietary elimination 
during pregnancy and lactation. In 1986, Chandra and colleagues performed a study on 121 
women who had a sibling with an allergic condition. These women were randomly allocated into 
an antigen avoidance group or a control. The dietary restriction was the elimination of milk, 
dairy products, egg, fish, beef and peanuts throughout pregnancy and lactation. It was observed 
that a reduced occurrence and milder form of atopic eczema was present in the infants of the 
intervention group. The benefit of a reduced exposure of infants to allergenic proteins during 
gestation and lactation was also observed by Zeiger et al (1989), who reported a more stringent 
programme. Mothers followed a diet excluding milk, dairy products, eggs and peanuts during
27
the last trimester of pregnancy and lactation. A casein hydrolysate formula was given to the 
infant at weaning with the avoidance of solid food until the infant was 6 months of age. 
Although both studies observed a benefit to "at risk" infants of maternal dietary avoidance, it 
was not possible to determine whether these results were due to intervention of diet during 
pregnancy, or during lactation.
A number of studies have therefore addressed the question of the benefit of maternal 
dietary avoidance during pregnancy. Falth-Magnusson et al (1987a and 1987b) conducted a study 
on 212 women in Sweden. They were randomly allocated into a diet group taking no cow’s milk 
or eggs from week 28 until delivery, with extra calcium and casein hydrolysate formula, or a 
control group following an unaltered diet. No significant difference was observed in cord blood 
IgE levels in either of the groups, although a significant decrease in maternal serum IgG levels 
was observed in the group that complied with the restricted diet. In addition, no protection was 
observed against infant allergy. Lilja et al (1988 and 1989) performed a study which investigated 
the effect of various quantities of egg and milk protein in a maternal diet during the last 
trimester of pregnancy on the outcome of allergy in the infants. 165 women (with respiratory 
allergies) and their infants were observed. Lilja et al reported that although the maternal IgG 
antibody levels reduced due to the elimination of these foods from the maternal diet, the cord 
blood IgE and IgG antibody levels did not change significantly. They also observed no 
significant differences in the distribution of atopic disease among the infants in relation to 
maternal diet during pregnancy.
From the results described above, it could be suggested that maternal dietary avoidance 
during lactation, is of greater benefit than during pregnancy. Jakobsson and Lindberg (1978) 
illustrated that colic in infants can be "cured" by the removal of milk from the mothers diet. 
Cant et al in 1986, also observed that maternal dietary exclusion of cow’s milk and eggs benefits 
some breast fed babies with eczema. Chandra et al (1989) performed a study which involved 
the comparison between breast and bottle fed infants. Half of the mothers who were breast 
feeding their infants were allocated a restricted diet, avoiding milk, dairy products, eggs, fish, 
peanuts and soy. Mothers who bottle fed their infants were allocated cow’s milk formula, soy 
formula or a casein hydrolysate. He reported that the incidence of allergy was greatly effected 
by the infant formula used, with the incidence of eczema at 70%, 63% and 21% respectively. 
He also observed that eczema was less common and milder in babies who were breast fed and 
whose mothers were following the diet. Hattevig et al (1989 and 1990) also reported a lower 
incidence of atopic dermatitis in the infant group whose mothers followed a milk and egg free 
diet during lactation.
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In conclusion, maternal elimination of major food allergens during pregnancy did not appear 
to result in clear manageable benefits with the "high risk" infants. However, during lactation, 
the use of elimination diets by mothers nursing "high risk" infants resulted in a significant 
decrease in the incident and severity of atopic eczema, the major symptom of food and 
especially milk allergy, during the first year of life. It must be borne in mind, however, that 
severe dietary restriction may be impractical for many mothers to undertake and for this reason 
the potential benefit of such a diet must be seriously considered.
1.7 COW’S MILK
Cow’s milk contains a vast array of potential allergens. Approximately 20 individual proteins 
have been identified which may lead to antibody production in man. The protein of milk can 
be divided into two groups, the caseins which are phosphoproteins and comprise 78% of the 
total weight, and the milk serum proteins which make up 17% of the total weight. The latter 
group includes B-lactoglobulin (8.5%), a-lactalbumin (5.1%), immune globulins (1.7%) and 
serum albumins (DeMan, 1982). For the purpose of this study we were interested in a milk 
protein from the casein fraction, a-casein, and a protein from the whey fraction, B-lactoglobulin 
B.
1.7.1 a-Casein
Casein exists in milk as relatively large, nearly spherical particles of 30-300nm in diameter. 
Casein is a nonhomogeneous protein which can be separated by electrophoresis into three 
major components, a-, B- and gamma-casein in decreasing order of mobility. The proportions 
of these fractions are about 75, 22 and 3%. a-casein is composed of a number of subfractions: 
a s-casein is precipitated by calcium ions "calcium sensitive casein" and the k-casein is believed 
to confer stability upon the casein micelle, and is removed by the action of rennet, a-casein has 
a molecular weight of 30,000 and apparently consists of a single polypeptide chain with the N- 
terminal amino acid arginine, and the C-terminal amino acid tryptophan. Limited and specific 
hydrolysis of casein with proteolytic enzymes has produced a number of large polypeptides 
which resist further hydrolysis (DeMan, 1982).
1.7.2 B-lactoglobulin
B-lactoglobulin is the most abundant of the whey proteins with a molecular weight of 36,000. 
This protein is rich in lysine, leucine, glutamic acid and aspartic acid. The molecule consists
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of two peptide chains linked at some point along the chain with the same end groups, namely 
N-terminal leucine and C-terminal isoleucine (DeMan, 1982). 8-Lg appears in two different 
forms, apparently under the control of allelic genes. The two phenotypes differ in isoelectric 
point. Another difference is that B-Lg A has two more carboxyl groups than B-Lg B per 
molecule. Chromatography revealed that B-Lg A has one more residue each of aspartic acid and 
valine, and one less residue each of glycine and alanine in a subunit of 18,300, than B-Lg B, 
(Piez et al, 1961). Low-resolution X-ray studies have shown that the monomer is roughly 
spherical containing an a-helical rod and possibly a slab of B-sheet. It is said to consist of 45% 
B-sheet and 10% a-helix (Creamer et al, 1983).
1.7.3 Antigenicity of Cow’s Milk Proteins
The reason why some proteins are more allergenic then others is still a mystery. It has not 
been possible to identify any physicochemical feature that is characteristic of major allergens 
reacting with IgE antibodies, except for the fact that these allergens are proteins with a 
molecular weight usually between 10,000 and 100,000 daltons. They must possess sufficient 
epitopes to bind to the B cells, and after internalization, the helper T cell surface (Aas, 1988).
Although casein is the most predominant cow’s milk protein, it is not generally considered 
to be the most immunogenic one. Judged by the percentage of positive antibody responses in 
cow’s milk sensitive patients, immune responses against B-Lg are seen most often (82%), 
followed by casein and a-lactalbumin (43 and 41% respectively) and bovine gamma globulin and 
serum albumin (27 and 18% respectively) (Strobel, 1986). There is even heterogeneity between 
protein variants such as 8-Lg A and B. Malik et al (1988) reported that B-Lg A showed a 
slightly higher immune response in sensitised guinea pigs compared to B-Lg B. This was 
probably due to amino acid residues found only in the A variant.
The effect of heat and protein digest on the allergenicity of cow’s milk has been 
investigated by many groups. Heppell et al (1988) showed that heating diafiltered whey for 30 
min at 100°C and 115°C drastically reduced its antigenicity. Proteolytic degradation of proteins 
has also been looked at in relation to antigenicity. Otani (1981), reported that after pepsin, 
chromotrypsin and trypsin hydrolysis at 37°C for 12 hours, no loss of antigenicity was observed 
in B-Lg, but 75% of the original antigenicity was lost in casein. From this study, it can be 
concluded that the more antigenic nature of B-Lg could be due to its higher stability and 
degradation resistance, compared with a-casein. Huang et al (1985) suggested that antigenic 
determinants of B-Lg allergen involved in reactivity with IgE molecules, comprise a relatively 
restricted part of the molecule, in contrast to the antigenic determinants reactive with rabbit
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IgG molecules.
Both heat treatment and protein hydrolysis of cow’s milk, have been used in an attempt to 
obtain a less allergenic formula, more appropriate for infant feeding. However, it is possible that 
such treatment could result in a more allergenic fragment than before, due to the exposure of 
epitopes previously shielded within the large protein structure.
1.8 INFANT FORMULAE FOR FOOD ALLERGIC INFANT
1.8.1 Soy Formule
Soy formula was first developed in 1929 by Hill and Stuart as an infant formula to prevent 
milk allergy. It is a protein with a high biological value if supplemented with L-methionine, and 
shows no cross-reaction with cow’s milk protein. Although a number of studies have shown that 
soy formulae are useful for management of a milk allergic child (Burr, 1983) and in the 
prevention of allergic disease development (Buscino et al, 1989 and Chandra et al, 1989), it has 
been shown to be as potentially allergenic as cow’s milk protein (Eastham et al, 1978, Heppell 
et al, 1987 and Miskelly et al, 1988) with several individual proteins with differing levels of 
allergenicity. The benefit of its use as an infant formula is therefore controversial.
1.8.2 Goats Milk
In some cases goat’s milk has been used as a replacement in patients who are allergic to 
milk protein. However, this should be considered the least suitable alternative, because goat’s 
milk shows considerable cross-reactivity with cow’s milk. In addition to the immunological cross­
reactivity, the composition of goat’s milk is unsuitable for infant feeding. It contains high levels 
of protein, minerals and fat, in addition to low levels of carbohydrate and vitamins (Passmore 
and Eastwood, 1986). Also the pasteurisation law is not as stringent for goats milk compared 
with cow’s milk, which could be a potential risk of infection.
1.8.3 Meat Based Formulae
Little is known about the suitability of meat-based formulae as an alternative to milk-based 
formulae. A number of studies have been performed in an attempt to determine the suitability 
of using a meat formula in the management of atopy. The small body of evidence is promising, 
although far from conclusive (Godard et al, 1989).
1.8.4 Hypo-allergenic Formulae
These formulae are intended to offer a nutritionally complete food, which affords protection
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against allergy development. The protein, usually cow’s milk derived, is hydrolysed. The reason 
for this is that the most effective means of reducing the allergenicity of food proteins is by 
decreasing their molecular size. However the question arises as to optimal extent of hydrolysis. 
It has been stated that there is no definite molecular weight above which peptides are allergenic 
and below which they are non-allergenic. In general, there appears to be a limit for antigenicity 
of peptides with a molecular weight of approximately 1200-1600 dalton to elicit an IgG or IgM 
response, or 3500 dalton for an IgE mediated reaction (Aas, 1988).
The potential benefit of casein and whey protein hydrolysates is controversial. Although 
casein is believed to be the least allergenic of the milk proteins, it does not necessarily follow 
that casein hydrolysates are less allergenic. Studies have reported adverse reactions being formed 
against casein hydrolysates (Seban et al, 1977) and whey hydrolysates (Businco et al, 1989). One 
of the major drawbacks in using protein hydrolysates is the high cost and the poor palatability 
(Businco et al, 1989). It is reported that whey protein has the advantage over casein formula 
in this respect.
There are two main uses of such formulae. The first is therapeutic for dealing with subjects 
with cow’s milk allergy, and the other is prophylactic. This includes feeding the formula to "at 
risk" infants from birth, or for the use in maternal elimination diets during pregnancy and/or 
lactation. Clinical experience of the management of food allergy in infancy with protein 
hydrolysate formulae is generally considered to be very good (Chandra et al, 1989). In studies 
on the influence of maternal dietary restriction during lactation, a casein hydrolysate formula 
given as a "top-up" feed, and after the cessation of breast feeding, was found to afford a degree 
of protection which enhanced the benefit of the maternal dietary avoidance during lactation 
(Hattevig et al, 1989 and Zeiger et al, 1989). Chandra et al (1989) also reported that the allergy 
incidence for the group taking a hydrolysed milk formula was equivalent to the breast fed group 
whose mother followed a restricted diet.
Although the data on the use of these hypoallergenic formulae is quite promising to date, 
data on the immunological and nutritional implications of long term feeding will give us a 
better insight into their protracted use.
1.9 ENZYME LINKED IMMUNOSORBANT ASSAY
The concept of the enzyme linked immunosorbant assay (ELISA) was that of the Swedish 
researchers Envall & Perlmann (1971). The development of the ELISA is best appreciated in 
the context of the development of the preceding radioimmunoassay (RIA). This technique
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depended on the competition between radiolabelled (Ag*) and unlabelled antigen (Ag) for a 
limited number of antibody binding sites (Ab). It involved a separation step to distinguish 
between bound (Ag*-Ab & Ag-Ab) and free (Ag* & Ag) labelled antigen. Non-specific agents 
were used to enhance the precipitation of the antigen-antibody complex. It was later found 
that by using a solid-phase to immobilise the second antibody, the efficiency and speed of 
separation increased. It was at this stage the immunoradiometric assay developed.
There are two different types of enzyme immunoassays, ELISA and enzyme multiplied 
immunoassay technique. Although both ELISA and immunoradiometric assay use solid supports 
and are based on the principle of reagent excess, the ELISA technique offers a number of 
advantages over an immunoradiometric assay. The reaction in an ELISA can be read visually 
without the need for expensive apparatus. The labelled reagents used are stable and easily 
stored without loss of activity (Montoya & Castell, 1987). Microtitre plates are easy to wash and 
handle and offer the luxury of being able to assay large numbers of samples (Voller et al, 1978). 
The obvious health risk of radioisotopes is eliminated, with enzyme labels being easy to 
produce, or cheap to buy. Furthermore, the potential sensitivity of an ELISA is greater than 
a RLA as many molecules of product can be generated by one enzyme molecule (Jackson & 
Ekins, 1986). As a result the ELISA technique has been extensively applied to the detection 
of the presence and quality of antibodies and antigens in a wide variety of fluids and scientific 
areas.
1.10 SUMMARY OF INTRODUCTION AND AIMS
Quantitatively, the daily food comprises the largest antigenic load for the mucosal immune 
system and contributes a major stimulus for the immune system. In addition, the systemic 
immune system may be activated through cellular migration, through mucosal sites, or through 
interaction with antigenic substances taken up through the mucosal membrane.
Cow’s milk has become an integral part of the Western diet. It is therefore of interest to 
determine the immune mechanisms involved with the handling of this food protein in normal, 
healthy individuals in an attempt to elucidate the pathogenic mechanism that occurs in cases 
of food allergy or intolerance.
This thesis includes studies performed by the author, on healthy and atopic adults and 
infants in an attempt to obtain a better understanding of the uptake of cow’s milk protein, its 
transfer from mother to infant and the immune reaction to this protein.
The relationship between cow’s milk protein absorption and the immune reaction against
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it, was examined in healthy and atopic adults. The transfer of cow’s milk specific antibodies and 
6-Lg antigen from mother to infant via the placenta and breast milk was also investigated, 
together with the influence on the infant’s immune response and any subsequent allergy 
development, of parental atopy and maternal ingestion of cow’s milk during pregnancy and 
lactation.
34
CHAPTER 2
DEVELOPMENT OF AN ELISA FOR THE DETERMINATION OF COW’S MILK 6-Lg 
AND ct-CAS SPECIFIC ANTIBODIES IN BIOLOGICAL FLUIDS
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2.1 INTRODUCTION
An enzyme linked immunosorbant assay (ELISA) relies on the inherent characteristic of 
antigen and antibody to bind with high avidity and specificity, and is broadly analogous with an 
immunoradiometric assay which is a "sandwich-type" solid phase radioimmunoassay using labelled 
antibodies rather than antigens. The first radioimmunoassay was developed in the late 1950’s, 
(Yalow & Berson, 1959), and since then has afforded extensive appreciation, being used for the 
detection of, amongst others, antibodies, antigens, hormones and viruses.
ELISA is believed to have a number of major advantages compared with its preceding 
technique, the radioimmunoassay system. These include the reduced health risk, relative low 
expense of reagents and equipment, ease of performance, sensitivity and the relatively long shelf 
life of the reagents. It was for these reasons that it was thought the most appropriate technique 
for the quantitation of B-Lg and a-cas antibodies within human fluids (Envall et al, 1971). A 
number of methods have been reported for the measurement of B-Lg and a-cas antibody levels. 
These include a modified Farr radioimmunoassay (Husby et al, 1985c) and a fluorescent 
immunosorbant assay (Burgin-Wolff et al, 1980). However due to the high sensitivity and 
specificity of the ELISA, this has become the preferred technique for food antibody detection.
2.1.1 INDIRECT ELISA
A number of ELISA assay systems are available for the quantitation of antibodies within 
biological fluids. The indirect ELISA system is popular for the determination of food specific 
antibodies, and has been used by many groups (Husby et al, 1986b; Falth-Magnusson et al, 1988; 
Lilja et al, 1988 and Hattevig et al, 1990).
The use of a streptavidin-biotin amplification system has been found to increase the 
sensitivity of the assays (Guesdon et al, 1979 and Husby et al, 1986b). Biotin consists of two 5- 
membered rings, one is a thiol ring and the other is formed by fusion of the side opposite the 
sulphur of this ring to an -NH-CO-NH group. Avidin (or streptavidin) is a protein found in egg 
white. The mechanism of this amplification technique depends on the high affinity of avidin for 
the vitamin biotin. Since one molecule of avidin is capable of binding four molecules of biotin, 
the use of streptavidin-horseradish peroxidase complexes increases the surface concentration of 
horseradish peroxidase molecules, giving the method even greater sensitivity (Kemeny & 
Chandler, 1989).
Quantitation of antibody standards to obtain absolute concentrations is always preferable 
to arbitrary values. Food antibody standards are not available and the levels of these antibodies 
in other studies have been expressed as arbitrary units. These included: optical densities
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(Campbell, 1987), as a percentage of a reference serum (Gunther, 1960 and Fallstrom, 1986), 
as a percentage inhibition (Barnes, 1983), as qualitative detection (Husby et al 1985 and 
Halpern, 1988) or as arbitrary units (mU/ml) (Husby et al 1989). Due to the inevitable variation 
of standards used, results between study groups were incomparable. For this reason, a method 
of quantifying the specific antibodies within the samples was developed. It included affinity 
purification and nephelometry, and was applied to all of the biological fluids collected.
2.1.2 POTENTIAL PROBLEMS ENCOUNTERED WITH ELISA
Despite the many advantages offered by an ELISA system for antibody detection, assay 
development was often fraught with difficulty. Probably the most common problem encountered 
was that of non-specific binding. It was thought of great importance to quantify this and reduce 
it to a minimum.
The performance of an immunoassay is directly dependent on the quality of the antigen 
used as target or as labelled detector, and the antibody used as capture or detector. For these 
reasons the purest forms of capture antigens were used and great care went into producing the 
enzyme labels. It was thought necessary to validate the assays produced, performing rigorous 
controls of quality by testing for parallelism, cross-reactivities, inter- and intra- assay 
reproducibility, in addition to the inclusion of quality controls within each assay. Assays were 
developed which could be routinely used with the minimum of worker training.
2.1.3 AFFINITY PURIFICATION
Affinity chromatography is the only technique in separation technology which enables 
purification of almost any biomolecule on the basis of its biological function or individual 
chemical structure. This technique takes advantage of the high affinity of many proteins for 
specific chemical groups. The molecule to be purified is specifically and reversibly adsorbed by 
a complementary binding substance (ligand) immobilized on a solid support (matrix). The 
specifically adsorbed protein can be eluted simply by altering the composition of the solvent to 
favour dissociation (Pharmacia Fine Chemicals, Technical Report. Affinity Report).
The matrix used for affinity chromatography must possess chemical groups which can be 
activated or modified to permit covalent linkage of a variety of ligands. In addition, a high 
degree of porosity is required to allow good flow properties, which do not hinder the 
penetration of macromolecules. The ligand should exhibit specific and reversible binding affinity 
for the substance to be purified, and should have chemically modified groups which allow it to 
be attached to the matrix without destroying its binding activity, which could compromise the
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specificity of the reaction with the substance to be purified (Pharmacia Fine Chemicals. 
Technical Report. Affinity Report).
Release of the bound protein needs to occur under conditions innocuous to their specific 
activity. High affinity binding between the ligand and the protein can cause problems with 
dissociation, but this can be overcome by lowering the pH to less than 3 (Lowe & Dean, 1974). 
Affinity purification provides a rapid and easy separation method in essentially one step. This 
leads to the ready resolution of the antibody from whatever media it is present.
2.1.4 AIMS OF THE STUDY
The aim of the study was to develop indirect ELISAs for the determination of cow’s milk 
B-Lg IgG and a-cas IgG antibody levels in serum, and IgA antibody levels in saliva and breast 
milk, against the same food antigens. A method of B-Lg and a-cas antibody quantitation was 
devised. The assays were subsequently validated, and used for the determination of cow’s milk 
specific B-Lg and a-cas antibodies in various biological fluids.
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2.2 METHODS
2.2.1 APPARATUS
A microtitre plate washer (Titertek Microplate Washer S8/12) and reader (Titertek Multiscan 
Plus) were purchased from Flow Laboratories (Rickmansworth, Hertfordshire) and a 
spectrophotometer (Ultraspec 4050) from LKB Pharmacia (Milton-Kenes)
2.2.2 MATERIALS
Aldrich (Gillingham, Dorset, UK) Dimethyl sulphoxide
Amersham International (Amersham, UK) Biotin streptavidin peroxidase complex, Sodium iodide 
(IMS 30).
Boehnnger Mannheim (Mannheim, Geimany) 3,3’,5,5’ Tetramethylbenzidine 
Clifmar Associates (University of Surrey, Guildford. UK) 1000A aminopropyl porous glass beads 
Costar (Cambiidge, Massachusetts) Spin-X centrifuge filter unit 
Cow & Gate (Trowbridge, Wilts, UK) Peptijunior, Formula S
Dynatech Laboratories (Billinghurst, UK) Polypropylene flat bottomed microtitre plates 
(Immuno-2), polyvinyl chloride, flexible, flat bottomed microtitre plates 
Evergreen Scientific (Los Angeles, California) Disposable columns
Imperial Laboratoiies (Salisbury, Wiltshire, UK) Normal Horse Serum (Batch 3870113 and 
260653)
LKB-Produkter AB. (Bromma, Sweden) LKB DEAE Zetaprep 15 disk 
Medical International Ltd (London, UK) Viscing dialysis tubing 
Nunc (Denmark) Polystyrene flat bottomed microtitre plates (Maxisorb)
Pierce (Illinois, USA) N-hydroxysuccinimidobiotin
Sera-Lab Ltd (Sussex, England) Normal horse serum (Batch 704035)
Serotec (Kidlington, Oxford), Human IgG subclasses (IgGl, IgG2, IgG3 and IgG4)
Sigma Chemical Company Ltd (Poole, Dorset, UK) Biotinylated goat anti-goat IgA, biotinylated 
goat anti-human IgG, B-lactoglobulin B, bovine serum albumin (Fraction V), a-casein (bovine), 
a-casein (goat), a-casein (sheep), human serum albumin, human IgG preparation (Lyophilised) 
gluteraldehyde (Grade II 25% aqueous solution), horseradish peroxidase (type VI), a- 
lactalbumin, O-phenylenediamine dihydrochloride tablets (30mg), Tris (hydroxymethyl) 
aminomethane, polyoxyethylene sorbitan monolaurate (Tween 20), Sephadex (G15 & G75). 
All other chemicals were purchased from Bntish Dmg House Ltd (Poole, Dorset, UK).
All water used was double glass distilled.
All buffer recipes are shown in Appendix
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2.2.3 ASSAY DEVELOPMENT OF B-Lg IgG AND a-CAS IgG ELISA IN SERA
2.2.3.1 Assay Protocol for B-Lg IgG and a-cas IgG ELISA in sera
The inner 60 wells of a flexible PVC flat bottomed microtitre plate were coated with 200/xl 
of either B-Lg or a-cas (10/tg/ml) in 0.1 M bicarbonate/carbonate buffer pH 9.6 and incubated 
in a moist chamber at 4°C overnight. The plate was then washed three times (250/i.l/weII) in 
0.15 M phosphate buffered saline pH 7.4, containing 0.05% (v/v) Tween 20 and 0.1% (w/v) 
gelatin (PBSGT). All further dilutions and washing steps were carried out in this buffer. All 
incubations were carried out at 37°C unless otherwise stated. The standard serum (200/i 1/well) 
was added to the appropriate wells at an initial concentration range of 0.04-5.6jLig/ml and 0.01- 
l.OjLig/ml (and at a dilution of 1:40 and 1:80 for B-Lg and a-cas respectively). The samples were 
diluted at a ratio of 1:50, or at a dilution which enabled them to be read from the standard 
curve (1:50-1:200), and added (200/ri/well) with the 3 quality controls to the plate, which was 
incubated for 2 hours. After washing, 200ju. 1/well of biotinylated goat anti-human IgG was added 
to all wells at an initial concentration of 1:30,000, and incubated for 2 hours. After washing, 
200/il/well of streptavidin-biotin horseradish peroxidase conjugate was added at an initial 
concentration of 1:1000. The plate was washed again and 150/xl of 3,3’,5,5’-tetramethylbenzidine 
hydrochloride (TMB) substrate was added to all wells and incubated for 15 min. The reaction 
was stopped by the addition of 50/xl of 2.5 M sulphuric acid. The coloured end-point was read 
at 450nm. A standard curve was constructed, and the concentration of B-Lg IgG and a-cas IgG 
antibody levels within the samples and quality controls were calculated.
For the determination of B-Lg IgG and a-cas IgG antibody levels in infant heel prick blood 
samples, the assay protocol was identical to that described above, with one modification. The 
volume of analyte added to the wells was reduced from 200/z 1/well to 100/xl/well. The samples 
were diluted at an initial concentration of 1:80.
2.2.3.2 Assay Optimisation
i) Microtitre plates
A  number of microtitre plates were used during assay optimisation. These included flexible 
flat bottomed PVC and flat bottomed polystyrene Immuno-2 microtitre plates and flat bottomed 
polystyrene Maxisorb microtitre plates. The non-specific binding was determined by coating the 
wells with 0.1 M bicarbonate/carbonate buffer pH 9.6 containing no antigen preparation. The 
assay was then performed as described above and the optical density of the reagent within these 
wells was taken as the non-specific binding.
40
ii) Coating Antigen Conditions
In determining the optimum conditions, antigen coating concentrations of 10-100/ig/ml were 
compared, together with incubation times of 16, 3, 2 and 1 hours and temperatures of 4°C 
and 37°C. 0.1 M bicarbonate/carbonate buffer pH 9.6 and PBS pH 7.4 were used as the coating 
buffers.
iii) Blocking Steps and Buffers
Initially problems were experienced with non-specific binding and attempts to reduce this 
by using a number of different blocking proteins were tried. These included bovine serum 
albumin, human serum albumin, gelatin, Polypep, casein and normal horse serum in 
concentrations ranging from 0.5-5%. Different assay buffers were also compared. These included 
PBSGT with both Tween 20 and Tween 80 pH 7.4, casein buffer pH 7.6 and Tris buffered 
saline pH 7.6.
iv) Enzyme Label Conditions
The initial enzyme label concentration of 1:500-1:40,000 was optimised by using a 
checkerboard assay, and a variation of the incubation time, from 1-3 hours, at a temperature 
of 37°C. A checkerboard assay defines an assay in which one reagent is added to the plate in 
a range of dilutions in columns and another reagent (eg an enzyme label) is added in a range 
of dilutions in rows, the optimum concentration of both the reagents can be determined.
v) Substrate
Two substrate solutions: 3,3’,5,5’-tetramethylbenzidine hydrochloride (TMB) and ortho- 
phenylenediamine (OPD) were compared during assay development.
2.2.3.3 Standard and Sample Preparation for B-Lg IgG and a-cas IgG ELISA in Sera
The preparation of the standard and sera samples was identical. Human blood was obtained 
by venepuncture and collected into a plain tube. The blood was allowed to clot for an hour 
before centrifugation at 1000 g at 4°C for 15 min. The serum was then either stored in bulk, 
or aliquoted and stored at -20°C until required for analysis.
For the standard serum, a human sample containing a high circulating B-Lg IgG or a-cas 
IgG antibody titre was chosen. 50 ml of blood was taken and prepared as described above. 
Quantitation of this sample was performed by a novel method which used affinity purification 
together with nephelometry.
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2.2.3A Affinity Purification of the B-Lg IgG and a-cas IgG Standard
The following procedure was followed for the preparation of the affinity column:
1000A aminopropyl porous silica beads (0.25g) were placed into a disposable column with 
2ml of PBS. To this, 0.5ml of gluteraldehyde (Grade II 25% aqueous) was added and rolled for 
2 hours. The beads were then washed thoroughly with PBS.
B-Lg or a-cas (5mg) was dissolved in sodium acetate buffer pH 4.4. PBS buffer was expelled 
from the column before the addition of this solution, and the column was then rolled for 4 
hours. The liquid was run through and discarded. The column was washed thoroughly with PBS. 
3ml of PBS and 0.22g glycine was added and rolled for 1 hour. This was left to stand overnight 
before washing again with PBS. 3ml of 0.3% HC1 in PBS was then added and rolled for 30 min. 
The column was finally washed thoroughly with PBS and was ready for use.
For affinity purification the following procedure was followed. 2ml of serum was passed 
down the antigen (either B-Lg or a-cas) affinity column and rolled for 30 min. The serum was 
then run through and collected. After washing with PBS, 3ml of 0.1 M HC1 glycine pH 2.2 was 
applied, and then rolled for 30 min. An additional 2ml of HC1 glycine pH 2.2 was added and 
the eluate collected. The column was then re-equilibrated by the addition of PBS, and stored 
in PBS with 0.02% thiomersal as a preservative. The eluate was dialysed overnight against PBS 
to return it to a neutral pH.
2.2.3.5 Quantitation of B-Lg IgG and a-cas IgG Antibody Serum Standard
After lyophilising the sample, and rehydrating in 1ml of double distilled water, the quantity 
of IgG within the eluate was determined by nephelometry (Finley et al, 1979) and the Coomasie 
blue method (Scopes, 1982). The nephelometric method used was based on the method by 
Finley et al (1979) and was performed by the employees in the Clinical Biochemistry 
Department, St. Lukes Hospital, Guildford, Surrey. An ELISA technique was used to determine 
the recovery of the specific IgG antibodies from the column, and in combination with the 
nephelometric value, the quantities of B-Lg IgG and a-cas IgG in the whole serum standards 
were calculated. The B-Lg and a-cas serum standards were diluted 1:40 and 1:80 to give initial 
concentrations of 5jug/ml and 1/xg/ml respectively.
The sample dilution, preparation and storage were optimised in an attempt to prevent the 
occurrence of high non-specific binding.
2.2.3.6 Enzyme Conjugation of Sheep anti-human IgG
The periodate coupling method reported by Wilson & Nakane (1978) was modified for the
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conjugation of horse radish peroxidase to sheep anti-human IgG (Beyzavi et al, 1987). 
Horse-radish peroxidase (type VI Sigma), lOmg, was dissolved in 2ml of double glass distilled 
water, and mixed at room temperature for 30 min, after the addition of 1ml of 0.1 M sodium 
periodate. The solution was then dialysed against 1 mM sodium acetate buffer, pH 4.4, at 4°C 
overnight.
5ml sheep anti-human IgG (HP/S/901-B1) (2.2mg/ml) was dialysed overnight against 0.1 M 
bicarbonate/carbonate buffer pH 9.6, and was then added to the enzyme and mixed at room 
temperature for 2 hours. After the addition of 1ml M ethanolamine buffer pH 7.5, the solution 
was mixed at room temperature for 1 hour, and then dialysed against PBS, with 0.02% 
thiomersal (as a preservative) at 4°C overnight. The label was screened by ELISA.
In addition to the horse-radish peroxidase enzyme label, a biotin-streptavidin amplification 
system was used in an attempt to increase the positive signal. Biotinylated goat anti-human IgG 
and streptavidin horse-radish peroxidase conjugate were used.
With all of the enzyme labels tried, optimisation of the enzyme concentration was performed 
by checkerboard assay.
2.2.4. ASSAY DEVELOPMENT OF B-Lg IgG AND a-CAS IgG SUBCLASSES ELISA IN 
SERA
2.2.4.1 Assay protocol of B-Lg IgG and a-cas IgG Subclass ELISA in Sera.
96 wells of a flat bottomed flexible PVC microtitre plate were coated with 200/ri of B-Lg 
or a-cas (Kfrig/ml) in 0.1 M bicarbonate/carbonate buffer pH 9.6 and incubated in a moist 
chamber overnight at 4°C. After washing (250/il/well) with PBSGT, used as washing and diluent 
buffer, a negative standard (containing undetectable quantities of B-Lg or a-cas specific IgG 
subclass antibodies), was diluted 1:50, 200jLil/well of 3 quality controls (low, medium and high) 
and 8 samples diluted 1:50 were added to the plate. The plate was then incubated for 2 hours 
at 37°C. After washing, polyclonal sheep antisera against IgGl, IgG2, IgG3 and IgG4 were 
diluted in PBSGT (initial concentration of 20/xg/ml), and 200/x1/well was added to the 
appropriate well. The plate was incubated at 37°C for 2 hours, after which it was washed, and 
200/r 1/well of donkey anti-sheep horseradish peroxidase conjugate (gift from Dr SM Hampton) 
was added, at an initial dilution of 1:5000. This was incubated for a further 2 hours at 37°C. 
150/x 1/well of TMB substrate was added after a final wash, and the plate was incubated for 15 
min at 37°C. The reaction was then stopped by the addition of 50/tl/well of 2.5 M sulphuric 
acid. The end-point coloured reaction was read at 450nm. The levels of the specific IgG
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subclasses were expressed as a percentage of the negative standard (%/ml).
2.2.4.2 Assay Optimisation of B-Lg IgG and ct-cas IgG Subclass ELISA in Sera
The standard serum sample used was optimised. Initially 3 normal horse sera samples (Batch 
3870113 and 260653, Impereal Laboratories and Batch 704035, Sera-Lab Ltd) were used as a 
B-Lg IgG and a-cas IgG subclass standard, and compared with a number of human sera samples.
The concentration of the donkey anti-sheep horseradish peroxidase conjugate was optimised 
by performing a checkerboard assay. The incubation times of the sheep antisera and enzyme 
label were varied from 1 to 3 hours. The remaining conditions were as described for the B-Lg 
IgG and a-cas IgG assays.
2.2.5. ASSAY DEVELOPMENT OF B-Lg IgA AND a-CAS IgA ELISA IN BREAST MILK
2.2.5.1 Assay Protocol of B-Lg IgA and a-cas IgA ELISA in Breast Milk
The inner 60 wells of a flexible (PVC) microtitre plate were coated with 200/xl of B-Lg or 
a-cas (10/Ltg/ml) in 0.1 M bicarbonate/carbonate buffer pH 9.6, and incubated at 37°C for 2 
hours. The plate was then washed (250/tl/well) three times in 0.9% saline with 0.5% (v/v) 
Tween 20, pH 7.4. All washing steps were carried out in this buffer and all incubations were 
at 37°C. The plates were then blocked with 3% (v/v) normal horse serum in 0.9% saline and 
0.5% (v/v) Tween 20, pH 7.4 (220jLtl.well), for 30 min. The breast milk standard was diluted in 
0.9% saline and 0.5% (v/v) Tween 20 containing 1% (v/v) normal horse serum, pH 7.4, 
(STNHS) at a dilution of 1:100-1:12,800 to produce an 8 point standard curve. The samples 
were diluted in STNHS at a dilution which enabled them to be read from the standard curve 
(1:50-1:800). Standard, samples and 3 quality controls (200/rl/well) were added to the 
appropriate wells, and incubated for 2 hours. The plate was washed, before the addition of 
200/xl/well of sheep-anti-human IgA peroxidase label (at an initial dilution of 1:5000) to all 
wells. It was then incubated for a further 2 hours, after which time it was washed, and TMB 
substrate (150/rl/well) was added to all wells. The plate was incubated for 15 min and the 
reaction was stopped by the addition of 2.5 M sulphuric acid (50^1/well). The coloured end­
point reaction was read at 450nm.
A standard curve was constructed from which the levels of B-Lg IgG and a-cas IgA 
antibodies in the breast milk samples were calculated in arbitrary units of percentage of the 
positive standard (%/ml).
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2.2.5.2 Assay Optimisation of B-Lg IgA and a-cas IgA ELISA in Breast Milk
The optimisation steps described in section 2.2.3.2 were followed for this assay. In addition
to the buffers described in the previous section, 0.9% saline containing 0.5% (v/v) Tween 20
and 1% (v/v) normal horse serum, was also used for a diluent buffer.
2.2.5.3 Quantitation of the Standards for B-Lg IgA and a-cas IgA ELISA in Breast Milk
A number of breast milk samples were screened, and a sample with a high B-Lg or a-cas 
IgA titre was chosen for the positive breast milk standards. Quantitation of the breast milk 
standards was attempted. The protocols described in section 2.2.3.4 and 2.2.3.5 were followed.
2.2.5.4 Collection and Preparation of Samples for B-Lg IgA and a-cas IgA ELISA in Breast 
Milk
Breast milk samples were taken by the mother either manually, or by using a breast pump, 
at approximately the same time of day. They were collected in plain sterile tubes and frozen. 
After defrosting, the samples were either used whole, or were spun for different lengths of time 
and at various centrifugal speeds (ranging from 200-5000 g) at 4°C, after which, the aqueous 
supernatant was removed, diluted and used for analysis.
2.2.5.5 Enzyme Conjugation of Sheep anti-human IgA
The periodate method (Beyzavi et al, 1987) was used to conjugate horseradish peroxidase 
to sheep anti-human IgA (HP/S/620-B1) as described in section 2.2,3„6.
2.2.6 ASSAY DEVELOPMENT OF B-Lg IgA AND a-CAS IgA ELISA IN SALIVA
2.2.6.1 Protocol of B-Lg IgA ELISA in Saliva
The protocol for the determination of B-Lg IgA antibody levels in saliva was similar to that 
for B-Lg IgA determination in breast milk, with slight modifications. The same assay buffers 
were used. The high saliva standard was diluted 1:40-1:5000 and the samples at 1:20, or at a 
dilution that enabled them to be read from the standard curve (1:20-1:40). The standard, 
samples and quality controls were added to the appropriate wells (200 i^l/well) and the plate was 
incubated at 4°C overnight. After the plate was washed, 200/fr/well of biotinylated sheep anti­
human IgA (at an initial dilution of 1:800) was added and incubated for 2 hours. The plate was 
then washed and 200/xl/well of streptavidin-biotin horseradish peroxidase conjugate (at an initial 
dilution of 1:1000) was added and incubated for 1 hour. The remaining assay protocol was as
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described in section 2.2.5.1.
The protocol for the determination of a-cas IgA in saliva was identical to that described in 
2.2.6.1, with one modification. The high saliva standard was diluted in STNHS at a dilution of 
1:30-1:3000 and the sample at a ratio of 1:20, or at a dilution that enabled them to be read 
from the standard curve (1:20-1:60). For the determination of B-Lg IgA and a-cas IgA in infant 
saliva samples, the protocols described above were followed with one modification. The volume 
of analyte added to the wells was reduced from 200;/, 1/well to 100/ri/well.
2.2.6.2 Assay Optimisation for B-Lg IgA and a-cas IgA in Saliva
The optimisation steps described in section 2.2.3.2 were followed for this assay. In addition 
to the buffers described in the previous section, 0.9% saline containing 0.5% (v/v) Tween 20 
and 1% (v/v) normal home serum, was also used for a diluent buffer. A number of different 
enzyme labels were used during assay development, these included, sheep anti-human IgA 
horseradish peroxidase conjugate, and 2 biotinylated sheep anti-human IgA conjugates in 
conjunction with biotin-streptavidin horseradish peroxidase conjugate.
2.2.6.3 Quantitation of the Standards for B-Lg IgA and a-cas IgA ELISA in Saliva
A number of saliva samples were screened, and a sample with a high B-Lg or a-cas IgA titre 
was chosen for the high saliva standards. Quantitation of the saliva standards was attempted. 
The protocols described in section 2.2.3.4 and 2.2.3.5 were followed.
2.2.6.4 Collection and Preparation of Saliva for B-Lg and a-cas IgA ELISA 
Unstimulated saliva (5ml) was collected in a plain sterile tube. The adult subjects had been
instructed not to consume food or drink in the two hours prior to collection, but to rinse their 
mouths with water. The samples were then frozen at -20°C immediately after collection and 
thawed as required.
A number of methods were attempted for the collection of infant saliva. These included 
aspiration using a syringe with and without a tube, and cotton wool or cloth covered sticks. In 
the latter collection method, saliva removal from the buds also posed a problem, and two 
methods of extraction were compared.
The first involved the total volume of saliva collected being estimated by comparing the 
weight of the two buds and their containing tube, before and after saliva collection. The weight 
difference was taken to be the weight of saliva. TTie volume of buffer to give a final dilution 
of 1:20 (the dilution used in the assay) was added to the cotton wool, which had been removed
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from the sticks, and placed into a Spin-X centrifuge filter unit with the filter paper removed. 
This was then spun in an Eppindorf microcentrifuge for 10 min. The recovery of the saliva was 
calculated by comparing the antibody level in the eluate compared to the uneluted saliva 
(diluted 1:20).
The other method involved simply spinning the cotton wool in a Spin-X for 10 min. and 
diluting the saliva obtained (1:20). From this point, the saliva preparation was identical to the 
protocol used for adult saliva.
The saliva samples were defrosted. They were either heated to 56°C for 20 min, or left at 
room temperature. They were then used undiluted, or after centrifugation at 1000 g for 15 
min when the aqueous supernatant was removed and used in the assay.
2.2.6.5 Biotinylation of Sheep anti-human IgA
The sheep anti-human IgA (HP/S/620-B1) was affinity purified using a human IgA affinity 
column, and following the protocol described in 2.2.3.4. The immunoglobulin content of the 
sample was calculated by determining the optical density at 280nm, and dividing this value by
1.4, giving the concentration in mg/ml. The sample was then diluted in double glass distilled 
water to give a concentration of lmg/ml. This was dialysed against 0.1 M sodium hydrogen 
carbonate buffer pH 8.2 at 4°C for 2 hours. To this, 120jil of N-hydroxysuccinimidobiotin 
(lmg/ml in DMSO) was added for every ml of sample. This was allowed to stand at room 
temperature for 2 hours. It was then dialysed against PBS with 0.02% thiomersal (as a 
preservative) at 4°C overnight. It was screened by ELISA at a dilution range of 1:50-1:50,000.
This method of labelling sheep anti-human IgA with biotin was attempted twice. Firstly 
using N-hydroxysuccinimidobiotin (NHS) dissolved in DMSO to give a final concentration of 
lmg/ml immediately before use, and the second attempt using a solution of NHS biotin 
prepared previously. Both of these labels were compared to a goat anti-human IgA biotinylated 
label.
2.2.7 ASSAY VALIDATION FOR B-Lg AND a-CAS ANTIBODY ELISA’S
Rigorous validation steps were undertaken in order to develop workable assay systems.
i) Recoveiy
The recovery of B-Lg and a-cas specific antibodies were determined by adding a series of 
concentrations of the standard, ranging from 0.6-5.0jLig/ml and 0.1-0.8/xg/ml for B-Lg and a-cas 
specific serum respectively, and in the range of 10-90%/ml for both 6-Lg and a-cas IgA breast
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milk and saliva standards. This was added to a sample diluted 1:50, 1:50 and 1:20 for serum, 
breast milk and saliva respectively. The recovery of the added antibodies were calculated from 
this.
ii) Parallelism
Parallelism between the standard and the B-Lg and a-cas antibody levels in the samples was 
established by comparing the slope of serially diluted and superimposed samples, containing 
high milk specific antibody levels diluted in the appropriate assay buffer, with that of the 
standard.
iii) Cross-reactivity
The cross-reactivity of the antibodies with other protein antigens was shown. The cross­
reactant was added with the sample to the plates at a concentration of 50jitg/ml. The 
displacement of the serum curve caused by the added protein was determined by calculating the 
percentage displacement of the treated and neat standard curves. This was expressed as a 
percentage displacement from the untreated curve. The cross-reaction of each different antigen 
was performed on four different serum samples.
iv) Assay Reproducibility
The intra- and inter- assay coefficients of variation (CV) were calculated. The values for 
the high, medium and low quality controls were used for this purpose.
v) Assay Sensitivity
Assay sensitivity was defined as 2 standard deviations from zero. It was calculated for all of 
the developed assays.
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2.3. RESULTS
2.3.1 MATERIALS AND REAGENTS
Fig 2:1 shows the affinity of antibodies from two different sera samples to the B-Lg isotypes 
(B-Lg A, B and C). The affinity was comparable, and B-Lg B was chosen for routine use in all 
of the assays.
Flexible PVC microtitre plates were used routinely for the 6-Lg and a-cas specific IgG and 
IgA antibody ELISAs. Optimisation of the coating antigen (B-Lg and a-cas) concentration was 
performed. A concentration of 10/rg/ml diluted in 0.1 M bicarbonate/carbonate buffer pH 9.6 
was found to be the optimum antigen coating concentration for all of the developed assays, as 
shown in Fig 2:2.
2.3.2 ASSAY DEVELOPMENT OF B-Lg IgG AND a-CAS IgG ELISA IN SERA
2.3.2.1 Quantitation of B-Lg IgG and a-cas IgG Sera Standards
Quantitation of the standard sera samples was successfully performed. Table 2:1 shows the 
calculated value for the total B-Lg IgG and a-cas IgG antibody levels within the two standard 
sera.
Protein determination by nephelometry was found to give a protein level of approximately 
60% of the value determined by the Coomasie blue method. The nephelometry value was used 
for calculating the specific IgG level within the standard.
The standard serum dilution was chosen to give a sensitive standard curve, and the dilution 
of each sample was chosen to enable it to be read from the linear portion of the standard 
curve.
2.3.2.2 Enzyme Conjugation of Sheep anti-human IgG
Initially horseradish peroxidase conjugation of sheep anti-human IgG antiserum was 
attempted (Beyzavi et al,1987) but the resulting conjugate proved unsuccessful. An avidin-biotin 
amplification system was then tried. The use of biotinylated goat anti-human IgG and 
streptavidin-biotin peroxidase conjugate proved to be very successful, increasing the specific 
binding by approximately 250% with only a 30% increase in non-specific binding as shown in 
Fig 2:3. The analyte concentrations were optimised, goat anti human IgG was used at an initial 
dilution of 1:30,000, and the streptavidin horse radish peroxidase conjugate was used at an initial 
dilution of 1:1000.
2.3.2.3 Optimisation of B-Lg IgG and a-cas IgG ELISA in Sera
Blocking steps did not prove to be of any great advantage. The use of casein, either as a 
block or in the assay buffer, afforded very low non-specific binding, but also reduced any
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specific binding. PBSGT was used as the assay buffer giving acceptably low non-specific binding 
and high specific binding.
Sample preparation affected the non-specific binding. Bulk storage, and frequent freeze- 
thawing of the samples, resulted in high non-specific binding, and it was observed that the non­
specific binding reduced dramatically when aliquoting of samples became routine practice.
The specific and non-specific binding was observed to increase with longer incubation times 
and higher temperatures. The optimum coating incubation time was found to be at 4°C 
overnight. This gave low non-specific binding levels and high specific binding, as shown in Fig 
2:4. The sample and biotinylated goat anti-human IgG incubation times were chosen as 2 hours, 
as the different incubation times resulted in only small differences in the assay sensitivity.
The use of TMB substrate compared with OPD resulted in more colour in a shorter time 
period, with negligible increase in non-specific binding, as shown in Fig 2:5, and this was used 
routinely.
2.3.2.4 Validation of B-Lg IgG and a-cas IgG ELISA in sera
Standard curves for B-Lg IgG and a-cas IgG antibody quantitation are shown in Fig 2:6a 
& 2:6b. The sensitivity of B-Lg IgG and a-cas IgG antibody assays were 5ng/ml and 2.5ng/ml 
respectively. The inter-and intra-assay CV for B-Lg IgG and a-cas IgG ELISA’s are shown in 
Table 2:2.
Fig 2:7a and 2:7b illustrates B-Lg IgG and a-cas IgG antibody ELISA parallelism 
respectively. Recoveries of B-Lg and a-cas IgG antibodies over a range of 0.6-5.0jLig/ml and 0.1- 
0.8/j.g/ml respectively, were 107%, range 100-115% (n=4) and 101%, range 90-110% (n=4) 
respectively. Cross-reactivity of the antibodies with other proteins is shown in Table 2:3.
2.3.3 ASSAY DEVELOPMENT OF B-Lg IgG AND a-CAS IgG SUBCLASS ELISA IN SERA
2.3.3.1 Quantitation of B-Lg IgG and a-cas IgG Subclass Serum Standard
Initially normal horse serum, diluted 1:50, was used as a standard. This was found to give 
optical density readings higher than the majority of the samples. After screening a large number 
of human sera samples, two samples which expressed negligible B-Lg IgG or a-cas IgG subclass 
activity were chosen as the negative standards for the respective assays.
2.3.3.2 Optimisation of B-Lg IgG and a-cas IgG Subclass ELISA in Sera
Identical conditions were used for coating and sample addition for B-Lg IgG and a-cas IgG 
antibody quantitation. It was found that the period of time for antibody and enzyme label 
incubation had little effect on the final assay. The incubation time of 2 hours for the antibody 
and enzyme label was chosen for convenience.
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The concentration of the sheep anti-human IgG subclass antisera was 20/xg/ml. This was 
chosen so that comparison could be made between the 4 subclasses. The dilution of the enzyme 
conjugate was also optimised by using a checkerboard assay, and used routinely at an initial 
dilution of 1:5000.
2.3.3.3 Validation of B-Lg IgG and a-cas IgG Subclass ELISA in sera
The inter- and intra- assay CV for B-Lg IgG and a-cas IgG subclass determination in sera 
are shown in Table 2:4.
2.3.4 ASSAY DEVELOPMENT OF B-Lg IgA AND a-CAS IgA IN BREAST MILK
2.3.4.1 Quantitation of B-Lg IgA and a-cas IgA Breast Milk Standard
A breast milk standard for B-Lg IgA and a-cas IgA antibodies was chosen after screening 
numerous breast milk samples. Both of the standards expressed high specific IgA antibody titres. 
Quantitation of the breast milk standards by affinity purification and nephelometry (as described 
in section 2.2.3.1) proved unsuccessful, with very low recovery of the antibodies from the affinity 
column. The units of the specific IgA antibody levels were therefore expressed as a percentage 
of the high standard.
2.3.4.2 Enzyme Conjugation of Sheep anti-human IgA
The periodate method of horseradish peroxidase conjugation (Beyzavi et al, 1987) proved 
successful, and the enzyme label was used at an initial dilution of 1:5000.
2.3.4.3 Optimisation of B-Lg IgA and a-cas IgA ELISA in Breast Milk
Assay sensitivity was a major problem initially. A large number of buffers, blocks and assay 
conditions were considered and attempted. The use of a higher concentration of Tween 20 
within the buffer, and normal horse serum as the protein, proved to be very successful. Fig 2:8 
illustrates the benefit of a higher (3%) concentration of normal horse serum in the blocking 
buffer on reducing the non-specific binding.
Optimisation of the sample preparation proved to be a significant contribution to non­
specific binding reduction. Fig 2:9 illustrates the benefit of using breast milk samples that had 
been centrifuged at 1000 g for 10 minutes and then a further centrifugation step in an 
Eppindorf microcentrifuge for 10 mins before analysis. This preparation step resulted in 
significantly reduced non-specific binding.
Incubating the plate at any stage overnight proved unnecessary, and all incubation 
temperatures were 37°C, for 2 hours. A blocking time of 30 min was found to be sufficient to 
reduce the observed non-specific binding.
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2.3.4.4 Validation of B-Lg IgA and a-cas IgA ELISA in Breast Milk
Standard curves for B-Lg IgA and a-cas IgA ELISA in breast milk are shown in Fig 2:10a 
and 2:10b respectively. The sensitivity of the ELISA for 6-Lg and a-cas IgA determination in 
breast milk was 0.8%/ml of the appropriate standard (with an initial dilution of 1:100). The 
intra- and inter- assay CV are shown in Table 2:5.
Fig 2:11a and 2:11b illustrates assay parallelism for 6-Lg IgA and a-cas IgA antibodies in 
breast milk respectively. The recovery of B-Lg IgA from breast milk in a concentration range 
of 10-90%/ml, was 100%, (range 90-110%, n=4) and for a-cas IgA from breast milk in a 
concentration range of 10-90%/ml, was 101%, (range 98-104%, n=4). Cross-reactivity of B-Lg 
IgA and a-cas IgA ELISA in breast milk with other proteins is shown in Table 2:6.
2.3.5 ASSAY DEVELOPMENT OF B-Lg IgA AND a-CAS IgA ELISA IN SALIVA
2.3.5.1 Quantitation of B-Lg IgA and a-cas IgA Saliva Standard
A saliva standard for B-Lg IgA and a-cas IgA antibodies was chosen after screening a 
number of saliva samples. The B-Lg IgA and a-cas IgA saliva standards were both samples with 
high specific IgA antibody titres. Quantitation of the saliva standards by affinity purification and 
nephelometry (as described in section 2.2.3.1) proved unsuccessful, with a very low recovery of 
the antibodies from the affinity column. The units of the specific IgA antibody levels were 
therefore expressed as a percentage of the high standard.
2.3.5.2 Biotinylation of Sheep anti-human IgA
Biotinylation of sheep anti-human IgA was attempted using freshly prepared biotin solution. 
This produced the best label for this assay, compared to goat anti-human IgA and the label 
using home-made biotin succinamide solution. The label concentration was optimised, and used 
at an initial dilution of 1:800 for the determination of 6-Lg IgA in saliva.
2.3.5.3 Optimisation of B-Lg IgA and a-cas IgA ELISA in Saliva
Assay sensitivity proved to be a problem initially. The use of normal horse serum and a 
higher concentration of Tween 20 in the buffers proved successful in reducing the observed 
high non-specific binding. In addition to this, saliva preparation proved to have a significant 
effect on the non-specific binding. Untreated saliva samples resulted in unacceptably high non­
specific binding, and for this reason different techniques of sample preparation were compared. 
Saliva centrifugation, and the heating of the saliva to 56°C for 20 min prior to use, afforded 
a greater displacement between the specific, compared to the non-specific binding, as shown in 
Fig 2:12.
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The recovery of the saliva from the bandages was 13-60%, and from the cotton wool 
between 50-90%. The cotton wool proved the preferable material to use.
The recovery of IgA antibodies from the cotton buds using the first method was variable 
and unpredictable with a recovery range of 50-90%. The total quantity of saliva recovered from 
the cotton wool buds by simple centrifugation (method 2) ranged from 60-80%. The latter 
method was used routinely, as it not only gave undiluted saliva, but also resulted in a reduced 
non-specific binding.
2.3.5.4 Validation of B-Lg IgA and a-cas IgA ELISA in Saliva.
Standard curves for B-Lg IgA and a-cas IgA ELISA in saliva are shown in Fig 2:13a and 
2:13b respectively. The sensitivity of the B-Lg IgA and a-cas IgA ELISA for saliva were 0.8%/ml 
of the appropriate standard, diluted 1:50 and 1:30 respectively. The inter- and intra- assay CV 
are shown in Table 2:7.
IgA
Fig 2:14a and 2:14b illustrates B-Lg and a-cas; ELISA parallelism. The recovery of 
exogenously added B-Lg IgA and a-cas IgA antibodies from saliva over a concentration range 
of 10-90%/ml was 105%, (range 95-111%, n=3) and 98%, range (94-104%, n=3) respectively. 
The cross-reactivity of milk specific IgA antibodies within saliva, with other proteins is shown 
in Table 2:8.
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Results of affinity purification and protein determination for B-Lg IgG and a-cas IgG serum 
standards quantitation.
Table 2:1
B-Lg IgG a-cas IgG
Eluted volume* (ml) 1 1
Total Prot. (mg/ml) 
[Coomasie blue]
0.28 0.17
Total Prot. (mg/ml) 
[Nephelometry]
0.17 0.10
Recovery column (%) 74 94
IgG standard (mg/ml) 0.23 0.11
* After lyophilising and rehydration.
Table 2:2
Intra- and inter-CV for B-Lg IgG and a-cas IgG antibody ELISA in sera.
B-Lg IgG a- casIgG
Intra-CV 
High (x±SD) 
(CV)
255.0 ±7.7jLig/ml 
3%
47.0±1.4jLtg/ml
3%
Med (x±SD) 
(CV)
48.0±1.4/ig/ml
3%
15.0±0.8/xg/ml
5%
Low (x±SD) 
(CV) '
20.0±1.0/ig/ml
5%
4.0±0.1/xg/ml
3%
Inter-CV 14% 12%
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Table 2:3
Cross-reactivity of B-Lg IgG and a-cas IgG antibody ELISA in sera.
6-Lg IgG a-cas IgG
[50/xg/ml]
a-lactalbumin (cow) 0-5% 4-12%
Peptijunior <0.1% <0.01%
BSA 0-3% 0-1%
6-lactoglobulin - <0.01%
a-casein (cow) <1% -
a-casein (goat) <1% 5-17%
a-casein (sheep) <1% 10-14%
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Table 2:4
Inter- and Intra- CV for B-Lg and a-cas specific IgG subclass ELISA in sera
B-Lg IgG 
x±SD CV
a-cas IgG 
x±SD CV
Ig G l
Inter-CV
High 52 ±3 %/ml (5% 26 ±1 %/ml 4%
Med 30±3%/ml 5% 18 ±1 %/ml 3%
Low 26 ±1 %/ml 5% 16± 1%/ml 6%
Intra-CV 15% 15%
IgG2
Inter-CV
High 96 ±5 %/ml 5% 144±4%/ml 3%
Med 25 ±1 %/ml 5% 75 ± 2%/ml 2%
Low 18±l%/ml 4% 47±2%/ml 4%
Intra-CV 15% 16%
• T
IgG3
Inter-CV
High 155±2%/ml 2% 145±3%/ml 2%
Med 122±2%/ml 1% 98 ± 2%/ml 2%
Low 80±2%/ml 3% 74 ±1 %/ml 1%
Intra-CV 12% 13%
IgG4
Inter-CV
High 170±2%/ml 1% 188±2%/ml 1%
Med 104 ±3 %/ml 3% 112±3%/ml 3%
Low 98 ± 4%/ml 4% 51±3%/ml 6%
Intra-CV 17% 16%
56
Table 2:5
Intra- and Inter-CV for fi-Lg IgA and a-cas IgA ELISA in breast milk.
6-Lg IgA a-cas IgA
Intra-CV
High (x±SD) 57.0 ± 2.9%/ml 56.0± 1.1 %/ml
(CV) 5% 2%
Med (x±SD) 26.0 ±1.3 %/ml 23.2± 1.4%/ml
(CV) 5% 6%
Low (x±SD) 12.3±0.7%/ml 3.1 ±0.1 %/ml
(CV) 6% 4%
Inter-CV 17% 14%
Table 2:6
Cross-reactivity of fi-Lg IgA and a-cas IgA ELISA in breast milk.
6-Lg IgA a-cas IgA
[50/tg/mI]
a-lactalbumin (cow) < 0.1% < 0.1%
Peptijunior 0-4% 0-5%
BSA 0-7% 0-6%
B-lactoglobulin - 0-2%
a-casein (cow) 0-10% -
a-casein (goat) 0-2% 5-20%
a-casein (sheep) 0-1% 3-21%
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Table 2:7
Intra- and Inter- CV for B-Lg IgA and a-cas IgA ELISA saliva.
B-Lg IgA a-cas IgA
Intra-CV
High (x±SD) 26.1±0.8%/ml 61.2± 1.8%/ml
(CV) 3% 3%
Med (x±SD) 13.6±0.4%/ml 40.4 ± 1.6%/ml
(CV) 3% 4%
Low (x±SD) 5.1 ±0.3 %/ml 4.5 ±0.3 %/ml
(CV) 5% 7%
Inter-CV 14% 15%
Table 2:8
Cross-reactivity of B-Lg IgA and a-cas IgA ELISA in saliva.
B-Lg IgA a-cas IgA
[50jiig/ml]
a-lactalbumin (cow) < 0.1% 0-5%
Peptijunior 0-2% < 0.1%
BSA 0-1% 0-3%
B-lactoglobulin - < 0.1%
a-casein (cow) 0-6% -
a-casein (goat) 0-1% 5-24%
a-casein (sheep) 0-2% 6-27%
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Fig 2:1
Comparison of serum sample binding to different B-Lg isotypes.
Optical Density (450nm)
Serum Dilution
B-Lg A B-Lg B - a -  B-Lg AB
Fig 2:2
Comparison of serum B-Lg and a-cas IgG ELISA varying coating antigen concentration.
Optical Density (450nm)
Antigen Concentration (tig/ml)
B-Lg at css
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Comparison of serum B-Lg IgG ELISA standard curves using HRPO enzyme label and biotin- 
avidin amplification system.
Fig 2:3
Optical Density (460nm)
Serum Dilution
- + -  HRPO label ~+ - HRPO label NSB
Blotln-Avldln Blotln-Avldln NSB
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Comparison of serum B-Lg IgG ELISA standard curves varying coating incubation time and 
temperature.
Optical Density (450nm)
Fig 2:4
B-Lfl IqG (Mg/ml)
- t -  a T 't / lh  S7°C/2h -o- 37°C /3h-*-  4°C/ieh
+  '  NSB *  • NSB □ * NSB *  • NSB
NSB (non-apaciflc binding) at a B-Lg IgG 
eoncantratlon of 6.6ug/ml.
Fig 2:5
Comparison of serum B-Lg IgG ELISA standard curves using OPD and TMB substrate.
Optical Density (450nm)
B-lg IgG (pg/ml)
TMB OPD -+ - TMB NSB *■*“ OPD NSB
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Fig 2:6a
Standard curve of serum B-Lg IgG ELISA.
Optical Density (450nm)
B-Lg IgG (pg/ml)
Mean * SD
Fig 2:6b
Standard curve of serum a-cas IgG ELISA.
Optical Density (460nm)
0.001 0.01 0.1 1 10 
«.-cas IgG (pg/ml)
Mean ♦. SD
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Standard curve demonstrating parallelism between B-Lg IgG serum standard and a serum sample 
containing high B-Lg IgG levels.
Optical Density (450nm)
Fig 2:7a
B-Lg IgG (pg/ml)
Standard + Sera sample
A lt / IJ
Standard curve demonstrating parallelism between a-cas IgG serum standard and a serum 
sample containing high a-cas IgG levels.
Optical Density (450nm)
*-cas IgG (Mg/ml)
Standard + Sera sample
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Fig 2:8 ,
Comparison of breast milk B-Lg IgA EUSA standard curves varying normal horse serum
concentration for blocking buffer.
B-Lg IgA (%/ml)
3% NHS -+•- 3% NHS NSB
1% NHS 1% NHS NSB
Fig 2:9
Comparison of breast milk a-cas IgA ELISA standard curves varying sample preparation.
Optical Density (450nm)
•c-cas IgA (%/ml)
- + -  BM - + -  BM NSB
-a --  spun BM -B -  Spun BM NSB
Fig 2:10a
Standard curve of breast milk B-Lg IgA ELISA.
Optical Density (450nm)
B-Lg IgA (%/ml)
Mean a SD
Fig 2:10b
Standard curve of breast milk a-cas IgA ELISA.
Optical Density (450nm)
«.-cas IgA (%/ml)
Mean + SD
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Standard curve demonstrating parallelism between B-Lg IgA breast milk standard and a breast 
milk sample containing high B-Lg IgA levels.
Optical Density (450nm)
Fig 2:11a
B-Lfl IgA (%/ml)
Standard + BN sample
Fig 2:11b
Standard curve demonstrating parallelism between a-cas IgA breast milk standard and a breast 
milk sample containing high a-cas IgA levels.
Optical Density (450nm)
<*-cas IgA (%/ml)
Standard + BM sample
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jplg ^
Comparison of saliva a-cas IgA ELISA standard curves using a heated or untreated standard.
Optical Density (450nm)
*<-cas IgA (%/ml)
—*— Untred eal —1— Untred eal N3B
Htad sal HK— Kted aal NSB
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Fig 2:13a
Standard curve of saliva B-Lg IgA ELISA
Optical Density (460nm)
B-Lq IgA (%/ml)
Mean £ SD
Fig 2:13b
Standard curve of saliva a-cas IgA ELISA
Optical Density (460nm)
<*-cas IgA (%/ml)
Mean ±  SD
6 8
Standard curve demonstrating parallelism between B-Lg IgA saliva standard and a saliva sample 
containing high B-Lg IgA levels.
Optical Density (460nm)
Fig 2:14a
B-Lg IgA (%/ml)
— Standard + Seliiftsample
Fig 2:14b
Standard curve demonstrating parallelism between a-cas IgA saliva standard and a saliva sample 
containing high a-cas IgA levels.
Optical Density (450nm)
<x-cas IgA (%/ml)
—1 Standard + Saliva sample
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2.4. DISCUSSION
The ELISA technique developed and described here, proved to be sensitive and specific, 
fulfilling the many claims regarding the efficacy of it as a method for antibody detection. 
Indirect ELISAs to quantify B-Lg IgG and a-cas IgG antibody levels in sera samples, semi- 
quantitative indirect ELISAs to determine B-Lg IgG and a-cas IgG subclasses in sera and B- 
Lg and a-cas IgA levels in saliva and breast milk samples have been successfully developed.
Initially B-Lg AB isotype was used in assay development as it was believed to give an 
overview of B-Lg activity, however B-Lg B was later used routinely. This preparation offered 
the higher degree of purity required for enzyme labelling.
2.4.1 NON-SPECIFIC BINDING
A common problem encountered during ELISA development was the occurrence of high 
non-specific binding (Imagawa et al, 1982; Husby et al, 1985a & Kemeny & Chantler, 1989). 
Unfortunately, this was not due to a single variable. Soft (PVC) microtitre plates were used for 
all of the antibody assays offering high specific binding with low non-specific binding (De Savigy 
& Voller, 1980). Incubation temperature and time were shown to influence the production of 
non-specific binding. Imagawa et al (1982) reported that non-specific binding was reduced when 
the incubation temperature was changed from 37°C to 20°C. Although this temperature 
reduction was tried, no significant reduction was found. For this reason, and the impracticably 
of maintaining an environment at a constant room temperature of 20°C, 37°C or 4°C incubation 
temperatures were routinely used. The addition of a non-ionic detergent, such as Tween 20, and 
a non-interfering protein to the assay buffer and block, dramatically reduced non-specific 
binding. This has also been shown by other workers (Husby et al, 1985a). Although it was 
reported that casein was the most efficient blocking protein, it was essential, when choosing a 
blocking protein, that it did not interfere with the assay. Casein was not used since it may have 
given false positive results.
Freshly prepared buffer also prevented high non-specific binding, and it became routine 
practice to prepare buffers daily. Finally, the enzyme label could contribute to the presence of 
unwanted binding. During the development of the B-Lg and a-cas specific IgG ELISAs in sera, 
one label was found to be the main contributor to high non-specific binding. This could have 
been due to degradation or self-aggregation of the antibodies which have been found to 
increase non-specific binding to plastic surfaces (Monotoya & Castell, 1987). Over oxidation of 
the enzyme by the periodate conjugation method could also have contributed to the high non­
specific binding observed (Tyssen & Kurstak, 1984).
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2.4.2 FOOD ANTIBODY STANDARDS
For the development of an assay, a suitable standard was essential. Commercial preparations 
of food specific antibodies were not available, so in order to identify an appropriate standard 
a number of samples had to be screened. During the early stages of assay development the 
identification of a suitable standard was fraught with difficulties. The main reason being that 
the assay itself was not in a workable state, making it difficult to identify a high sample from 
one which simply gave high non-specific binding.
Successful quantitation of milk specific IgG antibodies enabled comparisons to be made 
between different food antibody levels and inter- individual levels. The discrepancy between the 
calculated protein content of the eluate determined by the Coomasie blue method and the 
nephelometric technique, was probably due to the presence of B-Lg or a-cas specific antibodies 
other than IgG class, or serum proteins within the sample. The Coomasie blue method 
quantified the total protein present within the sample, whereas nephelometry quantified only 
the IgG fraction of the sample (Finley et al, 1979). The much higher levels of protein calculated 
from the Coomasie blue protein determination, included not only the specific IgG, but also non­
specific proteins and specific antibodies of a different antibody class, and was therefore falsely 
high. For these reasons the nephelometry value was used to calculate the standard antibody 
concentration.
Recovery of the antibodies from the affinity column was rigorously quantified by an ELISA, 
a minimum of three times. Retention of antibodies by the affinity column was common and 
depended on the composition of the sample undergoing purification.
The inability of specific antibody quantitation in the saliva and breast milk samples by 
affinity purification and nephelometry, could have been due to the high levels of interfering 
substances within the samples, and the low antibody levels.
Myeloma protein standards were rare and very expensive, and for these reasons a semi- 
quantitative ELISA that enabled a comparison between the levels of the specific IgG subclasses 
was developed. A negative serum standard was chosen to allow a comparison between the 
calculated levels of the four isotypes within each sample, (a sample equally high for all of the 
isotypes would have been almost impossible to find).
Initially normal horse serum was used as the B-Lg IgG and a-cas IgG subclass low serum 
standards, as it was believed to contain no cow’s milk antibodies. It was confirmed by the 
suppliers that cow’s milk had not been given to the horses. Yet surprisingly, antibody activity 
was observed, in addition to a matrix effect not found with the human sera samples. A series 
of human sera samples were subsequently screened, and one that expressed undetectable
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amounts of all of the specific subclasses, was chosen as the working standard. This proved 
satisfactory, and the levels of B-Lg IgG and a-cas IgG subclasses were expressed as a percentage 
of the low standard.
2.4.3 SAMPLE COLLECTION AND PREPARATION
As previously shown in section 2.3, the collection and preparation of the samples markedly 
affected the assays sensitivity and non-specific binding.
Sera samples were initially stored in bulk, necessitating frequent freeze/thawing, which 
resulted in unacceptably high non-specific binding. This could have been due to antibody 
deterioration (Montoya & Castwell, 1987) and was dramatically reduced when sample aliquoting 
became routine practice.
The procedures for the preparation of the breast milk samples were optimised. The reduced 
non-specific binding observed after two centrifugation steps, was thought to be due to the 
reduced lipid content, in addition to the removal of particulate matter and cells from the 
sample. Breast milk centrifugation was also used by a number of other groups analysing breast 
milk samples for antibodies (Carlsson et al, 1976; Machtinger & Moss, 1986; Telemo et al, 1986 
and Ladjeva et al, 1989). As the lipid content of breast milk is variable, the use of the aqueous 
supernatant, compared with whole breast milk, resulted in a sample which was of greater 
uniformity.
Degrading enzymes are inactivated after saliva is heated to 56°C (Camling et al, 1987 and 
Frick & Rieger, 1987). A significant reduction in non-specific binding and an increased assay 
sensitivity was observed when this method was used. In addition, saliva centrifugation removed 
the large mucous proteins which resulted in lower non-specific binding levels.
The collection of infant saliva caused many problems. A method that was acceptable to the 
mother and infant, in addition to the collection of sufficient quantities of saliva, was developed. 
Saliva was required from the infant at 1 week to 18 month of age. Spitting is not an acquired 
reflex until approximately 12 months of age. An alternative method for the collection of the 
saliva was therefore sought. Use of a syringe and tube proved impracticable, mainly due to the 
discomfort it caused the infant, the long time period required for collection, and the inability 
to retrieve the very small volume of collected saliva from the tube.
The use of home-made cotton buds proved to be the most satisfactory method of saliva 
collection for all parties concerned. However removal of the collected saliva from the buds 
posed another challenge. Although the direct removal of the saliva from the cotton buds 
resulted in a loss of approximately 25% of that collected, the saliva was undiluted and could
72
be treated in a similar manner to the adult saliva. In addition, the cotton wool acted as an 
efficient filter, and removed significant quantities of the material which would produce non­
specific binding when washed off using the alternative method.
Another consideration was the possible interference of maternal IgA derived from breast 
milk. Although the mothers were asked to collect saliva from their infants at least 2 hours after 
a feed, in the first weeks of life mouth clearance was very slow, and small quantities of breast 
milk could possibly have been within the infants mouth. Although the potential contribution of 
breast milk to the measured specific IgA levels within the infant’s saliva could not be quantified, 
it was only a potential problem in the first few weeks of the infant’s life, after which, mouth 
clearance was much improved and by 6 months the majority of mothers were not breast feeding. 
However, this was an important aspect to consider when interpreting the data from early infant 
saliva samples.
The assay protocols were identical for adult and infant samples. It was found necessary to 
reduce the volume of analyte per well to 100/zl, when infant samples were used (both heel prick 
sera and saliva). This was due to the very small quantities of infant samples available. The 
sensitivity of the assays was not compromised by this volume reduction.
2.4.4 ASSAY OPTIMISATION
In all ELISA development, optimisation of the coating protein, sample dilution and enzyme 
label concentration was essential (Engvall & Perlmann, 1972). Much time was taken in assay 
optimisation and validation in an attempt to attain the most sensitive assay. In many cases the 
effect of the incubation time was negligible. This was probably a reflection of the relative 
speed of an equilibrium between the bound and free antibody. The shortest time was therefore 
chosen for ease of performance.
The biotin-avidin amplification system used by Guesdon et al (1979) and Husby et al (1986b) 
was successfully adopted for the amplification of the specific binding in a number of the assays 
reported here. This system could potentially increase the coloured endpoint by 300%, with three 
enzyme molecules bound to one avidin molecule (Goding, 1983). Although a 300% increase was 
not often found in practice, it did result in a significant increase in specific binding.
Assay sensitivity was of great concern initially with the B-Lg IgA levels and the a-cas IgA 
levels. Introduction of the alternative system of buffers and blocking proved successful. It was 
also found that an amplification system, biotin-streptavidin, was required for the B-Lg IgA 
determination in saliva.
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2.4.5 ASSAY VALIDATION
Validation of an assay is essential before it can be used routinely. Reproducibility both 
within and between assays has been the main criticism of the ELISA technique (Kemeny & 
Challacombe, 1989), a number of steps were taken in an attempt to reduce assay variation. To 
lower the risk of uneven heat distribution during incubation periods, the plates were never 
stacked, but always placed in a large moist chamber. They were also stored at 4°C, compared 
to room temperature storage, which varied considerably.
The results showed an inter-assay variation comparable to a RIA technique, and was 
achieved by disregarding any plates that did not fall within a narrow range of a theoretical 
threshold. Husby (1986) reported intra-assay CV as 9-17% and inter-assay CV as 17-27%, values 
considerably higher than those reported in this thesis.
Tests such as recovery and cross-reactivity were adapted from the conventional method for 
the application to antibody ELISA The concentration of cross-reactant added (50/rg/ml) was 
far in excess of naturally circulating food antigen levels (Paganelli & Levinsky, 1980). The 
reported cross-reaction was very low despite the high protein addition. The small cross-reaction 
of cow’s milk a-cas with a-cas from different species was not surprising as they shared a large 
number of similar epitopes (DeMan, 1982), and it must be stated that the significance of this 
was minimal. It must also be appreciated that the assays were quantitating human antibodies, 
which may vary considerable in specificity and avidity.
The developed ELISAs potentially have many uses. In this thesis they were applied to the 
quantitation of B-Lg and a-cas specific IgG antibody levels in maternal, cord, infant and adult 
sera, and to quantitate the B-Lg IgA and a-cas IgA antibody levels in adult and infant saliva 
and maternal breast milk.
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CHAPTER 3
DEVELOPMENT OF IMMUNOASSAYS FOR THE QUANTITATION OF COW’S MILK
B-Lg ANTIGEN IN BIOLOGICAL FLUIDS
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3.1 INTRODUCTION
The transfer of dietary antigens in an undigested or partially digested form across the intact 
gut wall has become of increasing interest in recent years, especially in relation to food allergy 
and intolerance. The development of sensitive, specific, reproducible and easy to perform assays 
for their detection in body fluids is therefore of fundamental importance. Due to their high 
sensitivity and specificity, immunoassays have become the most commonly used technique.
3.1.1 ANTISERUM PRODUCTION
The most important single factor in establishing a satisfactory immunoassay is the production 
of a suitable antiserum. This depends predominantly on the production of antibodies that 
possess a high avidity and selectivity for the material to be assayed (Kemeny & Challacombe, 
1989).
The immunogenicity of a compound is related to its molecular weight and the rigidity of 
the compound’s structure. Substances with molecular weights in excess of 5000 dalton are 
generally sufficiently immunogenic and do not require conjugation with larger antigenic proteins. 
Purity of antigens is also an important consideration. It was reported that impure substances 
could improve antisera production compared to pure preparations, with the impurities acting 
as adjuvants (Hurn & Landon, 1971).
The use of an adjuvant, such as mineral oil, was shown to increase the chance of an 
antibody response. The adjuvant was mixed with the immunogen to form a stable emulsion. It 
is believed to work by releasing the immunogen over the course of a week, thereby preventing 
its rapid uptake by the circulation avoiding excessive degradation. The adjuvant also facilitates 
phagocytosis of the immunogen, an essential step of antibody production, in addition to causing 
the formation of local granulomatous lesions which can act as a focus of antibody production 
(Morris, 1985).
In theory, antisera can be obtained from any animal able to initiate an immune response. 
The choice depends on the nature of the immunogen, and the use to which the antiserum is 
to be put. Rats can be used for screening some preparations prior to injecting into larger 
species (Robinson et al, 1975). Antisera to most large molecular weight compounds can be 
produced in rabbits, however the relatively small volume of antisera produced can be limiting. 
For this reason sheep and goats are increasingly used. Second antibodies (an antibody raised 
against the immunoglobulin (usually IgG) of the species in which the primary antibody was 
raised) are best raised in donkeys (Morris, 1985). The immune response of an animal is 
genetically determined and a randomly bred animal is believed to be best for antisera
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development (Hurn and Landon, 1971). It is preferable to immunize a large number of animals 
to increase the chance of attaining a suitable antisera, although in reality the number of animals 
is often limited by space and money.
The route of immunogen administration is also important. Few critical studies have been 
made of the effect of this, but Hum and Landon (1971) reported sites in decreasing order of 
effectiveness: lymph nodes, intra-articular, intradermal, intra-muscular, intraperitoneal, 
subcutaneous and intravenous. The timing of bleeds and boosting injections is a matter for 
conjecture, although Aherne and Marks (1979) favoured a rest period of several months (4-6) 
between boosts.
3.1.2 RADIOIMMUNOASSAY
The radioimmunoassay (RIA) technique was first described by Yalow and Berson (1959), 
when they developed an assay for the measurement of insulin in serum. This technique has 
been applied to an almost infinite number of compounds including proteins, viruses, tumour 
antigens and vitamins.
Although there have been many improvements to this technique during the 30 year period 
since its initiation, the basic principle of saturation analysis remains the same. It depends on 
the competition of a constant amount of radiolabelled compound (Ag*) and a variable amount 
of unlabelled compound (Ag) for a limited number of antibody binding sites (Ab). Separation 
of the bound (Ag-Ab+Ag*-Ab) and unbound fractions (Ag+Ag*) is essential and a number of 
methods are used. The separation techniques exploit physical or chemical differences between 
the two fractions, or use a second antibody to precipitate the first (Aherne and Marks 1979).
The RIA technique became a very popular method for cow’s milk protein determination 
(Paganelli & Levinsky, 1980; Kilshaw & Cant, 1984; Telemo et al, 1986; Koritz et al, 1987 and 
Cavagni et al, 1988) and for this reason it was first thought the appropriate technique to use 
for B-Lg quantitation.
The production of a high specific activity tracer is also required for a sensitive assay. 
125iodine is generally used in peptide RIA because of its relatively long half-life (60 days). The 
iodination reaction consists of a substitution of iodine, produced by oxidation of iodide, into an 
ionized tyrosine or histidine residue in the protein. Two common methods used are: chloramine 
T (Hunter and Greenwood, 1962) and the iodogen method (Salacinski et al, 1979).
3.1.3 ELISA
Due to the lack of acceptable displacement of the sheep antisera, the feasibility of using
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an ELISA technique for the milk antigen determination was investigated. In 1966 Laurell 
reported the development of an electroimmunoassay for the determination of circulating B-Lg 
in sera samples. Since that time a number of other groups have developed ELISA for the 
determination of cow’s milk B-Lg. These include Husby et al (1985); Kaminogawa et al (1989) 
and Marcon-Genty et al (1989) and it has proved to be the preferred technique compared to 
a RIA for milk protein detection in biological fluids.
3.1.4 AIMS OF THE STUDY
The aim of the study was to produce an immunoassay for the quantitation of circulating 
cow’s milk B-Lg and a-cas within human serum and breast milk samples. A sandwich ELISA was 
developed for the quantitation of cow’s milk B-Lg in serum and breast milk samples.
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3.2 METHODS
3.2.1 APPARATUS
The apparatus as described in section 2.2.1 was used for this study, in addition to a 1260 
Multigamma counter II purchased from LKB.
3.2.2 MATERIALS
Section 2.2.2 lists all of the reagents and the suppliers used in this study.
3.2.3 ANTISERUM PRODUCTION
Cow’s milk B-Lg and a-cas antisera were prepared : Non-ulcerative complete adjuvant (gift 
from BA Morris) (1ml) was emulsified with either B-Lg (36,000 dalton) or a-cas (30,000 dalton) 
(lmg/ml in sterile water).
The prepared immunogen was injected intra-muscularly into the chosen animal. Two Suffolk 
sheep [HP/S/1405 and HP/S/C13] were immunised against B-Lg and one against a-cas 
[HP/S/1705]. The immunogen was emulsified with the complete adjuvant and injected into the 
upper leg of the sheep. Eight injection sites were used with 0.5mg as the total weight of 
immunogen given. The sheep were bled monthly, the antiserum screened, and the sheep 
boosted when the titre decreased or plateaued. The same method of immunisation was used for 
boosting, with only 0.25mg as the total weight of immunogen given with incomplete adjuvant, 
to each animal.
Rabbits were also immunised against B-Lg and a-cas. Two, three month old female half­
lop rabbits (high antibody producing strain, Ranch Rabbits Ltd) were primed with B-Lg and a- 
cas using the same immunogen preparation as above. They were injected intra-muscularly in 
four sites with 0.2mg as the total weight of immunogen given. The rabbits were bled weekly and 
the antibody titre assessed. They were boosted only when the titre decreased or plateaued, 
the timing of which depended on the individual animal’s response. Identical immunisation 
protocol was followed for boosting with only O.lmg as the total weight of immunogen given with 
incomplete adjuvant.
The antisera titre was assessed by an ELISA: 200/tl of B-Lg or a-cas (10jLtg/ml) in 0.1M 
bicarbonate/carbonate buffer pH 9.6 was coated onto a Immuno-2 polystyrene microtitre plate 
and incubated at 37°C for 2 hours. After washing three times with 250/i.l/well of the assay 
buffer: 0.05M phosphate buffered saline with 0.1% (w/v) gelatin and 0.05% (v/v) Tween 20 
(PBSGT) pH 7.4, 200/il/well of the antisera was added to the plate in a series of initial 
dilutions, ranging from 1:50-1:32,000. This was incubated at 4°C overnight. After washing
79
(250jLil/well), 2 0 0 1/well of donkey anti-rabbit peroxidase complex was added at an initial dilution 
of 1:35,000, and incubated at 37°C for 2 hours. 150/tl of 3,3’,5,5’-tetramethylbenzidine 
hydrochloride (TMB) substrate was added to all wells and incubated at 37°C for 15 min. The 
reaction was stopped by the addition of 50g\ of 2.5 M sulphuric acid, and the coloured endpoint 
reaction read at 450nm. The antisera titre was calculated from this.
3.2.4 RIA DEVELOPMENT FOR B-Lg DETERMINATION
3.2.4.1 Iodination of B-Lg
Two methods were attempted for the iodination of B-Lg. This protein contained histidine 
or tyrosine residue which was essential for iodine substitution. This was determined by amino 
acid HPLC analyzer (Waters Picotag) by Dr E Ah Sing.
i) Chloramine T  iodination procedure
The chloramine T iodination procedure used was a modification of the Hunter and 
Greenwood (1963) method. B-Lg was weighed out using a Am2 Autobalance (Perkin-Elmer, 
Uninsa) and dissolved in 0.5 M sodium phosphate buffer (P04) pH 7.4 to a concentration of 
100/ig/ml. This solution was then aliquoted into plastic autoanalyzer cups, each containing 5gg  
of protein. These were freshly prepared before each iodination. For iodination, the reagents 
were added in the following order to the autoanalyzer cup:
a) 5pg  B-Lg dissolved in 50/xl of 0.05M P04 buffer pH 7.4
b) 18.5 MBq (0.5mCi) in 5g\ aliquot of Na125I
c) 20/zg chloramine T in 20/xl of 0.05M P 04 buffer pH 7.4 
15 seconds
d) 50pg  sodium metabisulphite dissolved in 200/tl of 0.05M P04 buffer pH 7.4 
10 seconds
e) lOOjtig potassium iodide dissolved 50/il of 0.05M P 04 buffer pH 7.4
The reactants were mixed throughout this process with a small magnetic flea.
The reactants were then added to the purification column.
ii) Iodogen Iodination Procedure
The iodogen iodination procedure used was a modification of the method reported by 
Salacinski et al (1979). 10 gg  of iodogen (1,3,4,6 Tetrachloro 3a 6a diphenylglycouril) was 
dissolved in 10g\ of Analar dichoromethane in a small polypropylene tube and allowed to dry. 
The iodination procedure was as follows:
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a) lO/xg of iodogen contained within a polypropylene tube
b) 18.5 MBq (0.5mCi) in a 5/rl aliquot of Na125I
c) 5 (Jig B-Lg dissolved 25fi\ of 0.1M P 04 buffer pH 7.4
The reactants were mixed by gentle shaking of the tube for 10 minutes
d) 240/ig sodium metabisulphite dissolved in 200/tl of 0.04M P04 buffer pH 7.4 
The reactants were then added to the purification column.
iii) Purification o f  Iodinated fi-Lg
Purification of the iodinated proteins was performed using Sephadex G15 gel for both of 
the methods described above. A 20 X 1cm column of Sephadex G15 was equilibrated with 0.05 
M P 04 buffer pH 7.4 containing 0.5% bovine serum albumin. The iodinated mixture was 
applied to the column with 0.05 M P04 buffer pH 7.4 containing 0.5% bovine serum albumin. 
Forty, 500/ri fractions were collected using a fraction collector, and the unreacted iodide peak 
was eluted after the protein peak. The purified tracer was aliquoted and stored at -20°C.
3.2.4.2 RIA Protocol
The diluent buffer used in the assay was 0.05 M P 04 buffer pH 7.4 which contained 0.5% 
bovine serum albumin. Antiserum dilution curves were initially performed to determine the titre 
of the antiserum. 100/rl of buffer and 100/xl of antiserum, diluted 1:100-1:3200 in assay buffer, 
were added to a series of polystyrene LP3 tubes. All tubes was set up in duplicate. A set of 
tubes were set up without antiserum to measure the non-specific binding. Tracer was diluted 
to give approximately 6000cpm/100jLil and 100/xl was added to all tubes. The tubes were then 
vortexed and incubated at 4°C for 24 hours. Separation of bound from free 125I B-Lg was 
carried out by double antibody precipitation. Donkey anti-sheep IgG (Batch no.HP/D/43-IC) 
was used at varying dilutions depending on the antiserum dilution. Double antibody precipitation 
time was reduced by the addition of 400/xl of 4% polyethylene glycol (PEG) to every tube apart 
from the total tube. They were then vortexed, and incubated at 4°C for 2 hours. The tubes 
were spun in a refrigerated centrifuge for 20 min at lOOOg. After the supernatant was aspirated 
the protein pellet, which contained the antibody bound 125I B-Lg, was counted in a automatic 
gamma counter (1260 Multigamma n, Wallac). The counts in the non-specific binding tubes 
were subtracted from the counts of the other tubes. These corrected values were used for the 
construction of an antiserum dilution curve.
Displacement curves were carried out by the addition of lng/ml, lOng/ml or zero unlabelled 
B-Lg with the buffer.
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3.2.5 ELISA DEVELOPMENT FOR fi-Lg DETERMINATION
3.2.5.1 ELISA Protocol
The inner 60 wells of an Immuno-2 polystyrene microtitre plate were coated with 200/il of 
affinity purified rabbit anti-B-Lg antibodies (5/ig/ml) in 0.1 M bicarbonate/carbonate buffer pH
9.4, and incubated in a moist chamber at 37°C for 3 hours. The plate was then washed three 
times in PBSGT (250/ll/well). All further dilutions and washing steps were carried out in this 
buffer. 200/ll/well of the 6-Lg standard was added to the plate at a concentration of 0.04- 
lOng/ml diluted in immunostripped, pooled, fasted human serum at a dilution of 1:4 in buffer, 
or 1.3% human serum albumin diluted in PBS. 200/xl/well of the samples and quality controls 
were also added to the appropriate wells either at a dilution of 1:4 in assay buffer for the 
serum samples, or undiluted for the breast milk samples. The plate was then incubated at 4°C 
overnight. After washing, 200/il/well of the rabbit anti-B-Lg enzyme label (1:500) was added to 
all wells and incubated at 37°C for 2hr. After washing again, 150/il of TMB substrate was added 
to all wells and incubated at 37°C for 15 min. The reaction was stopped by the addition of 
50/tl/well of 2.5 M sulphuric acid. The coloured end point was read at 450nm. A 10 point 
standard curve was constructed. The concentration of free B-Lg within the samples and quality 
controls were calculated from this.
*3.2.5.2 Optimisation of B-Lg ELISA
Coating, sample and enzyme label incubation times were varied between 1-16 hours, with 
temperatures of both 4°C and 37°C.
Two substrates, TMB and orthophenylene diamine (OPD), were compared in the ELISA.
i) Microtitre plates
A  number of microtitre plates were used during assay optimization. These included flexible 
PVC and Immuno-2 polystyrene microtitre plates, and Maxisorb polystyrene microtitre plates. 
The non-specific binding was also determined by coating the wells with 0.1 M 
bicarbonate/carbonate buffer pH 9.6 which did not contain any capture antibody. The assay was 
then performed as described above, and the optical density of the reagents in these wells was 
taken as the non-specific binding.
ii) Preparation o f  Coating Antibody
Unpurified, affinity purified and ion exchange purified anti-B-Lg antibodies were used for 
coating during assay optimization.
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The procedure used for affinity purification of the antibody was as described in section
2.2.3.4, using the B-Lg antigen column.
Ion exchange purification was also performed using a LKB DEAE Zetaprep 15 disk. Initially 
the disc was regenerated by the addition of 75ml of 1 M acetic acid, followed by 75ml of 0.1 
M phosphate buffer pH 7.4, and finally 75ml of 0.01 M phosphate buffer pH 7.4. 2 ml of the 
antiserum was diluted 1:10 with 0.01 M phosphate buffer. This was then passed through the 
column, and twelve 5ml fractions were collected. The optical density of these fractions was read 
at 280nm. The protein content of the fractions (mg/ml) was calculated by dividing the optical 
density value at 2S0nm, by 1.4.
3.2.5.3 Preparation of B-Lg Standard
i) Sem m  Standard
Various sera were used as the diluent to mimic human serum. These included normal horse 
sera, Batch 3870113 & 260653 (Imperial Laboratories, UK) and Batch 704035 (Sera-Lab Ltd, 
Sussex, England), normal donkey sera (gift from Dr SM Hampton) and fasted immunostripped 
pooled human serum.
Immunostripping of the fasted, human serum was carried out using an anti-B-Lg affinity 
column. Preparation of this column was as follows: Rabbit anti-B-Lg antisera, 2ml, [MF/R/HL1], 
was affinity purified as described in section 2.2.3.4 and the total protein content of the eluate 
was determined by measuring the optical density at 280nm and dividing by 1.4 to give the 
protein content in mg/ml. 0.25g of amino activated porous silica beads were packed into a 
disposable column and washed thoroughly with 0.15 M phosphate buffered saline pH 7.4 (PBS). 
The antibody was added to the column and allowed to roll for 4 hours. It was washed 
thoroughly with PBS before 1 M glycine (0.22g dissolved in 3ml PBS) was added and rolled for 
1 hour. It was again washed thoroughly with PBS, before the addition of 3ml of 0.3% HC1 
dissolved in PBS, and rolled for 30 min. After a final wash with PBS, the column was ready for 
use.
The immunostripping protocol was as described below: Serum (5ml) was added to the 
column and rolled for 30 min. The immunostripped serum was allowed to run through the 
column, collected into a sterile bottle, and frozen at -20°C until required. The column was 
cleaned by the addition of 4ml 0.1 M glycine HC1, pH 2.2 and rolled for 10 min. The eluate 
was allowed to run through the column and discarded. The column was then re-equilibrated by 
the addition of PBS, and stored at 4°C in PBS with the addition of 0.02% thiomersal as a 
preservative.
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ii) Breast Milk Standard Preparation
Infant formulae which claimed not to contain allergenic milk proteins were used for the 
standard diluent. These included Peptijunior, Formula S and Nieda (gift). In addition, a solution 
of 1.3% human serum albumin in PBS was used. Both untreated and defatted samples of the 
different milks were tried in the assay.
The removal of the lipid component of breast milk was achieved by centrifugation at 1000 
g at 4°C for 15 minutes. The lipid layer was removed and the aqueous supernatant was 
aliquoted and stored frozen until required. A final centrifugation in an Eppindorf 
microcentrifuge for 10 minutes was carried out before the removal of the aqueous supernatant 
for use in the ELISA
3.2.5.4 Enzyme Conjugation of Rabbit anti-B-Lg
During assay development a number of different methods were attempted for the 
conjugation of horseradish peroxidase to B-Lg antigen. These included periodate method 
(Beyzavi et al, 1987) and gluteraldehyde method (Beyzavi et al, 1987).
The method used for enzyme conjugation to the rabbit anti-B-Lg antibody, was based on 
the method reported by Beyzavi et al (1987). Horse radish peroxidase was used as the enzyme 
at a ratio of 1:1 (enzyme:antibody) by weight. The method was as described in 2.2.3,6, and the 
label was screened using an ELISA to determine the optimal concentration. Sensitivity of the 
assay was increased by purifying the enzyme label, using a G75 Sephadex column. 0.05M PBS 
was added to the column, the enzyme label (5ml) was then added and forty 5ml fractions were 
collected. The Sephadex column was then stored with PBS 0.02% thiomersal as a preservative.
3.2.6 VALIDATION OF B-Lg ELISA
i) Recovery
A  range of concentrations (0.6-10ng) of B-Lg standard were added to a pooled serum sample 
and pooled defatted breast milk sample. The recovery of the exogenous B-Lg was calculated.
ii) Parallelism
Serum and a breast milk samples, which had high circulating B-Lg levels, were serially 
diluted with the appropriate standard diluent, superimposed and compared with the standard 
curve.
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Hi) Cross-reactivity
A  standard curve of the cross-reactant (4-1000ng) was compared with the B-Lg standard
curve (0.04-10ng/ml). The %  cross-reactivity was calculated using the formula:
%  x-reac. = ______ conc. of 1A> maximum OD of top standard______  X 100
conc. of cross-reactant at 1/2 maximum OD of top standard
The cross-reactants used were a-la, bovine serum albumin, a-cas, (cow), a-cas (goat) and a-cas 
(sheep).
iv) Reproducibility
The intra- and inter- assay coefficient of variation (CV) were calculated. The values for the 
high, medium and low quality controls were used for this purpose.
v) Sensitivity
Assay sensitivity was defined as two standard deviations from zero.
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33 RESULTS
3.3.1 ANTISERUM PRODUCTION
The first sheep (HP/S/1405) that was immunised against B-Lg was a non-responder, with no 
detectable production of B-Lg antibodies. The second sheep immunised against fi-Lg (HP/S/C13) 
and the sheep immunised against a-cas (HP/S/1705) both produced antisera with high titres 
shown in Fig 3:1. Although these antisera had detectable anti- B-Lg and a-cas activity, when 
used in both RIA and ELISA systems for the detection of the specific proteins, adequate 
displacement was not observed and sensitive assay systems could not be developed.
The rabbit immunised against B-Lg (MF/R/HL1) produced an immune response after 
priming, as shown in Fig 3:2. Bleeds collected over the 4 week period after the initial priming 
immunisation, were successfully used in an ELISA for the quantitation of B-Lg in serum and 
breast milk samples. Antiserum from the rabbit immunised against a-cas (MF/R/HL2) did not 
show such a good immune response. When bleeds of this anti-a-cas serum were used in an 
ELISA system, a sensitive assay could not be developed.
The definition of antisera titre was the dilution of an antisera which bound 50% of a 
specified amount/fraction of a stated quantity of the labelled antigen. RIA was the usual method 
for antisera titre assessment, so adaptation to the above definition was required for an ELISA 
determination. A reference antiserum was run every time antisera titre was being assessed. 
Maximum binding was arbitrarily defined as an optical density value of 2.0, so the titre of the 
reference antisera was the dilution that produced an optical density of 1.0. For all subsequent 
assessments the optical density that related to the initially calculated titre of the reference 
antisera was taken to be the optical density that corresponded to the titre of the test antisera. 
This method of antisera assessment proved to be satisfactory.
3.3.2 IODINATION
Fig. 3:3 illustrates the iodination profile of iodinated B-Lg using both the chloramine T and 
iodogen method. A larger free iodine peak was observed when the chloramine T method was 
used. Very little iodine was incorporated into the protein with either method. Both the 
chloramine T and iodogen method of iodination proved unsuccessful, with maximum tracer 
binding of 8% and no displacement with either of the sheep antisera (HP/S/C13 or HP/S/1405). 
In an attempt to improve the tracer produced, the reaction time between the antigen and 
iodogen was varied: 10, 5 and 2.5 minutes. This did not prove to be of any benefit.
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3.3.3 DEVELOPMENT OF ELISA FOR a-CAS DETERMINATION
Indirect, modified indirect and sandwich ELISAs were attempted for the quantitation of a- 
cas in human serum and breast milk samples. Both of the developed antisera, the sheep 
(HP/S/1705) and the rabbit (MF/R/HP2), were used in these systems, and proved unacceptable. 
Displacement of the antiserum was only observed with the addition of 500ng/ml of a-cas. It was 
not possible to develop a more sensitive assay system with the available antiserum.
3.3.4 ELISA DEVELOPMENT FOR B-Lg DETERMINATION
A sandwich ELISA protocol proved to be the preferred method for the quantitation of B- 
Lg within both human serum and breast milk samples.
3.3.4.1 Optimisation of B-Lg ELISA 
Fig 3:4 shows the effect of the specific and non-specific binding of the assay using different 
microtitre plates. Hard Immuno 2 microtitre plates were chosen for the assay, resulting in the 
greatest displacement of the non-specific compared to the specific binding.
Optimisation of the appropriate incubation times and temperatures were performed at each 
stage. Fig 3:5 illustrates the advantage of the longer incubation time at the coating stage and 
Fig 3:6 illustrates the effect of varying the incubation time and temperature, at the stage of 
standard and sample addition.
Fig 3:7 shows the effect of using OPD and TMB substrate. TMB substrate was chosen for 
the purpose of this assay.
Two different buffers, 0.15 M PBS pH 7.4 and 0.1 M bicarbonate/carbonate pH 9.6, were 
compared as the coating buffers, this is shown in Fig 3:8. 0.1 M bicarbonate/carbonate pH 9.6 
was chosen as the coating buffer as it gave a slightly higher specific, compared to a non-specific 
binding. Purification of the coating or capture antibody was an important consideration. Both 
undiluted and ion exchange purified antisera gave minimal colour when compared to affinity 
purified antisera. Due to its superior binding, the latter purification method was routinely used. 
The optimum concentration of the coating antibody was found to be 5/tg/ml.
Normal horse serum and normal donkey serum when used as standard diluents, even when 
diluted 1:4 with assay buffer, gave very elevated standard curves, with the zero standard having 
a higher optical density reading with the majority of the samples. Pooled, fasted, human serum 
also had a high zero standard, and for this reason immunostripping of the serum seemed 
essential. Fig 3:9 illustrates the necessity of immunostripping serum even when circulating milk 
proteins were theoretically not present. Dilution of the serum proved to be unavoidable as
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undiluted sera resulted in an unacceptable flattening of the standard curve, as shown in Fig 
3:10.
All of the milks when used untreated gave severe flattening of the standard curve. Fig 3:11 
illustrates the effect of the different milks on the 6-Lg standard curve. 1.3% human serum 
albumin in PBS was chosen as the most appropriate standard diluent, which resulted in a 
sensitive standard curve and a low zero value. The standards and samples were added to the 
plate undiluted.
3.3.4.2 Enzyme Conjugation of Rabbit anti-B-Lg
The periodate method (Beyzavi et al, 1987) for the conjugation of horseradish peroxidase 
to rabbit anti-B-Lg was successful. The label was purified using a G75 Sephadex column in an 
attempt to increase the assay sensitivity. Fig 3:12 shows the elution profile of the purified 
enzyme label, illustrating the relatively large quantity of uncongugated antibody. Fractions 5- 
11 were pooled and subsequently used as the label. A checkerboard ELISA was performed to 
determine the optimum enzyme label concentration, which was found to be 1:500.
3.3.3.3 Validation of B-Lg ELISA
A standard curve for the 6-Lg ELISA in serum and breast milk is shown in Fig 3:13a and 
3:13b respectively. The sensitivity of the B-Lg ELISA in both serum and breast milk samples, 
was 80pg/ml. The inter- and intra-assay CV for the B-Lg ELISA in both serum and breast milk 
is shown in Table 3:1.
Fig 3:14a and 3:14b illustrates assay parallelism for B-g in sera and BM samples respectively. 
The cross-reactivity of the assay is shown in Table 3:2. The mean recovery of exogenous B-Lg 
added to serum at a concentration range of 0.5-8.0ng, was 98% (range 85-105%) and for breast 
milk was 96% (range 90-102%).
Table 3:1
Intra- and Inter-CV of B-Lg ELISA
Sera Breast milk
Intra-CV 
High (x±SD) 
(CV)
4.45 ± 0.25ng/ml 
6%
5.62 ± 0.28ng/ml 
5%
Med (x±SD) 
(CV)
1.82 ± 0.07ng/ml
4%
1.47 ± 0.07ng/ml 
5%
Low (x±SD) 
(CV)
0.24 ± .0.01ng/ml
4%
0.33 ± 0.02ng/ml 
6%
Inter-CV 15% 14%
Table 3:2
Cross-reactivity of 6-Lg ELISA
a-la PJ BSA a-cas
(cow)
a-cas
(goat)
a-cas
(sheep)
Sera/Bm <0.001 <0.01 <0.001 <0.001 <0.001 <0.001
NB a-la=a-lactalbum in, PJ=Peptijunior, B SA —bovine serum albumin, a-cas—a-casein.
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Profile of sheep serum antibody titres over time. [HP/S/1405, HP/S/C13 and HP/S/1705]
Fig 3:1
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Fig 3:2
Profile of rabbit serum antibody titres over time. [MF/R/HL1 and MF/R/HL2].
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Comparison of the elution profiles using a Sephadex G15 column for B-Lg iodination using the 
chloramine T and Iodogen methods.
Fig 3:3
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Optical Density (450nm)
Fig 3:4
Comparison of serum B-Lg ELISA standard curves varying the type of microtitre plate.
B-Lg (ng/ml)
—f— Hard (Nunc) Hard (Dyn) Soft (Dyn)
+  • NSB *  * NSB D * NSB
NSB: non-apeolfic binding at a B-Lg 
concentration of lOng/ml
Fig 3:5
Comparison of serum B-Lg ELISA standard curves varying coating antibody incubation time and 
temperature.
B-Lg IgG (pg/ml)
-+ -  37°C /1h 3 7 °0 /2 h  ' *  37°C /3h  4°C/16h
+  * NSB *  * NSB a  * NSB *  * NSB
NSB ; non-epeclflc binding at a B-Lg 
concentration of 10ng/ml
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Comparison of serum B-Lg ELISA standard curves varying sample incubation time and 
temperature.
Optical Density (460nm)
Fig 3:6
B-Lfl (ng/mi)
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NSB : non-specific binding at a B-Lg 
concentration of 10ng/ml
Fig 3:7
Comparison of serum B-Lg ELISA standard curves using OPD and TMB substrate.
Optical Density (450nm)
B-Lg (ng/ml)
TMB OPD - + -  TMB NSB OPD NSB
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Comparison of serum B-Lg ELISA standard curves varying coating buffers.
Optical Density (460nm)
Fig 3:8
B-Lg (ng/ml)
—l— Bloarb/carb pH0.4 PBS pH 7.6
+  * NSB *  • NSB
NSB : non-specific binding at a B -lg  
concentration of 10ng/ml
Fig 3:9
Comparison of serum B-Lg ELISA standard curves varying standard diluent (sera at a dilution 
of 1:4 with buffer).
B-Lg (ng/ml)
—  Buffer Human IS NHS 1
- B -  NHS 2 NHS S
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Optical Density (450nm)
Fig 3:IU
Comparison of serum B-Lg ELISA standard curves varying the dilution of the standard.
B-Lg (ng/ml)
— -  Neat aerum - + -1 :2  aerum 1,4 * 0rum
Fig 3:11 . *•,
Comparison of breast milk B-Lg ELISA standard curves varying standard diluent.
B-Lg (ng/ml)
——  Buffer 1.3% H8A 14% PJ
~ H _ 14% Wyeoy 14% Nleda
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Comparison of the elution profiles using a Sephadex G75 column read at an optical density of 
280nm and 405nm of rabbit anti B-Lg enzyme label.
Optical Density (280nm) Optical Density (405nm)
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Fig 3:12
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Fig 3:13a
Standard curve of serum B-Lg ELISA
Optical Density (450nm)
B-Lg (ng/ml)
Mean ♦ SD
Fig 3:13b
Standard curve of breast milk B-Lg ELISA.
Optical Density (450nm)
B-Lg (ng/ml)
Mean ♦. SD
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Standard curve demonstrating parallelism between exogenous B-Lg and endogenous B-Lg in sera.
Fig 3:14a
Optical Density (460nm)
B-Lg (ng/ml)
Standard x Sera sample
Standard curve demonstrating parallelism between exogenous B-Lg and endogenous B-Lg m 
breast milk.
Optical Density (450nm)
B-lg (ng/ml)
— Standard x BM sample
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Fig 3:15
Cross-reactivity of B-Lg ELISA with other milk proteins.
<pg/ml)
—I— B-Lfl La * PJ —x -  BSA
-4-«.Ca«(Boat)-A-t4Caa{cow)-B-<^Cai(ahB«p)
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3.4. DISCUSSION
A sensitive, specific and reproducible ELISA was developed for the determination of cow’s 
milk B-Lg in both human sera and breast milk samples.
3.4.1 ANTISERUM PRODUCTION
The first sheep [HP/S/1405] that was immunized against B-Lg did not produce any 
detectable B-Lg antibodies. Although the second sheep [HP/S/C13] had seemingly acceptable 
anti-B-Lg antibody titre, all bleeds of this antisera gave very poor displacement when relatively 
high quantities of B-Lg were added. Steward & Lew (1985) reported that antibody affinity was 
of crucial importance in immunoassays. Despite a high antibody titre, a low antibody affinity 
could explain why all of the sheep antisera were unusable within the assay systems described.
All of the reported methods for milk protein quantitation in biological samples used rabbit 
antisera (Dahl et al, 1984; Huang et al, 1985 and Koritz et al, 1987). For this reason, and the 
fact that the other antisera proved unworkable, rabbits were immunised in an attempt to 
produce antisera against a-cas and B-Lg. An intra-muscular method of immunisation was 
followed. Due to the lack of time, the more efficient intradermal immunisation procedure (Hurn 
& Landon, 1971) was not used, however workable anti-B-Lg antisera was produced even after 
the initial immunisation. Although an immune response was observed after priming and boosting 
of the a-cas rabbit, the antisera titre were not as high as those observed with B-Lg 
immunisation. It has been reported that B-Lg is more allergenic than other milk proteins even 
after heat treatment (Marcon-Genty et al, 1989b), which may explain low antibody response of 
the a-cas rabbit. All of the immunogens used were a pure preparation. Some workers believed 
that it was preferable to immunise with relatively impure natural material. It was thought that 
the impurities could have an adjuvant effect (Hurn & Landon, 1971). However because of the 
concern about potential cross-reaction with other milk proteins which could be present in the 
human sera samples, it was thought prudent to use a pure immunogen for the production of 
this antisera.
3.4.2 IODINATTON OF B-Lg
The chloramine T method of iodination yielded radiolabels which were unstable, and of low 
avidity, which was also reported by Salaciski et al (1979) and Knight (1978). Loss of tracer 
immunoreactivity was observed at 3-4 weeks. This premature loss of activity could be due to 
the influence of non-specific factors such as pH and ionic strength, or over-iodination of the 
protein (Aherne & Marks, 1979).
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The low binding observed with the B-Lg tracer reflected either a poor tracer, or antiserum 
with a low titre or avidity, it could also be caused by a combination of both of these factors 
(Morris, 1985).
The iodogen method of iodination, for B-Lg, proved to be a preferable technique, although 
it still did not result in a workable assay. This was also reported by Knight (1978), Salacinski 
et a l (1979) and Weir (1986). The improved results could be attributed to the reduced oxidative 
damage to the protein, in addition to the less severe reaction conditions. However even this 
method did not produce a tracer which could be used for the quantitation of B-Lg.
3.4.3 ELISA TECHNIQUE FOR B-Lg DETERMINATION
Compared to a RIA an ELISA technique had a number of advantages. In addition to the 
reduced health risk, an ELISA proved to be easy to perform, relatively cheap, with a longer 
label half life (Montoya & Castell, 1987 and Fickling et al, 1990). It was a technique in which 
it was possible to assay a large numbers of samples without the need of tediously numbered 
tubes, and it was also reported to have similar, if not higher, sensitivity, specificity and 
reproducibility compared to a RIA (Voller et al, 1978).
3.4.4 ASSAY OPTIMISATION
The assay sensitivity was of utmost importance, as the levels of circulating B-Lg in sera had 
been reported to be between 0.01-0.03ng/ml (Cavagni et al, 1988) and 0.1-3ng/ml (Paganelli & 
Levinsky, 1980) and in breast milk between 5-800ng/ml (Axelsson et al, 1986) and 0.2-4ng/ml 
(Machtinger & Moss, 1986). Discrepancy in the reported levels of the protein in human fluids 
probably reflected the methods used, subjects studied and antiserum avidity. The disadvantage 
inherent in all the immunoassay systems was the measurement of immunoreactivity, as opposed 
to the biological activity of the compound. The sensitivity of our assay (80pg/ml) was 
comparable, and in most cases higher, than other reported methods. The reported assay 
sensitivities ranged from lOpg/ml (Cavagni et al, 1988) to 800pg/ml (Koritz et al, 1987). In the 
B-Lg assay, due to the necessity of serum sample dilution, the lowest level of B-Lg detected in 
sera samples was 320pg/ml after the appropriate dilution had been considered.
The choice of microtitre plate depended on personal preference. PVC plates were 
reported to possess a greater capacity for protein (De Savigny & Voller, 1980), although they 
were not reported to bind more than the irradiated polystyrene plates now available (Urbanek 
et al, 1985). It was observed that the irradiated polystyrene Immuno 2 microtitre plates generally 
possessed higher capacity for both specific and non-specific binding, which supported the finding
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of Urbanek et al (1985). No problems with high non-specific binding were encountered during 
assay development, so the use of a polypropylene microtitre plates was thought appropriate. The 
Immuno 2, compared to the Maxisorb microtitre plate, showed marginally better standard curve 
production.
The performance of an immunoassay was directly dependent on the quality of the labelled 
detector and capture antibodies. The most important requirement for a capture antibody was 
that once bound to the solid phase, it should have a high binding capacity for the relevant 
antigen (Voller et al, 1978). The use of whole rabbit serum resulted in low B-Lg binding. This 
was probably due to competitive binding, and the possible interference of the many other 
proteins present in serum (Kemeny & Chantler, 1988). Affinity purified antisera was infinitely 
better than ion exchanged antisera, although it was reported that such a purification could result 
in loss of the highest affinity antibodies (Kemeny & Chantler, 1988). As with any assay, 
optimisation of the capture antibody concentration was essential for a sensitive and reproducible 
assay. Low concentrations of the antigen could not be detected if the coating antibody 
concentration was too high or too low (Engvall & Perlmann, 1972). The mechanism of protein 
adsorption to plastic surfaces is not fully understood, but is known to be reversible. It therefore 
followed that excess capture antibody adsorption would increase protein loss and reduce assay 
sensitivity (Engvall et al, 1971). The optimum antibody concentration, 5/ig/ml, was determined 
by a checkerboard assay. Optimum incubation times were also determined. A 3 hour coating 
time was in agreement with Engvall et al (1971).
The standard curves produced by both TMB and OPD substrate were comparable, with 
only a slight curve flattening observed with the use of OPD. However TMB possessed a number 
of advantages compared with OPD, and was therefore used routinely in this assay. OPD was 
classed as both carcinogenic and mutinogenic and is therefore inadvisable to use unless 
possessing major assay improvement.
3.4.5 STANDARD PREPARATION
Ideally, the diluent which was selected for the reference preparation should closely 
resemble the sample matrix. Sera was therefore chosen for the diluent. However it was observed 
that some of the sera used expressed matrix variations, which gave rise to non-specific effects. 
These probably altered the antibody-antigen interaction resulting in artifacts. There was a 
number of possible reasons why the normal horse serum and normal donkey serum produced 
an elevated curve when used as a standard diluent. Two of the samples were haemolysed. This 
could have interfered with the antibody binding, and also the peroxidase released during
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haemolysis which would react with the substrate. TMB substrate was not specific for horseradish 
peroxidase, and could produce the coloured end point in the presence of any peroxidase 
enzyme, resulting in falsely high background levels. Fasted human serum was used to reduce 
the risk of circulating B-Lg. However it was still necessary to immunostrip the serum as antigen 
clearance from the blood could take a number of days (Marcon-Genty et al, 1989b). Due to 
the matrix effects of a number of the diluent sera used, parallelism of the standard and test 
samples was essential. Four samples were used to determine their parallelism with the standard, 
and as reported, these were satisfactory. Undiluted serum was observed to be inappropriate in 
this application as it gave a flattened curve. This could probably be attributed to serum protein 
interference.
The protein content of mature breast milk was 1.3g/100ml (Paul and Southgate, 1979). 
Human serum albumin was the closest available protein to that of breast milk, and was diluted 
to a similar protein concentration as in breast milk. This proved to be the most appropriate 
standard diluent. The commercial milk formula varied in the quantity of antigenically intact B- 
Lg they contained, and could therefore not be used as diluent for the standard.
3.4.6 ENZYME CONJUGATION
All attempts to conjugate horseradish peroxidase to B-Lg antigen resulted in an unusable 
label and so it was thought prudent to look at the feasibility of labelling an antibody. It had 
been reported that it was preferable, but not essential, that the two antibodies used in a 
sandwich ELISA should be from the same species, to reduce the possibility of species cross- 
interaction (Kemeny & Chantler, 1985). During assay development it was observed that the 
optimal assay system was attained with the use of the same bleed, from the same rabbit, for 
both the capture and detector antibody, supporting Kemeny and colleagues observations. The 
periodate method of enzyme conjugation produced a satisfactory label which retained similar 
activity for the period of use. This method has been reported as the most efficient by a number 
of other groups (Williams, 1984; Tijssen & Kurstak, 1984 and Beyzavi et al, 1987). Purification 
of the enzyme label showed that relatively large quantities of unconjugated antibody had been 
present which could have reduced the assay sensitivity.
3.4.7 VALIDATION OF B-Lg ELISA
Validation of an assay was essential to determine how robust the assay was under routine 
use. Recovery of exogenous B-Lg from a test sample was satisfactory. The assay possessed 
negligible cross-reactivity with all of the milk proteins tested. It could therefore be concluded
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that only B-Lg derived from dietary cow’s milk was being determined. However it would be 
naive to claim that only whole B-Lg was being detected as it was known that food proteins, 
both undigested and partially digested, are absorped across the gut wall of healthy and atopic 
individuals (Paganelli & Levinskey, 1980; Kilshaw & Cant, 1984 and Cavagni et al, 1988) and 
are therefore present in the blood. The immunogen used for antisera development was whole 
B-Lg, however the antibodies produced were polyclonal, therefore recognising more than one 
epitope. The concentration of B-Lg reported to be in the samples could therefore include both 
whole and partially digested B-Lg molecules, the quantity of which could only be determined 
by high performance liquid chromatography (HPLC) or other high resolution chromatography 
methodologies.
Another important consideration is the presence and influence of antibody bound B-Lg 
(immune complexes) within the test specimens. Within the sample an equilibrium between free 
and bound B-Lg would be present. When this sample was introduced into the assay system there 
would be competition between the endogenously bound B-Lg and the capture antibody, and the 
equilibrium would be disrupted. The B-Lg detected in the assay would be free B-Lg and not that 
involved with immune complexes contained within the sample. Therefore to appreciate the total 
B-Lg absorbed across the gut wall, there should also be consideration of the amount of B-Lg 
contained within the immune complexes. Quantitation of these antigens should be performed 
in addition to quantitation of free B-Lg. Alternatively a procedure to separate the bound B-Lg 
and then to establish the total free B-Lg would be of considerable value.
104
CHAPTER 4
OBSERVATIONAL STUDY TO INVESTIGATE THE TRANSFER OF COW’S MILK 
fi-Lg AND a-CAS SPECIFIC ANTIBODIES AND fi-Lg ANTIGEN FROM MOTHER TO
INFANT IN NON-ATOPIC SUBJECTS
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4.1 INTRODUCTION
4.1.1 FOOD SPECIFIC ANTIBODIES
Antibodies to dietary antigens have been detected in the sera from a considerable 
proportion of the normal population. Gunther et al (1960) reported more than 50% of adult 
blood donors had detectable serum antibodies to cow’s milk. Rothberg & Farr (1965) detected 
serum antibodies to bovine serum albumin in approximately 8-25% of adults. Foucard et al 
(1985) reported an incidence of 70% of adult blood donors who had serum antibodies to bovine 
gamma globulin, and in a limited number of sera samples from adults, a high incidence of 
antibodies to different antigens were reported (Husby et al, 1985c and Hampton et al, 1989).
The majority of normal (Gunther et al, 1960 and Kletter et al, 1971) and preterm 
(Rothberg, 1969; Muller et al, 1986 and Helms & Rieger, 1987) infants were reported to 
develop antibodies to cow’s milk after weaning during the first weeks/months of life, although 
the production of these specific antibodies in premature infants was reported to be lower 
compared with term infants (Helms & Rieger, 1987).
The presence of food specific antibodies implies the passage of antigenic food proteins 
across the gut wall. The factors that determine the quantity of transferred antigen is a matter 
of controversy. The relationship of this, with the quantity of food ingested, has been 
investigated in this study.
4.1.2 PLACENTA AND TRANSFER
The relationship between the mother and her developing fetus is a unique one. The 
placenta develops from the chorion and the endometrium, performing vital functions. Transport 
across the placental membrane includes diffusion of respiratory gases, and active transport of 
substances such as nutrients and excretory substances such as urea. The fetus is not rejected 
as a transplant would be, as the placenta also protects it from the mother’s immune system. The 
placenta allows the transfer of maternally derived immunoglobulins of the IgG class (Bell et al,
1980).
Studies have found that at delivery the quantity of IgG antibodies were significantly higher 
in the fetal derived cord blood, compared with the maternal blood (Kohler & Farr, 1966; 
Carlsson et al, 1976 and Iikura et al, 1989). A facilitated transport process was suggested as an 
explanation for the higher levels of the antibodies, which depended on the presence of a 
specific placental transmission site on the Fc fragment (Iikura et al, 1989). This antibody transfer 
has been reported to offer the relatively immature infant, immune protection until it develops 
the ability to synthesis its own antibodies at about 2-3 months postnatally (Roitt, 1989). The
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presence of milk specific IgG antibodies in cord blood have been found, and have also been 
reported to be in higher quantities, compared to maternal blood, in normal women (Lilja et al, 
1988 and Falth-Magnusson et al, 1988). The purpose of the transferred food antibodies is 
controversial, it has been suggested that they could perhaps lead to a state of tolerance to these 
foods in the newborn (Telemo et al, 1987).
The placenta protects the developing fetus by providing a physical barrier and by preventing 
the passage of potentially damaging agents. However there is evidence regarding the 
intraplacental transfer of dietary antigens. This transfer has been demonstrated in a number of 
animals, including rabbits (Gallagher et al, 1980 and Pathirana et al, 1981), rats (Dahl et al, 
1984) and guinea pigs (Telemo et al, 1987). The physiological benefit of this antigen transfer 
could be the induction of tolerance to the food proteins in the young animal. Pathirana et al 
(1981) reported that there was a tenfold increase in food specific antibody levels in soya-fed 
rabbits of milk-fed mothers (and vice versa), compared with little or no change in food specific 
antibody levels in young fed the same diet as their dams had received in pregnancy and 
lactation. This data indicates that contact with the antigen prior to birth and during suckling 
could be important in the induction of immune tolerance of the young. Human studies are less 
frequent, but there is a growing body of clinical evidence indicating that the mother and her 
offspring frequently share sensitivities to a variety of specific antigens. This evidence implicates 
the prenatal passage of antigens, cells or immunologic mediators to the fetus prior to birth 
(Cramer et al, 1974).
4.1.3 SECRETORY IgA ANTIBODIES
Breast milk contains a variety of soluble and cellular components such as lactoferrin, 
lysozymes and lactoperoxidase, in addition to maternally derived antibodies which provide 
passive immune protection against antigens of microorganisms and foods present within the 
gastrointestinal tract of the mother (Hanson & Windberg, 1972). Secretory IgA (slgA) is the 
predominant antibody in breast milk (with levels of 6g/l in colostrum to 0.6g/l in mature breast 
milk), although significant levels of IgG and IgM have also been detected (with mean colostral 
levels of 0.3g/l and 0.4g/l respectively, and 0.1g/I and 0.04g/l in mature milk respectively) (Jatsyk 
et al, 1985). It has been reported that the levels of slgA antibodies have been found to fall 
dramatically by day five postpartum (Cruz & Arevalo, 1985; Jatsyk et al, 1985 and Hennart et 
al, 1991) have shown no set pattern (Cruz & Arevalo, 1985), or have been reported to fall over 
the first five days and then show fluctuation (Machtinger & Moss, 1986).
The protective mechanism of slgA antibodies is believed to include binding to the mucosal
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surface of the infant, complexing with antigenic molecules and thus preventing their absorption. 
(Walker, 1987). slgA antibodies were found to be resistant to proteolytic degradation rendering 
them particularly suited to this function (Jatsyk et al, 1985). The presence of antigens, derived 
predominantly from the maternal gut, have also been demonstrated in breast milk samples 
(Kilshaw & Cant, 1984; Axelsson et al, 1986 and Machtinger & Moss, 1986). This has been 
reported in healthy and atopic mothers, suggesting that this is a natural process. Sensitisation 
of "at risk" infants has been implicated as a disadvantage of this antigen transfer (Jakobsson 
& Lindberg, 1978; Machtinger & Moss, 1986 and Cant et al, 1986), with oral tolerance offered 
as a possible advantage (Rothberg & Farr, 1965 and Andre et al, 1975).
Secretory IgA antibodies are also the predominant antibody within saliva (0.14g/l) with IgG 
and IgM present in much smaller quantities (0.02g/l and 0.004g/l respectively) (Gronbald- 
Saksela, 1986). A number of studies have investigated specific slgA antibodies in serum and 
saliva (Cernelc & Zalokar 1982 and Allansmith et al, 1983). No relationship has been found, 
suggesting that IgA production in these two pools is under separate regulatory systems. The age 
at which adult levels of antibodies are reached depends on the antibody class. slgA antibodies 
within the saliva have been detectable in infants soon after birth (Crisp et al, 1989), with 
increased levels in breast fed infants (Ostergaard, 1985 and Glesson et al, 1986). Adult levels 
of these antibodies are reached at approximately 12 months of age (Allansmith et al, 1968).
4.1.4 AIM OF THE STUDY
The aim of this study was to determine the transfer of milk specific (B-Lg and a-cas) 
antibodies and B-Lg antigens, from non-atopic, healthy mothers to their infants, via the placenta 
and breast milk. The subsequent immune development of the infants was monitored for a one 
month period, in addition, the relationship between the food ingested and the circulating B-Lg 
and a-cas specific antibodies and B-Lg was investigated. The use of saliva as a means of 
monitoring the immune status of an individual was investigated. This was an observational study, 
which acted as a protocol which provided preliminary results and a basis for the protocol of the 
long-term intervention study.
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4.2 M E T H O D S
4.2.1 SUBJECTS
Women who were attending the Midwives Clinic in St. Luke’s Hospital, Guildford, Surrey 
at 30 weeks gestation, were approached by the investigator, between April 1988 and April 
1989. The study protocol was explained to them, and suitable subjects were followed up at 
home. All women agreeing to participate in the study read and signed an informed consent 
form. Interested subjects were given an allergy and environmental questionnaire. Those with 
severe allergies were not included in the study. 24 women were recruited, 12 with no previous 
children, 9 with one child and 3 mothers with 2 children.
4.2.2 WEIGHED FOOD INVENTORY AND QUESTIONNAIRE
All of the subjects were asked to complete a 7 day weighed food inventory, which included 
a weekend, at 36-38 weeks gestation. Mothers were requested not to alter their diet during 
this period, to record the weight of the food when cooked, the method of cooking and the 
brand, when appropriate. This was used to calculate the daily nutrient intake and the estimated 
daily cow’s milk protein ingestion.
A questionnaire was also given to the mothers regarding famillial allergy incidence and 
anthropometric data. The womens pre-pregnancy weight and height were required, and from 
these measurements their body mass index (BMI) was calculated using the formula below:
BMI = Weight (kg)
Height (M)2
4.2.3 SAMPLES REQUIRED
A 10 ml blood sample was taken, by venepuncture, from each woman at approximately 36 
weeks gestation. This was spun at 1000 g for 10 min at 4°C, the serum was removed, 
aliquoted and stored at -20°C until required for analysis. At this time a 10 ml unstimulated 
saliva sample was also required, before the ingestion of food or drink, but after rinsing the 
mouth with water. At birth, a cord blood sample was collected by a midwife, (Labour Ward, 
St. Luke’s Hospital, Guildford, Surrey) from the placental end of the cord, and was treated in 
the same way as the maternal blood sample.
Breast milk samples were also collected by the mother, once a day for the first 10 days, and 
then once a week for the next 3 weeks postpartum. It was requested that the samples were 
collected at approximately the same time of day, into plain, sterile 10 ml tubes, and frozen.
Saliva samples were required from the infants once a week for the first 4 weeks. These 
were collected by the mothers, onto cotton buds, and frozen. The sample preparation is
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described in 2.2.6.4, Infant heel prick blood samples were taken at approximately one week 
postnatally, and collected into a microcentrifuge tube. After standing for one hour, the serum 
was separated by centrifugation in an Eppindof microcentrifuge for 5 minutes. It was then 
removed, aliquoted and frozen at -20°C until required for analysis.
4.2.4 BIOCHEMICAL ANALYSIS
Quantitation of total B-Lg IgG and a-cas IgG in maternal, cord and infant serum was 
determined as described in 2.2.3.1. Circulating B-Lg was also quantified in the maternal and cord 
serum samples as described in 3.2.5.I. B-Lg IgA and a-cas IgA levels were determined in the 
maternal and infant saliva samples, and in the mothers breast milk samples as described in
2.2.6.1 and 2.2.5.1 respectively.
4.2.5 STATISTICAL ANALYSIS
Paired Student’s t-tests, Random Fixed Model analysis of variance and Pearson’s correlations 
were performed where appropriate.
4.2.6 ETHICAL APPROVAL
The study received ethical approval from the West Surrey Authority on 7 June 1988.
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4 3  RESULTS
4.3.1 SUBJECTS
Table 4:1 shows the allergy incidence amongst the women, their partners, families and 
children. Only 2 mothers of the 24 recruited, reported mild eczema and 2 mothers had mild 
reactions to soap powders. The mean age of the subjects was 30±5 years (range 22-41 years) 
with a pre-pregnancy mean BMI of 21.0+3.9 (range 18.0-34.8). All of the mothers delivered 
between 40-44 weeks gestation, with no complications. 12 mothers had a parity of 1, 9 mothers 
had a parity of 2 and 3 mothers had a parity of 3 after delivery of their infant.
All mothers attempted to breast feed their babies, 3 mothers were unsuccessful and bottle 
fed their infants from birth. All used a commercial infant formula based on cow’s milk.
4.3.2 MATERNAL DIETARY INTAKE
Table 4:2 shows the daily nutrient intake of the mothers calculated from a 7 day weighed 
food inventory, at approximately 36-38 weeks gestation. The individual nutrient intakes varied 
considerably. All of the mean daily nutrient intakes were within the UK Recommended Daily 
Allowances (RDA) (DHSS Report No. 15, 1979), except the mean daily energy (9.5 ±2.1 MJ), 
vitamin D (2.3 ±1.4 gg) and calcium (1058 ±279 mg) intakes which were below the RDA. Milk 
was consumed by all of the mothers, with the mean quantity of protein derived from a cow’s 
milk source as 21±7g (range 7-36g).
4.3.3 INFANTS
15 male and 9 female infants were born. The mean birth weight was 3.5 ±0.5 kg (range 2.9-
4.6 kg). All but one of the infants were healthy. One infant was diagnosed as having leukaemia, 
and very regrettably died at 2 months of age.
4.3.4 BIOCHEMICAL ANALYSIS
4.3.4.1 Sera samples
Cow’s milk B-Lg IgG and a-cas IgG antibodies were detected in all of the maternal, cord 
and infant serum samples. Table 4:3 shows the mean levels of B-Lg IgG and a-cas IgG 
antibodies within the various sera samples. These levels are also shown graphically in Fig 4:1. 
A higher concentration of B-Lg IgG and a-cas IgG antibodies was found in the cord sera 
compared to the maternal sera, which was found to be significant for the B-Lg IgG antibody 
levels (p<0.05). The levels of B-Lg IgG found within the infant sera samples were higher, 
although not significantly, compared to matched cord sera samples. The a-cas IgG antibody
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levels in infant sera were found to be lower, although not significantly, compared to matched 
cord sera samples. The 6-Lg IgG and a-cas IgG antibody levels within the infant 1 week sera 
samples were, however, correlated with the cord sera samples (r=0.78, p=0.0001 and r=0.64, 
p<0.005 respectively).
A significant correlation was also found between the 6-Lg IgG and a-cas IgG levels in 
maternal, cord and infant sera samples (r=0.82, p<0.0001; r=0.78, p<0.0001 and r=0.6, 
p<0.0001 respectively).
Circulating antigenic 6-Lg protein was found in 58% of the maternal sera samples, and in 
only 17% of the cord sera samples. The levels of 6-Lg were significantly lower in the cord sera 
compared to the maternal sera (p<0.01) as shown in Fig 4:1. No correlation was found between 
the circulating fi-Lg IgG antibody levels and fi-Lg levels in any of the sera samples.
Fig 4:2 illustrates the levels of fi-Lg IgG and a-cas IgG in the maternal and cord sera. There 
was found to be a significantly higher concentration of fi-Lg IgG antibodies compared to a-cas 
IgG antibodies in the maternal sera samples (p<0.01), although the maternal and cord sera fi- 
Lg IgG and a-cas IgG levels were positively correlated (r=0.98, p<0.0001 and r=0.94, p<0.0001 
respectively).
No correlation was found between the cow’s milk protein intake, and the fi-Lg IgG and a- 
cas IgG antibody levels, or the circulating fi-Lg levels within the maternal serum samples.
4.2.4.2 Breast milk samples
The 6-Lg IgA and a-cas IgA antibody levels in the breast milk samples for a period of 4 
weeks postpartum are shown in Table 4:4. A significant decrease in the fi-Lg IgA and a-cas IgA 
antibody levels in the breast milk samples was observed over the time period (p< 0.001 and 
p <0.001 respectively), as shown in Fig 4:3, The concentrations of 6-Lg IgA and a-cas IgA 
antibodies were found to dramatically reduce over the first 5 days postpartum, from 
121.4±61.5%/ml and 84.7±70.8/ml respectively, to 23.5± 17.5/ml and 23.4±214.0/ml respectively, 
and then plateau reaching the lowest level at 4 weeks postpartum. A significant correlation was 
found between these two antibody levels (r=0.80, p <0.0001).
4.2.4.3 Saliva samples
Detectable levels of both 6-Lg IgA and a-cas IgA antibodies were reported in the majority 
of the saliva samples, the mean±SD and range of these antibodies in the maternal and infant 
saliva samples is shown in Table 4:5. The mean maternal levels of 6-Lg IgA antibodies were 
not significantly different from the infant levels. However the levels of a-cas IgA antibodies
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within the maternal saliva samples were found to be significantly higher than the maternal 
salivary B-Lg IgA levels (p<0.05). Fig 4:4 shows the relationship between the maternal and 
infant levels of B-Lg IgA and a-cas IgA antibodies. No correlation was found between the two 
IgA antibody levels in either the maternal or infant saliva samples, or between the salivary IgA 
antibody levels and the sera IgG antibody levels against either B-Lg or a-cas.
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Table 4:1
Allergy incidence in the mothers, their partners, families and children.
Allergy Eczema Asthma Rash Hayfever
Mother 4 2 - 2 -
" family 11 3 1 1 7
Partners 6 3 - 2 4
" family 9 - 5 2 4
Children 3 2 - 1 -
Table 4:2
Mean ± SD (range) daily nutrient intake for 24 normal healthy pregnant women calculated 
from a 7 day weighed food inventory.
Nutrient Mean SD Range
Energy (Mj) 9.50 2.10 5.98-12.80
Protein (g) 79 115 59-109
Fat (g) 100 25 56-153
P:S ratio 0.24 0.06 0.12-0.40
CHO (g) 275 80 127-579
Vit. D (jig) 2.3 1.4 0.7-5.8
Vit. C (mg) 96 52 18-210
Calcium (mg) 1058 279 600-1708
Milk Protein (g) 21 7 7-36
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Mean ± SD (range) of B-Lg IgG, a-cas IgG and B-Lg levels in the maternal, cord and 1 week 
infant sera samples.
Table 4:3
B-Lg IgG 
(Mg/ml)
a-cas IgG 
(Mg/ml)
B-Lg
(ng/ml)
Maternal sera 22.5±21.1*f 10.6±9.5f 1.1 ±1.7X
(4.4-170.2) (0.7-34.5) (UD-7.9)
Cord sera 31.5 ±36.1* 13.0±10.7 0.4±0.8X
(5.9-176.0) (0.7-32.7) (UD-3.2)
Infant sera 64.9 ±53.4 6.2±6.3 NA
[1 week] (33.1-229.4) (1.8-35.7)
B-Lg IgG and the a-cas IgG levels (p<0,01). 
and cord sera B-Lg IgG levels (p<0.05). 
and cord sera B-Lg antigen levels (p<0.01).
NA = Not analysed 
UD = Undetected
f Significant difference between the maternal 
* Significant difference between the maternal 
x Significant difference between the maternal
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Table 4:4
Mean ± SD (range) of B-Lg IgA and a-cas IgA antibody levels in maternal breast milk samples 
for 1 month post-partum.
B-Lg IgA a-cas IgA
(%/ml) (%/ml)
Day 1 121.4±61.5* 84.7±70.8X
(6.6-188.0) (20.0-200.0)
Day 2 59.0 ±50.8 38.8±9.1
(13.2-74.4) (21.8-50.0)
Day 3 54.1 ±55.1 41.9±31.4
(11.2-200) (11.0-190.0)
Day 4 36.7 ±36.8 23.8 ±14.0
(4.0-104.2) (3.6-133.2)
Day 5 23.5 ±17.5 23.4±14.0
(3.8-181.2) (5.8-75.0)
Day 6 17.4 ±9.1 13.5 ±10.2
(1.7-28.9) (3.6-30.3)
Day 7 20.0±15.5 13.6±9.8
(1.0-53.4) (1.2-41.3)
Day 8 22.4 ±22.4 15.4±12.0
(1.9-100.0) (2.7-83.9)
Day 9 22.4±19.3 12.8 ±8.9
(3.0-57.2) (4.4-68.2)
Day 10 12.0 ±7.8 11.5±7.1
(2.8-54.1) (4.2-30.6)
Day 14 10.6±8.9 10.9±8.2
(2.1-40.7 (3.3-12.8)
Day 21 8.6 ±7.5 10.4±11.9
(1.0-39.6) (2.4-48.3)
Day 28 6.5 ±3.1 8.6 ±9.2
(1.7-20.5) (0.7-45.1)
* Significant reduction of B-Lg IgA levels with time (p <0.001). 
x Significant reduction of a-cas IgA levels with time (p <0.001).
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Mean ± SD (range) of fi-Lg IgA and a-cas IgA antibody levels in maternal and infant saliva 
(week 1-4 postpartum)
Table 4:5
fi-Lg IgA 
(%/ml)
a-cas IgA 
(%/ml)
Maternal 10.7±21.5 * 52.3 ±44.4 *
(UD-100.0) (4.0-196.0)
Infant
Week 1 11.1 ±23.3 10.2 ±20.1
(UD-85.5) (UD-17.1)
Week 2 5.7 ±10.7 8.4 ±18.3
(UD-40.2) (UD-52.7)
Week 3 4.6 ±7.6 4.9±13.9
(UD-30.3) (UD-56.3)
Week 4 14.8 ±23.2 7.0 ±18.2
(UD-87.2) (UD-33.0)
UD = Undetected
* Significant difference between maternal fi-Lg IgA and a-cas IgA levels (p<0.05).
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Mean -  SE of B-Lg IgG, a-cas IgG antibody levels and B-Lg antigen levels in maternal, cord 
and infant sera (1 week) in 24 healthy non-atopic women.
Fig 4:1
Maternal 1. ...J Cord H H  Infant (1wk)
Mean -  SE 
• p<0.05 
x p<0.01
Fig 4:2
Mean -  SE of B-lg IgG and a-cas IgG in maternal and cord sera samples in 24 healthy non- 
atopic women.
IgG antibody (pg/ml)
RWWNi B-Lg IgG L_J»ca# IgG
M e in  -  SE
•  p‘0.01
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Mean B-Lg IgA and a-cas IgA antibody levels in breast milk samples for a month postpartum 
in 21 healthy non-atopic lactating women.
IgA antibody (%/ml)
Fig 4:3
Time post-partum (Days)
B-Lg IgA “+<A-ca8 IgA
Significant reduction In 0-Lg & -caa  
IgA antibody level* (p<0,001)
* *© ■fit t
Mean B-Lg IgA and a-cas IgA antibody levels in maternal (36 weeks gestation) and infant (1- 
4 weeks postpartum) saliva samples.
IgA antibody (%/ml)
Saliva
B-Lg IgA ~*A-cae IgA
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4.4 DISCUSSION
Ail of the women were healthy and had normal pregnancies. The mean pre-pregnancy BMI 
ratios were within the normal range, although 2 women were classed as underweight and 1 
overweight. The pre-pregnancy BMI did not seem to have any effect on the birth weight of 
their infants.
4.4.1 NUTRIENT INTAKE
The mean energy intake was below the recommended daily amount reported by the DHSS 
(1979), 10 MJ, and marginally below the USA NRC/NAS (1989) recommended daily amount,
9.6 MJ. However several studies have indicated that women can have normal pregnancies and 
breast feed their children adequately even though their energy and nutrient intake is far below 
recommended standards (Morgan, 1988). Durnin et al (1985) reported that the energy intake 
of women does not increase greatly during pregnancy, and that the additional energy 
requirements were satisfied by changes in activity, or by enhanced efficiency of metabolism. 
Therefore, the lower energy intakes, would not seem to be detrimental to the health of the 
mother or her infant. The calculated Vitamin D and calcium intakes were also lower than the 
recommended levels, but may not be significant in the light of the finding of Durnin et al 
(1985). Vitamin D is synthesised by the action of sunlight on the skin. 7-dehydocholesterol (pro­
vitamin D3) is photolyzed by ultraviolet light to pre-Vitamin D3, which spontaneously 
isomerizes to Vitamin D3. This is converted to active hormone by hydroxylation reactions 
occurring in the liver and kidney (Stryer, 1981). In the summer season this endogenous synthesis 
accounts for a significant amount of the required Vitamin D.
Although the 7 day weighed food inventory is the most accurate method of nutrient 
assessment, it does have drawbacks. These include: dietary change, failure to record snack foods 
eaten or "left overs" (Passmore and Eastwood, 1986). The women on this study were in the last 
trimester of pregnancy, a period during which dietary intake can be erratic and unrepresentative. 
This could explain the unexpectedly low nutrient and energy intakes reported by some of the 
subjects.
No significant relationship was found between the ingested milk protein level and the 
circulating B-Lg IgG or a-cas IgG antibodies or the B-Lg levels in maternal serum. The lack of 
correlation between the quantity of ingested food and antibody levels, was also reported by 
Gallagher et a l (1983), who, in healthy adults found equal levels of IgG, IgA and IgM classes 
to soya bean and cow’s milk protein in healthy volunteers consuming variable amounts of the 
food protein. Although the amount of ingested food protein is not directly related to the
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circulating food antibody levels, it has been reported that the food specific antibody levels can 
be manipulated by the quantity of food protein consumed (Falth-Magnusson et al, 1987a and 
Lilja et al, 1988).
4.4.2 IgG ANTIBODIES IN ADULT AND INFANT FLUIDS
This study revealed that the maternal sera levels of B-Lg IgG antibodies were significantly 
higher than the a-cas IgG levels. The reason for this is uncertain. It could reflect the higher 
antigenicity of B-Lg compared with a-cas, which has been supported by the observation of 
Strobel (1988) who found a significantly higher proportion of cow’s milk sensitive patients 
reacting to B-Lg compared to the other milk antigens. Husby et al (1985d) reported a higher 
proportion of healthy subjects with B-Lg compared with a-cas antibodies. In addition to this, 
higher concentrations of B-Lg IgG compared to a-cas IgG antibodies were observed by Helm 
and Rieger (1987) in 4 week old infants and by Kletter et al, 1971. The evidence is, however, 
controversial with a number of other studies reporting higher incidences of a-cas compared to 
B-Lg antibodies. Barnes et al (1988a & 1988b) reported that in healthy subjects, significant 
inhibition of antibody binding to bovine milk was obtained only with a-cas. Higher levels of a- 
cas IgG antibodies were also observed in healthy subjects (Burgin-Wolff et al, 1980; Muller et 
al, 1985 and Burks et al, 1990). It is known that each individual reacts differently, and inter­
individual variation is very large. The inconsistencies within the literature could in part be 
explained by individual immune responses within the different groups used. However, it must 
be emphasised that many of the assays used for milk specific IgG determination in sera, were 
semi-quantitative, rendering the comparison between individual food specific antibody levels 
inappropriate. Cord and infant sera concentrations of these specific antibodies also mirrored 
the antibody levels in the maternal sera.
The study revealed that there was always a distinct correlation between the levels of B-Lg 
and a-cas specific IgG antibodies in sera samples. The considerable quantitative variation 
between individuals reflected the range of levels which could be expected from any group. The 
significance of these quantitative variations between subjects cannot be defined. It would be of 
interest to investigate these individual differences with reference to allergic responses.
The levels of B-Lg IgG and a-cas IgG antibodies in cord sera were found to be higher than 
the maternal sera concentrations, although this was only found to be significant for B-Lg 
antibody concentration. On further examination of the results it was found that the individual 
variation of a-cas IgG antibody levels in the cord sera samples was very large, which probably 
negated a statistically significant difference in levels between the cord and maternal sera
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samples. Higher IgG antibody levels in cord sera, compared to maternal sera has also been 
shown by Carlsson et al (1976), who was looking at antibodies against E. coli O antigens, and 
Kohler & Farr (1966) and Lilja et al (1988) who were interested in food antibodies, including 
OV, ovomucoid and fi-Lg. Although the premature infant was found to be capable of producing 
specific IgG antibodies to ingested bovine serum albumin at an age corresponding to 36 weeks 
gestation (Rieger & Rothberg, 1975), it was reported that stimulation of cord blood B 
lymphocytes resulted in a significant increase in IgM but not in IgA or IgG (Andersson et a l, 
1981). It therefore seems reasonable to conclude that the IgG antibodies in the cord sera and 
newborn sera were derived from the maternal circulation (Lilja et al, 1988). These observations 
suggest a mechanism of positive antibody transfer of both bacterial and food antibodies from 
the maternal circulation to the fetus, the purpose of which is to protect the newborn in the first 
few months of life, until its own immune apparatus matures.
The levels of IgG antibodies within the infant sera samples taken at 1 week postnatally, 
were expected to be similar to the levels of those antibodies in the cord sera samples, as both 
are derived from the fetus circulation (Andersson et al, 1988). The quantity of fi-Lg IgG 
antibodies within the infant sera was found to be approximately 100% higher than that observed 
in the cord sera, whereas the a-cas IgG antibody levels were approximately 50% of the cord 
sera values. Re-examination of the individual levels revealed that four infants, three of whom 
received cow’s milk formula, had elevated levels of fi-Lg IgG antibodies within their 1 week sera 
samples. This resulted in an elevated mean value. Whether the enhanced B-Lg IgG antibody 
levels were due to synthesis by the infant is uncertain, and the explanation for the discrepant 
values is not clear.
4.4.3 fi-Lg ANTIGEN IN MATERNAL AND CORD SERA
The concentration of antigenieally intact 6-Lg in the maternal serum was not found to 
correlate with the circulating fi-Lg IgG antibody levels. This lack of correlation was not 
unexpected, as the sera samples were taken at random times during the day, with no 
consideration of the milk ingestion. The presence of circulating cow’s milk 6-Lg antigens within 
the maternal serum, supported the theory of a transfer of dietary antigens across the gut wall 
of healthy individuals (Walker & Isselbacher, 1977). Circulating dietary antigens within sera 
samples have been reported in a large proportion of individuals tested (Paganelli & Levinsky, 
1980 and Husby et al, 1985b, 1986a & 1990), suggesting that the transport of these proteins 
is a natural occurrence, the purpose of which is uncertain.
There was found to be antigenieally intact 6-Lg proteins in a small proportion of the cord
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sera samples. As the cord sera is ultimately derived from the mother, the presence of B-Lg was 
only observed if similar proteins were present in the maternal circulation. There were some cord 
sera samples, however, which did not contain these proteins, although they had been shown to 
be present in the mother.
The passage of food antigens across the placenta has been studied in animal models, and 
occurs across intact placental membranes (Hemmings & Hemmings, 1979 and Dahl et al, 1984). 
The presence of B-Lg antigens within the cord sera in some of the subjects in this study raises 
the question of the effect of this on the immunologically immature fetus. Studies on animal 
models have implicated the possible benefit of transferred antigens, on the development of 
immune tolerance in the neonate to the specific antigens transferred (Gallagher et al, 1980 and 
Pathirana et al, 1981). An immune hyporesponsiveness to a particular antigen, was observed in 
rabbits whose mothers received the food antigen during pregnancy and lactation. The transfer 
of the antigen, either via the placenta or the maternal colostrum, could well induce this state 
of low-zone tolerance (Pathirana et al, 1981). It has been stated, however, that this tolerance 
may not be produced by the food antigens themselves, but by antigen-specific lymphokine 
produced by suppressor cells in the gut associated lymphoid tissue, GALT (Pathirana et al,
1981), or by the suppressive effect of placentally or colostrum transferred immunoglobulins on 
the antibody production in the young rabbit (Gallagher et al, 1982). How these results can be 
extrapolated to man is not clear.
The question of intra-uterine sensitisation to placentally transferred food proteins has also 
been proposed (Matsumura et al, 1975), with evidence of immediate reactions to food antigens 
on first exposure supporting this hypothesis (Lifschitz et al, 1988). Determination of IgE 
antibodies in cord sera has also provided indirect evidence for intra-uterine sensitisation (Michel 
et al, 1980), as IgE is unable to cross the placenta, and is therefore of fetal origin. Despite 
these findings intra-uterine sensitisation occurs in only a small percentage of infants (Michel et 
al, 1980 and Lifschitz et al, 1988) who may be predisposed to hypersensitive reactions 
genetically. The influence these placentally transferred antigens have on the fetal immune 
response requires further investigation to determine the reason why some infants react 
detrimentally to these antigens, whilst others do not.
4.4.4 IgA ANTIBODIES IN MATERNAL BREAST MILK
IgA antibodies against B-Lg and a-cas were significantly higher in colostrum compared with 
mature breast milk. This was also reported by Machtinger & Moss (1986) who were interested 
in anti-cow’s milk IgA antibodies in breast milk. The levels of the two milk IgA antibodies were
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found to correlate, following similar profiles within the breast milk samples. Other groups have 
reported similar patterns of total breast milk slgA antibodies over a comparable time period, 
with initially high colostral antibody concentrations which dramatically fell at 5-8 days 
postpartum, and then plateaued, with slight fluctuations in their concentrations, over the first 
month (Cruz & Arevalo, 1985; Jatsyk et al, 1985; Machtinger & Moss, 1986 and Hennart et a l, 
1991). This dramatic decline in antibody concentrations during the first week of lactation 
appears to be compensated for by increases in milk volume (Carlsson et al, 1976). The observed 
antibody reduction is therefore a dilution effect (Cruz & Arevalo, 1985), with the infant 
receiving a relatively constant concentration of slgA antibodies for the first month of lactation 
(Hannart et al, 1991), as the volume of breast milk ingestion increases.
slgA antibodies have been found against a large repertoire of bacterial, viral and food 
antigens (Ladjeva et al, 1989). Although the results from this study, and that of Machtinger & 
Moss (1989), showed that milk specific IgA antibodies followed a similar concentration profile 
as total IgA antibodies, Cruz & Arevalo (1985) demonstrated large fluctuations of bacterial 
specific slgA antibodies in human milk, as lactation progressed. He suggested the irregular 
fluctuations in antibody levels reflected the antigenic exposure at the intestinal level, which in 
the case of bacterial derived antigens, could be very erratic, as reported in women in areas of 
poor sanitation (Cruz & Arevalo, 1985).
The quantity and specificity of slgA antibodies in the breast milk is believed to be indicative 
of the close relationship between lymphoid tissue of the mammary gland and that of the GALT 
(Hanson et al, 1977), with the antibodies in breast milk reflecting the current and earlier 
immunological experience of the mother, and subsequently that of the immature infant 
(Carlsson et al, 1976).
Breast milk slgA is believed to prevent the mucosal penetration and systemic absorption of 
foreign antigens by the immature infant (Walker, 1987). slgA breast milk antibodies have not 
been confirmed to function at the mucosal surface, but studies in rats have located IgA and 
secretory component on the luminal surface of the villi in the proximal third of the small 
intestine (Nagura et al, 1978). In some animals, increased immunoglobulin absorption has been 
reported in early infancy (Cunningham-Rundles, 1987). Immunoglobulin transfer across the 
intestinal epithelium in humans, however, is not believed to be a significant process, although 
Ogra et al, 1979 have shown a possible absorption of IgA antibodies to polio virus across the 
gut mucosa in very young infants, which may suggest a possible route for breast milk IgA 
antibodies.
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4.4.5 IgA ANTIBODIES IN MATERNAL AND INFANT SALIVA SAMPLES
B-Lg IgA and a-cas IgA antibodies were detected in all of the maternal saliva samples, in 
58% of the infant samples at 1 week and in 88% of the infants at 4 weeks. No correlation was 
found between the B-Lg IgA and a-cas IgA levels in either the infant saliva samples or maternal 
saliva samples. This is in contrast to the B-Lg and a-cas specific IgG and IgA antibody levels 
in sera and breast milk samples, respectively. This lack of correlation could reflect the distinct 
regulatory mechanisms of the different antibody systems (Gmoshinsky et al, 1990). The presence 
of slgA antibodies within the saliva of newborn infants has been detected by a number of 
groups (Mellander et al, 1984; Frick & Rieger, 1987; Cripps et al, 1989; Archibald et al, 1990 
and Renz et al, 1991a & 1991b). Adult levels of salivary slgA are not reached until 
approximately 6 years of age, but evidence suggests that early production is common. The 
stimulus of the reported salivary slgA antibodies in neonatal saliva is unclear. One possible 
mechanism could be contamination of the amniotic fluid by foreign antigens which may pass 
across the placenta from the maternal circulation (Renz et al, 1991a). It has also been suggested 
that factors present within breast milk ma\ provide rapid and effective secretory immunity 
actively, as well as passively (Roberts & Freed, 1977), with possible stimulation by maternal anti- 
idiotypic antibodies (Archibald et al, 1990).
The question of contamination of the neonatal saliva samples with antibodies derived from 
maternal breast milk should be addressed, but the probability is that this is unlikely (Archibald 
et al, 1990; Renz et al, 1991a & 1991b). Detectable levels of 6-Lg slgA and a-cas slgA 
antibodies were found in saliva samples collected from newborn infants before the initiation of 
feeding (Archibald et al, 1990 and Renz et al, 1991). It has also been observed that neonatal 
breast milk contained fi-Lg specific IgA antibodies in the second week of life (Roberton et al, 
1986). These observations illustrate that neonates are capable of synthesising specific secretory 
antibodies at birth, suggesting that the observed salivary antibody levels were probably not due 
to breast milk contamination.
Our study confirms the ability of the neonate to elicit an immune reaction against foreign 
antigens at birth, although the significance of this early slgA synthesis is not known. Rapid 
immunological maturation of the mucosal IgA may be important during the neonatal period 
since IgA is the prime immunoglobulin of the mucosal surfaces, crucial in the defence against 
infection and sensitisation (Gmoshinsky et al, 1990). Salivary antibodies are believed to reflect 
the antigenic exposure of the intestinal tract, with selective homing of antigen committed cells 
to neonatal salivary glands (Hanson et al, 1975 and Walker, 1987). These salivary antibodies 
may be a useful way to monitor mucosal antigenic exposure and immune response in these
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neonates.
It was found that there was no relationship between the systemic IgG immune response and 
the salivary IgA response in either the infant or adult saliva samples. This is not totally 
unexpected and it has been suggested that these two systems are controlled independently 
(Walker, 1987). Although it was obvious that salivary IgA antibody levels would not offer any 
information on the systemic immune status, as previously suggested, it may be revealed with 
further research, that salivary IgA antibodies could be used to monitor the humoral secretory 
status of the infant with the minimum of inconvenience to the infant or investigator.
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CHAPTER 5
AN INTERVENTION STUDY TO INVESTIGATE THE EFFECT OF A MATERNAL 
MILK-FREE DIET DURING LATE PREGNANCY AND LACTATION AND PARENTAL 
ATOPY ON THE IMMUNE DEVELOPMENT AND THE ALLERGY INCIDENCE IN 
THE NEONATES: A PROSPECTIVE STUDY
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5.1 INTRODUCTION
5.1.1 BREAST FEEDING AND ALLERGY DEVELOPMENT
As previously discussed in section 1.6.5 the evidence for and against breast feeding, in the 
prevention of food allergy in infants, is controversial. The majority of studies have confounding 
variables and major weaknesses (Zeiger, 1987), and for these reasons, it is unrealistic to 
compare them. However, despite the inconsistent results, the body of evidence did suggest that 
prolonged breast feeding compared to formula feeding, afforded a degree of protection to the 
infant against allergy development (Zeiger, 1987 and Kramer, 1988). Exclusive breast feeding 
was found to give a higher degree of protection (Aberg et al, 1989). However, even prolonged, 
exclusive breast feeding did not eliminate infant allergy development entirely. This was suggested 
as being due to the food antigens within breast milk (Kilshaw & Cant, 1984; Stuart et al, 1984; 
Axelsson et al, 1986; Machtinger & Moss, 1986 and Troncone et al, 1987), which were found 
to sensitise "at risk" infants and lead to subsequent allergy development (Van Aspem et al, 
1983 and Lifschitz et al, 1988).
5.1.2 FOOD ANTIGENS AND BREAST MILK
Studies in rats have shown that the transfer of food antigens, which included cow’s milk 
protein, appeared in the milk of a lactating rat 6 hours after ingestion (Telemo et al, 1986). 
This time period was also reported for the appearance of orally administered food antigens in 
human breast milk (Kilshaw & Cant, 1984), although a 12 hour period was reported by Stuart 
et a l (1984).
The transfer of such food antigens into breast milk seems to be a physiological, rather than 
a pathological occurrence, as cow’s milk antigens have been reported in a significant quantity 
of normal maternal breast milk samples (Machtinger & Moss, 1986). Not all infants who 
ingested milk containing food antigens, showed adverse reactions to them. Cavagni et al (1988), 
reported reaginic reactions to cow’s milk in seven out of thirteen babies whose mother’s breast 
milk contained detectable B-Lg. However some infants, perhaps with a genetic predisposition 
to allergy development, react adversely to their presence within milk. For this reason it would 
seem advantageous to eliminate the potentially harmful antigens from the maternal diet, 
preventing their transfer to the mother’s breast milk.
5.1.3 MATERNAL DIETARY ELIMINATION STUDIES
The elimination of the offending food from the mother’s diet has been recognised as an 
important way of alleviating allergy symptoms in breast fed infants. As far back as 1918, Talbot
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reported that the removal of chocolate from a mother’s diet eliminated her infant’s eczema. 
Many other studies have reported the benefit of removing foods, especially milk and eggs, from 
maternal diets during breast feeding, as a means of reducing their infants’ eczema (Jakobsson 
& Lindberg, 1978 and Cant et al, 1986).
More recently intervention studies have been used as a prophylactic technique, to prevent 
allergy development in infants. The benefit of a maternal exclusion diet during pregnancy, 
lactation or both, has been investigated for a number of years. Studies performed by Chandra 
et al (1986) and Zeiger et al (1989) reported that avoidance of common dietary allergens 
during pregnancy and lactation, enhanced the benefit of exclusive breast feeding on the 
incidence of atopic eczema in "high risk" infants. Two other groups, Falth-Magnusson et al 
(1987a, 1987b & 1988) and Lilja et al (1988 & 1989), looked at the benefit of maternal dietary 
exclusion of milk and eggs during the last trimester of pregnancy. Both of the groups 
independently reported that the incidence of infant allergy development, and antibody levels, 
were unaffected by the mothers’ diet, although maternal antibody levels were reported to be 
affected by the levels of ingested proteins.
The results of these studies suggested that dietary intervention during lactation should be 
of more benefit than during pregnancy. This hypothesis was supported by the results from 
studies by Chandra et al (1989) and Hattevig et al (1989 & 1990). Both groups concluded that 
maternal dietary intervention during the period of breast feeding, in addition to the use of 
hypoallergenic milks, afforded a significant reduction in the incidence of atopic eczema in "at 
risk" infants. Lower milk specific antibody levels were also found in the intervention group at 
6 months (Hattevig et al, 1990).
From these studies it has been concluded that infants from parents with a history of allergic 
disease, or infants with a sibling with food allergy, could benefit from a maternal elimination 
diet during lactation, although it has been suggested that this reduction in allergy incidence 
could be a postponement, rather than a prevention (Aberg et al, 1989).
5.1.4 HYPOALLERGENIC MILK FORMULAE
The definition of a hypoallergenic formula is one that does not contain large molecules able 
to elicit an immune response after ingestion. These formulae can be produced from a variety 
of foods, although cow’s milk is the most popular source. Reduction in protein size and 
immunogenicity occurs by hydrolysis and heat treatment (Anderson et al, 1979 and Heppell et 
al, 1984). Such formulae have been implicated in allergy prevention (Powell, 1985; Chandra et 
al, 1989 and Zeiger et al, 1989), in addition to being used to alleviate a number of other infant
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disease states (Taylor et al, 1988).
Their routine use as a prophylactic milk is marred by their poor palatability and relative 
expense. However, with advancing technology and increased awareness of their potential benefit, 
studies have been performed to determine their true benefit.
5.1.5 AIM OF THE STUDY
The aim of this study was to determine the effect of a maternal milk free diet during late 
pregnancy and lactation, on the allergy development and immune response of "at risk" infants 
compared to normal, and "at risk" infants whose mothers were following an unrestricted diet. 
The suitability of a hypoallergenic formula (Peptijunior) to use as a milk alternative for the 
mother and infants was considered. The transfer of cow’s milk 6-Lg and a-cas specific antibodies 
and B-Lg from mother to infant was determined, in addition to the immune response of the 
mother during compliance to a milk free diet.
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5.2 METHODS
5.2.1 SUBJECTS
Women were approached by the investigator at a Midwives Clinic at St. Luke’s Hospital, 
Guildford, Surrey, at 30 week gestation, between May 1988 and November 1989. The study 
protocol was explained to all women, and those who showed an interest were subsequently 
followed up at home. All women agreeing to participate in the study, read and signed an 
informed consent form. Each woman was given an allergy and environmental questionnaire. 
Women who had an allergy themselves, or whose partner had an allergy were defined as atopic. 
These mothers were randomly allocated into either a diet or unrestricted diet group. The non- 
atopic group also followed an unrestricted diet. 12 atopic women followed an elimination diet, 
12 non-atopic and 14 atopic women followed an unrestricted diet.
5.2.2 INTERVENTIONS 
Prophylactic Group Diet
From approximately 36 weeks gestation and during breast feeding, the women in the 
prophylaxic-treated group were instructed to avoid totally, all milk and dairy products. As a 
milk alternative, a hypoallergenic, complete infant formula, "Peptijunior" (Cow & Gate. 
Trowbridge, Wiltshire), was given to the mothers to consume as required. If breast feeding was 
supplemented or stopped, this whey hydrolysate was offered to the infants. In addition to this, 
1000 mg of a calcium supplement was given daily to each woman in the form of "Calcichew" 
(Shire Pharmaceuticals), a supplement derived from calcium carbonate.
The women who were following the diet were initially given information regarding the 
dietary changes required, food lists, recipes and product sources. During the period of dietary 
compliance, the subjects were frequently contacted by the investigator to ensure that they were 
coping with the restriction and receiving adequate nutrients.
On admittance to hospital, the nurses were informed about the maternal dietary restriction, 
and the necessity not to give the babies "top up" bottle feeds.
Control Group Diet
Pregnant and lactating control-group women were encouraged to follow standard diets for 
pregnancy and lactation. All diets included at least 500 ml of cow’s milk daily.
Infant Feeding
All mothers were encouraged to practise breast feeding alone for as long as possible and
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preferably for 6 months. Solid feeding was discouraged until 3 months and started with baby 
rice and vegetables. In all groups, consumption of cow’s milk was discouraged until at least 6 
months or longer. Other weaning practices were performed at the mother’s discretion.
5.2.3 WEIGHED FOOD INVENTORIES
All of the subjects were asked to complete seven consecutive days weighed food inventory 
at 36-38 weeks gestation. Soehnle scales (CMS Weighing Equipment. London), capable of 
weighing up to 1kg to an accuracy of lg, were used. Each subject was instructed on how to 
use the scales. Cooked weights were taken, and details such as brand name and method of 
cooking were added as appropriate. From these records the quantity of nutrients consumed 
daily, and the estimated cow’s milk protein ingested was calculated using COMPEAT computer 
program (Lifeline Ltd, London) and related to the specific antibody and antigen levels within 
the samples.
5.2.4 SAMPLES REQUIRED
A 10 ml venous blood sample was taken from the mothers following the prophylaxis diet 
and those on the control diet, at 34 weeks and 36-38 weeks gestation respectively. Venous 
blood samples were taken from the atopic diet group at 1 week, 3, 6 and 12 months postpartum 
or until they ended their dietary compliance. An unstimulated saliva sample was also required 
from each subject at approximately the same time as blood sampling. The mothers were also 
requested to express a 10 ml breast milk sample daily for the first 10 days postpartum, and 
weekly for the next 3 weeks. They were instructed to take the sample into a plain tube, at 
approximately the same time of day. The sample preparation is described in section 2.2.5.4.
Heel prick blood samples were taken from the infants by using an autolet (Owen Mumford 
Ltd. Medical Division, Brookhill, Oxon.) at 1 week 3, 6 and 12 months postpartum. The blood 
was collected into a 200/xl Eppindorf microcentrifuge tube, and spun in an Eppindorf 
microcentrifuge for 5 min, the serum was then aliquoted and stored at -20°C until required for 
analysis. Infant saliva samples were also collected by the mother once a week for the first 
month, once a month for the next 5 months and then at 12 and 18 months. The collection and 
preparation of these samples is described in section 2.2.6.4.
5.2.5 BIOCHEMICAL ANALYSIS
Quantitation of total B-Lg IgG and a-cas IgG in maternal, cord and infant serum samples 
was determined as described in section 2.2.3.1. Circulating B-Lg was also quantified in the
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maternal and cord serum samples and maternal breast milk samples, as described in section 
3.2.5.I. B-Lg IgA and a-cas IgA levels were determined in the maternal and infant saliva 
samples, and in the mothers breast milk samples as described in section 2.2.5.1.
5.2.6 STUDY DESIGN
Assignment o f  Patients
The pregnant women selected for the study were designated as atopic or non-atopic, 
identified by the questionnaire as described in 5.2.1. The atopic group were randomly allocated 
into the prophylaxis diet group or the control diet group. Before changing their diet, all women 
assigned to the prophylaxis group ingested "normal" amounts of cow’s milk and dairy products.
Maternal Compliance
In order to evaluate the compliance with the dietary regimen, the women were asked to 
complete a 7 day weighed food inventory as previously described. This was used to quantify any 
milk protein which may have been inadvertently consumed. The women following the restricted 
diet were asked to record any times of dietary non-compliance. These occasions were considered 
when assessing the biochemical analysis of the samples.
Physical Examination
All children were examined at 6, 12  and 18  months of age. A paediatrician performed a "blind" 
physical examination, unaware to which group the infants’ mothers were assigned. The allergy 
incidence was scored on a scale of 1-3 with the least severe as 1. The allergy incidence at 6, 
12  and 18  months for the infants born to the mothers in the three groups was recorded, in 
addition to the mean severity score.
5.2.7 STATISTICAL ANALYSIS
A random fixed model analysis of variance, paired and unpaired Student’s t-test, Chi 
Squared test and Pearson’s correlation were performed where appropriate.
5.2.8 ETHICAL APPROVAL
The study received ethical approval from the West Surrey Authority 7 June 1988.
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5.3 RESULTS
5.3.1 SUBJECTS
The numbers of women in the atopic, non-atopic and atopic diet groups were 14, 12 and 
12 respectively. All women were healthy and had uncomplicated pregnancies. Table 5:1 shows 
the data from the questionnaire for the women in the three groups. The mean age for the 
women was 31 ±6 years with the three groups having the same mean age. The mean pre- 
pregnancy BMI of the groups were comparable, 4 women were classed as underweight (2 in the 
atopic group and 1 in the non-atopic and atopic diet group) and 2 women were classed as 
overweight (1 in the atopic and non-atopic group).
Three women had a parity of 0, 8 a parity of 1 and 3 a parity of 2 in the atopic group, 7 
women had a parity of 0, 3 a parity of 1 and 2 a parity of 2 in the non-atopic group, 4 women 
had a parity of 0, 5 a parity of 1 and 3 a parity of 2 in the atopic intervention group. The 
parity of the women within the three groups was comparable as shown in Table 5:1.
The allergies suffered by the atopic women in the unrestricted diet group and intervention 
group were similar, with a mean period of suffering reported as 15 ±7 years and 19±9 years 
respectively, as shown in table 5:1. Within the intervention group two of the women did not 
report suffering from any known allergies, but both had partners and previous children with 
allergies. The allergy incidence in the family of the atopic, non-atopic and atopic diet group 
were 11, 8 and 11 respectively. The allergy incidence of the women’s children, partners and the 
partner’s family were comparable in the two atopic groups but lower in the non-atopic group 
as shown in table 5:2.
5.3.2 MATERNAL DIETARY INTAKE
Table 5:3 shows the mean nutrient intakes of the three groups of women. The mean 
nutrient intakes were within the UK recommended daily allowances (RDA) (DHSS, 1979), 
although the mean energy intake of the non-atopic and atopic diet group 9.7 ±2.2 MJ and 
8.9 ±3.2 MJ respectively, were 97% and 89% of the RDA. The quoted calcium values were 
derived from the foods eaten and excluded that derived from the calcium supplements taken 
daily by the intervention group. The calcium intake was found to be significantly correlated 
(r=0.97, p <0.0001) with the milk protein intake.
The nutrient intakes of the three groups were not significantly different, except for the 
calculated P:S ratio. The value for the atopic, non-atopic and atopic diet group were 0.2 ±0.1, 
0.2 ±0.1 and 0.5 ±0.2 respectively. The atopic diet group had a significantly higher (p<0.01) 
mean P:S ratio compared to the other two groups.
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The mean period of dietary compliance i.e. milk restriction, during late pregnancy was 
39±12 days (range 17-60 days), during lactation was 125 ±120 days (range 31-365 days), with 
a total mean dietary compliance of 174±149 days (range 70-431 days). Women recorded any 
incidence of dietary non-compliance, which more often than not occurred during their hospital 
stay. Usually cow’s milk protein ingestion was in the form of cakes, pies, biscuits and margarine. 
Only one woman admitted the ingestion of whole cow’s milk on an occasion during her stay in 
hospital.
5.3.3 INFANTS
All of the infants were born within 40-44 weeks gestation. All of the births were singletons 
except for one set of non-identical twins bom to a non-atopic mother. All the babies were 
healthy, with only two babies, bom to atopic women on the intervention diet, requiring a short 
stay, for a period of 2 and 4 days, in the special care unit.
There was no significant difference between the mean birth weights of the infants within 
the three groups, although the atopic infants had a higher mean birth weight compared to the 
non-atopic infants as shown in table 5:4. The male:female ratios within the atopic, non-atopic 
and atopic diet groups were 10:4, 6:7 and 4:8 respectively.
Allergy assessment was completed, blind, by the same paediatrician at 6, 12 and 18 months 
postpartum. The allergy incidence and the mean severity scores are shown in Table 5:4. A Chi 
Squared test was performed on the data cross tabulating the maternal groups with the allergy 
incidence. The Chi Squared value was 16.85, degrees of freedom 2, and a significant difference 
of p<0.0005 was found between the allergy incidence in the infants bom to the mothers in the 
atopic group who followed an unrestricted diet compared with the mothers assigned to the non- 
atopic group. However the time variable did not have a significant effect on the allergy 
incidence in the three groups. It was reported that the 2 infants who went to the special care 
unit were both given a cow’s milk formula on at least one occasion. Another infant in the 
atopic diet group also received cow’s milk formula on day 7 and 8 postpartum. Peptijunior was 
offered to the infant, but it was not tolerated. These three infants who were in the atopic diet 
group were diagnosed as having allergies. When the data relating to these three infants was 
removed from the total atopic diet group allergy incidence data, there was found to be a 
significant difference (p<0.0005) between the allergy incidence between the infants bom to 
atopic women who followed an unrestricted compared to atopic women who followed a milk- 
free diet.
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5.3.4 INFANT FEEDING
All mothers attempted to breast feed their infants, the minimum time of breast feeding was 
1 month, although the majority of women breast fed until 4 months. The duration of breast 
feeding in the atopic diet group was longer (12±3 months), although not significantly, from the 
other two groups (9±4 months and 9±3 months for the atopic and non-atopic group 
respectively). Due to the natural resistance of the mothers in the atopic diet group, to cow’s 
milk introduction into their infants diet, the time of cow’s milk formula, cow’s milk and yoghurt 
introduction, was significantly later by the women in this group, compared with the non-atopic 
group (p<0.05). The introduction of the other foods was not significantly different between the 
three groups as shown in Table 5:5.
5.3.5 WHEY PROTEIN HYDROLYSATE FORMULA (PEPTIJUNIOR)
Peptijunior was used routinely by 5 of the women in the intervention group as a cow’s milk 
alternative. It was reported that Peptijunior was unpalatable when ingested unadulterated, but 
was well tolerated if mixed with sugar, tea and coffee, or if used in composite dishes such as 
custards. The main criticism was that the appearance of the reconstituted milk was thin and 
colourless, when compared to full cow’s milk.
Peptijunior was offered to 6 of the infants born to the mothers in the intervention group, 
and used routinely as a milk feed for 4 of these infants.
5.3.6 MATERNAL AND CORD SERA SAMPLE ANALYSIS
The maternal and cord sera B-Lg IgG, a-cas IgG and B-Lg levels are shown in Table 5:6. 
Detectable levels of B-Lg IgG and a-cas IgG were found in all of the sera samples analysed. 
The wide ranges reflect the large individual variation. The a-cas IgG antibody levels were 
consistently lower in all of the sera samples analysed, compared with the B-Lg IgG antibody 
levels, although this difference was not found to be significant in any group. A significant 
correlation was found between the B-Lg IgG and a-cas IgG antibody levels in the maternal and 
cord sera samples (r=0.89, p <0.0001 and r=0.71, p <0.001 respectively).
The levels of 6-Lg IgG and a-cas IgG were higher in the cord sera samples compared with 
the maternal sera samples, excluding the a-cas IgG antibody levels in the atopic group, as 
illustrated in Fig 5:1 and 5:2 respectively. A significant correlation was found between the B- 
Lg IgG level in the maternal and cord sera samples (r=0.89, p<0.0001), and between the a- 
cas IgG antibody levels in the maternal and cord sera (r=0.97, p<0.0001).
The levels of B-Lg IgG antibodies within the sera samples of the three groups of women
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were comparable. However the levels of a-cas IgG antibodies were found to be highest in the 
atopic diet group and lowest in the unrestricted atopic group. On further examination of the 
individual data, it was observed that one individual had dramatically elevated antibody levels. 
The antibody levels in the three groups were not significantly different.
Circulating antigenieally intact B-Lg was observed in 64% (9/14), 58% (7/12) and 33% (4/12) 
of the maternal sera, and in 43% (6/14), 25% (3/12) and 8% (1/12) of the cord sera samples 
in the atopic, non-atopic and atopic diet groups respectively. The three women in the atopic 
diet group, who had detectable B-Lg levels in their sera at 1 week postnatally, admitted the 
ingestion of cow’s milk protein during their stay in hospital. After the omittance of these three 
women, no detectable B-Lg was found within the maternal or cord sera samples of the other 
women within this group. In all of the groups the B-Lg levels in the cord sera samples were 
lower, and less frequent than the levels in the paired maternal sera samples.
5.3.7 EFFECT OF THE INTERVENTION DIET ON SERA B-Lg IgG AND a-CAS IgG 
ANTIBODY LEVELS
Table 5:7 shows the mean levels of B-Lg IgG, a-cas IgG and B-Lg in maternal sera samples 
before and after a milk-free diet for a period of 7 weeks (6 weeks before and 1 week after 
delivery). The 6-Lg IgG and a-cas IgG antibody levels were found to decrease during the diet 
period. This was found to be significant for the 8-Lg IgG antibody levels (p<0.05). The 
reduction was found to be greater in the individuals with an initially high antibody level as 
shown graphically in Fig 5:3. The B-Lg IgG and a-cas IgG antibody levels decreased over the 
whole period of dietary intervention, with the greatest difference being in the initial 7 week 
period.
The quantities of B-Lg detected in the sera of women in the atopic diet group, before 
dietary restriction, and the atopic women following an unrestricted diet, were 2.18±2.14 ng/ml 
and 1.38 ±2.22 ng/ml respectively. These levels were comparable. No detectable B-Lg was 
observed in the sera of subjects in the atopic diet group who had strictly adhered to their milk 
free diet, and even when a level of non compliance was reported, with some ingestion of milk 
protein, the quantity of B-Lg in the sera samples of these subjects was lower, when compared 
with their pre-diet levels (Table 5.7).
5.3.8 INFANT SERA SAMPLES
The levels of B-Lg IgG and a-cas IgG antibody levels in infant sera samples over a 12 
month period, are shown in Table 5:8 and 5:9 respectively. A higher B-Lg IgG antibody level
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compared to a-cas IgG antibody level was seen in the sera samples of the three groups, and 
these levels were significantly correlated (r=0.89, p<0.0001)
No significant variation with time between groups or groups with time were found using a 
mixed model analysis of variance for the 1 year infant sera samples. However it was observed 
that the infants born to the women in the atopic group showed a dramatic increase in B-Lg IgG 
and a-cas IgG antibody levels at 6 months which was seen to drop to values comparable with 
the other two groups by 12 months. The levels of B-Lg IgG and a-cas IgG antibodies in the 
infants bom to the atopic mothers on the milk restricted diet, had the lowest mean antibody 
levels. The B-Lg IgG and a-cas IgG antibody levels in the infant sera samples for the first year 
are shown graphically in Fig 5:4 and 5:5 respectively.
The B-Lg IgG and a-cas IgG antibody levels were found to dramatically increase after the 
introduction of cow’s milk into the infants diet. This was found to be significant for both B-Lg 
IgG antibody levels (p<0.01) and a-cas IgG antibody levels (p<0.05) as shown in Fig 5:6.
5.3.9 BREAST MILK SAMPLES
Table 5:10 and 5:11 show the mean B-Lg IgA and a-cas IgA antibody levels in the breast 
milk samples for the three groups of women for a period of one month post-partum. Using a 
mixed model analysis of variance a significant reduction with time was observed (p <0.001) in 
the breast milk B-Lg IgA and a-cas IgA antibody levels of all of the three groups. In other 
words a significant reduction in the B-Lg and a-cas specific IgA antibody levels was found over 
the first 5 days. No significant difference between the groups was observed, although the mean 
levels of B-Lg IgA and a-cas IgA antibodies in colostrum, for the atopic group, were 
approximately 50% of those found in the non-atopic and atopic diet group, as shown in Fig 5:7 
and 5:8 respectively. By day 5-7 the antibody levels in the three groups dropped significantly 
to comparably low levels. The antibody levels plateaued at approximately 14 days. A significant 
difference (p <0.001) was observed for the atopic diet group B-Lg IgA antibody level variation 
with time. Fig 5:7 illustrates that the mean B-Lg IgA antibody levels were found to fall at 6-7 
days compared to the atopic and non-atopic groups levels, which fell by day 4. The 8-Lg IgA 
and B-Lg IgA antibody levels were significantly correlated in the breast milk samples (r=0.59,
p<0.0001).
Table 5:12 provides the mean circulating B-Lg levels in the breast milk samples over a 
months period postpartum. There was no significant difference in the antigen levels between 
groups or between groups with time. The non-atopic women had quantitatively less B-Lg in 
their breast milk compared with the atopic groups. Only 25% (3/12) of the mothers on the milk
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exclusion diet had detectable B-Lg in any of their breast milk samples. The appearance of the 
B-Lg milk protein corresponded to the times of reported dietary non-compliance. It was also 
observed that the amount of B-Lg in the breast milk samples of the atopic women on the 
restricted diet was quantitatively higher than that observed in the non-atopic women on the 
unrestricted diet.
5.3.10 SALIVA SAMPLES
Table 5:13 shows the mean B-Lg IgA and a-cas IgA antibody levels in the three groups of 
women. There was found to be. a significantly higher a-cas IgA antibody level in all of the 
saliva samples compared with the B-Lg IgA levels. However it must be stressed that the two 
ELISAs were semi-quantitative and therefore it was inappropriate to directly compare the 
values. The mean levels of B-Lg IgA antibodies were comparable between the three groups. 
However the mean a-cas IgA antibody level found in the atopic diet group, 75.1+115.0 %/ml 
(range 5.4-410.5 %/ml), was found to be over a 100% higher than the levels in the atopic 
group 25.6±26.3 %/ml (range 2.3-87.2 %/ml) and non-atopic group 34.2±18.8 %/ml (range 0- 
60.0 %/ml). On further examination of the individual data it was observed that one individual 
in the atopic diet group had a level of 410.5 %/ml of a-cas IgA antibody in her saliva. When 
this value was excluded the mean a-cas IgA antibody level for the atopic diet group fell to 
44.6±29.0 %/ml (range 5.4-100.0 %/ml).
Table 5:14 and 5:15 shows the B-Lg IgA and a-cas IgA antibody levels in the infant saliva 
samples over an 18 month period postpartum. No significant variation with time or differences 
between the three groups was observed for the B-Lg IgA and a-cas IgA antibody levels. 
However a significant difference (p<0.05) was observed for the variation of the non-atopic 
group with time. It was observed that the mean B-Lg IgA and a-cas IgA antibody levels in the 
non-atopic group were higher between week 2 and month 2. The levels were then found to 
dramatically fall and reach comparable levels with the other two groups by 12 months. All of 
the groups showed an antibody peak at 1-2 months with levels then falling and plateauing at 
6 months (Fig 5:9 and 5:10) respectively.
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Table 5:1
Data of the subject recruited onto the long-term dietary intervention study
Atopic Non-atopic Atopic, diet
n 14 12 12
Age (Years) 31±2 31 ±3 31 ±5
(27-34) (25-35) (21-36)
BMI 22.6 ±4.2 22.7±4.5 21.5 ±1.8
(17.5-32.2) (16.1-33.0) (18.9-24.2)
Parity 1±1 1±1 1±1
(0-2) (0-2) (0-2)
Allergy
incidence
12 - 10
Eczema 5 _ 4
Asthma 6 - 2
Rash 4 - 6
Hayfever 7 - 3
Period of 15±7 _ 19±9
symptoms (years) (Birth-1) (Birth-1)
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Table 5:2
Allergy incidence of the subjects family, partners and children.
Atopic Non-atopic Atopic, diet
n 14 12 12
M other
Sibling 2±2 2±1 2±2
(1-6) (1-3) (1-6)
Allergy incid. 
[family]
11 8 11
Paitner
Allergy incid. 
[partner]
8 3 7
Sibling 2±2 1±1 2±2
(1-6) (0-4) (1-8)
Allergy incid. 
[family]
7 3 10
Children 1±1 1±1 1±1
(0-2) (0-2) (0-2)
Allergy incid. 
[children]
7 - 6
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Mean ± SD (range) of daily nutrient intake of women in the atopic, non-atopic and atopic diet 
group (at approximately 36 weeks gestation) calculated from a 7 day weighed food inventory.
Table 5:3
Nutrient Atopic Non-atopic Atopic, diet
n 14 12 12
Energy (MJ) 10.0 ±2.1 9.7 ±2.2 8.9±3.2
(7.0-14.3) (6.0-13.3) (3.8-15.7)
Protein (g) 84 ±19 88 ±14 77 ±29
(50-122) (59-112) (34-151)
CHO (g) 300±98.4 291 ±81 285 ±105
(201-579) (142-395) 122-459)
Fat (g) 103 ±22 96 ±22 86 ±40
(67-151 (68-140) (33-172)
P:S ratio 0.20 ±0.10* 0.20±0.10/ 0.50±0.20*/
(0.12-0.40) (0.14-0.4) (0.19-1.0)
Iron (mg) 15.7 ±7.1 15.6 ±4.8 17.4 ±7.1
(9.1-33.7) (7.8-22.4) (7.4-32.5)
Vit. C (mg) 102 ±51 136 ±101 140 ±50
(37-193) (37-344) (44-221)
Calcium (mg) 1261 ±411 1250±272 434±135
(860-2297) (809-1770) (236-667)
Vit. D (fig) 2.8±1.6 2.4 ±1.8 2.8±1.8
(0.9-5.3) (0.7-7.0) (0.4-5.6)
* Significant difference between atopic and atopic diet groups P:S ratio (p< 0.001). 
f Significant difference between non-atopic and atopic diet group P:S ratio (p <0.001).
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Table 5:4
Data of the infants born to the subjects on the long-term intervention study. Allergy incidence 
(incid.) and severity was assessed blind by a paediatrician.
Atopic Non-atopic Atopic, diet
n 14 13 12
Male 10 6 4
Female 4 7 8
Weight (Kg) 3.7±0.5 3.2±0.3 3.6 ±0.5
(3.1-4.7) (2.8-3.7) (3.1-4.5)
6 months
Allergy incid. 4 2 3 [-]
Severity 2±1 2±1 2±1 [-]
(1-3) (2-3) (1-3) [-]
12 months
Allergy incid. 8 2 5 [2]
Severity 2±1 1±1 2±1 [1±1]
(1-3) (1) (1-3) [1-2]
18 months
Allergy incid. 7 2 4 [1]
Severity 2±1 1±0 1±1 [2±0]
(1-3) (i) (1-2) [2]
NB [ ]  indicates the data from the atopic, diet group excluding 3 infants who inadvertently received 
a t least one feed o f  commercial infant formula deiived from cow’s milk shortly after delivety. 
NB. 13 infants (11+twins)
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Table 5:5
Mean ± SD (range) time, postpartum, of the introduction of foods into the diet of the infants
born to the atopic, non-atopic and atopic diet group.
Atopic Non-atopic Atopic, diet
n 14 13 12
Breast Feeding 9±4 9±3 12±3
(Duration) (1 ±-14 (2 ±13) (7±15)
Food introduction
5 ±2/Bottle feeding l ± l * f 3 ±2*
(0-2) (1-6) (2-8)
Cow’s milk 10±2 8±3* 12 ±4*
(6-12) (6-12) (6-18)
Yoghurt 8±3* 6±2 9±4*
(4-13) (4-8) (4-18)
Cheese 8±3 7 ±2* 10±4*
(4-13) (4-12) (5-18)
Egg 11 ±5 12±5 9±3
(4-18) (5-18) (6-13)
Fruit juice 5±3 5 ±2 5±2
2-14 2-9 2-10
Vegetable 5±1 5±2 5±1
(4-8) (4-10) (3-6)
Bread 7 ±2 6±2 7±2
(5-10) (4-10) (3-11)
Cereals 7 ±3 5±2 6±1
(3-14) (4-10) (4-9)
Rice 7±2 6±3 5±1
(4-11) (4-11) (3-7)
* Significant difference between atopic and non-atopic group introduction of bottle feeding and 
yoghurt (p<0.05), and a significant difference between the non-atopic and atopic diet group 
introduction of cow’s milk, yoghurt and cheese (p<0.05).
 ^ Significant difference between the atopic and atopic diet group introduction of a bottle 
feeding (p<0.005).
NB. 13 infants (11-{-twins)
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Table 5:6
Mean ± SD (range) B-Lg IgG, a-cas IgG antibody levels and B-Lg levels in maternal and cord
sera samples in atopic, non-atopic and atopic diet groups.
Atopic Non-Atopic Atopic, Diet
n 14 12 12
fi-Lg IgG
(Mg/ml)
Maternal 19.0±21.3 27.2 ±29.1 25.6±33.4
sera (2.3-79.7) (2.3-90.7) (0.8-735.8)
Cord sera 25.9 ±36.5 29.3 ±28.4 29.8±33.7
(2.2-138.3) (3.4-50.6) (1.1-474.4)
a-cas IgG
(Mg/ml)
Maternal 5.0±8.4 8.3 ±13.7 15.4 ±29.4
sera (0.3-31.4) (0.3-41.6) (0.9-102.5)
Cord sera 4.2±5.2 10.9±20.9 19.8±41.0
(0.4-17.7) (0.3-65.7) (0.5-140.3)
fi-Lg
(ng/ml)
Maternal 1.93 ±2.58 1.05 ±1.29 1.38±2.22 [0]
sera (UD-7.52) (UD-3.80) (UD-6.85)
Cord sera 0.76±i.29 0.20 ±0.33 0.48 ±1.38 [0]
(UD-4.42) (UD-1.13) (UD-4.80)
[ ] Levels excluding mothers who reported ingesting cow’s milk protein during their stay in 
hospital.
UD = undetected
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T able 5:7
Mean ± SD (range) of B-Lg IgG, ct-cas IgG antibody levels and 6-Lg levels in maternal sera 
before and during a milk-free diet for a 7 week period.
Pre-Diet Diet (7 week)
n 12 12
fi-Lg IgG 123.4 ±265.6* 96.6 ±226.8*
(Mg/ml) (1.6-862.8) (0.8-735.8)
a-cas IgG 25.8±56.3 15.4 ±29.4
(Mg/ml) (0.8-194.5) (0.8-102.4)
fi-Lg 2.18 ±2.24 1.38±2.22 [0±0]
(ng/ml) (UD-8.00) (UD-4.82) [0]
* Significant reduction in the levels of B-Lg IgG antibodies during a 7 week compliance to a 
milk-free diet (p<0.05).
[ ] Excluding those mothers who reported ingesting cow’s milk protein.
UD = Undetected
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Table 5:8
Mean ± SD (range) of B-Lg IgG antibody levels (/ig/ml) in sera samples of infant born to
mothers in the atopic, non-atopic and atopic diet group for a 12 month period postpartum.
Atopic Non-Atopic Atopic, Diet
n 14 13 12
Week 1 46.5 ±29.7 52.1 ±47.2 62.1 ±68.8
(11.8-104.0) (10.0-187.7) (6.2-265.8)
Month 3 68.8 ±113.0 61.6 ±127.8 33.1 ±82.0
(44-480.0) (7.1-498.6) (0.9-306.1)
Month 6 301.8±256.0 135.7 ±106.6 86.3 ±133.6
(11.4-896.0) (10.0-453.6) (3.0-432.0)
Month 12 190.6± 176.8 232.7 ±186.9 165.5±185.9
(25.2-500.0) (32.1-453.0) (2.5-505.5)
NB. 13 infants (11+twins)
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Table 5:9
Mean ± SD (range) of a-cas IgG antibody levels (/xg/ml) in sera samples of infants born to the
women in the atopic, non-atopic and atopic diet groups for a 12 month period postpartum.
Atopic Non-Atopic Atopic, Diet
n 14 12 12
Week 1 10.6 ±10.1 7.6 ±7.1 14.5 ±22.8
(0.8-35.4) (1.9-29.2) (1.8-88.2)
Month 3 16.5 ±28.5 26.2 ±64.7 5.4 ±8.0
(0.1-101.8) (0.8-238.0) (0.9-30.4)
Month 6 53.7 ±42.8 39.4 ±69.5 14.1 ±23.0
(2.6-112.9) (0.9-254.2) (0.5-83.0)
Month 12 54.2 ±38.7 70.6±80.3 47.2 ±47.6
(6.4-109.0) (3.5-214.4) (2.4-153.0)
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Table 5:10
Mean ± SD (range) of B-Lg IgA antibody levels (%/ml) in breast milk samples from women
in the atopic, non-atopic and atopic diet groups for one month postpartum.
Atopic Non-Atopic Atopic, Diet
n 14 12 12
Day 1 93.5 ±95.5* 178.9 ±68.6X 188.1±155.1^
(4.0-220.0) (30.4-231.3) (46.2-404.2)
Day 2 66.0 ±64.7 90.9 ±61.7 146.3 ±129.4
(3.2-200.0) (18.0-344.4) (38.0-400.1)
Day 3 38.3 ±41.3 124.1 ±108.9 99.1 ±89.2
(3.2-152.5) (15.8-394.8) (18.0-324.0)
Day 4 40.2 ±43.0 48.9±33.0 82.3 ±62.6
(6.2-170.4) (4.6-120.6) 7.2-312.4)
Day 5 33.2±28.9 53.8±26.9 96.4 ±110.8
(5.8-100.0) (17.8-100.2) (5.6-398.6)
Day 6 25.4±7.5 52.0 ±30.5 65.9 ±90.4
(8.0-38.0) (12.0-110.0) (7.7-296.0)
Day 7 21.6±8.0 41.8±27.3 44.6 ±43.0
(8.9-28.4) (15.7-102.0) (11.0-132.4)
Day 8 24.6 ±12.1 55.2±21.5 44.6 ±29.0
(10.4-48.1) (13.7-86.2) (16.2-102.4)
Day 9 27.6 ±8.3 37.6 ±11.9 37.0 ±31.0
(15.1-44.9) (20.5-59.5) (8.0-116.8)
Day 10 22.4 ±9.2 37.2±17.1 26.2 ±16.6
(9.5-31.5) (9.6-67.2) (11.7-66.4)
Day 14 18.8 ±8.6 30.5 ±26.3 24.1 ±14.5
(4.4-27.8) (5.9-45.7) (13.3-53.0)
Day 21 17.2±11.4 24.7 ±13.2 18.6±11.7
(7.9-36.3) (4.0-35.5) (6.9-30.4)
Day 28 12.7 ±6.2 17.1 ±12.9 14.1 ±9.2
(6.4-22.3) (3.8-26.8) (2.5-31.2)
* x f  Significant reduction of B-Lg IgA antibody levels with time for all three groups (p<0.001).
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Table 5:11
Mean ± SD (range) of a-cas IgA antibody levels (%/ml) in breast milk samples of women in
the atopic, non-atopic and atopic diet group for one month postpartum.
Atopic Non-Atopic Atopic, Diet
n 14 12 12
Day 1 67.2±72.1* 161.1 ±59.7X 131.1 ±70.9^
(10.6-192.4) (8.0-210.0) (49.6-180.4)
Day 2 42.4 ±42.6 90.1 ±59.7 85.1 ±55.6
(7.6-121.0) (10.6-177.6) (23.1-220.0)
Day 3 25.3 ±25.9 101.9 ±73.2 86.9 ±94.7
(3.8-71.2) (4.0-200.0) (7.6-259.6)
Day 4 19.9 ±15.7 47.7 ±57.9 48.0 ±34.0
(4.4-36.4) (0.5-200.1) (8.4-108.6)
Day 5 10.4±8.1 57.4 ±43.5 42.4±24.8
(0.4-61.7) (11.8-133.6) (6.2-79.8)
Day 6 15.3 ±9.2 39.5 ±23.5 17.8±16.1
(6.0-78.1) (15.2-79.4) (6.0-53.3)
Day 7 13.2±8.0 35.1 ±26.9 27.9 ±18.3
(4.3-30.3) (8.5-96.7) (6.5-60.7)
Day 8 13.3 ±8.8 32.9 ±20.5 25.4 ±20.9
(4.0-23.4) (8.4-65.4) (6.4-67.0
Day 9 16.6 ±5.6 36.0±25.7 19.4 ±13.3
(4.0-30.1) (13.6-100.1) (6.1-43.0)
Day 10 12.2 ±5.0 36.0 ±22.1 23.8 ±20.1
(4.5-37.8) (13.1-98.0) (7.1-57.9)
Day 14 15.4 ±4.3 29.0±21.0 23.4±11.7
(5.0-21.2) (1.7-26.0) (2.0-40.0)
Day 21 10.1 ±7.8 15.3 ±11.5 17.0±10.0
(3.7-25.1) (1.8-34.2) (2.0-43.2)
Day 28 6.6 ±2.9 11.8±5.2 9.5 ±7.6
(2.2-10.0) (7.3-17.6) (3.3-24.9)
* x /  Significant reduction of a-cas IgA antibody levels with time for all three groups (p<0.001).
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Table 5:12
Mean ± SD (range) of B-Lg levels (ng/ml) in breast milk samples of women in the atopic, non- 
atopic and atopic diet groups for one month postpartum.
Atopic Non-Atopic Atopic, Diet
n 14 12 12
Day 1 5.07 ±5.9 0.06 ±0.08 2.71 ±3.66
(UD-15.00) (UD-0.17) (UD-7.89)
Day 2 2.64 ±4.2 1.42±3.01 2.82 ±1.93
(UD-13.00) (UD-8.15) (UD-6.62)
Day 3 2.10±3.46 0.79±1.73 0.96 ±2.16
(UD-12.00) (UD-5.35) (UD-4.05)
Day 4 3.45 ±3.92 0.96 ±2.04 0.98 ±2.16
(UD-10.00) (UD-7.80) (UD-7.05)
Day 5 0.37 ±0.62 0.91 ±1.43 1.23 ±2.59
(UD-18.00) (UD-4.66) (UD-5.50)
Day 6 2.71 ±4.30 0.47 ±0.67 0.83 ±1.45
(UD-14.0) (UD-5.03) (UD-4.34)
Day 7 0.59±0.86 0.43 ±0.36 1.17±1.49
(UD-2.63) (UD-1.15) (UD-3.36)
Day 8 1.04±2.11 0.37±0.83 1.10±1.74
(UD-5.74) (UD-7.95) (UD-5.38)
Day 9 1.57 ±2.48 0.57 ±1.53 1.46±2.93
(UD-6.74) (UD-2.48) (UD-10.0)
Day 10 2.07±3.10 0.18±0.41 1.55 ±2.95
(UD-2.42) (UD-5.59) (UD-2.63)
Day 14 1.86±3.15 0.17 ±0.35 1.00±3.00
(UD-7.02) (UD-7.6) (UD-10.00)
Day 21 1.67 ±3.54 0.25 ±0.36 0.86 ±2.21
(UD-11.01) (UD-1.3) (UD-6.70)
Day 28 1.15 ±0.95 0.30±0.81 0.63 ±1.77
(UD-2.41) (UD-25.9) (UD-5.66)
UD = Undetected
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Table 5:13
Mean ± SD (range) of 13-Lg IgA and a-cas IgA antibody levels in saliva samples of women in 
the atopic, non-atopic and atopic, diet group (approximately 36 weeks gestation).
Atopic Non-Atopic Atopic, Diet
n 14 12 12
fl-Lg IgA 2.8 ±2.6* 5.6±13.3X 3.2±2.8/
(%/ml) (UD-7.7) (UD-45.4) (UD-128.7)
a-cas IgA 25.6 ±26.3* 34.2±18.8X 75.1 ±115.0^
(%/ml) (2.3-87.2) (UD-60.0) (5.4-410.5)
& x f  Significant difference between the 13-Lg IgA and a-cas IgA antibody levels in the atopic, 
non-atopic and atopic diet group respectively (p<0.05).
UD = Undetected
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Table 5:14
Mean ± SD (range) of fi-Lg IgA antibody levels (%/ml) in saliva samples of infants born to
women in the atopic, non-atopic and atopic diet group for an 18 month period postpartum.
Atopic Non-Atopic Atopic, Diet
n 14 12 12
Week 1 0.3 ±0.7 4.7 ±7.9 1.3 ±2.6
(UD-1.9) (UD-23.6) (UD-7.9)
Week 2 0.4 ±0.7 8.2±13.3 2.6±3.9
(UD-2.0) (UD-41.9) (UD-12.2)
Week 3 5.8±13.3 11.4 ±28.8 3.0±4.5
(UD-40.8) (UD-100.0) (UD-14.4)
Week 4 1.4±2.5 18.4±32.6 2.9±2.6
(UD-8.3) (UD-101.0) (UD-9.0)
Month 2 0.8 ±0.7 4.4±10.5 0.7 ±1.3
(UD-2.3) (UD-40.2) (UD-3.0)
Month 3 0.9±1.3 1.6±2.0 1.3 ±2.3
(UD-4.5) (UD-7.0) (UD-8.0)
Month 4 0.6 ±1.4 1.2±1.8 0.6 ±1.2
(UD-6.2) (UD-5.4) (UD-3.9)
Month 5 0.6 ±0.7 0.5 ±0.7 0.5 ±1.2
(UD-2.1) (UD-2.3) (UD-4.1)
Month 6 1.3 ±1.7 1.1 ± 1.6 0.5 ±1.3
(UD-6.2) (UD-3.3) (UD-4.6)
Month 12 2.0 ±3.5 1.0±1.5 1.0±1.1
(UD-13.3) (UD-4.5) (UD-2.4)
Month 18 1.7±2.0 1.2±1.4 1.1 ±1.0
(UD-5.8) (UD-5.2) (UD-2.5)
UD = Undected
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Table 5:15
Mean ± SD (range) of a-cas IgA antibody levels (%/ml) in saliva samples of infants bora to
women in the atopic, non-atopic and atopic diet groups for an 18 month period postpartum.
Atopic Non-Atopic Atopic, Diet
n 14 12 12
Week 1 0.4 ±1.2 18.1 ±38.6 2.4 ±4.3
(UD-4.1) (UD-105.6) (UD-8.1)
Week 2 0.4 ±0.7 23.6±39.8 1.1 ±2.1
(UD-1.5) (UD-101.3) (UD-7.0)
Week 3 0.6 ±0.9 32.6±45.6 5.6 ±9.3
(UD-2.2) (UD-113.0) (UD-30.1)
Week 4 3.1 ±8.5 23.5 ±41.9 6.0 ±8.69
(UD-27.2) (UD-100.0) (UD-23.3)
Month 2 4.4 ±4.9 31.8±45.5 1.4±2.1
(UD-13.1) (UD-93.0) (UD-6.7)
Month 3 3.4±4.4 16.0±28.0 0.5 ±1.0
(UD-14.0) (UD-111.3) (UD-3.0)
Month 4 3.7±7.5 9.6 ±26.3 0.5 ±0.9
(UD-27.7) (UD-102.4) (UD-2.6)
Month 5 2.2 ±5.1 1.7 ±2.5 1.1 ±1.8
(UD-18.5) (UD-9.6) (UD-3.8)
Month 6 2.0±3.2 5.8±11.7 0.3 ±0.7
(UD-8.6) (UD-43.6) (UD-2.1)
Month 12 1.1±1.4 1.9±3.0 0.5 ±0.7
(UD-4.5) (UD-8.6) (UD-2.8)
Month 18 1.4 ±0.2 0.3 ±0.4 0±0
(UD-1.6) (UD-1.0) (UD)
UD = Undetected
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Fig 5:1
Mean -  SE of B-Lg IgG antibody levels in maternal and cord sera samples for women in the
atopic (n=14), non-atopic (n=12) and atopic diet (n=12) groups.
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Mean -  SE of a-cas IgG antibody levels in maternal and cord sera samples for women in the 
atopic (n=14), non-atopic (n=12) and atopic diet (n=12) groups.
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Individual B-Lg and a-cas specific IgG antibody levels in sera samples of women before and 
during a milk-free diet (7 week compliance).
Fig 5:3
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•  Significant reduction In mean 6-Lg 
IgG levels after 7  wk diet (p<0.05)
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Fig 5:4
Mean B-Lg antibody levels in infant sera samples for a 12 month period postpartum in infants
bom to women in the atopic (n—14), non-atopic (n—13) and atopic diet (n 12) groups.
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Fig 5:5
Mean a-cas IgG antibody levels in infant sera samples for a 12 month period postpartum in 
infants bora to women in the atopic (n=14), non-atopic (n=13) and atopic diet (n=12) groups.
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cow’s milk introduction into their diet.
Fig 5:6 _ j  tu
Individual levels of B-Lg IgG and a-cas IgG antibodies in infant sera samples before and after
IgG  a n t ib o d y  (y g /m l)  1000 a . *
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Fig 5:7
Mean B-Lg IgA antibody levels in breast milk samples from women m the atopic (n=14), non-
atopic (n=12) and atopic diet (n=12) groups.
T im e  p o s tp a rtu m  (d a y s )
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Significant reduction In B-Lg IgA level* 
w ith time (p<0.001) In all groups.
Fig 5:8
Mean a-cas IgA antibody levels in breast milk samples from women in the atopic (n=12), non- 
atopic (n=12) and atopic diet (n=12) groups.
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Significant reduction ln*-cas IgA levele 
w ith time (p<0.001) in all groups
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Fig 5:9
Mean B-Lg IgA antibody levels in infant saliva samples for infants born to women in the atopic
(n=14), non-atopic (n=13) and atopic diet (n=12) groups.
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Fig 5:10
Mean a-cas IgA antibody levels in infant saliva samples for infants bom to women in the atopic 
(n=14), non-atopic (n=13) and atopic diet (n=12) groups.
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5.4 DISCUSSION
Modification of the maternal diet during pregnancy and early lactation has been suggested 
as a means of preventing perinatal sensitisation (Hamburger et al, 1983 and Chandra et al, 
1986), or inducing tolerance in the fetus and newborn (Pathirana et al, 1981; Notley et al, 1984 
and Telemo et al, 1987). In this prospective, randomized study it was found that a strict 
maternal milk-free diet during late pregnancy and lactation, in addition to a delayed introduction 
of milk into infants’ diet, had a significant preventative effect on allergy development in infants 
born to atopic women. It was also observed that there was an obvious hereditary influence in 
allergy incidence seen between the infants bom to women in the atopic group following an 
unrestricted diet compared to women in the non-atopic group following an unrestricted diet. 
However there was found to be no significant serological differences in the infants B-Lg IgG 
or a-cas IgG antibody levels in relation to family atopy or maternal diet, or in the salivary fi- 
Lg IgA or a-cas IgA antibody levels.
5.4.1 STUDY GROUPS
The age, pre-pregnancy BMI and parity of the women in the three groups were 
comparable. The incidence and types of allergies in the two atopic groups were not significantly 
different. A questionnaire was used to collect the data regarding allergies, and although these 
were not verified by a doctor at the time of the study, all the allergies had been previously 
diagnosed by a doctor. The incidence of allergy in the subject’s family, children, partners and 
partner’s family was also comparable between the two atopic groups, with the non-atopic 
subjects having a lower reported allergy incidence in previous children, partners and partner’s 
family compared with the other groups. These results favour the theory of a hereditary basis 
for allergy development (Peltonen et al,1988).
5.4.2 THE SEROLOGICAL AND NUTRITIONAL EFFECT OF A MATERNAL MILK- 
FREE DIET.
Maternal dietary restriction of any kind is a laborious procedure for a pregnant women. The 
timing of the diet for maximal benefit to the infant and minimal inconvenience to the mother 
is necessary. Previous studies have reported that maternal dietary restrictions during pregnancy 
alone, had no significant effect on infant allergy development (Falth-Magnusson et al, 1987a; 
Falth-Magnusson & Kjellman, 1987b and Lilja et al, 1988 & 1989), but was of benefit during 
lactation (Chandra et al, 1989 and Hattevig et al, 1989 & 1990) or during both late pregnancy 
and lactation (Chandra et al, 1986 and Zeiger et al, 1989). It was thought important in this
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study, that the mother commenced any dietary restriction during late pregnancy in order for 
her to become accustomed to the diet, for absolute clearance of circulating milk antigens from 
her blood and to reduce the risk of an inadvertent intake of cow’s milk protein during the more 
important lactation period.
The nutritional consequences of any dietary intervention programme must be critically 
assessed, especially when pregnant and lactating women are involved. It was observed that the 
nutrient intake of the women following a milk-free diet was not significantly different from 
those following an unrestricted diet, apart for the calcium intake and P:S ratio. The reduced 
calcium intake was not unexpected, and the significant correlation between the milk protein 
intake and the calcium ingestion emphasised the importance of milk and its products, as a 
calcium source in the Western diet. The reduced calcium intake was compensated by calcium 
supplements (lg/day). Calcichew (Shire Pharmaceuticals) was chosen as the calcium supplement, 
as it was derived from calcium carbonate, not from a milk source, and was very palatable.
The importance of calcium supplementation in subjects on a milk-free diet, even with the 
prescription of a cow’s milk substitute, is necessary (Devlin et al, 1989). Calcium 
supplementation has therefore become common practice with the prescription of a milk-free 
diet (Falth-Magnusson et al, 1987b; Lilja et al 1988; Hattevig et al, 1989 & 1990 and Zeiger et 
al, 1989).
A significantly higher mean P:S ratio was observed in the milk-free diet compared to the 
unrestricted diet. This alteration in the proportion of polyunsaturated fats to saturated fats 
reflected the significant contribution cow’s milk and its products have on the saturated fat 
intake in the Western diet. The nutrient intake of those mothers in the intervention group 
was considered adequate.
Due to the nature of the restriction, the women assigned the milk-free diet were frequently 
visited by the investigator who helped with any queries and problems. Recipes, information 
sheets and lists of commercially available milk-free products were also supplied to aid in strict 
dietary compliance. Despite this, total compliance of the mother to the diet was not absolute. 
The mothers were, however, asked to note any occasions of dietary non-compliance, which 
allowed a record to be kept of these occasions. From these records it was observed that the 
mothers complied to their diets very conscientiously and without many deviations.
The presence of antigenically active B-Lg antigen in the maternal sera and breast milk 
samples corresponded well with the occasions of known dietary non-compliance. B-Lg was not 
always detected in the sera or breast milk of women who did report the ingestion of cow’s milk 
protein, which was probably due to the individual variation of mucosal antigen exclusion
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(Walker & Isselbacher, 1974; Paganelli et al, 1980, Husby et al, 1985b). The reduced incidence 
of food protein in breast milk has also been reported in women following a milk-free diet by 
Jakobsson et al (1985). The determination of milk protein antigens within sera samples of 
individuals on a milk-free diet was a reliable means to evaluate dietary compliance. From the 
levels of B-Lg within the sera samples, it was concluded that the majority of the mothers 
complied well with the diet.
It was observed that the sera B-Lg IgG and a-cas IgG antibody levels reduced, significantly 
for B-Lg IgG, after a period of 7 weeks dietary compliance, and continued to fall if the mother 
remained on the restricted diet. Although the milk specific IgG antibody levels did not correlate 
with the ingested milk protein, these results suggested that the IgG response was influenced by 
the quantity of antigen ingested by the mother. A reduction in food specific antibody levels in 
maternal sera samples after a dietary restriction was also observed by Lilja et al (1988) and 
Falth-Magnusson et al (1987a). The observed relative changes in the maternal milk specific IgG 
antibody levels in the atopic diet group, also gave an indication of dietary compliance. Changes 
of food specific IgG antibody levels have been suggested by others, as a possibility to evaluate 
the dietary compliance (Hamburger et al, 1983).
The levels of cord blood B-Lg IgG and a-cas IgG antibodies showed no significant 
difference between the groups, despite differences in the maternal consumption of cow’s milk. 
This was also reported by (Falth-Magnusson et al, 1988 and Lilja et al, 1988). This may indicate 
the presence of a regulating mechanism in the distribution of IgG between mother and fetus, 
in favour of the latter (Lilja et al, 1988).
Although abstention from cow’s milk causes a decline of serum antibody levels in mothers 
on the diet (Falth-Magnusson et al, 1987 and Lilja et al, 1988), indicating an influence of 
antigen exposure on the humoral immunity, breast milk antibody production was found not to 
be effected in this, and other studies. Falth-Magnusson (1989) observed no significant difference 
between the B-Lg, OV or gliadin specific IgG and IgA antibody levels in colostral samples, 
between women following a milk and egg free diet from 28 weeks gestation, and those following 
an unrestricted diet. However, these findings are in contrast with others which indicated a 
relation between maternal diet and breast milk antibody levels in malnourished women see 
(Cruz et al, 1981). An explanation for this discrepancy may be that the period of dietary 
compliance in this and Falth-Magnusson’s study (1989), was insufficient to obliterate the 
previous maternal enteric experience. This is in accordance with reports by Machtinger & Moss 
that cow’s milk avoidance and later challenge, in 2 women did not affect the breast milk 
antibody levels (Machtinger & Moss, 1986).
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The whey hydrolysate infant formula (Peptijunior) was used and well tolerated by 37% 
(4/12) of the women in the intervention group and the same proportion of infants. None of the 
infants who routinely ingested Peptijunior had developed allergies by 18 months. Allergic 
manifestation, however, were observed in the three infants who were inadvertently given cow’s 
milk. Chandra et al (1989) and Hattevig et al (1989) also reported the benefit of using protein 
hydrolysates, compared with other formulae, in the prevention of allergy development in infants.
Due to the small number of subjects using Peptijunior, in unregulated quantities, no firm 
conclusions should be formulated regarding the benefit of this formula on the prevention of 
allergy development in infants. However the limited data from this study suggests the use of this 
formula could potentially be of benefit to the "at risk" infant.
5.4.3 ATOPY AND ANTIBODY LEVELS
Quantitatively the levels of B-Lg IgG antibodies were higher than a-cas IgG antibodies in 
all of the adult and infant sera samples, perhaps reflecting the higher antigenicity of B-Lg 
compared to a-cas. This result supported the finding of some groups (Husby et al, 1985d; and 
Helm & Rieger, 1987) but not others (Biirgin-Wolff et al, 1980; Muller et al, 1985; Barnes et 
al, 1988a & 1988b and Burks et al, 1990). The conflicting observations could reflect the 
methodology used, with most of the assays being semi-quantitative and inappropriate to make 
true comparisons.
A significant correlation was observed between the B-Lg IgG and a-cas IgG antibody levels 
in all of the sera samples, although the individual variation was always very large. This indicates 
a heterogeneity in IgG synthesis, with "high and low responders", and is in agreement with 
earlier studies (Dannaeus et al, 1978 and Lilja et al, 1988). Another explanation for the large 
individual variation in circulating milk specific antibody levels, is the lack of standardisation of 
the blood samples in relation to the last meal taken. This could lead to varying degrees of 
antibody neutralisation by the absorped food antigens (Lilja et al, 1988). However, this probably 
did not have a compounding effect, as blood samples taken from the women on the milk-free 
diet were still very varied.
It has been reported that atopic women have higher food IgG antibodies compared with 
non-atopic subjects (Falth-Magnusson et al, 1987a, 1987b & 1988), and that atopic women seem 
to transfer larger amounts of milk and egg antibodies to the fetus compared to non-atopic 
women (Dannaeus et al, 1978). However our results did not support these findings, with the 
non-atopic group having higher mean maternal and cord sera a-cas IgG antibody levels 
compared with the two atopic groups. High levels of IgG antibodies to food allergens have been
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suggested to afford protection against the development of atopic symptoms during the first two 
years of life (Casimir et al, 1985), although their predictive capacity with respect to atopic 
disease was not found to be convincing in this or other studies (Dannaeus et al, 1977 and Falth- 
Magnusson et al, 1988). A tendency to higher levels of milk specific IgG antibodies in ldren, 
who were considered to suffer from atopic disease, was noted at 18 months of age in this and 
the study by Falth-Magnusson et al (1988).
The transfer of IgG antibodies via the placenta has been demonstrated in a number of 
studies (Kohler & Farr, 1966; Carlsson et al, 1976; Falth-Magnusson et al, 1988 and Lilja et 
al, 1988). The correlation between the milk specific IgG antibody levels in the maternal and 
cord sera samples, in addition to the higher cord sera milk specific antibody levels, support an 
active transport mechanism of these antibodies from mother to fetus. This transfer offers passive 
protection to the newborn infant for the first few months of life, and until it becomes 
immunocompetent. No significant difference was observed between the 1 week infant sera 
samples and the cord sera samples, although the infant samples were higher. This, and the very 
close correlation of the B-Lg and a-cas specific IgG antibody levels in the cord and infant sera 
samples, supports the theory that the cord sera IgG antibodies are maternally derived.
Although serum food antibody levels were found to be higher in atopic subjects (Dannaeus 
et al, 1978 and Falth-Magnusson et al, 1987a), in breast milk samples there was no such 
difference between the levels of B-Lg IgA and a-cas IgA antibodies in atopic and non-atopic 
subjects. This confirms previous observations by Machtinger & Moss (1986) regarding IgA to 
whole cow’s milk and casein, and Falth-Magnusson (1989) who looked at IgA and IgG 
antibodies against B-Lg, OV and gliadin.
The B-Lg and a-cas specific IgA antibody levels in all three of the groups showed a 
significant variation with time, supporting earlier observations (Carlsson et al, 1976; Cruz & 
Arevalo, 1985; Machtinger & Moss, 1986 and Hennart et al, 1991). The apparent dramatic 
reduction in antibody levels over the first 5 days, can be explained by a dilution effect due to 
a large breast milk volume increase at approximately 4-5 days postnatally (Carlsson et al, 1976 
and Cruz & Arevalo, 1985). The infant, however, receives a relatively constant concentration 
of IgA antibodies for the first month of lactation (Hennart et al, 1991).
Although the atopic mothers did not show any significant difference to each other in their 
milk specific antibody levels, infants with likely atopic disease received milk with lower mean 
levels of antibodies to cow’s milk protein than infants without clinical manifestations. Although 
the results of this study did not reveal significant differences in the atopic and non-atopic, or 
diet and no diet breast milk B-Lg and a-cas specific IgA antibody levels, the atopic diet group
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had lower levels of 6-Lg IgA and a-cas IgA antibody levels compared to the other two groups, 
and had the highest allergy incidence. This finding, and that of Machtinger & Moss (1986) 
could explain in part, the confusing and controversial data regarding the efficacy of breast 
feeding in preventing the expression of atopic disease in infancy.
These results further suggest that nursing mothers with low levels or absence of breast milk 
IgA antibodies to major allergens represent a "high-risk" group, for whom appropriate dietary 
restriction and environmental allergen avoidance measures might prove valuable in preventing 
infantile allergy.
Adult salivary B-Lg IgA and a-cas IgA antibodies were detected in all of the samples 
analysed.. The presence of atopy did not have any significant influence on these values. 
Statistically the levels of a-cas IgA antibodies in all of the subjects were significantly higher than 
the B-Lg IgA levels. However, because the assays were semi-quantitative, this difference may 
not have been real, and may have reflected the strength of the binding of the antigen to the 
microtitre plate. The mucosal immunity is believed to be linked at different sites by common 
antigen-processing and antibody-producing mechanisms (Walker, 1987). The higher salivary a- 
cas IgA antibody levels, if real, could reflect the gut mucosal experience required to deal with 
a higher amount of the milk protein a-cas (75% of milk protein) compared with B-Lg. It would 
be interesting to investigate the relation between the gut mucosal slgA antibody levels and 
salivary IgA antibody levels. Due to the relative ease, of saliva collection, this secretion could 
provide relevant information on the mucosal immunological state. It could be very useful, for 
in the gastrointestinal tract, slgA antibodies prevent the mucosal penetration and systemic 
absorption of foreign antigens (Walker, 1987), and any deficiencies would put the individual at 
greater risk of a pathologically high antigen absorption and possible allergy development 
(Cunningham-Rundles et al, 1979).
Circulating antigenically active B-Lg was detected in both normal and atopic women, 
supporting, the theory that the transfer of food antigens is a natural occurrence (Walker & 
Isselbacher, 1977). The frequency and quantity of transferred B-Lg was higher in the atopic 
group compared to the non-atopic group. However due to the relatively small numbers and 
large individual variation, this was not found to be statistically significant. Jackson et al (1981), 
Heyman et a l (1988) and Husby et al (1990) also reported a higher quantity of antigen 
absorption across the gut mucosa in atopic, compared with non-atopic subjects. This increased 
transfer has been related to a mucosal slgA deficiency (Cunningham-Rundles et al, 1979) and 
intestinal lesions (Jackson et al, 1981).
The presence of detectable B-Lg antigen was also reported in some of the cord blood
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samples, and as the cord sera is ultimately derived from the mother, the presence of B-Lg was 
only observed if similar proteins were present in the maternal circulation. The frequency and 
quantities of B-Lg within the cord sera samples was also found to be higher in the atopic 
women. The influence of this antigenieally intact food protein on the developing fetus is not 
known. Studies on animals have suggested immune tolerance development to the specific 
antigen transferred (Gallagher et al, 1980; Pathirana et al, 1981 and Gallagher et al, 1982) or 
a possible sensitisation (Van Asperen et al, 1983.)
The occurrence of maternal dietary antigens, within breast milk has been well documented 
(Stuart et al, 1984; Kilshaw & Cant, 1984; Jakobsson et al, 1985; Axelsson et al, 1986; 
Machtinger & Moss, 1988 and Host et al, 1988). No significant variation with time or between 
atopic and non-atopic groups was observed in this study, supporting previous reports (Axelsson 
et al, 1986), although a higher frequency and quantity of B-Lg was observed in the atopic 
mothers. No correlation was found between the B-Lg IgA antibody levels in breast milk or the 
dietary antigen levels in this study, and other studies making similar comparisons (Axelsson et 
al, 1986 and Machtinger & Moss, 1986).
5.4.4 EFFECT OF MATERNAL DIET AND ATOPY ON INFANT IMMUNE 
DEVELOPMENT
The immunological influence of maternally transferred milk specific antibodies and milk 
antigens, to the fetus and infant was considered in this study. Infant IgG antibody development 
over a 12 month period postnatally was investigated. No significant difference in the B-Lg and 
a-cas specific IgG levels in the sera samples was observed between the three groups. This was 
also found by Hattevig et al (1990) who was investigating the immune development of infants 
born to atopic and non-atopic women, following either an unrestricted diet or a milk, egg and 
fish free diet during lactation. No significant difference in the IgG antibodies to OV or B-Lg 
was detected between the groups of infants. Falth-Magnusson et al (1988) also reported no 
significant difference in the B-Lg IgG antibody levels in infants born to mothers following a 
milk-free diet during pregnancy and lactation, although the babies from the allergen-free group 
were reported to have higher levels of IgG, IgA and IgM to OV and gliadin.
The infants born to the atopic mothers following an unrestricted diet showed a dramatic 
increase in B-Lg IgG and a-cas IgG antibody levels at 6 months, which fell to concentrations 
comparable with the other two groups by 12 months. Infants born to the atopic women on the 
milk-free diet and the non-atopic women, showed a more gradual increase in 8-Lg IgG and a- 
cas IgG antibody levels, which were found to be highest at 12 months postpartum. Infants B-
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Lg IgG and a-cas IgG sera antibody levels significantly increased after the ingestion of cow’s 
milk for the first time, which has also been reported by Zieger et al (1986) and Hattevig et al 
(1989). It could be speculated that the observed trend of a higher milk specific IgG antibody 
response by the infants born to the atopic women at 6 months, reflected an earlier introduction 
of cow’s milk into the infant’s diet. This is not a plausible explanation, however, as the mean 
time of the introduction of cow’s milk, yogurt and cheese into the diet of the atopic infant 
group, was at a later time compared with the non-atopic group.
On further examination of the data the trend for a higher IgG response against milk 
antigens by the infants bom to the atopic mothers was also compounded by a tendency for 
those mothers to transfer more antigenically intact B-Lg via the placenta and breast milk, and 
have lower B-Lg and a-cas specific IgA antibody levels in their breast milk samples. The 
placental and breast milk transfer of food antigens does occur in non-atopic mother causing no 
detrimental effects in the majority of infants. Antigen exposure via breast milk did not differ 
between mothers feeding eczematous babies and non-eczematous babies (Cant et al, 1985). 
Further, the presence and quantity of B-Lg was unrelated to antibody levels, infantile allergy 
symptoms and maternal atopic history (Machtinger & Moss, 1986). It could be, therefore, 
speculatively suggested that a genetic predisposition could have significant influence on the 
infant’s immune reaction to the ingested food proteins.
Total cow’s milk restriction by the mother was believed essential in an attempt to prevent 
fetal or infant sensitisation. It has been reported that the transfer of small quantities of milk 
protein via the placenta or breast milk, in connection with a defect in T-suppressor function, 
can sensitise an "at risk" infant (Jarrett, 1977; Hamburger et al, 1983 and Chandra et al, 1988). 
These circumstances have been reported to predispose IgE synthesis within the infant (Jarrett, 
1977). However, some experiments on animals have reported a suppressive effect on IgE 
(Jarrett & Hall, 1984) and IgG synthesis (Gallagher et al, 1980; Pathirana et al, 1981 and Notley 
et al, 1984) in the offspring of mothers who have ingested large quantities of food proteins 
during pregnancy. This is believed to be due to the induction of oral tolerance in the animals 
by the transfer of food antibodies or antigens.
In this study the atopic women on the unrestricted diet ingested at least 500 ml of cow’s 
milk daily and the allergy incidence of their infants was found to be significantly higher 
compared with the atopic mothers who strictly followed a milk-free diet. It was also found by 
Lilja et al (1989) that even the ingestion of 1 litre of cow’s milk daily by the mother did not 
reduce her infant’s milk specific IgE antibody levels or allergy incidence. This discrepancy 
between the results of the animal studies and the human studies regarding oral tolerance
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induction and high maternal intakes of dietary protein, may be due to the fact that the quantity 
of cow’s milk ingested by the mothers was not high enough, when compared with the amount 
presented to animals by Jarrett & Hall (1984) to induce a protective effect on the fetal 
(newborn) IgE synthesis. The study of Lilja et al (1989) may have given different results if the 
diet was altered at the beginning of pregnancy, and the subjects could have been genetically 
identical!
The salivary immune response was also monitored in the three groups of infants over an 
18 month period postnatally. B-Lg IgA and a-cas IgA antibodies were detected in 45% of the 
1 week infants’ saliva samples. Although adult levels of salivary IgA antibody levels are not 
reached until approximately 6 years of age (Gmoshinsky et al, 1990), evidence suggests that 
early salivary IgA production is common (Mellander et al, 1984; Frick & Rieger, 1987; Cripps 
et al, 1989; Arbald et al, 1990 and Renz et al, 1991a & 1991b). It was observed that although 
there were no significant differences in the B-Lg and a-cas specific IgA antibody levels between 
the three groups, the infants in the non-atopic group had higher mean IgA antibody levels at 
1-2 months, which dropped to levels comparable to the other two groups by 12 months. This 
was in contrast to Renz et al (1991a and 1991b) who reported significantly elevated B-Lg slgA 
and a-cas slgA levels in infants in the "high risk" group. However the data presented here 
regarding the peak of milk specific IgA antibody levels at about a month postpartum, and the 
gradual decline by 18 months was also reported by other groups (Mellander et al, 1984; Cripps 
et al, 1989 and Renz et al, 1991a & 1991b).
The stimulus of the reported salivary IgA antibodies in neonatal saliva is unclear. As stated 
in section 4.4.5, contamination of the amniotic fluid by foreign antigens which pass across the 
placenta from the maternal circulation (Renz et al, 1991a) and factors present in breast milk 
(Roberts & Freed, 1977) such as maternal anti-idiotypic antibodies (Archibald et al, 1990) have
all been suggested as possible stimulants. Sceptics have blamed the early salivary IgA antibody 
levels on breast milk contamination of the infant saliva samples. However detectable levels of 
B-Lg and a-cas specific slgA antibodies have been detected in infant saliva samples before 
commencement of breast feeding (Archibald et al, 1990 and Renz et al, 1991a & 1991b). The 
ability of the neonate to synthesis slgA antibodies at an early age was supported by the 
presence of B-Lg IgA antibodies within neonatal breast milk at 2 weeks of age (Robertson et 
al, 1986). The levels of milk specific slgA antibodies have been suggested as a means of 
predicting the potential allergy risk of the infant, with elevated levels suggesting an increased 
risk of allergy development (Renz 1991a & 1991b). Due to the connection between the salivary 
antibody levels, the antigenic exposure, and the immunological status of the intestinal tract
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(Hanson, 1975 and Walker, 1987), infant saliva could give invaluable insight into the mucosal 
handling of food antigens. Obviously further research is required in this area to quantify the 
potential use of saliva as a monitoring device.
5.4.5 THE INFLUENCE OF PARENTAL ATOPY AND MATERNAL DIET ON ALLERGY 
INCIDENCE.
The influence of parental atopy and maternal diet on the immune response in the 
developing infant is interesting, but could be considered as academic. The primary concern is 
the effect that these factors have on the ultimate allergy development within the infants.
The allergy incidence of the infants whose mothers followed a milk-free diet during late 
pregnancy and lactation, in addition to a late milk introduction, was comparable to the non- 
atopic group and significantly lower than the atopic group at 12 and 18 months postnatally, (this 
was after the exclusion of three of the infants who had received a cow’s milk formula within 
their first week of life due to unavoidable circumstances). Zieger et al (1989) reported that a 
strict maternal dietary regimen during late pregnancy and lactation in addition to delayed 
introduction of food-allergens into the infants diet, reduced food sensitisation and allergy, 
primarily during the first year of life. A similar study performed by Chandra et al (1986) also 
reported that a strict dietary regimen of allergen-avoidance during late pregnancy and lactation 
enhanced the preventative benefit of exclusive breast feeding on the incidence of atopic eczema 
in "high risk" infants.
In this study, parental atopy was also found to have a significant influence on the allergy 
development in infants born to mothers following an unrestricted diet. A number of other 
groups have reported this, which reinforces the theory that infants with atopic parents have a 
genetic predisposition to allergy development (Kjellman, 1976 and Danneaus et al, 1978). From 
the results of this study, it was concluded that maternal exclusion diets were only appropriate 
for "at risk" infants, as the risk of an infant bom to non-atopic parents developing an allergy 
is minimal. A view also held by a number of others groups (Chandra et al, 1986; Falth- 
Magnusson et al, 1988; Zieger et al, 1989 and Hattevig et al, 1990).
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CHAPTER 6
LEVELS OF COW’S MILK B-Lg AND a-CAS SPECIFIC IgG AND IgG SUBCLASSES, 
TOTAL IgE AND B-Lg ANTIGEN IN ADULTS WITH DIFFERENT ALLERGIC
DISORDERS
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6.1 INTRODUCTION
6.1.1 FOOD SENSITIVITY
Two types of food sensitivity are recognised, immediate onset and delayed onset (Roitt, 
1989). In the former type, symptoms occur within 1 hour and can induce angioedema, urticaria, 
asthma and anaphylaxis. The immunological mechanism underlying this type of reaction is IgE- 
dependent, and IgE antibodies specific to the food concerned are demonstrable by skin prick 
test and radio-allergosorbent tests (RAST). In the delayed onset reaction, which is most 
commonly induced by cow’s milk, symptoms occur several hours to several days after ingestion 
of the offending food and include asthma and eczema (Foucard, 1985). The immunological 
basis for this type of reaction is not clear as the skin prick test and RAST are usually negative 
(Roitt, 1989).
In seeking to explain the negative IgE tests in the cases of delayed onset reactions, there 
are suggestions that the formation of de novo allergens by digestion could lead to IgE 
production against them (Foucard, 1985). In support of this theory, Haddad et al (1979) claimed 
to have detected IgE antibodies to peptic and tryptic digests of B-Lg in milk intolerant children, 
who had no detectable native milk protein specific IgE. Increasing attention was given to the 
possible involvement of other antibodies in hypersensitive reactions. IgG antibodies to milk 
were detected in a larger proportion of patients with delayed onset food sensitivity compared 
with controls (Kletter et al, 1971; Galant et al, 1973; Burgin-Wolff et al, 1980 and Fallstrom 
et al, 1986), however their pathological relevance remains uncertain. The problem was at least 
partly due to a failure to appreciate the great heterogeneity of IgG and the four subclasses, 
which made it difficult to accurately interpret the relevance of the total IgG levels, as small 
changes which could be restricted to one or two subclasses were bound to be overlooked 
(Merret et al, 1984).
6.1.2 DEVELOPMENT OF IgG SUBCLASSES
To determine whether the appearance of differences in IgG subclass levels was a natural 
occurrence, or one of pathological importance, the levels of these subclasses were determined 
in atopic compared with normal subjects. It was found by a number of groups that total IgG4 
antibody levels were higher in individuals with atopic dermatitis compared with controls (Shakib 
et al, 1977; Gwynn et al, 1979 and Reinhold et al, 1988). Reports of elevated IgE antibodies 
were also found in subjects suffering from atopic dermatitis, which suggested a possible role of 
these antibodies in the pathogenesis of this disease (Shakib et al, 1977 & Reinhold et al, 1988).
As differences in total subclass levels could mask the differences of specific IgG subclass
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levels, specific subclass assays have seemed an appropriate step to take in the determination of 
the possible involvement of IgG subclasses in food allergy.
6.1.3 IgG4 AND FOOD SPECIFIC ANTIBODIES
Restriction of food specific antibodies to one subclass have been reported in atopic 
individuals, for example IgG4 antibodies against OV and gliadin were demonstrated in subjects 
suffering from atopic dermatitis (Barnes et al, 1988a and Husby et al, 1989). However milk 
specific IgG subclasses which were reported to be predominantly against a-cas (Shakib, 1988b 
and Barnes et al, 1988b), showed elevation in specific IgG4, IgGl and IgG2 subclasses (Barnes 
et al, 1988b & Husby et al, 1989). From these results it was seen that the IgG4 subclass could 
be an important subclass in atopic disease, and for this reason many studies looked solely at this 
one, neglecting the other three. It was reported that milk and egg specific IgG4 antibodies were 
elevated in atopic dermatitis (Shakib et al, 1984 and Husby et al, 1989) and in milk intolerance 
(Shakib et al, 1986b and Shakib, 1988b). These antibody levels were not related to severity of 
the disease or specific IgE levels, and therefore have not been regarded as a useful diagnostic 
test for allergy (Shakib, 1988b).
Deficiencies in IgG subclasses have also been found in atopic disease. The most abundant 
deficiency was found to be IgG3, which was often accompanied by elevated IgG4 levels 
(Morgan & Levinsky, 1988).
6.1.4 MECHANISM OF IgG4 AND FOOD ALLERGY DEVELOPMENT
The possible involvement of the IgG4 subclass in allergy development is controversial. It is 
known that IgGl is the subclass produced early in antigen exposure, with IgG4 increasing, and 
sometimes predominating, in long term exposure (Aalberse et al, 1983 and Roitt, 1989). There 
is reasonable indirect evidence to suggest that IgG4 is cytophilic for basophils (Hurn & Landon, 
1971). It has been found that heterologous anti-IgG4 antisera could stimulate peripheral blood 
leukocytes from normal and allergic individuals to degranulate and release histamine (Shakib, 
1986a and Shakib, 1989). The monovalence of IgG4, and the inability to cross-link when cell- 
bound, with the allergen, was suggested as a reason for the inability of IgG4 to elicit such a 
response. However, rheumatoid factor -like IgM antiglobulin- was found in atopic patients, 
which was capable of reacting with IgG4 and releasing histamine. The production of these 
autoantibodies could be the result of an excessive production of IgG4 antibodies due to over­
stimulation, leading to an abnormal load of denatured IgG4 and the subsequent autoantibody 
production (Shakib, 1986a and Shakib, 1988a).
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6.1.5 AIMS OF THE STUDY
The aim of the study was to investigate the involvement of IgGl, IgG2, IgG3 and IgG4 
subclasses in sensitivities of a number of different types. Cow’s milk B-Lg IgG and IgG 
subclasses, a-cas IgG and IgG subclasses, total IgE and circulating B-Lg antigen levels were 
determined in adults suffering from eczema, asthma or food intolerance and compared with a 
control group.
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6.2 METHODS.
6.2.1 SUBJECTS
Volunteers were recruited from the students and staff at the University of Surrey, Guildford, 
and from the general public in the county of Surrey. 46 subjects completed a questionnaire 
relating to allergies suffered by themselves and their immediate family. This information was 
used to allocate each subject into the appropriate group, which were defined by the major 
presenting symptom: 1. asthma, 2. eczema, 3. food allergy/intolerance and 4. control (suffering 
from no known allergies). 12, 12, 11 and 11 subjects respectively, were recruited into each 
group.
6.2.2 SAMPLES
A 5 ml non-fasting, venous blood sample was taken from each subject, within the month 
of December 1989. The blood was left to clot for 1 hour and then spun at 1000 g for 10 min 
at 4°C. The serum was then aliquoted and frozen at -20°C until it was required for analysis.
6.2.3 BIOCHEMICAL ANALYSIS
The total cow’s milk 6-Lg IgG and a-cas IgG antibody levels in the serum samples were 
quantitated by ELISA as described in section 2.2.3.1. In addition, the cow’s milk IgG subclass 
levels were determined as described in section 2.2.4.1 and the circulating 6-Lg antigen levels 
described in section 3.2.5.1. The total IgE levels were also determined using a Pharmacia Kit. 
This was kindly performed by a Clinical Biochemist of the Clinical Biochemistry Department, 
St. Mary’s Hospital, London.
The levels of the specific B-Lg IgG and a-cas IgG subclass levels were expressed as arbitrary 
units, and calculated using the following formula:
U/ml = OD (sample) X 100 
OD (standard)
6.2.4 STATISTICAL ANALYSIS
A Random Fixed Model analysis of variance, an unpaired Student’s t-test and Pearson’s 
correlation were used as the statistical test where appropriate.
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6.3 RESULTS
6.3.1 SUBJECTS
All of the subjects were healthy, excepting their specific allergies. The average age of the 
subjects was 30.5 ±9.2 years (range 16-55). No significant difference was found between the 
mean ages of the four groups. Table 6:1 shows the mean values of the anthropometric data for 
group 1-4. There was no significant difference between the four groups of the mean weight, 
height or BMI. Group 1 [asthma] had a mean BMI ratio of 23.1, slightly higher, although not 
significantly from the other 3 groups. This was also reflected in the higher mean weight value 
of 70.1 ±13.8 Kg. However these differences were not found to be significantly different and 
it was assumed, therefore, that the four groups could be compared.
6.3.2 QUESTIONNAIRE INFORMATION
The symptoms of the subjects, and the allergy incidence in the subjects’ family and children 
is shown in Table 6:2. The major symptom of each subject determined to which group they 
were assigned. The majority of subjects in groups 1,2 and 3 also suffered from other symptoms 
associated with allergies. The familial allergy incidence in the three allergy groups (1, 2 and 
3) were similar at 93%, 83% and 91% respectively. A familial allergy incidence in the non- 
atopic groups was found to be 27%. The incidence of allergy in their respective offspring was 
75%, 75%, 67% and 25% for groups 1-4 respectively. Due to the small number of children, this 
difference was not significant.
6.3.3 BIOCHEMICAL ANALYSIS
All subjects had detectable total B-Lg IgG antibody levels as shown in Table 6:3. The levels 
of total B-Lg IgG and a-cas IgG antibody levels in sera samples were significantly correlated 
(r=0.97, p <0.0001) in all of the subjects. The 6-Lg IgG levels were higher, although not 
significantly, compared with the a-cas IgG levels, in all subjects.
Table 6:3 shows the mean levels of the total B-Lg IgG, total a-cas IgG, total IgE antibody 
levels and the circulating B-Lg antigen levels for groups 1-4. The mean levels of B-Lg IgG, a- 
cas IgG and total IgE antibodies were higher in the food allergic group (group 3) compared 
with the other groups, with the lowest values of these three antibody levels, in the non-atopic 
group (group 4). These differences for the three antibodies measured, however, were not found 
to be statistically significant. A significantly lower quantity of circulating B-Lg antigen, however, 
was revealed in the non-atopic group, when compared with the asthma group (group 1) 
(p<0.05) and the food allergic group (group 3) (p<0.05) using an unpaired Student’s t-test.
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Table 6:4 shows the values for B-Lg IgG subclasses and a-cas IgG subclasses for the 46 
subjects taken as a single population. The B-Lg IgG subclass and a-cas IgG subclass levels were 
ranked quantitatively in decreasing order respectively IgG4>IgG2>IgG3>IgGl and 
IgG4>IgG3>IgG2>IgGl, as shown in Fig 6:1 and 6:2. The B-Lg IgG4 and a-cas IgG4 antibody 
levels were found to be significantly higher than the other three subclass levels (P <0.0.001 and 
p <0.001 respectively).
The mean values of the four B-Lg IgG and a-cas IgG subclass levels for groups 1-4 are 
and 6:6
shown in Table 6:5, ana graphically in Fig 6:3 and Fig 6:4 respectively. The mean B-Lg and a- 
cas IgG subclass levels for the food allergic group (group 3) were consistently higher than the 
corresponding mean levels in the other three groups. This difference was found to be significant 
for the a-cas IgG4 subclass (P<0.01). It was observed that 9/11 subjects in the food allergic 
group were specifically milk sensitive, and of these 55% (5/9) had elevated levels of the B-Lg 
IgG4 subclass and 45% (4/9) had elevated levels of the a-cas IgG4 subclass, when compared 
with the non-atopic group, who had 18% (2/11) and 27% (3/11) respectively (any level above 
the mean value for the non-atopic group was taken as raised).
The correlation coefficient between the total B-Lg IgG antibody levels and the sum of the 
B-Lg IgG subclass levels was r=0.84 (P <0.001) and between the total a-cas IgG antibody levels 
and the sum of the a-cas IgG subclass levels was r=0.81 (P <0.001).
A positive correlation was also found between the total IgE levels and the B-Lg IgG4 and 
the a-cas IgG4 levels (r=0.6, p <0.0001 and r=0.6 in both cases). No relationship was reported 
between the total IgE antibody levels and the B-Lg and a-cas specific IgG subclasses 1, 2 and 
3.
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Anthropometric data for adults in the asthma (group 1), eczema (group 2), food allergy (group 
3) and control (group 4) groups.
Table 6:1
Group 1 
[Asthma]
Group2
[Eczema]
Group3 
[Food Algy]
Group 4 
[Control]
n 12 12 11 11
Male 4 3 3 2
Female 8 9 8 9
Age 34±9 31±8 33 ±13 26±6
(Years) (20-50) (23-52) (16-58) (22-43)
Weight 70.1 ±13.8 60.8 ±10.9 59.3 ±7.6 61.9±8.1
(Kg) (49-92) (46-87) (49-73) (49-71)
Height 1.72±0.12 1.69±0.10 1.71 ±0.06 1.70 ±0.09
(M) (1.60-1.88) (1.60-1.92) (1.60-1.18) (1.61-1.85)
BMI 23.1 ±2.9 21.4±1.8 20.7 ±1.4 21.3 ±1.8
(19.9-27.7) (18.0-23.6) (18.3-22.7) (18.9-23.4)
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Table 6:2
Allergy incidence in subjects, their families and children.
Group 1 
[Asthma]
Group 2 
[Eczema]
Group 3 
[Food Algy]
Group 4 
[Control]
n 12 12 11 11
Subject
Asthma 12 2 6 -
Eczema 3 12 10 -
Rash 4 3 6 -
Hayfever 9 5 6 -
Food Allergy - - 11 -
Medication 12 12 11 -
Family
Allergy 11 10 10 3
Children 
n with child 8 4 3 4
Allergy 6 3 2 1
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Table 6:3
Mean ± SD (range) of B-Lg IgG, a-cas IgG, total IgE antibody and B-Lg antigen levels in
adults in the asthma (group 1), eczema (group 2), food allergy (group 3) and control (group
4) groups.
Group 1 
[Asthma]
Group 2 
[Eczema]
Group 3 
[Food Algy]
Group 4 
[Control]
n 12 12 11 11
B-Lg IgG 
(Mg/ml)
18.5 ±18.9 
(5.8-62.8)
35.5 ±56.4 
(4.6-205.2)
114.3 ±323.1 
(3.1-1088.0)
11.4±8.4
(5.1-29.0)
a-cas IgG 
(Mg/ml)
12.9±30.5
(UD-109.0)
22.3 ±38.4 
(UD-130.0)
70.1 ±171.4 
(UD-580.0)
4.9±5.1
(UD-13.0)
Total IgE 
(U/ml)
179±199
(23-740)
1252±3643 
(2-12,800)
3086±5604
(3-17,500)
195 ±464 
(3-1570)
B-Lg
(ng/ml)
3.31 ±4.15* 
(UD-10.64)
1.09 ±0.86 
(UD-3.12)
3.66 ±5.12^ 
(UD-14.50)
0.41 ±0.52*  ^
(UD-1.16)
* and f Significantly different B-Lg antigen levels in control group (gp 4) compared with the 
asthma group (gp 1) and food allergy group (gp 3) respectively (p<0.05).
Table 6:4
Mean ± SD (range) of B-Lg IgG subclass and a-cas IgG subclass levels for the 46 subjects 
(data combined).
IgG IgGl IgG2 IgG3 IgG4
(Mg/ml) (U/ml) (U/ml) (U/ml) (U/ml)
B-Lg 44.2 ±161.5 18±66 73±162 60±170 320 ±464 *
(3.1-1088) (UD-432) (UD-707) (UD-1124) (UD-2279)
a-cas 27.1 ±88.1 72±142 251±366 266±362 601±1087x
(UD-580) (UD-782) (UD-2122) (UD-1788) (UD-5078)
UD = undetected
* IgG4 significantly higher than the other 3 subclasses (p <0.001) 
x IgG4 significantly higher than the other 3 subclasses (p <0.001)
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Table 6:5
Mean ± SD (range) of B-Lg IgG subclass levels for adults in the asthma (group 1), eczema 
(group 2), food allergy (group 3) and control (group 4) groups.
Group 1 
[Asthma]
Group 2 
[Eczema]
Group 3 
[Food Algy]
Group 4 
[Control]
n 12 12 11 11
IgGl (U/ml) 8±10 4±6 54 ±128 6±8
(UD-31) (UD-20) (UD-432) (UD-20)
IgG2 (U/ml) 31 ±51 66 ±127 117±208 84±234
(UD-137) (UD-446) (UD-562) (UD-707)
IgG3 (U/ml) 29 ±34 43 ±59 148 ±328 19±32
(UD-87) (UD-212) (UD-1124) (UD-99)
IgG4 (u/ml) 287 ±425 181 ±182 582±716 235 ±296
(UD-1529) (UD-643) (UD-2279) (UD-941)
UD = Undetected
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Table 6:6
Mean ± SD (range) of a-cas IgG subclass levels for adults in the asthma (group 1), eczema 
(group 2), food allergy (group 3) and control (group 4) groups.
Group 1 
[Asthma]
Group 2 
[Eczema]
Group 3 
[Food Algy]
Group 4 
[Control]
n 12 12 11 11
IgGl (U/ml) 55 ±40 
(9-145)
44 ±61 
(UD-168)
162 ±265 
(2-782)
28 ±33 
(UD-103)
IgG2 (U/ml) 186 ±157 
(20-426)
211 ±209 
(4-564)
427 ±654 
(UD-2122)
181 ±204 
(UD-458)
IgG3 (U/ml) 183 ±167 
(39-426)
280±233
(16-778)
501 ±455 
(10-1788)
234±213
(UD-1235)
IgG4 (U/ml) 320±290 
(71-936)
285 ±238 
(33-416)
1664±1512* 
(43-5078)
436±396 
(UD-1640)
UD = Undetected
* a-cas IgG4 antibody level in food allergy group significantly higher than the other three 
groups (p<0.01).
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Mean -  SE of B-Lg IgG subclass levels of 46 subjects in adult study.
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Fig 6:2
Mean -  SE of a-cas IgG subclass levels of 46 subjects in adult study.
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Mean -  SE of B-Lg IgG subclass levels in the eczema-gp 1 (n=12), asthma-gp 2 (n=12), food 
allergic-gp3 (n=ll)  and control-gp4 (n=ll) groups.
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Fig 6:4
Mean -  SE of a-cas IgG subclass levels in the eczema-gpl (n=12), asthma-gp2 (n=12), food 
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6.4 DISCUSSION
6.4.1 ELISA FOR B-Lg IgG AND a-CAS SPECIFIC IgG SUBCLASS DETERMINATION
In an attempt to establish the validity of the ELISA for the determination of B-Lg and a-
cas specific IgG subclass levels, the units of antibody in each subclass were added together, and 
compared to the total amount of B-Lg or a-cas specific IgG antibody. The summation of the 
individual subclass specific antibodies agreed well with the total IgG antibody in all subjects (fi- 
Lg r=0.83 and a-cas r=0.81). This data showed that the assays described here appear to be able 
to semi-quantitate the two cow’s milk specific antigens. This method of assay validity was also 
undertaken by Kemeny et al (1987) who reported a correlation of r=0.84 for bovine casein IgG 
subclass quantitation. This value is in agreement with our findings.
It was observed that the levels of a-cas IgG subclasses were higher than the B-Lg IgG 
subclass levels in all of the four groups. These results could be misinterpreted, as the assays 
were semi-quantitative, and care should be taken with comparisons. The apparent higher levels 
of a-cas IgG subclasses could simply reflect the more efficient coating of a-cas antigen onto the 
PVC microtitre plate compared with B-Lg. In order to compare antigen specific antibody levels 
accurately, therefore, the assays should be quantitative, with the levels in absolute units. Higher 
levels of a-cas IgG subclasses compared to B-Lg IgG subclasses were also observed by Shakib 
et al (1988b) and Barnes et al (1988b).
6.4.2 ALLERGY INCIDENCE
A higher record of family allergy in individuals presenting with allergic manifestations was 
observed, compared with the incidence in the families of individuals without allergies. This 
suggests a hereditary relationship of allergy development which has also been established by 
other groups (Vandenplas & Sacre, 1986 and Cookson & Hopkin, 1988). It has been suggested 
that atopy is inherited as an autosomal dominant character, but its clinical expression depends 
on interaction with other factors (Cookson & Hopkin, 1988).
6.4.3 IgG SUBCLASS LEVELS IN NORMAL INDIVIDUALS
The presence of IgG antibodies to food proteins is not restricted to atopic individuals, or 
those with a damaged gut wall, and has been found in a large proportion of the normal 
population (Gunther et al, 1960; Rothberg & Farr, 1965; Husby et al, 1985c; Lovegrove et a l, 
1989 and Hampton et al, 1989) and also in the non-atopic group in this study. In this study a 
positive correlation between the B-Lg IgG and a-cas IgG levels was observed. This suggests that 
an individual has a similar inherent reaction to both of these milk antigens, resulting in either
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a high immune response or a low immune response to them.
The presence of food specific antibodies in non-atopic individuals has led to the hypothesis 
that these antibodies are involved with the normal mechanism of antigen handling (Husby et 
al, 1985d and Burks et al, 1990). However, it has been reported that the total cow’s milk 
specific IgG antibody levels were elevated in subjects with atopic dermatitis (Husby et al, 1986b; 
Falth-Magnusson et al, 1987b; Martino et al, 1988 and Husby et al, 1989 ) and milk induced 
enterocolitis (McDonald et al, 1984) compared with controls. This suggests the possible 
involvement of these antibodies, or more importantly the IgG subclasses, in the manifestation 
of allergic symptoms.
The circulating levels of IgG subclasses within the normal population in decreasing order 
of occurrence is IgGl>IgG2>IgG3>IgG4 (Aucouturier et al, 1985). Recently, interest has been 
directed towards the involvement of IgG subclasses, especially IgG4, in the handling of food 
proteins within the blood. Circulating levels of food specific subclasses were detected in the 
majority of the individuals in this study, including those of the non-atopic group, supporting 
previous findings (Layton & Stanworth, 1984; Merret et al, 1984; Husby et al, 1985d and Barnes 
et al, 1988a). The levels of food specific subclasses have been found to be in the reverse order 
to the levels of total IgG subclasses (Gwynn et al, 1979 and Reinhold et al, 1988). In this study, 
the concentrations of both B-Lg and a-cas specific IgG subclasses supported the levels reported 
by Husby et al (1985e & 1986c), Reinhold et al (1988), and Barnes et al (1988a), with IgG4 
concentrations significantly higher than the other three subclass levels. Also a shift of subclass 
predominance against food antigens from IgGl to IgG4, supports the hypothesis that IgG4 is 
synthesised in preference to IgGl after prolonged antigen exposure (Aalberse et al, 1983). 
Merret et al (1984) reported no change in total IgG levels in atopic eczema subjects compared 
to controls, but found a significant increase in IgG4 levels. He also suggested a shift from IgGl 
to IgG4 subclass antibodies in atopic dermatitis.
Food specific antibodies have been reported to be restricted to different IgG subclasses 
depending on the individual food protein. OV was found to be either predominately IgG4 
subclass (Shakib et al, 1984 & 1986b; Barnes 1988a and Shakib 1988b), IgGl and IgG4 
subclasses (Husby et al, 1986c & 1989), or IgG4 and IgG3 (Morris, unpublished). Cow’s milk 
specific antibodies have been found to be predominantly in the IgG4 subclass with some groups 
also finding elevated IgGl (Husby et al, 1986c & 1989) or IgG2 (Barnes et al, 1988a & 1988b). 
Although the most frequently detected milk specific antibody was IgG4, B-Lg and a-cas specific 
antibodies were also found to be present in the three other subclasses including IgG3. The 
presence of IgG3 has not been reported by some groups, (Husby et al, 1986b) but has been
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found to be present by others (Martino et al, 1988; Shakib et al, 1986a and Barnes et al, 1988a 
& 1988b). The significance of these results is not clear.
Barnes et al (1988a & 1888b) reported that the predominant milk antigen to stimulate an 
IgG subclass response was a-cas, found mainly in the IgG4 and IgG2 subclasses. He suggested 
that the restriction of a-cas antibodies to the IgG4 and IgG2 subclasses may have been 
influenced by the formation of micelles, as in fresh milk, Deman, 1982, expressing repeating 
glycosylated epitopes analogous to those of bacterial polysaccharides. Human serum antibodies 
reactive with carbohydrate and polysaccharide antigens, are commonly restricted to the IgG2 
isotype (Barnes et al, 1988a). Although elevated a-cas IgG2 levels were reported in this study, 
they were also accompanied by equivalent levels of a-cas IgG3. The possible explanation for 
this is that bovine casein micelles are spherical particles containing a-, fi- and k-casein 
molecules, with k-casein dominating the surface, and more than half of the k-casein in the 
glycosalated form (Barnes et al, 1988a). The antigen used in the study reported in this thesis, 
was a-casein, differing from that used by Barnes et al (1988a & 1988b) which was a whole 
casein preparation containing the highly glycosylated k-casein. This k-casein probably accounted 
for the IgG2 restriction, not found to such a degree with a-casein. The restriction of food 
antigens to individual subclasses could reflect the different ways in which the body handles food 
proteins. Husby et al (1985b) reported low grade intestinal absorption of OV, but not B-Lg, in 
healthy adults. This difference of absorption was probably due to the relative resistance of OV 
to enzymatic digestion and may be relevant in the immunological response of the body to the 
transferred protein and the observed subclass restrictions.
6.4.4 IgG SUBCLASS LEVELS IN ATOPIC INDIVIDUALS
The presence of increased total or food specific IgG subclasses, especially IgG4, has been 
investigated by a number of groups in an attempt to determine the role, pathological or 
otherwise, of these antibodies in allergy development. Total food specific IgG and food specific 
IgG subclass levels have been reported to be elevated in individuals with cow’s milk allergy 
(McDonald et al, 1984; Husby et al, 1986c & 1989), but not others (Barnes et al, 1988a and 
Burks et al, 1990). The results of this study showed that the mean B-Lg IgG and a-cas IgG 
antibody levels in the non-atopic group respectively, were 10% and 7% of the mean levels of 
the food allergic groups. Despite this difference, it was not found to be significant using a 
multiple analysis of variance. This was probably due to the very high individual variation and 
the relatively small subject numbers. However, it can be concluded that there was a greater 
tendency for the subjects with food allergy to have elevated total B-Lg and a-cas specific IgG
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antibody levels compared with individuals without food allergy. When compared with the other 
3 groups, a quantitative increase in all of the IgG subclasses against B-Lg and a-cas, was also 
observed in the food allergic group. This difference was only found to be significant for the a- 
cas IgG4 levels, with the B-Lg and a-cas specific IgG4 antibody levels similar in the asthma, 
eczema and non-atopic group. Husby et al (1986c) reported significantly higher B-Lg IgG4 levels 
in atopic compared to non-atopic groups. Elevated a-cas IgG4 antibody levels were also 
reported by Shakib (1988b), who claimed that high a-cas IgG4 antibody concentrations appeared 
to be diagnostic of milk intolerance, causing eczema in adults. Barnes et a l (1988a & 1988b) 
observed that a-cas was the most reactive of the milk proteins, with elevated IgG4 levels in 
subjects with allergies. However, it is unlikely that B-Lg IgG4 or a-cas IgG4 levels can be used 
as a tool for milk allergy diagnosis, as was suggested by Shakib (1988b). The reason for this 
scepticism is that high levels were observed in this study in some of the individuals with no 
allergies and also in some individuals with eczema or asthma.
The increased milk specific IgG4 antibody levels in milk allergic individuals found in this, 
and other studies (McDonald et al, 1984; Shakib et al 1988b and Husby et al, 1986c & 1989), 
suggests a possible pathological role for these antigens in milk intolerance. However some 
groups have reported the inability to find elevated milk specific IgG4 antibody levels in 
individuals with milk allergy (Barnes et al, 1988a and Burks et al, 1990). However, Fallstrom et 
al (1986), when investigating the levels of 6-Lg IgG and IgE antibody levels in children with 
cow’s milk protein intolerance, found that those with a slow adverse reaction to cow’s milk 
feeding had significantly higher titres of IgG antibodies against both native and digested B-Lg 
compared with children with an immediate type of reaction or intolerance. These results suggest 
that IgG4 antibodies could be important, in a pathological capacity, in delayed onset milk 
allergy. In the study reported in this thesis, and others, the type of cow’s milk intolerance 
present within the subjects was not defined. If the milk intolerant groups were divided into the 
two clinical presentations - individuals with a slow adverse reaction, and those with an 
immediate adverse reaction - the levels of milk specific IgG4 antibodies, might be more 
informative.
In this study, individuals in the milk intolerant groups who did not show raised B-Lg IgG 
or a-cas IgG antibody levels may have been of the group showing an immediate adverse 
reaction to milk. They could alternatively have been of either group, exhibiting slow or 
immediate adverse reactions to milk, and have had undetected raised antibodies to other, more 
relevant milk proteins. Cow’s milk has approximately 20 antigenic components all capable of 
inducing antibody formation (Gjesing et al, 1984). This could be an important explanation of
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why single milk protein antibody levels are not suitable markers for clinical milk allergy, and 
could explain the inconsistencies in the B-Lg IgG and a-cas IgG subclass values in individuals 
reporting milk allergies. Two of the subjects, in the food allergic group, had low circulating B- 
Lg and a-cas specific total IgG and IgG subclasses, despite reporting violent reactions after milk 
ingestion. On further questioning, they were found to have strictly avoided milk ingestion over 
a long period. This has been shown to reduce circulating milk specific IgG antibody levels and 
could explain the low antibody levels observed in these individuals (Lilja et al, 1988 and Falth- 
Magnusson et al, 1989).
6.4.5 IgE ANTIBODY LEVELS AND ALLERGIES
The role of IgE antibodies in allergies is well established (Shakib, 1988b). IgE antibodies 
have the ability to bind to mast and basophil cells resulting in the release of vasoactive 
substances including histamine (Roitt, 1989). The pathological role of these antibodies has been 
supported by the elevated levels found in individuals with atopic dermatitis (Shakib et al, 1977; 
Husby et al, 1986c; Martino et al, 1988 and Peltonen et al, 1988), asthma (Gleich et al, 1971 
and Gwynn et al, 1979) and immediate cow’s milk intolerance (Bjorksten et al, 1983; Fallstrom 
et al, 1986 and Firer et al, 1987).
In this study it was observed that the levels of total IgE were highest in the food allergic 
group, but with the eczema group also having high levels compared to the asthma and control. 
It was interesting to note that the major symptom reported by the food allergic group was 
eczema, which as reported in this study, has been associated with elevated total and specific IgE 
levels (Shakib et al, 1977; Husby et al, 1986c; Martino et al, 1988 and Peltonen et al, 1988). 
This data would suggest that IgE antibodies have a pathological role in the manifestation of 
eczema, and not solely in milk allergy.
Despite these findings, elevated IgE antibody titres have not been found to be correlated 
with the severity of the disease (Gwynn et al, 1979; Burgin-Wolff et al, 1980 and Husby et al, 
1986c), or with elevated levels of milk specific IgG4 (Husby et al, 1986c and Martino et al, 
1988). A significant correlation was observed between the total IgE and B-Lg IgG4 and a-cas 
IgG4 antibody titres in this study. This supports Gwynn et al (1979) who suggested that the 
same polygenic factors may govern the IgE and IgG4 levels. However, this result contradicts 
the finding of Fallstrom et al (1988) and other groups, who found that either IgG4 antibodies 
or IgE antibody levels, but not both, were elevated, depending on the clinical manifestation of 
the disease. Not all patients with allergies have increased serum IgE, positive skin tests or 
measurable specific IgE antibodies (Biirgin-Wolff et al, 1980; Bjorksten et al, 1983 and Fallstrom
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et al, 1988). The existence of non-IgE reagins of the IgG-class have been found and are 
believed to reside in the IgG4 subclass. Elevated levels of this subclass has been found to be 
present in individuals with allergies, as previously mentioned in section 6.4.3.
6.4.6 THE PATHOLOGICAL ROLE OF IgG4 ANTIBODIES
The presence of elevated IgG4 antibodies in atopic individuals has stimulated research into 
the possible pathological mechanism of this antibody. There is evidence that mast cells have 
receptors for IgG4 antibodies in addition to IgE antibodies (Shakib, 1988b). The scepticism 
about the ability of IgG4 antibody to stimulate the release of mediators from the basophil cells 
is due to the insufficient cross-linking of the cell bound IgG4 antibodies with the allergen, which 
is essential for mediator release. This is believed to be due to the IgG4 antibody’s monovalency 
(Aalberse et al, 1983). However the recent demonstration of a rheumatoid factor like IgM 
antiglobulin in atopic patients, capable of reacting with the IgG4 and releasing histamine from 
basophils (Shakib et al, 1988a), has offered an explanation for this apparent discrepancy, and 
illustrates the possible role that an anaphylactoid IgG4 antibody may have in allergy 
development.
Despite evidence for the pathological role of IgG4 antibodies, it is controversial. Elevated 
IgG4 antibodies have also been reported in non-atopic individuals (Shakib et al, 1984 and 
Martino et al, 1988), and have been associated with hyporesponsiveness after immunotherapy 
(Halpern & Scott, 1988 and Peng et al, 1990). In the latter case, the IgG4 antibodies are 
described as blocking antibodies, with the ability to bind to the mast cell. This stops the binding 
of IgE antibodies and prevents mediator release (Shakib, 1988a).
This paradoxical situation, where IgG4 antibodies are found to have both anaphylactoid and 
protective features, has been suggested to have arisen due to the presence of a molecular 
heterogeneity within the IgG4 subclass (Krunkel et al, 1970). It would therefore be interesting 
to establish whether anaphylactic molecules are associated with one IgG4 subtype, where 
blocking IgG4 molecules are associated with another.
6.4.7 S-Lg ANTIGEN LEVELS AND ATOPIC CONDITION
The absorption of small quantities of antigenieally active food proteins from the intact gut 
wall, has been observed by a number of groups (Walker & Isselbacher, 1974; Paganelli & 
Levinsky, 1980 and Husby et al, 1986a). In the study reported in Chapter 6 the mean levels of 
circulating antigenieally intact cow’s milk B-Lg in the non-atopic group was significantly lower 
than that found in the food allergic and asthma groups. These two groups had mean
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concentrations of a similar magnitude. The samples were taken randomly with no consideration 
to the time of the last milk ingestion. However the significantly higher B-Lg levels observed in 
the food allergic and asthma groups and the higher levels in the eczema group (although not 
significant), when compared with the non-atopic group, suggests increased B-Lg absorption.
An increased absorption of antigens in subjects showing cow’s milk intolerance has been 
found by other groups (Heyman et al, 1988; Husby et al, 1990 and Schrander et al, 1990). 
Excessive uptake of cow’s milk antigen has been associated with cow’s milk allergy,- and has 
been suggested as a causative factor (Walker & Isselbacher, 1974). However the pathogenesis 
of cow’s milk allergy is still unclear, and it is not known whether the increased intestinal 
permeability to dietary protein antigens, abnormally stimulates the immune system, or if normal 
intestinal permeability to proteins leads to a pathological immune response in some given 
individuals. Heyman et al (1988) reported that the increased absorption of horseradish 
peroxidase in milk allergic children, was probably not the primary cause of allergy, and that it 
could have been due to the abnormal immune response leading to inflammation and mucosal 
damage. It was also observed that the absorption of Polyethylene glycol 400 or 1000 was similar 
in allergic subjects on an elimination diet, with no reported allergic manifestations, compared 
to healthy subjects (Falth-Magnusson et al, 1984). From the results of this study it is not 
feasible to make any conclusions regarding the pathogenic role of the increased antigen 
absorption, but it can be seem that even if the increased antigenic absorption is a secondary 
fact of the allergy, it has been found to be significantly elevated in many atopic subjects.
The results from this study illustrate the importance of the determination of all the B-Lg 
and a-cas IgG subclasses in addition to the total B-Lg and a-cas specific IgG antibody levels. 
Quantitation of the total food specific IgG antibody levels could be misleading, masking changes 
in the food specific IgG subclass levels (Shakib et al, 1986b and Merrett et al, 1984). In 
addition, the elevated levels of individual IgG subclasses can also be overlooked if the total IgG 
subclass is determined (Husby et al, 1985d). It was also found that food allergic individuals, 
especially if they were milk allergic, had a tendency to have higher levels of fi-Lg and a-cas 
specific IgG subclasses, especially IgG4. Total IgE antibody levels were also found to be 
elevated in the eczema and food allergic group suggesting the involvement of this antibody in 
eczema pathology. An increased mean antigen absorption was also observed in the atopic 
individuals compared to the non-atopic, which was found to be significant in the food allergy 
and asthma group.
Although the levels of B-Lg or a-cas specific IgG antibodies cannot be used as a diagnostic 
tool for milk allergy, which has also been concluded by other groups (Shakib et al 1986b, 1988
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& 1989; Barnes et al, 1988a and Reinhold et al, 1988), the results from this study have 
demonstrated that in food allergic individuals, the levels of a-cas IgG4 antibodies are 
significantly higher than the levels in controls and individuals with eczema and asthma. However, 
the data also emphasises the importance of determining the levels of milk specific IgGl, IgG2 
and IgG3 subclasses, as it was found that all of these were raised in atopic subjects compared 
to controls.
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CHAPTER 7
A STUDY TO INVESTIGATE THE COW’S MILK G-Lg ANTIGEN LEVELS AND THE 
COW’S MILK SPECIFIC B-Lg IgG AND a-CAS IgG ANTIBODY LEVELS IN HEALTHY
ADULTS AFTER A MILK LOAD
7.1 INTRODUCTION
7.1.1 CIRCULATING FOOD ANTIGENS
A large number of mechanisms are present within the gastrointestinal tract (GI) which 
provide for the exclusion of undigested macromolecules from systemic compartments. Despite 
the occurrence of these components there is increasing experimental and clinical evidence that 
large antigenically active molecules can penetrate the intestinal epithelial surface, not in 
sufficient quantities to be of nutritional importance, but in quantities that can be of 
immunological significance (Walker & Isselbacher, 1974; Paganelli & Levinsky, 1980 and Husby 
et al, 1986a). Since most healthy, non-immunocompromised humans develop and maintain serum 
antibodies to specific food antigens, it is assumed that the continual absorption of small amounts 
of such molecules is a normal event (Walker, 1987). The vast majority of adults show no ill 
effect to this physiological phenomenon. However when the barrier is disturbed and increased, 
(pathological) quantities of antigenic molecules gain access to the systemic circulation. This has 
been linked to local intestinal, or systemic disorders (Husby, 1988 and Walker, 1987).
The presence of precipitins to food in human serum was an early observation (Andersson 
et a l; 1925), and was taken to support the theory for the passage of dietary antigens across the 
GI tract. The description of passive cutaneous anaphylaxis by Prausnitz and Kustner (1921), was 
further support for antigen absorption. A direct demonstration of dietary antigen uptake (a- 
lactalbumin) in infant’s sera was first accomplished by the use of the complement fixation 
technique (Lippard et al, 1936). Following this, more sensitive tests were developed for the 
quantitation of circulating food antigens, such as RIA (Paganelli & Levinsky, 1980; Kilshaw & 
Cant, 1984; Telemo et al, 1986; Koritz et al, 1987 and Cavagni et al, 1988) and an ELISA 
(Husby et al, 1985; Kaminogawa et al, 1989 and Marcon-Genty et al, 1989a).
7.1.2 QUANTITATION OF FOOD ANTIGEN ABSORPTION
Paganelli and Levinsky (1980) detected B-Lg in the blood of 3 healthy individuals after a
1.2 litre milk load. The antigen was detectable in amounts up to 3ng/ml, and was reported to 
be transferred into the blood in a biphasic pattern. Uptake of dietary antigens in healthy adults 
was also observed by Kilshaw & Cant (1984), who measured nanogram quantities of OV in the 
serum of lactating women after ingestion of one raw egg. This transfer was further supported 
by Husby et al (1985b) who observed OV in the sera from 7 out of 8 healthy adults, after the 
intake of 60 ml of raw egg and 500 ml of milk. However, no B-Lg was detected in any of the 
serum samples, and the biphasic appearance of the B-Lg after a meal was not confirmed.
The consequence of the simultaneous presence of serum antibodies and of food antigens
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crossing the gut mucosa, leads to the formation of immune complexes (Paganelli et al, 1983; 
Gallagher et al, 1983 and Walker, 1987). Food specific immune complex formation was indicated 
by Paganelli et al (1983). Antigen non-specific assays for immune complexes in serum after 
meals was observed by Gallagher et al (1983), but was not consistently demonstrable (Husby 
et al, 1985b).
An important point to be considered in antigen absorption is the size distribution to 
determine whether whole or partially digested molecules are able to traverse the gut epithelium 
wall. Husby et al (1986b) reported the presence of OV, either in a high molecular weight 
fractions or native OV, in all 8 subjects studied. No B-Lg was detected. In addition to this, 
immune complexes were also found to contain native ovalbumin (Husby et al, 1985b).
7.1.3 PATHOLOGICAL CONSEQUENCES OF FOOD ANTIGEN ABSORPTION
The clinical interest in absorped food antigens and the subsequent antibody development, 
is of increasing concern, because of its association with a large number of pathological 
conditions. The GI diseases possibly associated with antigen absorption are GI allergy, 
inflammatory bowel disease, coeliac disease, toxigenic diarrhoea, chronic hepatitis, necrotizing 
enterocolitis and autoimmune disease (Walker, 1987).
In a number of disease states the permeability of the gut has been found to increase. 
Patients with IgA deficiencies were reported to contain higher levels of immune complexes 
(Cunningham-Rundles et al, 1979) which suggested an increased antigen transfer. Atopy was 
reported to give rise to higher levels of circulating antibodies (Husby et al, 1986b and Falth- 
Magnusson 1887a & 1987b), antigens (Heyman et al, 1988 and Husby et al, 1990) and certain 
types of immune complexes (Paganelli et al, 1983).
7.1.4 NORMAL LEVELS OF FOOD ANTIGEN ABSORPTION
In order to quantify how much mucosal permeation could be considered abnormal, it was 
essential to determine the quantity absorbed by healthy individuals. Antibodies to dietary 
antigens have been detected in the sera of a considerable proportion of the "normal" population 
(Gunther et al 1960; Husby et al, 1985c; Hampton et al, 1989 and Lovegrove et al, 1989). These 
antibodies were also found in varying quantities in term infants (Gunther et al, 1960 and Kletter 
et al, 1971) and premature infants (Rothberg, 1969). The antibody titres were reported to 
decline during the first decade of life in normal children, but not in food-allergic children (May 
et al, 1977). The presence of the antibodies, and the immune response after food antigen 
ingestion, is an area of increasing interest. To provide a possible explanation for the
195
development of oral tolerance in some individuals, and a pathological condition in others, the 
absorption and antibody development after milk ingestion needs to be considered.
7.1.5 AIMS OF STUDY
The aim of the study was to investigate the absorption of a cow’s milk protein, B-Lg, and 
cow’s milk proteins B-Lg and a-cas specific IgG antibody levels after a milk load. This was 
performed on healthy, non food allergic subjects, over a 6 hour period.
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7.2 METHODS
7.2.1 SUBJECTS
Eight healthy adult subjects, five male and three female, were recruited from the 
undergraduate student population at the University of Surrey. The requirement for inclusion 
on the study was that they had no history of food intolerance. Subjects were included if they 
suffered from allergies other than food allergies. All subjects were given an information sheet 
explaining the study protocol. The subjects were weighed, using a metric beam balance (accurate 
to lOOg) and had their height measured using a stadiometer, accurate to 1cm (Nivotoise, Paris). 
All subjects were asked to complete a questionnaire regarding age, sex, drinking and smoking 
habits, and the presence of any family allergies.
7.2.2 WEIGHED FOOD INVENTORIES
All subjects were instructed to record a weighed inventory of his/her food and drink intake 
immediately before the test meal, for a continuous five day period, of which two days were a 
weekend. Soehnle scales (CMS Weighing Equipment. London), capable of weighing up to 1kg 
to an accuracy of lg, were used. Each subject was instructed on how to use the scales. Cooked 
weights were taken, and details such as brand name and method of cooking were added as 
appropriate. To ensure correct recording of food and drink each subject was visited 1-2 days 
after the commencement of the study to discuss the records while the foods were being coded.
All records were coded using McCance and Widdowson’s Composition of Foods (Paul and 
Southgate, 1978). Analysis of food records were carried out using COMPEAT Nutritional 
analysis Computer Programme (Lifeline Ltd. London). The quantity of nutrients was obtained, 
and the approximate daily milk protein intake and E-Lg protein intake was calculated from this.
7.2.3 STUDY PROTOCOL
A cannula was placed into the antecubital vein at which time the first blood sample was 
taken (-10 min). Immediately before ingestion of the milk load the second blood sample was 
taken (0 min). The subjects were all fasted overnight (approximately 14 hours) and were only 
allowed to consume water for the duration of the study period. Each subject was given lOml/kg 
body weight of pasteurised full fat milk (Ryde Farm Estate Dairy. Leatherhead, Surrey) to 
consume orally over a period of 10 min. Blood samples (15ml) were taken at 15 and 30 minute 
intervals for the first 4 hours and then hourly for the next 2 hours.
The blood was collected into a plain sterile glass tube and allowed to clot for 1 hour. It was 
then spun at 1000 g for 5 min. The serum was removed from the clot, aliquoted and stored
197
at -20°C until required for analysis.
7.2.4 BIOCHEMICAL ANALYSIS
For each sample collected the quantity of circulating cow’s milk 6-Lg IgG and a-cas IgG 
antibodies were quantified as described in 2.2.3.I. In addition, the free circulating B-Lg antigen 
levels were determined, using the method described in 3.2.5.
7.2.5 STATISTICAL ANALYSIS
An one way analysis of variance, unpaired Student’s t-test and Pearson’s correlation were 
used as the statistical test where appropriate.
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7.3 RESULTS
7.3.1 ANTHROPOMETRIC DATA
The anthropometric data of the subjects is shown below in Table 7:1. All subjects were 
within the recommended BMI range, with the males and females having comparable values.
7.3.2 WEIGHED FOOD INVENTORIES
All subjects successfully completed a five day weighed food inventory. After comparing the 
calculated mean nutrient intake of the subjects with the recommended daily amounts (DHSS 
Report No. 15, 1979), it was observed that their diets supplied sufficient nutrients. Table 7:2 
shows the mean nutrient intake for the studied group.
7.3.3 QUESTIONNAIRE
Only one subject smoked regularly. One male and one female subject exceeded the 
recommended alcohol intake. Two subjects reported having a mild pollen allergy, in addition 
to their parents. One subject’s mother also was reported to suffer from a mild pollen allergy.
7.3.4 MILK LOAD
Before the study all subjects had been fasted for a minimum of 14 hours and had not 
consumed milk or milk products for a 18 hour period. The volume of milk given to each subject 
was lOml/kg body weight and was in a range of 555-770ml. Table 7:3 shows the nutrient 
composition of the milk load given to each subject.
7.3.5 BIOCHEMICAL DATA
All of the analysed samples had detectable cow’s milk B-Lg IgG and a-cas IgG antibody 
levels. The mean B-Lg IgG and a-cas IgG antibody levels over a 6 hour period after the orally 
administered milk load are in Table 7:4, and shown graphically in Fig 7:1 and 7:2 respectively. 
No significant change in the B-Lg IgG or a-cas IgG antibody levels with time was detected.
The mean B-Lg antigen levels over a 6 hour period after a milk load are shown in Fig 7:3. 
A significant variation of these mean antigen levels over time was observed (p<0.01). The 
individual B-Lg levels of the 8 subjects are shown in Fig 7:4. One subject (no. 7) had circulating 
B-Lg levels which were significantly higher than the remaining subjects (p<0.01). Subject 2 had 
no detectable B-Lg levels. B-Lg antigen was detected in the circulation of the majority of 
subjects 30 min after administration, and peak levels were observed between 30-90 mins and 
165-240 mins. The absorption was in a biphasic pattern.
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A significant correlation was found between B-Lg IgG and a-cas IgG levels (r=0.6, 
p<0.001), but no correlation was found between the mean daily milk protein ingestion and total 
basal B-Lg and a-cas IgG levels or the circulating B-Lg IgG, a-cas IgG antibody levels and the 
circulating B-Lg level.
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Table 7:1.
Anthropometric data mean ± SD (range) for the 8 subjects involved with the milk load study.
Male Female
Number 5 3
Age (years) 21 ±1 20±1
(20-22) (19-21)
Weight (kg) 68.4±4.8 66.0 ±10.8
(64.0-75.0) 55.5-77.0)
Height (M) 1.81 ±8.2 1.73 ±3.3
(1.73-1.94) (1.70-1.77)
BMI 20.9±2.2 21.9±3.0
(17.8-23.0) (18.7-24.6)
Mean ± SD 
(Range)
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Table 7:2.
Mean ± SD (range) of daily nutrient intake for study subjects involved with the milk load study 
(n=8).
Mean±SD Range
Energy (MJ) 9.9 ±1.7 7.5-12.3
Prot. (g) 73 ±13 51-84
Fat (g) 96±17 74-115
P:S ratio 0.28 ±0.09 0.20-0.49
CHO (g) 299±69 245-430
Ale. (% eng) 4±4 0-11
Milk (g) 20±10 10-38
Vit A (/ig) 711 ±475 297-1787
Vit D (/ig) 2.8±1.5 0.7-4.8
Vit C (mg) 100±98 14-325
Calcium (mg) 1274±410 861-2300
Iron (mg) 13 ±2 10-15
Table 7:3
The approximate nutrient content of the milk load given to each subject (/100ml whole cow’s 
milk)
Energy Protein Fat CHO B-Lg
(kcal) M) (g) (g) (g) (g)
65 272 3.3 3.8 4.7 0.33
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Mean ± SD (range) of B-Lg IgG, a-cas IgG and B-Lg levels for a 6 hour period after a milk 
ingestion of lOml/kg body weight of cow’s milk (n=8)
Table 7:4
B-Lg IgG 
(Mg/ml)
a-cas IgG 
(Mg/ml)
B-Lg
(ng/ml)
-10 14.6 ±14.8 7.9 ±4.0 0.96±1.11
(0.3-47.28) (0.5-15.3) (UD-3.23)
0 13.3 ±15.1 6.7±3.8 1.10±1.34
(0.4-48.6) (0.4-14.3) (UD-4.01)
15 13.1 ±13.4 6.8 ±4.0 3.84±6.49
(0.3-44.0) (0.4-12.8) (UD-19.61)
30 12.8 ±15.2 6.5 ±3.3 3.86±7.22
(0.4-48.6) (0.4-11.7) (UD-21.40)
60 10.8 ±10.2 6.3 ±3.8 3.72±7.03
(0.5-33.0) (0.3-14.0) (UD-3.93)
90 12.0±15.3 6.4 ±3.8 4.03 ±9.05
(1.0-48.2) (0.4-13.9) (UD-26.34)
120 13.9±15.7 6.3±3.9 2.97 ±4.56
(0.6-49.6) (0.3-14.1 (UD-14.01)
135 13.3 ±15.1 6.1 ±3.1 3.20±4.72
(0.9-48.2) (0.3-13.6) (UD-5.03)
150 13.3 ±14.4 6.7 ±4.1 3.65 ±6.42
(0.6-45.3) (0.3-14.9) (UD-19.27)
165 11.6±14.1 6.5 ±4.3 1.20±1.40
(0.8-45.0) (0.4-15.7) (UD-4.35)
180 13.4±15.9 6.3 ±3.5 1.05±1.13
(0.6-50.6) (0.2-12.6) (UD-3.41)
195 12.0±11.5 6.4 ±3.8 2.90±6.34
(0.7-36.2) (0.2-13.8) (UD-18.66)
210 11.8±14.0 6.3 ±3.8 4.00±8.79
(0.7-43.7) (0.3-13.4) (UD-28.52)
240 12.1 ±16.2 6.3 ±3.8 2.15±2.76
(1.0-50,5) (0.3-15.3) (UD-8.21)
300 U.2±10.7 6.4±4.1 1.15 ±1.26
(0.7-33.5) (0.3-14.7) (UD-4.00)
360 12.6±14.5 6.1 ±4.1 0.94±1.05
(0.9-46.2) (0.4-15.0 (UD-2.88)
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M ean ±  SE o f B-Lg IgG antibody concentrations in adult sera (n = 8) over a 6 hour period 
following a test meal containing 10ml milk/kg body weight.
B-Lg IgG antibody (iig/tnl)
Fig 7:1
Time (min) after milk load
Mean a  SE (n»8)
Fig 7:2
Mean ±  SE o f a-cas IgG antibody concentration in adult sera (n = 8) over a 6 hour period 
following a test meal containing 10ml milk/kg body weight.
«c-cas IgG antibody (|jg/mt)
-6 0  0 60 100 160 200 260 300 350 400
Time (min) after milk load
Mean *. SE (n>8)
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Mean ±  SE o f B-Lg concentration in sera adult (n = 8) over a 6 hour period following a test 
meal containing 10ml milk/kg body weight.
fi-Lg (ng/ml)
Fig 7:3
Time (min) after milk load
Mean ♦ 8E (n«8)
Significant variation with time p<0.Q1
Fig 7:4
Individual B-Lg concentration in sera over a 6 hour period following a test meal containing 
10ml milk/kg body weight.
B-Lg (ng/ml)
Time (min) after milk load
—  1 2 a ' □ " 4
—w — 5 —6— e —A — 7 - S -  8
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7.4 DISCUSSION
7.4.1 APPEARANCE OF MILK ANTIGEN IN THE SERA AFTER A  MILK LO AD
In this study the majority o f subjects (7/8) had detectable levels o f  B-Lg antigen in their 
sera, after a milk load which contained approximately 1.9-2.5g B-Lg protein. O ne o f the subjects 
had circulating 6-Lg levels significantly higher than the remaining seven subjects after the milk 
load, although her basal B-Lg level was very low. The maximum antigen concentration in this 
subject was 25ng/ml, which was considerably higher when compared to the 3ng/ml maximum 
levels in normal individuals reported by Paganelli & Levinsky (1980) and the 2ng/ml levels in 
infants with cows milk allergy, after a milk challenge (Husby et al, 1990). However, the 
maximum levels in the other subjects with detectable B-Lg, o f between 1.5-4.4ng/ml, were more 
in agreement with Paganelli & Levinsky (1980) and Husby et al (1990). It could be speculated 
that the subject who had high levels o f B-Lg could have been a high absorber relative to the 
normal population as a whole, and therefore was not a representative subject.
The other six subjects showed varying, but low levels o f B-Lg antigen in their blood. This 
supports the observation that the amount o f antigen absorped into the circulation is an 
individual phenomena, dependent upon many factors (Paganelli & Levinsky, 1980 and Husby 
et al, 1985b,1986a & 1990).
In this study the antigen absorption was found to follow an approximate biphasic pattern, 
which was also reported by Paganelli & Levinsky (1980), but not Husby et al (1985b). The peak 
levels o f B-Lg appearance in the blood varied between individuals, but most showed an initial 
peak around 30-90 mins and a second at approximately 165-240 mins. Husby et al (1985b) 
reported the appearance o f ovalbumin in the sera o f seven subjects as monophasic, after a test 
meal contain egg protein. Maximum levels o f ovalbumin were reported at approximately 120- 
300 min after the test meal, which correlated with the second peak o f B-Lg appearance in the 
blood. This monophasic appearance o f food antigens in the circulation was also reported by 
Troncone et al (1987). It is possible that the handling o f antigen absorption depends on the 
specific antigen in question, explaining the aforementioned discrepancies.
Trace amounts o f  B-Lg were found at time 0 in 5/8 subjects in this study. This has also 
been reported by Husby who found small quantities o f ovalbumin 48 hours after egg ingestion  
(Husby et al, 1986a), and B-Lg 24 hours after a milk challenge (Husby et al, 1990). This 
probably reflects the slow clearance o f food antigens from the blood o f som e individuals, the 
significance o f which is not clear, but does emphasise the need for an extended fasting period 
before the commencement o f feeding studies.
Husby et al (1985b) studied the absorption o f B-Lg into the blood after a milk load, but
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was unable to demonstrate the presence o f 6-Lg within any o f the subjects’ samples. The 
reason for the lack o f detectable food antigens in some subjects is not certain, but possible 
explanations include, the quantity, treatment and form o f the milk ingested, the possible 
interference o f antibodies present within the subjects gut or circulation, or the specificity o f  the 
rabbit antisera used.
Husby et al (1985b) initially gave a 500 ml milk load with egg and sugar. An explanation 
for the lack o f 6-Lg detection could have been the interference o f the egg protein on the 
absorption o f 6 -Lg. Studies on mice have found that the uptake o f OV was significantly reduced 
by the presence o f 6 -Lg, with the absorption o f B-Lg reduced, but not significantly, by the 
presence o f O V (Roberts et al, 1981). Husby et al (1985b) gave a 1000ml milk load to these  
subjects alone, and still reported no detectable B-Lg levels, suggesting the interference o f other 
food proteins was not the reason for the lack o f detectable B-Lg in the subject’s sera.
Milk processing (pasteurization) could effect antigen absorption, facilitating enzymatic 
degradation o f B-Lg in the gastrointestinal tract. Husby et al (1985b) also investigated the 
absorption o f 6 -Lg after an intake o f 1000 ml o f raw milk, and still reported no detectable 
serum B-Lg. The possible reason for this lack o f antigen detection after the ingestion o f  a 
sufficient quantity o f milk protein could have been that the test subjects did not take up 
antigenieally intact B-Lg above 0.3ng/ml (the ELISA detection limit), although this seems 
unlikely in view o f the observations by Paganelli & Levinsky (1980) and this study.
The detection o f B-Lg antigens by immunological reactivity with rabbit antibodies suggests 
that the detected 6 -Lg was antigenieally intact and therefore capable o f immunising an 
individual (Walker, 1987 and Husby, 1988), although this does not necessarily indicate that the 
protein is in an undigested, whole form. The intestinal digestibility o f food proteins influences 
the form in which there are absorped. B-Lg has been found to be the most resistant milk 
protein to enzyme hydrolysis (Otani, 1981 and Marcon-Genty et al, 1989a) and is therefore 
absorped in greater quantities compared to other milk proteins in animal studies (Koritz et al, 
1987 and Marcon-Genty et al, 1989a & 1989b). O V is reported to have an even higher 
proteolytic resistance (Husby et al, 1985b), with absorped antigenieally intact O V o f normal 
molecular weight in the form o f native molecules rather than degradation products (Kilshaw & 
Cant, 1984 and Husby et al, 1985b). Determination o f the size distribution o f the absorped food  
proteins is important, as it is believed to be involved with the induction o f immunisation or 
tolerance (Husby et al, 1985b), and would lead to a greater understanding o f the resistance o f  
the food protein to intestinal enzymic degradation. The size o f the B-Lg absorped in a study 
on cow’s milk protein intolerant children corresponded to small immune aggregates (Husby et
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al, 1990). This could explain why B-Lg levels have been found to be low in many o f the 
reported studies, with the smaller antigenic fragments eluding recognition by the specific rabbit 
antisera.
7.4.2 MILK SPECIFIC ANTIBODY LEVELS AFTER A  MILK LOAD
B-Lg IgG and a-cas IgG antibody levels were detected in all o f the subjects, with the 
individual concentrations varying considerably. However, despite the continuous antigenic 
challenge from daily milk ingestion, the antibody levels were relatively low. The B-Lg IgG and 
a-cas IgG antibody levels did not show any significant variation with time. This was also 
reported by (Gallagher et al, 1983 and Paganelli et al, 1983). An inverse relationship between  
the maximal serum levels o f antigen following a meal, and the levels o f serum B-Lg IgG  
antibody, were only apparent in the subjects with high or low antibody levels. This was also 
reported by Husby et al (1985b) and Dannaeus et al (1979). This could reflect the involvement 
o f other antibody classes in the handling o f the antigens.
Animal studies have shown that prior feeding o f protein antigens may reduce the 
subsequent adsorption o f that antigen without altering the rate o f its elimination (Swarbrick et 
al, 1979 and Lim & Rowley, 1982). This inhibitory effect is probably due to antibodies o f the 
slgA  class functioning by complexing and trapping the antigen at the mucosal surface, 
preventing its absorption (Walker, 1987). Studies in humans have also illustrated the importance 
o f mucosal antibodies in antigen exclusion. Cunningham-Rundles et al (1979) reported that the 
serum levels o f  circulating immune complexes correlated in IgA-deficient subjects with the 
presence o f  precipitins to milk. Therefore the lack o f slgA  at the mucosal surface may result 
in the uptake o f greater quantities o f dietary antigens into the circulation (Walker, 1987). 
Investigations into the antibody levels in human intestinal secretions may bring out further 
information regarding the relationship between the human mucosal and systemic immune system, 
and may help to explain why some individuals allow large quantities o f food antigens into the 
circulation.
Serum derived antibodies may also retard the penetration o f antigens, as shown in rabbits, 
although it is not known whether this is due to immune exclusion at the mucosal surface, or 
local elimination in the lamina propria (Tolo et al, 1977). In this study it was not possible to 
speculate whether the lack o f detectable B-Lg in some subjects was due to high mucosal slgA  
antibody levels, high serum IgG levels or a combination o f the two. Further investigations into 
the occurrence and classes o f B-Lg antibodies and immune complexes is required, to clarify this 
point.
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7.4.3 IM M UNE COMPLEXES A N D  THEIR IMPORTANCE IN ANTIGEN ABSORPTION
The presence o f milk specific antibodies and the absorption o f milk proteins, leads to the
formation o f  immune complexes in serum. This has been indicated in healthy adults (Paganelli 
et al, 1979 & 1983). The possible interference o f these circulating food specific antibodies have 
been blamed for the lack o f B-Lg detection in some individuals (Husby et al, 1985b). It was 
reported that subjects with substantial amounts o f O V antibodies, particularly in the IgG class, 
complexed with high molecular weight material, resulting in immune complexes unable to be 
quantified by the ELISA for free antigen detection (Husby et al, 1985b).
Following this observation food specific immune complex formation should increase after 
a test meal. This has been reported by Paganelli et al (1979 & 1983) who was investigating 
the formation o f B-Lg immune complexes, B-Lg antibody levels and the effect o f these on milk 
allergy, and Gallagher et al (1983). It was found that although the amount o f B-Lg incorporated 
in the complexes did not differ between atopic and non-atopic individuals, the type o f immune 
complex did. It was concluded that serum IgA (in addition to slgA  in the gut lumen) is 
concerned with safe food handling, suggesting that allergic symptoms produced after antigen 
exposure are not merely a reflection o f the amount absorbed (Paganelli et al, 1983).
Food immune complexes are involved with the development o f a hyporesponsive state by 
most individuals. Antibody titres against food antigens do not increase despite continued 
antigenic stimulation (Gallagher et al, 1983), suggesting a state o f tolerance. The mechanism 
o f oral tolerance development and maintenance, and the quantity o f antigen absorption are not 
directly related (Paganelli et al, 1983). It has been suggested that the liver plays an important 
role (Gallagher et al, 1983), in addition to the influence o f T rather than B lymphocytes, in 
mediating the hyporesposiveness to dietary antigens (Thomas et al, 1976) and IgA containing 
immune complexes (Andre et al, 1975). The significance o f food antigen absorption and the 
development o f a hyporesponsive state is important when related to the adverse effects caused 
by food allergy. If the mechanism o f absorption and tolerance could be determined, then the 
understanding and ability to treat food allergic individuals may be improved.
7.4.4 CONCLUSIONS
The ELISA assay technique used for the determination o f free B-Lg within human sera 
samples was sensitive and specific, although the quantity o f fractionated B-Lg protein it 
recognised could not be estimated. The levels o f immune complexed B-Lg antigen were not 
determined in this study, their determination would add to a greater understanding o f immune 
handling o f absorped milk proteins by normal individuals.
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The study provided information on the biphasic transfer o f 6 -Lg across the mucosal wall 
into the circulation in normal subjects after a milk load, quantitating the free 6 -Lg and 
emphasising that such a transfer was a physiological process, causing no detrimental effects in 
the studied subjects.
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CHAPTER 8
FINAL DISCUSSION A N D  FUTURE WORK
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8.1 INTRODUCTION
The study o f food allergy is incomplete without a fundamental knowledge o f how food is 
processed by the body in both normal and abnormal conditions, and o f how the majority o f  the 
population are tolerant, from an immune point o f view, to large quantities o f foreign protein 
to which the body is exposed every day. It is when this tolerance does not occur or when the 
process breaks down that maladaptation and disease occur.
As far as the pateint is concerned, the mechanism o f allergy is irrelevant with the proviso 
that the treatment alleviates the presenting symptoms. However, the more that is understood 
about mechanisms the closer the possibility o f diagnostic tests is and the means to treat and 
prevent allergies then becomes a reality. The studies presented in this thesis set out to address 
the question o f the natural and pathological immune response to the absorped milk antigens 
in adults and infants, and their subsequent consequences.
8.2 QUANTITATION OF MILK SPECIFIC ANTIBODIES A N D  ANTIGENS
As a prerequisite to the elucidation o f the immunological mechanisms involved in the 
natural and pathological handling o f ingested food antigens, reliable, sensitive and reproducible 
assays are required. A  significant proportion o f time devoted to this thesis was related to the 
development, optimisation and validation o f ELISAs for the accurate determination o f  B-Lg and 
a-cas specific antibody and B-Lg antigen levels in various human body fluids, serum, saliva and 
breast milk.
A  novel method o f antibody quantitation was developed and reported. This allowed an 
accurate comparison o f different food specific antibody levels within and between individuals. 
The technique included a combination o f affinity purification and nephelometry and proved to 
be quick and easy to perform. Reimer (1983) defined three levels o f standards that vary in their 
degree o f documentation and availability. According to this classification, our standard is a 
characterised "in-house" antibody standard ie. an antigen specific antibody standard which is not 
available from international or national sources. It would be valuable, scientifically, to compare 
the standards used in the developed assays with other quantified standards.
Quantitation o f the B-Lg and a-cas specific IgA antibody levels in both saliva and breast 
milk would also be o f value for the accurate comparison o f these levels. The development o f  
procedures for more extensive purification and concentration o f saliva and breast milk samples 
are suggested as future work. This may increase the recovery o f antibodies from the affinity 
columns, enabling standard quantitation.
The assays, once developed, proved to be easy to perform, sensitive and reproducible. In
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the case o f  both the cow’s milk specific antigen and antibody ELISA, it was not possible to 
quantitate the influence o f antibody complexes, and to determine whether one antibody 
complexed more or less than another. This would be interesting to investigate and could have 
significant relevance to the developed assays.
8.3 NO RM AL IM M UNE RESPONSE OF ANTIGEN ABSORPTION
To establish the pathological levels o f antibodies and antigens in various body fluids, studies 
on normal, non-immunocompromised individuals are required for the determination o f normal 
physiological levels. The study in Chapter 4 was an observational study, designed to examine 
the ranges o f antibody levels in healthy women during late pregnancy and lactation, and in their 
infants for a month postnatally. The results o f  this study, indicated that there were large 
individual variations in cow’s milk 6-Lg and a-cas specific antibody levels in a number o f  body 
fluids. This was also demonstrated in the studies performed on non-atopic individuals in the 
other three studies (Chapter 5, 6 and 7), and atopic subjects in the studies described in 
Chapters 5 and 6. D ue to this large individual variation, observed trends in antibody levels in 
atopic individuals proved not to be statistically significant. It would be worthwhile to pursue 
these studies in the future using larger subject groups, enabling any actual differences to be 
interpreted in relation to allergic diseases.
Standardisation o f sample collection may help to minimize the effect o f  previous food  
consumption on the observed individual variation o f food antibody levels (Lilja et al, 1988). The  
logistics o f  standardising the pregnant women’s meals with regard to cow’s milk protein intake 
including a period o f fasting before blood samples, would have proved very difficult. However, 
in the study investigating the antibody and antigen levels in sera samples after a milk load 
(Chapter 7), steps were employed to determine the effect of such standardisation. It was found 
that the 8 healthy adults who had not consumed milk products for a period o f 18 hours prior 
to the blood collection, and who were fasted for a 14 hours period, had a range o f basal 6 -Lg 
IgG and a-cas IgG antibody levels o f 0.3-47.3/ig/ml and 0.5-8.2/ig/ml respectively, comparable 
to the range observed in the unfasted subjects in the studies described in Chapters 4, 5 and 6. 
These results demonstrated that such short term standardisation measures did not effect the 
large individual variation, and it is speculatively suggested that the lack o f such standardisation 
in the other studies did not compromise the results obtained.
The serum levels o f 6 -Lg IgG and a-cas IgG antibodies in the non-atopic mothers in the 
mother/infant studies (Chapters 4 and 5) and the adults in the two adult studies (Chapters 6 
and 7) were comparable. The levels o f salivary and breast milk 6-Lg IgA and a-cas IgA also
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were not significantly different between the non-atopic women in the two mother/infant studies 
(Chapters 4 and 5). The results o f  such comparisons, suggest that the subject groups were 
randomly selected and representative o f the general population. This is an important 
consideration when relatively small sample numbers are used, and the data is extrapolated to 
the general population.
A  prerequisite for antibody production is the absorption o f antigenically intact protein, 
across the mucosal surface into the blood circulation (Walker, 1987). The factors that effect the 
quantity o f food antigen absorped across the gut wall is an area for conjecture. An ELISA for 
the determination o f free cow’s milk B-Lg was developed, and applied to the quantitation of 
this protein in adult sera and breast milk samples. No correlation was found between the levels 
o f B-Lg antigen and B-Lg IgG in sera samples o f the subjects in any o f the studies (Chapters 
4-7) or B-Lg antigen and B-Lg IgA in breast milk samples in the lactating women in the studies 
o f Chapters 4 and 5. Also, no correlation was found between the quantity o f cow’s milk protein 
ingested and the levels o f circulating free B-Lg antigen within sera samples reported in Chapters 
4, 5 and 7. It was found, however, that although the B-Lg antibody and antigen levels were not 
directly related to the quantity o f milk ingested, these levels could be modified by long-term  
dietary manipulation. A  significant reduction in B-Lg IgG antibody levels, and an elimination 
o f detectable free B-Lg antigen levels was demonstrated in women complying with a strict milk 
protein elimination (Chapter 5).
The study investigating the mucosal transfer o f B-Lg in healthy adults, demonstrated 
detectable 6 -Lg absorption after a relatively small dose o f B-Lg (0.033g/kg) ingestion in non- 
atopic subjects, and verified the biphasic absorption pattern reported by Paganelli et al (1983). 
However the consumption o f a single foodstuff, preceded and followed by a long fasting period 
was an atypical situation, and only provided information on the absorption o f one antigen, 
ignoring the influence o f other foods. A  study wliich investigated the absorption o f one food  
protein, in the presence o f others, would be o f value in an attempt to examine the competition  
for antigen absorption which must occur in reality.
Future work should be undertaken on the comparisons between atopic subjects, especially 
milk allergic individuals, and normal subjects, with respect to total milk antigen absorption, 
immune complex formation and the size o f the milk antigen fractions absorped. This would 
offer invaluable data in the confirmation o f theories on the differences, reasons and possible 
consequences o f dietary milk absorption. Determination o f B-Lg antigen in the infants sera 
samples would also help to elucidate whether higher quantities o f potentially antigenic food  
proteins are absorped by atopic infants compared to non-atopic, offering data on the mechanism
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o f allergy development.
8.4 ATO PY A N D  ANTIBO DY LEVELS
In the long-term intervention study, it was observed that the individual variation o f B-Lg and 
a-cas specific antibody levels in the atopic group o f women were not significantly different 
from those found in the non-atopic women, contrary to previous reports (Falth-Magnusson et 
al, 1987a, 1987b & 1988). The women who were assigned to the atopic group included subjects 
with a spectrum o f allergies. It is known that the development and presenting symptoms o f  
allergies vary considerably, as do the pathological mechanisms o f their occurrence. In an attempt 
to quantify any immunological differences between atopic and non-atopic subjects, a more 
stringent definition o f allergic disease was thought to be necessary. The study described in 
Chapter 6 was designed to investigate immunological differences in relation to various allergic 
symptoms. The subjects were assigned to a group determined by their main presenting symptom. 
Significantly higher a-cas IgG4 antibody levels were observed in the food allergic subjects 
compared to atopic individuals with non-food related allergic manifestations, and to non-atopic 
subjects. It was also noted that there was a tendency for atopic individuals to have elevated  
total IgE, B-Lg and a-cas specific IgG and IgG subclasses, although these differences were not 
found to be significantly different. During this study it was observed that B-Lg antigen and a- 
cas specific IgG or IgG subclass levels were not elevated in all milk allergic individuals. This 
apparent anomaly could be due to the vast array o f potential antigens in cow’s milk which could 
cause an allergic reaction, and it can be speculated that the levels o f IgG or other 
immunoglobulin classes could be raised against other more relevant antigens. The lack o f high 
B-Lg and a-cas specific IgG antibody levels in some individuals with a non-milk related atopic 
condition was not totally unexpected, and it may be that there were raised levels o f other 
immunoglobulin classes.
In an attempt to give less equivocal results, and to determine whether there is an 
immunological difference present within these groups, further work should be undertaken using 
larger numbers, more exactly defining allergic symptoms and causes.
The IgG4 subclass was shown to have a significance regarding food antigen handling. In all 
o f the subjects in the study described in Chapter 6, milk specific IgG4 antibody levels were 
significantly higher than the other milk specific subclasses. However, due to inconsistencies in 
B-Lg and a-cas specific IgG subclass levels in all individuals with allergies compared with 
controls, it would be interesting to establish whether the IgG4 antibodies associated with allergy 
are o f  one IgG4 subtype, whereas IgG4 antibodies associated with immunotherapy are another,
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and a study designed to investigate this in the future is suggested.
Many studies look solely at the food specific IgG4 subclass, because o f its apparent 
importance in food allergy, however, it became apparent that all o f the subclasses were involved 
with the immune handling o f milk antigens, as heightened levels o f all the milk specific 
subclasses were observed in food allergic subjects. This emphasises the importance o f the 
determination o f the total IgG subclass spectrum, as elevation can be in more than one subclass.
Future research on the involvement o f IgG subclasses on allergy development is required. 
The quantity o f maternally derived food specific IgG subclasses in the cord sera samples, and 
the subsequent IgG subclass development in infants would be interesting. It is also important 
to determine any variations between atopic and non-atopic individuals which could be used as 
a diagnostic test for allergy, or as a predictor o f future allergy development.
8.5 IM M UNE RESPONSES IN INFANTS COMPARED WITH ADULTS
The cow’s milk fi-Lg and a-cas specific antibody levels in the biological fluids o f the infants 
compared with the adults, represent different aspects o f the immune handling o f ingested milk 
protein. The monitoring o f antibody synthesis by infants from birth, in relation to atopy 
development, offers invaluable data on the possible fundamental differences in the immune 
response o f atopic and non-atopic infants on the first experience o f food antigens.
The true extent o f genetic and environmental influence on allergy development is not 
known. Data reported in the intervention study (Chapter 5) substantiates the theory that som e 
infants have a pre-disposition to allergy development. The presence o f allergy in the infants 
parents had a significant influence on the manifestation o f allergy in infants by 18 months 
postnatally, with a significantly higher allergy incidence in the infants born to women following 
an unrestricted diet in the atopic group compared to the non-atopic group. From the weighed  
food inventory data and the infant weaning records, the quantity o f  milk ingested by the 
mothers, and the time o f  milk and milk product introduction into their infants’ diet, was similar 
in the two groups. It was deduced that the significant difference in allergy development between  
the two groups o f infants, substantiated the inherent difference in the handling o f the ingested  
antigens.
Despite the important influence o f parental atopy on allergy development in their infants, 
no statistically significant differences were demonstrated in the serological or salivary antibody 
levels between the infants born to the women in the atopic compared with the non-atopic 
group, possibly due to the small sample sizes and large individual variation. However a higher 
initial IgG response was seen at 6 months in the infants born to the women in the atopic
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group, suggesting a tendency to develop a heightened immune response. It was also found that 
in all o f  the subjects involved with the studies presented in this thesis, a positive correlation was 
found between the levels o f B-Lg and a-cas specific antibody levels, and that the majority o f  
the atopic subjects in the adult study described in Chapter 6 showed elevated B-Lg and a-cas 
IgG subclass levels. This suggests, and is in agreement with Lilja et al (1988), that subjects are 
either "high" or "low" responders, probably determined by both genetic and environmental 
factors. A  study investigating the IgG and IgG subclass response o f "at risk" and "low risk" 
infants, with large subject groups, would seem a logical step in an attempt to determine whether 
the trends observed in this study could be substantiated.
Besides the genetic predisposition o f some infants to develop an allergy, the antibodies and 
antigens transferred from the mother could also influence the immune response o f the infant. 
In the mother/infant intervention study (Chapter 5), atopic women showed a tendency to 
transfer higher quantities o f antigenically intact B-Lg antigens to their infants, via the placenta 
and breast milk compared to non-atopic women. This could increase the antigenic load on the 
immature immune system which, together with the genetic predisposition o f the infant, would 
increase the potential risk o f allergy development. It would be o f interest to verify these results 
by more extensive studies.
Despite the presence o f a genetic predisposition to allergy development in some infants, it 
was found in this, and other studies (Chandra et al, 1989) that the incidence o f allergy 
development could be significantly reduced, at least on a short term basis, by strict maternal 
dietary manipulation during late pregnancy and lactation. From these observations it was 
deduced that the prevention o f potentially antigenic molecules from reaching the susceptible 
infant, reduces allergy development for at least 18 months in "at risk" infants. To establish 
whether this observed allergy reduction was long term or merely a postponement, a prospective 
study which would follow infants from birth, through childhood and ideally to adulthood, would 
be advisable.
N o conclusions regarding the immune mechanisms o f allergy can be formulated solely from 
the data presented in this thesis. Animal studies have demonstrated the importance o f the 
maternal diet on oral tolerance induction in her young. Milk ingestion by an animal during 
pregnancy and lactation results in a lower immune response in her offspring, compared to the 
young whose mother has not ingested the food protein during pregnancy and lactation 
(Pathirana et al, 1981). This model can be extended to experiences in humans, with the majority 
o f infants developing tolerance to the multitude o f food antigens in the mothers and their diet. 
Tolerance could be stimulated by the transferred food specific antibodies or antigens via the
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placenta or breast milk justifying their presence in these fluids. According to Jarrett et al (1977) 
T suppressor cells are stimulated by the presence o f high quantities o f a specific antigen 
resulting in a IgE antibody suppression in normal individuals. The sensitisation o f some infants 
by the transferred food specific antigens or antibodies would be a reflection o f the deficiency 
in T suppressor cell stimulation and not directly related to the presence o f the antigens. 
However, if antigens could be removed by maternal dietary manipulation in these suspectable 
individuals, the infants may be able to mature, allowing a tolerance state to develop.
More extensive human studies investigating the immune mechanism o f allergy development 
and the possible influence o f T  suppressor cell and mucosal slgA  antibody levels are required 
before it is possible to formulate any theories on the influence o f individual factors in this 
multi-factorial condition o f allergy.
8.6 CONCLUSIONS
Sensitive, specific, reproducible ELISAs were developed for the determination o f cow’s milk 
13-Lg and a-cas specific antibodies and B-Lg antigens in biological fluids. A  novel method o f  
antibody quantitation was successfully developed and reported in this thesis, for the quantitation 
o f B-Lg and a-cas specific IgG antibody levels in sera standards, allowing valuable absolute 
measurements o f these antibody levels.
Infants o f atopic parents were found to be at a higher risk o f allergy development, perhaps 
due to a genetic predisposition compared with infants o f non-atopic parents. However a strict 
elimination o f milk protein from the maternal diet during late pregnancy and lactation, and the 
delayed introduction o f milk products into the infant’s diet, reduced the allergy incidence to the 
levels o f  infants born to non-atopic parents.
The transfer o f cow’s milk B-Lg antigen into the blood circulation has been demonstrated 
to occur in a biphasic pattern in healthy, non-atopic adults after a milk load. Circulating levels 
o f free B-Lg were observed in non-atopic adults, atopic adults and pregnant women consuming 
cow’s milk. It was also demonstrated that cow’s milk B-Lg was transferred to the fetus via the 
placenta and the infant via breast milk. This transferred antigen in the majority o f  infants is 
tolerated, but in a minority has the potential to sensitise and produce a hyper-responsive state 
particularly in predisposed infants.
218
REFERENCES
REFERENCES
Aalberse RC, Van Der Gaag R and Van Leeuwen J. (1983) Serological aspects o f IgG4 antibodies.
1. Prolonged immunization results in an IgG4-restricted response. J. Immunol. 130 (2), 722-726.
Aas K. (1988) In: Food Allergy, ed. Reinhardt D  & Schmidt E. Nestle Nutrition Workshop Series. 
17. Nestec Ltd Vevy/Raven Press, Ltd. New York. 1-14.
Aberg N, Engstrom I & Lindberg U. (1989) Allergic diseases in Swedish school children. Acta 
Paediatr. Scand. 78 (2), 246-252.
Aherne CW & Marks V. (1979) Radioimmunoassay Techniques: Techniques in Metabolic Research. 
B218 1-9.
Allansmith M, McClellan BH, Butterworth M, Maloney JR. (1968) The development o f  
immunoglobulin levels in man. J. Pediatr. 72, 276-290.
Allansmith M, Ebersole JL, Bums CA. (1983) IgA antibody levels in human tears, saliva and serum. 
Ann. NY. Acad. Sci. 409, 766-768.
Andersson AF, Schloss OM & Myers C. (1925) The intestinal absorption o f antigenic protein by 
normal infants. Proc. Soc. exp. Biol. 23, 180-182.
Anderson KJ, McLaughlan P, Devey ME, & Coombs RR. (1979) Anaphylactic sensitivity o f guinea- 
pigs drinking different preparations o f cow’s milk and infant formulae. Clin. exp. Immunol. 35, 454- 
461.
Andersson U , Bird G & Britton S A  (1981) A  sequential study o f human B lymphocyte function 
from birth to two years o f age. Acta. Paediatr. Scand. 70, 837-842.
Andersson U, Sander B, Andersson J & Moller G. (1988) Concomitant production o f different 
lymphokines in activated T cells. Eur. J. Immunol. 18 (12), 2081-2084).
Andre C, Heremans JF, Vaerman JP & Cambiaso CI. (1975) A  mechanism for the induction o f  
immunological tolerance by antigen feeding: Antigen-antibody complexes. J. Exp. Med. 142. 1509- 
1519.
Archibald DW , Johnson JP, Nair P, Alger LS, Hebert CA, Davis E  & Hines SE. (1990) D etection  
o f salivary immunoglobulin A  antibodies to HIV-1 in infants and children. Aids. 4, 417-420.
Aucouturier P, Mounir S & Preud’Homme J-L. (1985) Distribution o f IgG subclass levels in normal 
adults sera determined by a competitive enzyme immunoassay using monoclonal antibodies. 
Diagnostic Immunology 3, 191-196.
Axelsson I, Jakobsson I, Lindberg T and Benediktsson B. (1986) Bovine B-lactoglobulin in the 
human milk: a longitudinal study during the whole lactation period. Acta. Paediatr. Scand. 75, 702.
Barnes RMR, Barton PG, Doig JE, Finn R, Harvey MM & Johnson PM. (1983) Distribution o f  
serum antibodies to wheat giadin and bovine milk in atopic and non-atopic healthy adults. J. Clin. 
Lab. Immunol. 12, 175-178.
Barnes RMR, Johnson PM, Harvey MM, Blears J & Finn R. (1988a) Human serum antibodies 
reactive with dietary proteins. IgG subclass distribution. Int. Arch. Allergy Appl. Immunol. 87, 184- 
188.
220
Barnes RMR, Johnson PM, Blears J, Harvey MM & Finn R. (1988b). Human serum antibodies 
reactive with dietary proteins. Antigenic specificity. Int. Arch. Allergy. Appl. Immunol. 87, 189-193.
Bell GH, Emslie-Smith D  & Paterson CR. (1980) Textbook o f Physiology. 10th Ed. Churchill 
Livingstone. Edinburgh. London and New York.
Bell SJD & Potter PC. (1988) Milk whey-specific immune complexes in allergic and non-allergic 
subjects. Allergy. 43, 497-503.
Beyzavi K, Hampton SM, Kwasowski P, Fickling S, Marks V  & Clift R. (1987) Comparison o f  
horseradish peroxidase and alkaline phosphatase labelled antibodies in enzyme immunoassays. Ann. 
Clin. Biochem. 24 145-153.
Bjorksten B, Ahlstedt S, Bjorksten F, Carlsson B, Fallstom SP, Juntunen K, Kajosaari M & Kober 
A. (1983) IgE and IgG4 antibodies to cow’s milk in children with cow’s milk allergy. Allergy 38, 
119-124.
Bockman D E  & Winborn WB. (1966) Light and electron microscopy o f intestinal ferrin absorption. 
Observations in sensitized and non-sensitized hamsters (Mesocricetus auratus). Anat. Rec. 155, 603- 
622.
Burks AW, Williams LW, Casteel HB, Fiedorek SC & Connaughton CA. (1990) Antibody response 
to milk proteins in patients with milk-protein intolerance documented by challenge. J. Allergy Clin. 
Immunol. 85, 921-927.
Burr ML. (1983) D oes infant feeding effect the risk o f allergy. Archieves o f  Disease o f Childhood. 
58, 561-565.
Biirgin-Wolff A, Signer E, Friess HM, Berger R, Birbaumer A  & Just M  (1980) The diagnostic 
significance o f antibodies to various cow’s milk proteins. (Fluorescent Immunosorbant Test). Eur. 
J. Pediatr. 133 17-24.
Businco L, Cantani A, Longhi A  & Giampietro. (1989) Anaphylactic reactions to a cow’s milk whey 
protein hydrolysate (Alfa-Re, Nestle) in infants with cow’s milk allergy. Ann. Allergy 62 (4), 333- 
335.
Cant AJ, Marsden R A  & Kilshaw PJ. (1985) Egg and cow’s milk hypersensitivity in exclusively 
breast fed infants with eczema, and the detection o f egg protein in breast milk. Br. Med. J. 291. 
932-935.
Cant AJ, Bailes JA, Marsden R A  & Hewitt D. (1986) Effect o f maternal dietary exclusion on  
breast fed infants with eczema: two controlled studies. BMJ. 293. 231-233.
Camling E, Gahberg L, Krasse B. (1987) The relationship between IgA antibodies to Srep. Mutans 
antigens in human saliva and breast milk and the numbers o f indigenous oral Srep. Mutans. Arch. 
Oral Biol. 32 (1), 21-25.
Campbell DE, Ngamphaiboon J, Clark MM, Harris MC, Kolski GB & Douglas SD. (1987) Indirect 
enzyme linked immunosorbant assay for measurement o f human immunoglobulin E  & G  to purified 
cow’s milk proteins: Application in diagnosis o f  cow’s milk allergy. J Clin. Microbiol. 25 ( 11), 2114- 
2119.
Carlsson B, Gothefors L, Ahlstedt S, Hanson LA & Winberg J. (1976) Studies o f E. Coli O antigen 
specific antibodies in human milk, maternal serum and cord blood. Acta Paediatr. Scand. 65, 216- 
224.
221
Casimir G, Gossart B, Vis HL & Duchateau J. (1985) Antibody against betalactoglobulin (IgG) and 
cow’s milk allergy. J. Allergy Clin. Immunol. 75, 206-207.
Cavagni G, Paganelli R, Caffarelli C, D ’Offizi GP, Bertolini P, Aiuti F  & Giovannelli G. (1988) 
Passage o f food antigens into circulation o f breast-fed infants with atopic dermatitis. Annals o f  
Allergy 61 361-365.
Catalano LW & Sever JL. (1971) The role o f viruses as causes o f congenital diseases. Annu. Rev. 
Microbiol. 25, 255-282.
Cernelc S & Zalokar L. (1982) Correlation between the concentration o f immunoglobulins in 
human serum and secretions. Allergol. et Immunopathol. 10 (5), 367-372.
Chandra RK, Puri S, Suraiya P & Cheema PS. (1986) Influence o f maternal food antigen avoidance 
during pregnancy and lactation on incidence o f atopic eczema in infants. Clin. Allergy. 16, 563- 
569.
Chandra RK. (1988) Nutrition and immunity. Recenti. Prog. Med. 79 (7-8), 305-309.
Chandra RK, Puri S & Hamed A  (1989) Influence o f maternal diet during lactation and the use 
o f formula feeds on development o f atopic eczema in high risk infants. BMJ. 299. 228-230.
Chantler S & Diment J A  (1981) Current status o f specific IgM antibody assays. In: Immunoassays 
for the 80’s (eds Voller A  Bartlett A  & Bidwell D ) MTP Press, Lancaster. 417-430.
Cookson WOCM & Hopkin JM. (1988) Dominant inheritance o f atopic immunoglobulin-E  
responsiveness. Lancet i, 86-87.
Cookson WOCM, Sharp P A  Faux JA & Hopkin JM. (1989) Linkage between IgE reesponses 
underlying asthma and rhinitis and chromosome l lq .  Lancet i, 1292-1295.
Cooper M D & Buckley RH. (1982) Developmental immunology and the immunodeficieny diseases. 
JAMA. 248 (20), 2658-2669.
Cramer DV, Kunz HW  & Gill TJ. (1974) Immunologic sensitization prior to birth. Am. J. Obstet. 
Gynecol. 120 (3), 431-439.
Creamer LK, Parry D A D  & Malcolm GN. (1983) Secondary structure o f bovine B-lactoglobulin B. 
Arch, o f Biochem. and Biophy. 227 ( 1), 98-105.
Cripps AW , Gleeson M & Clancy RL. (1989) Molecular characteristics o f  IgA in infant saliva. 
Scand. J. Immunol. 29, 317-324.
Cruz JR, Garcia B & Urrutia JJ. (1981) Food antibodies in milk from Guatemalan women. J. 
Pediatr. 99, 600-602.
Cruz JR & Arevalo. (1985) Fluctuation o f specific IgA antibodies in human milk. Acta. Paediatr. 
Scand. 74, 897-903.
Cunningham-Rundles C, Brandeis WE, Good R A  & Day NK. (1979) Bovine antigens and the 
formation o f circulating immune complexes in selective IgA deficiency. J. Clin. Invest. 64, 270-272.
Cunningham-Rundles C. (1987) Failure o f antigen exclusion. In: Food allergy and Intolerance. Ed: 
Brostoff J & Challacombe SJ. Balllie Tindall. London Philadelphia Toronto Mexico City Sydney 
Tokyo Hong Kong. 223-237.
222
Dahl GMK, Telemo E, Westrom BR, Jakobsson I, Lindberg T & Karlsson BW. (1984) The passage 
o f orally fed proteins from mother to foetus in rat. Comp. Biochem. Physiol. 11A (2), 199-201.
Dannaeus A, Johansson SGO and Foucard T. (1977) Clinical and immunological aspects o f food  
allergy in childhood.I Estimation o f IgG, IgA and IgE antibodies to food antigens in children with 
food allergy and atopic dermatitis. Acta Paediatr. Scand. 66, 31-37.
Dannaeus A, Johansson SGO and Foucard T. (1978) Clinical and immunological aspects o f food  
allergy in childhood. EL Development o f allergic symptoms and humoral immune response to food  
in infants o f atopic mothers during the fifst 24 months o f life. Acta Paediatr. Scand. 67, 497-504.
Dannaeus A, Inganas M, Johansson SGO & Foucard T. (1979) Intestinal uptake o f ovalbumin in 
malabsorption and food allergy in relation to serum IgG antibody and orally administered sodium  
cromoglycate. Clin. Allergy. 9, 263-270.
Dawe DL, Myers WL & Segre D . (1971) Enhancement of the immune response in rabbits by 
administration o f IgG. Immunology 18, 897-907.
DeBoth NJ, Van Der Kamp AW  & Van Dongen JM. (1975) The infleuence o f changing ciypt cell 
kinetics on functional differentiation in the small intestine o f the rat. Nucleotide and protein 
synthesis. Differentiation. 4, 175.
DeM an JM. (1982) Principles o f Food Chemistry. Avi Publishing Company, Inc. Westport, 
Connecticut. 4th Ed. 113-119.
D e Savigny D  & Voller A  (1980) The communication o f ELISA data from laboratory to clinician. 
J. Immunoassay 1, 105.
Devlin J, Stanton RHJ & David TJ. (1989) Calcium intake and cow’s milk free diets. Archives o f  
disease in Childhood. 64> 1183-1193.
DHSS (1979) Recommended Daily amounts o f Food Energy and Nutrients for Groups o f People  
in the United Kingdom. Report by the Committee on Medical Aspects o f Food Policy. No. 15.
Durnin JVGA, McKillop FM, Grant S & Fitzgerald G  (1985) Is nutritional status endangered by 
virtually no extra intake during pregnancy? Lancet ii, 823-825.
Eastham EJ, Lichauco T, Grady MI & Walker W A  (1978) Antigenicity o f infant formulas: role o f  
immature intestine in protein permeability. J. Pediatr. 93, 561-564.
Envall E, Jonsson K & Perlmann P. (1971) Enzyme-linked immunosorbant assay. II Quantitation 
assay o f protein antigen, immunoglobulin G, by means o f enzyme-labelled antigen and antibody- 
coated tubes. Biochimica et Biophysica Acta. 251 419-426.
Envall E  & Perlmann P. (1972) Enzyme-linked immunosorbant assay, ELISA: III Quantification o f  
specific antibodies by enzyme-labelled anti-immunoglobulin in antigen-coated tubes. J.Immunol. 109 
(1) 129-135.
Fallstrom SP, Ahlstedt S, Carlsson B, Lonnerdal B & Hanson L A  (1986) Serum antibodies against 
native processed and digested cow’s milk proteins in children. Clin. Allergy. 16, 417-425.
Falth-Magnusson K, Kjellman N-IM, Magnusson K-E & Sundquist T. (1984) Intestinal permeability 
in healthy and allergic children before and after sodium cromoglycate treatment assessed with 
different sized polyethyleneglycols (PEG 400 and PEG 1000). Clin. Allergy 14, 277-286.
223
Falth-Magnusson K, Oman H & Kjellman N-IM. (1987a) Maternal abstention from cow milk and 
egg in allergy risk pregnancies. Allergy. 42, 64-73.
Falth-Magnusson K & Kjellman N-IM. (1987b) Development o f atopic disease in babies whose 
mothers were receiving exclusion diets during pregnancy-A randomized study. J. Allergy Clin. 
Immunol. 80, 869-875.
Falth-Magnusson K, Kjellman N-IM & Magnusson K-E. (1988) Antibodies IgG, IgA, and IgM to 
food antigens during the first 18 months o f life in relation to feeding and development o f atopic 
disease. J. Allergy Clin. Immunol. 81 (4), 743-749.
Falth-Magnusson K  (1989) Breast milk antibodies to foods in relation to maternal diet, maternal 
atopy and the development o f atopic disease in the baby. Int. Arch. Allergy Appl. Immunol. 90. 
297-300.
Fickling SA, Hampton SM, Teale D, Middleton B A  & Marks V. (1990) Developm ent o f  an 
enzyme-linked immunosorbant assay for caffeine. J. o f Immunological Methods 129, 159-164.
Finley PR, Williams R-J, Lichti DA, Griffith F & Thies AC. (1979) Immunochemical determination 
o f human immunoglobulins: U se o f kinetic turbidimetry and a 36-place centrifugal analyser. Clin. 
Chem. 25 (4), 526-530.
Firer MA, Hoskings CS & Hill DJ. (1987) Humoral immune response to cow’s milk in children with 
cow’s milk allergy. Relationship to the time o f clinical response to cow’s milk challenge. Int. Archs. 
Allergy appl. Immun. 84, 173-177.
Foucard T. (1985) Developm ent o f food allergies with special reference to cow’s milk allergy. 
Pediatrics 75 (suppl), 177-181.
Frick M & Rieger CHL. (1987) Local antibodies to a-casein and B-lactoglobulin in the saliva o f  
infants. Ped. Res. 22 (4), 399-401.
Galant SP, Bullock J & Frick OL. (1973) An immunological approach to the diagnosis o f  food  
sensitivity. Clin. Allergy. 3, 363-372.
Gallagher PJ, Gibney MJ & Taylor TG. (1980) Dietary antigens, immune tolerance and 
atherosclerosis. Artery. 8 (4), 315-322.
Gallagher PJ, Goulding NJ, Pathirana C, Gibney MJ, Jones DB & Taylor TG. (1982) Immune 
tolerance and atherosclerosis in rabbits: Effect o f high fat and cholesterol supplemented diets. 
Atherosclerosis. 45, 115-127.
Gallagher PJ, Goulding NJ, Gibney MJ, Jones DB & Morgan JB. (1983) Acute and chronic 
immunological response to dietary antigen. Gut. 24 (9), 831-835.
G leeson M, Cripps AW, Clancy RL, Hensley MJ, Dobson AJ & Firman DW . (1986) Breast feeding 
conditions a differential development pattern o f mucosal immunity. Clin. Exp. Immunol. 66, 216.
Gleich GJ, Averbeck AK  & Swedlund HA. (1971) Measurement o f IgE in normal and allergic 
serum by RIA. J. Lab. Clin. Med. 77 (4), 691-697.
Gjesing B & Lowenstein H. (1984) Immunochemistry o f food antigens. Ann. Allergy. 53 (6 pt 2), 
602-608.
224
Gmoshinsky IV, Krahechkooskaya W  & Korin SN. (1990) Alteration o f immunochemical proprties 
o f B-lactoglobulin after proteolysis or some physio-chemical treatment. Voprosy Meditsinskoi Knimil. 
36 (5), 11-15.
Godard C, Bustos M, Munoz M & Nussle D . (1989) Value o f chicken based formula for refeeding 
of children with protractable diarhea and malnutrition in developing countries. J. Pediatr. 
Gastroenterol. Nutr. 9 (4), 473-480.
Goding JW. (1983) Monoclonal antibodies: Principles and Practice, led  Academic Press: London: 
New York. 232-233.
Guesdon JL, Ternynck T & Aurameas S. (1979) The use o f avidin-biotin interaction o f  
immunoenzymatic techniques. J. Histochem. & Cytochem. 27 (8), 1131-1139.
Gunther M, Aschaffenburg RH, Parish WE & Coombes R R A  (1960) The levels o f antibodies to 
cow’s milk in the serum o f normal human infants. Immunology. 3, 296-305.
Gronbald-Saksela E. (1986) Origin o f immunoglobulin in human saliva. J. Finnish Dental Soc. 
Suppl. 1. 1-36.
Gwynn CM, Morrison Smith J, Leon Leon G & Stanworth DR. (1979) IgE and IgG4 subclass in 
atopic families. Clin. Allergy 9, 119-123.
Haddad ZH, Kalra V  & Verma S. (1979) IgE antibodies to peptic and peptic-tryptic digests o f B- 
lactoglobulin: Significance in food hypersensitivity. Annals o f Allergy. 42, 368-371.
Halpern GM & Scott JR. (1988) Non IgE antibody mediated mechanisms in food allergy. Annals 
o f Allergy. 59 (11), 175-178.
Hamburger RN, Hellers S, Mellon MH, O ’Connor R  & Zeiger RS. (1983) Current status o f  clinical 
and immunologic consequences o f prototype allergic disease prevention programs. Ann. Allergy 51, 
281-290.
Hampton SM, Morgan JB, Smith MR, Morris R, Lovegrove JA and Marks V. (1989) Circulating 
and secretory antibodies to specific food proteins in adults. Eur. J. Clin. Nutr. 44, 151-156.
Hanson LA & Windberg J. (1972) Breast milk and defence against infection in the newborn. Arch. 
Dis. Child. 47, 845.
Hanson LA, Ahlstedt S, Carlsson B & Fallstom SP. (1977) Secretory IgA antibodies against cow’s 
milk proteins in human milk and their possible effect in mixed feeding. Int. Arch. Allergy Appl. 
Immunology. 54, 457.
Hanson L A  Ahlstedt S, Andersson B, Carlsson B, Fallstrom SP, Mellander L, Porras O, Soderstrom  
T & Svanborg Eden C. (1985) Protective factors in milk and the development o f the immune 
system. Pediatrics. 75 (suppl.), 172-176.
Harlow E D  & Lane D . (1988) Antibodies: A  laboratory manual. Cold spring Harbour Laboratory. 
Ed. Harlow E D  & Lane D. 1-139.
Harmatz PR, Hanson D G  & Walsh MK. (1986) Transfer o f protein antigens into milk after 
intravenous injection into lactating mice. AM. J. Physiol. 251. E227.
Hashem N. (1972) Is maternal lymphocyte sensitisation passed to the child. Lancet, i 40-41.
225
Hattevig G, Kjellman B, Sigurs N, Bjorksten B & Kjellman NIM. (1989) Effect o f maternal 
avoidance o f eggs, cow’s milk and fish during lactation upon allergic manifestations in infants. Clin. 
Exp. Allergy. 19, 27-32.
Hattevig G, Kjellman B, Sigurs N, Grodzinsky E, Hed J & Bjorksten B. (1990) The effect o f  
maternal avoidance o f eggs, cow’s milk, and fish during lactation on the development o f IgE, IgG, 
and IgA antibodies in infants. J. Allergy Clin. Immunol. 85 (no. 1, pt 1), 108-15.
Hayward AR. (1981) Development o f lymphocyte responses and interactions in human fetus and 
newborn. Immunol. Rev. 57, 39-60.
Helms I & Rieger CHL. (1987) Decreased production o f specific antibodies to cow’s milk proteins 
in premature infants during the first six months o f life. Eur. J. Pediatr. 146. 131-134.
Hemmings C & Hemmings W A  (1979) The passage o f macromolecules derived from dietary protein 
across the placenta in rats. In: Protein Transmission Through Living Membranes. Ed. Hemmings 
W A  Elsevier/North Holland Biochemical Press, 269-276.
Hennart PF, Brasseur DJ, Delogne-Desnoeck JB, Dramaix MM & Robyn CE. (1991) Lysozyme, 
lactoferrin, and sectretory immunoglobulin A  content in breast milk: influence o f duration o f  
lactation, nutrition status, prolactin status, and parity o f mother. Am. J. Clin. Nutr. 53, 32-39.
Heppell LMJ, Cant AJ & Kilshaw PJ. (1984) Reduction in the antigenicity o f  whey proteins by 
heat treatment: a possible strategy for producing a hypoallergenic infant formula. Br. J. o f Nutr. 
51, 29-36.
H eppell LMJ, Sisson JW and Pedersen HE. (1987) A  comparison o f the antigenicity o f soya-bean- 
based infant formulas. Br. J. Nutr. 58, 393-404.
H eppell A, Butterworth SV, Hollis RJ, Kennaugh AA, Beatty DW  & Taylor AM. (1988) Breakage 
o f the T cell receptor alpha chain locus in non malignant clones from patients with ataxia 
telangiectasia. Hum. Genet. 79 (4), 360-364.
Heyman M, Grasset E, Ducroc R & Desjeux J-F. (1988) Antigen absorption by the jejunal 
epithelium o f children with cow’s milk allergy. Pediatric Research 24 (2), 197-202.
Host A, Husby S & Osterballe O. (1988) A  prospective study o f cow’s milk allergy in exclusively 
breast fed infants. Acta Pediatr. Scand. 77 663-670.
Huang Q, Coleman JW & Stanworth DR. (1985) Investigation of the allergenicity o f B-lactoglobulin 
and it’s cleavage fragments. Int. Archs. Allergy appl. Immun. 78 337-344.
Hunter WM & Greenwood FC. (1962) Preparation o f Iodine131 labelled growth hormone o f  high
specific activity. Nature 194 495-496.
Hurn BAL & Landon J. (1971) Antisera for radioimmunoassay. In: Radioimmunoassay Methods. 
Ed. Kirkham and Hunter. Churchill Livingstone, Edinburgh and London. 121-142.
Husby S, Holmskov-Neilsen U , Jensenius JC & Erb K  (1985a) Increased non-specific binding o f  
heat treated proteins to plastic surfaces analysed by ELISA and HPLC-fractionation. J o f  
Immunoassay. 6 (1&2), 95-110.
Husby S, Jensenius JC & Svehag SE. (1985b) Passage o f undigested dietary antigen into the blood 
o f healthy adults. Quantification, estimation o f size distribution, and relation o f uptake to levels
o f  specific antibodies. Scand. J. Immunol. 22 83-92.
226
Husby S, Oxelius VA, Teiser B, Jensenius JC & Svehag SE. (1985c) Humoral immunity to dietary 
antigens in healthy adults. Int. Arch. Allergy Appl. Immuno. 77 416-422.
Husby S, Oxelius V-A, Teisner B, Jensenius JC & Svehag S-E. (1985d) Humoral immunity to 
dietary antigens in healthy adults. Occurance, isotype and IgG subclass distribution o f serum  
antibodies to protein antigens. Int. Archs. Allergy appl. Immun. 77, 416-422.
Husby S, Jensenius JC & Svehag S-E. (1985e) ELISA quantitation o f IgG subclass antibodies to 
dietary antigens. J. Immunol. 82 (2) 321-331.
Husby S, Jensenius JC, & Svehag S-E. (1986a) Passage o f undegraded dietary antigens into the 
blood o f  healthy adults. Further characterization o f the kinetics o f uptake and size distribution o f  
the antigen. Scand. J. Immunol. 24, 447-455.
Husby S, Schultz Larsen F, Hyltoft Petersen P & Svehag S-E. (1986b) Humoral immunity to dietary 
antigens in atopic dermatitis I. Biotin-avidin amplified ELISA-analysis o f  IgG antibodies. Allergy 
41 379-386.
Husby S, Schultz Larsen F, Ahlstedt S & Svehag S-E. (1986c) Humoral immunity to dietary 
antigens in atopic dermatitis. II Analysis o f IgE and IgG subclass antibodies. Allergy. 41, 386-391.
Husby S. (1988) Dietary antigens: Uptake and humoral immunity in man. APMIS 96 suppl.L, 5- 
40.
Husby S, Schultz Larsen F & Svehag S-E. (1989) IgG subclass antibodies to dietary antigens in 
atopic dermatitis. Acta. Derm. Venereol. (Stockh) Suppl 144, 88-92.
Husby S, Host A, Teisner B & Svehag S-E. (1990) Infants and children with cow milk 
allergy/intolerance. Allergy. 45, 547-551.
Iikura Y, Akimoto K, Odajima Y, Akazawa A  & Nagakura T. (1989) How to prevent allergic 
disease. 1. Study o f specific IgE, IgG and IgG4 antibodies in serum o f pregnant mothers, cord blood 
and infants. Int. Arch. Allergy Appl. Immunol. 88, 250-252.
Imagawa M, Yoshitake S, Hashida S & Ishikawa E. (1982) Effect o f temperature on the sensitivity 
o f sandwich enzyme immunoassay with Fab’-horseradish peroxidase conjugate. Analytical Letters 15 
(B18), 1467-1477.
Jackson PG, Baka RW R, Lessof MH et a l . (1981) Intestinal permeability in patients with eczema 
and food allergy. Lancet i, 1285-1286.
Jackson TM & Ekins RP. (1986) Theoretical limitations on immunoassay sensitivity - current 
practices and potential advantages o f fluorescent Eu3+ chelates on non-radiotopic tracers. J Imm. 
Methods. 87, 13.
Jakobsson I & Lindberg T. (1978) Cow’s milk as a cause o f infantile colic in breast fed infants. 
Lancet ii, 437.
Jakobsson I, Lindberg T, Benediktsson B and Hansson B-G. (1985) Dietary bovine B-lactoglobulin 
is transferred to human milk. Acta Paediatr. Scand. 74, 342-345.
Jarrett EE. (1977) Activation o f IgE regulatory mechanisms by transmucosal absorption o f antigen. 
Lancet II, 223-225.
227
Jarrett E E  & Hall E. (1984) The development o f IgE suppressive immunocompetence in young 
animals: influence o f exposure to antigen in maternal immunity. Immunology 53, 365-373.
Jatsyk GV, Kuvaeva IB & Gribakin SG. (1985) Immunological protection o f the neonatal 
gastrointestinal tract: the importance o f breast feeding. Acta. Paediatr. Scand. 74, 246-249.
Juto P & Bjorksten B. (1980) Serum IgE in infants and the influence o f type o f feeding. Clin. 
Allergy. 10, 593-600.
Kajosaari M. (1982) Food allergy in Finnish children aged 1-6 years. Acta. Paeddiatr. Scand. 71, 
815-819.
Kaminogawa S, Shimizu M, Ametani A, Hattori M, Ando O, Hachimura S, Nakamura Y, Totsuka 
M & Yamauchi K  (1989) Monoclonal antibodies as probes for monitering the denaturation process 
o f bovine B-lactoglobulin. Biochimca et Biophysia Acta. 998 50-56.
Kemeny DM , Urbanek R, Richards D  & Greenall C. (1987) Development o f a semi-quantitative 
enzyme linked immunosorbant assay (ELISA) for detection o f human IgG subclass antibodies. J. 
Immunological Methods. 96, 47-56.
Kemeny DM  & Chantler S. (1989) An introduction to ELISA. In: ELISA and other solid phase 
immunoassays. Ed Kemeny DM  & Challacombe SJ. John Wiley & Sons. 1-31.
Kilshaw PJ & Cant AJ. (1984) The passage o f maternal proteins into breast milk. Int. Archs. 
Allergy appl. Immun. 75 8-15.
Kindred B & Shreffler DC. (1972) Dependence o f co-operation between T and B cells in vivo. 
Immunology. 109. 938-943.
Kletter B, Freier S, Davies M & Gery I. (1971) The significance o f coproantibodies to cow’s milk 
protein. Acta Paediat. Scand. 60, 173-180.
Kletter B, Gery I, Freier S & Davies AM. (1971) Immune responses o f normal infants to cow’s 
milk I. Antibody type and kinetic o f production. Lit. Arch. Allergy. 40, 656-666.
Knight LC. (1978) Comparison o f iodogen and iodine monochloride method for radioiodination o f  
fibrogen. Journal o f  labelled compounds and radiophermaceuticals. XVII (1-2) 50.
Kohler PF & Farr RS. (1966) Elevation o f cord over maternal IgG immunoglobulins-Evidence for 
an active placental IgG transport. Nature. 210. 1070-1071.
Koritz TN, Suzuki S & Coombs RRA. (1987) Antigenic stimulation with proteins o f cow’s milk via 
oral route in guinea pigs and rats. 1. Measurement o f antigenically intact B-lactoglobulin and casein 
in the gastrointestinal contents o f duodenum, jejunum and ileum. Int. Archs. Allergy appl. Immun. 
82 72-75.
Kraft SC, Samuelson JS & Farr RS. (1967) Acriflavine - induced immunological paeralysis: the 
effect o f varying antigen doses. Immunology. 12 (1), 53-62.
Kramer MS. (1988) D oes breast feeding help protect against atopic disease? Biology, methodology, 
and a goldern jubilee o f controversy. J. Pediatr. 112 (2), 181-190.
Kunkel HG, Joslin FC, Penn GM and Natvig JB. (1970) Genetic varients o f gamma 4-globulin. A  
unique relationship o f different gamma G globulin. J. exp. Med. 132. 508-520.
228
Ladjeva I, Peterman JH & Mestecky J. (1989) IgA subclasses o f human colostral antibodies specific 
for microbial and food antigens. J. Clin. Exp. Immunol. 78, 85-90.
Laurell C-B. (1966) Quantitative estimation o f proteins by electrophoresis in agrose gel containing 
antibodies. Analyt. Biochem. 15 45-52.
Layton GT & Stanworth DR. (1984) The quantitation o f IgG4 antibodies to three common food  
allergens by ELISA with monoclonal anti-IgG4. J. Immunol. Meth. 73, 347-356.
Levi MI, Kravtzov EE, Levova TM & Fomenko G A  (1969) The ability o f  maternal antibodies to
increase the immune response in infants. Immunology 16. 145
Lippard VW, Schloss OM & Johnson P A  (1936) Immune reactions induced in infants by intestinal 
absorption o f incompletely digested cow’s milk protein. Am. J. Dis. Child. 51, 562-574.
Lifschitz CH, Hawkins HK, Guerra C & Byrd N. (1988) Anaphylactic shock due to cow’s milk 
protein hypersensitivity in breast-fed infants. J. Ped. Gastr. and Nutr. 7, 141-144.
Lilja G, Dannaeus A, Falth-magnusson K, Graff-lonnevig V, Johnsson SGO, Kjellman N-IM  & 
Oman H. (1988) Immune response o f the atopic women and foetus: effect o f high- and low- dose
food allergen intake during late pregnancy. Clin. Allergy 18, 131-142.
Lilja G, Dannaeus A  Foucard T, Graff-Lonnevig V, Johansson SGO & Oman H. (1989) Effects 
o f maternal diet during late pregnancy and lactation on the development o f atopic diseases in 
infants up to 18 months o f age- in vivo results. Clin, and Exp. Allergy. 19, 473-479.
Lovegrove J A  Hampton SM, Morgan JB and Marks V. (1989) Quantification o f total IgG levels 
against a-casein in human serum samples serum. Biochem. Soc. Trans. 17, 1059-1060.
McDonald PJ, Goldblum RM, Van Sickle GJ and Powell G K  (1984) Food protein induced 
enterocolitis: altered antibody response to ingested antigen. Pediatr. Res. 18, 751-755.
Machtinger S & Moss R. (1986) Cow’s milk allergy in breast fed infants: the role o f allergen and 
maternal secretory IgA antibody J. Allergy Clin. Immunol. 77 341.
Malik Z, Bottomley R & Austen B. (1988) A lergenic properties o f the genetic varient A  and B 
o f bovine B-lactoglobulin. Int. Archs. A lergy appl. Immunol. 86, 245-248.
Marcon-Genty D , Tome D, Dumontier A-M, Kheroua O & Desjeux JF. (1989a) Permeability o f  
milk protein across the intestinal epithelium in vitro. Reprod. Nutr. Dev. 29 717-723.
Marcon-Genty D, Tome D, Kheroua O, Dumontier A-M, Heyman M & Dasjeux J-F. (1989b) 
Transport o f B-lactoglobulin across rabbit ileum in vitro. Am. J. Physiol. 256 (6 pt 1) 943-948.
Martino DM, Ross ME, Novembre E & Vierucci A  (1988) Occurance and subclass distribution o f  
IgG antibodies to dietary antigens in children with atopic dermatitis and their mothers. Ann. A lergy  
61 (4), 253-258.
Matsumura T, Kuroume T, Ogari M, Iwasaki I, Kanbe Y, Yamada T, Kawabe S & Negishi K. 
(1975) Egg sensitivity and eczematous manifestations in breast-fed newborns with particular 
reference to intrauterine sensitivity. Annals. A lergy 35, 221-225.
May CD, Remigio L, Feldman J, Bock SH & Carr RI. (1977) A  study o f serum antibodies to 
isolated milk proteins and ovalbumin in infants and children. Clin. A lergy. 7, 583-595.
229
Mellander L, Carlsson B & Hanson LA. (1984) Appearance o f secretory IgM and IgA antibodies 
to E. coli in saliva during early infancy and childhood. J. Pediatrics. 104. 564-568.
Merrett J, Burr ML & Merrett TG. (1983) A  community survey o f IgG4 antibody levels. Clin. 
Allergy. 13, 397-407.
Merrett J, Barnetson R, Burr ML & Merrett TG. (1984) Total and specific IgG4 antibody levels 
in atopic eczema. Clin. Exp. Immunol. 54 645-652.
M ichel FB, Bousquet J, Greillier P, Levy MR & Coulomb Y. (1980) Comparison o f cord blood IgE  
concentrations and maternal allergy for the prediction o f atopic disease in infancy. J. Allergy Clin. 
Immunol. 65 (6), 422-430.
Miles LEM & Hales CN. (1968) Labelled antibodies and immunological assay systems. Nature 
(London) 219 186.
Miskelly FG, Burr ML, Vaughan-Wiliiams E, Fehily AM, Butland BK & Merrett TG. (1988) Infant 
feeding and allergy. Arch, o f Dis. in Childhood. 63, 388-393.
Mohr JA. (1972) Lymphocyte sensitisation passed to the child from the mother. Lancet 1, 688.
Montoya A  & Castell V. (1987) Long-term storage o f peroxidase-labelled immunoglobulins for use 
in enzyme immunoassay. J. Immunol. Meth. 99 13-20.
Morgan G & Levinsky RJ. (1988) Clinical significance o f IgG subclass deficiency. Archives o f  
Disease in Childhood 63, 771-773.
Morgan JB. (1988) Nutrition for and during prgnancy. In: Nutrition in the Clinical Management 
o f Disease. Ed. Dickerson JWT & L ee H A  2nd Edition Edward Arnold. London, Baltimore, 
Melbourne, Auckland. 1-29.
Morris BA. (1985) Principles o f immunoassay. In: Immunoassays in Food Analysis. Ed. Morris B A  
& Clifford MN. Elsevier Applied Science Publishers. London/ New York.
Moxey PC & Trier JS. (1975) Structural features o f the mucosa o f human fetal small intestine. 
Gastroenterology. 68, 1002-1009.
Muller W, Rieger CHL & Von der Hardt H. (1985) Increased concentrations o f milk antibodies 
in recurrent pulmonary aspiration in infants and young children. Acta. Paediatr. Scand. 74, 660- 
663.
Muller G, Bernsau I, Muller W, Weissbarth-Riedel E, Natzschka J & Rieger CNL. (1986) Cow milk 
protein antigens and antibodies in serum of permature infants during the first 10 days o f life. J. o f  
Pediatrics. 109 (5), 869-873.
Nagura H, Nakane PK & Brown WR. (1978) Breast milk IgA binds to jejunal epithelium in 
suckling rats. J Immunol. 120. 1333-1339.
Ngo TT & Lenhoff HM. (1985) Enzyme-mediated immunoassay. Plenum Press, NY.
Notley JR, Gibney MJ & Gallagher PJ. (1984) Absence o f an effect o f tolerance to milk protein  
on experimental atherosclerosis in rabbits. Atherosclerosis. 52, 199-202.
NRC/NAS. (1980) Recommended daily allowances 9th ed. Committee on dietary allowances Food  
and Nutrition Board. National Academy o f Sciences Publication: Washinhgton.
230
Ogra SS, Weintraub D  & Ogra PL. (1979) Immunological aspects o f human colostrum and milk. 
TTT Fate o f absorption o f cellular and soluble components in the gastrointestinal tract o f the 
newborn. J. Immunol. 119. 245-248.
Ostergaard P A A  (1985) Serum and saliva Ig-levels in infants o f non-atopic mothers fed breast milk 
o f cow’s milk-based formulas. Acta. Paediatr. Scand. 74, 555-559.
Otani H. (1981) Antigenicities o f B-lactoglobulin treated with proteolytic enzymes. Jpn. J. Zootech. 
Sci. 52 (1), 47-52.
Owen RL. (1977) Sequential uptake o f horseradish peroxidase by lymphoid follicle epithelium of  
Peyer’s patches in the neonatal unobstructed mouse intestine: an ultrastructural study. 
Gastroenterology. 72, 440-451.
Paganelli R, Levinsky RJ, Brostoff J & Wraith DG. (1979) Immune complexes containing food  
proteins in normal and atopic subjects after oral challenge and effect o f  sodium cromoglycate on  
antigen absorption. Lancet H, 1270-1272.
Paganelli R  & Levinsky RJ. (1980) Solid phase radioimmunoassay for detection o f circulating food  
protein antigens in human serum. J. Immuno. Meth. 37 333-341.
Paganelli R, Atherton DJ & Levinsky J. (1983) Differences between normal and milk allergic 
subjects in their immune response after milk ingestion. Arch. Dis. in Child. 58, 201-206.
Passmore R  & Eastwood M A (1986) Davidson & Passmore. Human Nutrition and Dietetics. 8th 
ed. Churchill Livingstone. Edinburgh London New York.
Pathirana C, Goulding NJ, Gibney MJ, Pitts JM, Gallagher PJ & Taylor TG. (1981). Immune 
tolerance produced by pre- and postnatal exposure to dietary antigens. Inter. Archs. Allergy appl. 
Immun. 66, 114-118.
Paul A A  & Southgate AAT. (1979). McCance & Widdowson’s The composition o f foods. 4th ed. 
H er Majestey’s Stationary Office :London.
Peltonen L, Havu V K  & Mattila L. (1988) Serum IgE in non-atopic adults and in dermatitis 
patients. Allergy. 43, 152-158.
Peng Z, L ee H-B, Proud D, Naclerio R  & Adkinson NF. (1990) Ragweed IgE and IgG4 antibody 
in nasel secretions during immunotherapy. Clin, and Exp. Allergy. 20, 571-579.
Pharmacia Fine Chemicals. Technical Report Affinity Chromatography.
Piez KA, Davie EW, Folk JE & Gladner J A  (1961) B-lactoglobulin A  and B. 1. Chromatographic 
separation and amino acid composition. J. o f Biol. Chem. 236 (11), 2912-2915.
Poysa L, Remes M, Korppi M & Juntunen-Backman K. (1989) Atopy in children with and without 
a family history o f atopy. I Clinical manifestations, with special reference to diet in infancy. Acta. 
Paediatr. Scand. 78, 896-901.
Powell GK. (1985) U se o f casein hydrolysate formulas in diagnosis and management o f  
gastrointestinal food sensitivity in infancy. In: Nutrition for Special Needs in Infancy. Protein 
Hydrolysates. Ed Litshitz. Marcel Dekker, Inc. New York & Basel. 131-143.
Prausnitz C & Kustner H. (1921) Studien bei die ueberempfindlichkeit. Centrlbl. f. Bakt. Akt. Orig. 
86, 160-169.
231
Quaroni A, Kirsch K, Herscovics A  & Isselbacher KJ. (1980) Surface-membrane biogenesis in rat 
intestinal epithelial cells at different stages o f maturation. Biochem. J. 192. 133.
Reimer CB. (1983) In: Diagnostic Immunology : Technology Assessment and Quality Assurance. 
Ed. Rippey JH & Nakamura RM. College o f American Pathologists, Skokie, IL, 130.
Reinhold U , Pawelec G, Wehrmann W, Herold M, Wernet P & Kreysel HW. (1988) 
Immunoglobulin E and Immunoglobulin G subclass distribution in vivo and relationship to in vitro 
generation o f interferon-gamma and neopterin in patients with severe atopic dermatitis. Int. Arch. 
Allergy appl. Immunol. 87, 120-126.
R enz H, Brehler C, Petzoldt S, Prinz H  & Rieger CHL. (1991a) Breast feeding modifies production 
o f slgA  cow’s milk-antibodies in infants. (In press)
R enz H, Vestner R, Petzoldt S, Brehler C, Prinz H  & Rieger CHL. (1991b) Elevated  
concentrations o f salivary secretory immunoglobulin A  anti-cow’s milk protein in newborns at risk 
o f allergy. Int. Arch. Allergy appl. Immunol. 355 (In press)
Rieger CHL & Rothberg RM. (1975) Development o f the capacity to produce specific antibodies 
to an ingested food antigen in the premature infant. J. Paediatr. 87, 515-518.
Roberts SA  & Freed D U . (1977) Neonatal IgA secretion enhanced by breast feeding. Lancet ii, 
1131.
Roberts SA, Wincup G  & Harris A A  Mucosal receptor for IgA in breast-fed neonate. Early, Hum. 
Dev. 4 (2), 161-166.
Roberton DM, Forrest PJ, Frangoulis E, Jones CL & Mermelstein N. (1986) Early induction o f 
secretory immunity in infancy: specific antibody in neonatal breast milk. Arch. Dis. in Child. 61, 489- 
494.
Robinson JD, Morris BA, Piall EM, Aherne GW & Marks V. (1975) The use o f rats in the 
screening o f drug-protein conjugates for immunoreactivity. In: Radioimmunoassay in Clinical 
Biochemistry, Pasternak, C.A. (ed.), Heyden, London. 101-111.
Roitt I. (1989) Essential Immunology. 4th ed. Blackwell Scientific Publications. Oxford London 
Edinburgh Melbourne.
Rothberg RM  & Farr RS. (1965) Anti-bovine serum albumin and anti-alpha lactalbumin in the 
serum o f children and adults. Pediatrcs. 33, 571-588.
Rothberg RM  (1969) Immunoglobulin and specific antibody synthesis during the first week o f life 
o f premature infants. J. Pediatr. 75, 391-399.
Royal College o f Physicians & British Nutrition Foundation. (1984) Food intolerance and food  
aversion. J. Royal College o f Physicians, 18, 83-121.
Salacinski P, H ope J, McLean C, Clement-Jones V, Sykes J, Price J, Lowry PJ. (1979) A  new  
simple method which allows theoretical incorporation o f radio-iodine into proteins and peptides 
without damage. J. Endocrinology. 81 (2) 131.
Schrander JJP, Unsalas-Hooyen RWM, Forget PP & Jansen J. (1990) [51Cr] E D T A  intestinal 
permeability in children with cow’s milk intolerance. J. Pediatr. Gastro. Nutr. 10, 189-192.
232
Scopes R (1982). Protein Purification. Principles and Practice. Springer-Verlag: New York, 
Heidelberg, Berlin. 266.
Seban A, Konijn AM  and Freier S. (1977) Chemical and immunological properties o f a protein 
hydrolysate formula. Am. J. Clin. Nutr. 30, 840-846.
Shakib F, McLaughlan P, Stanworth DR, Smith E & Fairburn E. (1977) Elevated serum IgE and 
IgG4 in patients with atopic dermatitis. Br. J. Dermatology. 97, 59.
Shakib F, Morrow Brown H, Phelps A  Redhead R  & McDonald D. (1984) Relationship between  
serum levels o f total and milk- and egg-specific IgG4 and the expression o f G2m(n) in atopic 
eczema patients. Expl. Clin. Immunogenet. 1, 185-188.
Shakib F, (1986a) The IgG4 subclass. Monogr. Allergy. 19, 223-226 (Karger, Basel).
Shakib F, Morrow Brown H, Phelps A  & Redhead R. (1986b) Study o f IgG sub-class antibodies 
in pateints with milk intolerance. Clin. Alergy. 16, 451-458.
Shakib F. (1988a) The role o f antiglobulins in IgG4 mediated allergic disease. NER. A lergy  Proc. 
9 (1), 35-39.
Shakib F. (1988b) Clinical relevence o f food-specific IgG4 antibodies. N ER  A lergy Proc. 9 (1). 63- 
66.
Shakib F  (1989) Antiglobulin-induced leucocyte mediator release. In: Autoantibodies to 
immunoglobulin. Shakib F (Ed) Monogr. Alergy. Basel, Karger. 26, 114-119.
Slade HB & Schwartz S A  (1987) Mucosal immunity: The immunology o f breast milk. J. A lergy  
Clin. Immunol. 80 (No.3, P tl), 348-358.
Sterzl J & Silverstein AM. (1967) Developmental aspects o f immunity. Adv. Immunol. 6 , 337-459.
Steward MW & Lew AM. (1985) The importance o f antibody affinity in the performance o f  
immunoassays for antibody. J. Immunol. Meth. 75 173-190.
Strobel S. (1988) Developmental aspects o f food allergy. In: Food A lergy Ed. Schmidt. N estle  
Nutrition Workshop Series. Nestec Ltd. Vevey/Raven Press Ltd. New York. 17, 99-119.
Stiyer L. (1981) Biochemistry. W H Freeman & Company. San Francisco. 2nd Ed. 793.
Stuart C A  Twiselton R, Nicholas MK & Hide DW. (1984) Passage o f cow’s milk protein in breast 
milk. Clin. A lergy. 14, 533-535.
Swarbrick ET, Stokes CR & Soothill JF. (1979) Absorption o f antigens after oral immunisation and 
the simultaneous induction o f specific systemic tolerance. Gut. 20, 121-125.
Talbot FB. (1918) Eczema in childhood. Medical Clinics o f North America. 1, 985.
Taylor B, Norman AP, Orgel HA, Stokes CR, Turner MW & Soothill JF. (1973) Transient IgA  
deficiency and pathogenesis o f infantile atophy. Lancet II, 111-113.
Taylor SL. (1985) Food allergies. Food Technology. Feb, 98-105.
Taylor CJ, Jenkins P & Manning D. (1988) Evaluation o f peptide formula (milk) in the 
management o f infants with multiple GIT intolerance. Clin. Nutr. 7, 183-190.
233
Telemo E, Westrom B, Dahl G & Karlsson B. (1986) Transfer o f orally or intravenously 
administered proteins to the milk o f lactating rat. J. Pediatr. Gastroenterol. Nutr. 5 305-309.
Telemo E, Jakobsson I, Westrom BR & Folkesson H. (1987) Maternal dietary antigens and the 
immune response in the offspring o f the guinea-pig. Immunology. 62, 35-38.
Thomas HC. Ryan CJ, Benjamin IS, Blumgart LH & MacSween RNM . (1976) The immune 
response in cirrhotic rats. The induction o f tolerence to orally administered protein antigens. 
Gastroenterology. 71, 114-117.
Thompson MP & Kiddy C A  (1964) Genetic polymorphism in caseins o f cow’s milk. HI. Isolation  
and properties o f a s l  caseins A, B and C. J. Dairy Sci. 47, 626-632.
Tijssen P & Kurstak E. (1984) Highly efficient and simple methods for the preparation o f  
peroxidase and active peroxidase-antibody conjugates for enzyme immunoassays. Analytical 
Biochemistry 136. 451-457.
Tolo K, Brandtzaeg P & Jonsen J. (1977) Mucosal penetration o f antigen in the presence or 
absence o f serum-derived antibody. Immunology. 33, 733-743.
Troncone R, Scarcella A, Donalietto A, Cannataro P, Tarabuso A  & Auricchio S. (1987) Passage 
o f gliadin into human breast milk. Acta Paediatr. Scand. 76, 341.
Udall JN, Colony P, Fritze L, Pang K, Trier JS & Walker WA. (1981) Developm ent o f  
gatrointestinal mucosal barrier. I The effect o f natural vs. artifical feeding on intestinal permeability 
to macromolecules. Pediatr. Res. 15, 245-249.
Urbanek R, Kemeney D M  & Samuel D. (1985) U se o f enzyme linked immunosorbant assay for 
measurement o f allergen specific antibodies. J. Imm. Methods 79, 123.
Van Asperen PP, Kemp AS & Mellis CM. (1983) Immediate food hypersensitivity reactions on  first 
known exposure to food. Arch, o f Dis. Child. 58, 253-256.
Vandenplas Y  & Sacre L. (1986) Influence o f neonatal serum IgE concentration, family history and 
diet on the incidence o f cow’s milk allergy. Eur. J. Pediatr. 145. 493-495.
Van Furth R, Schuit H RE & Hijmans W. (1965) The immunological development o f the human 
fetus. J. Exp. Med. 22, 1173-1187.
Voller A  Bartlett A  & Bidwell DE. (1978) Enzyme immunoassays with special reference to ELISA  
techniques. J. Clin. Path. 31 507-520.
Walker W A & Isselbacher KJ. (1974) Uptake and transport o f  macromolecules by the intestine: 
possible role in clinical disorder. Gastroenerology. 67, 531-550.
Walker W A & Isselbacher KJ. (1977) Intestinal antibodies. N. Engl. J. Med. 297, 767-773.
Walker W A  (1987) R ole o f the mucosal barrier in antigen handling by the gut In: Food Allergy 
and Intolerance. Ed: Brostoff J & Challacombe SJ. Bailliere Tindall. London Philadelphia Toronto 
Mexico City Sydney Tokyo Hong Kong. 209-222.
Weir GC, Knowlton SD & Martin DB. (1975) High molecular weight glucagon-like 
immunoreactivity in plasma. J. Clin. Endocrinol. Metab. 40 296-302.
234
Weir DM . (1986) A d s  to Immunology. Churchill Livingstone. Edinburgh London Melbourne New  
York.
Williams DG. (1984) Comparison o f three conjugation procedures for the formation o f tracers for 
use in enzyme immunoassays. J. Immunol. Meth. 72, 261-268.
Yalow RS & Berson S A  (1959) Immunoassay o f endogenous plasma insulin in man. J. Clin. Invest. 
39, 1157-1175.
Zeiger RS. (1987) Challenges in the prevention o f allergic disease in infancy. Clin. Rev. A lergy  5, 
349-373.
Zeiger RS, Heller S, Mellon MH, Forsythe AB, O’Connor RD, Hamburger R N  & Schatz M. (1989) 
Effect o f combined maternal and infant food-allergen avoidance on the development o f atopy in 
early infancy: A  randomized study. J. A lergy Clin. Immunol. 84, 72-89.
235
APPENDIX
APPENDIX 1
RECIPES FOR BUFFERS
Acetate buffer
0.3g sodium acetate
-+ 2 litre H 20  [pH 4.4, acetic acid]
0.1M Bicarbonate/carbonate buffer 
3.18g sodium carbonate 
5.88g sodium hyrogen carbonate 
-»• 1 litre H 20  [pH 9.6]
Casein buffer
9g sodium chloride
1.2g Tris base
5g casein
0.2g thiomersal
-  1 litre H20  [pH 7.6, HC1]
Citiic buffer 
5.22g citric acid
7.1g sodium hydrogen phosphate 
-v 1 litre H zO [pH ]
0.05 M Phosphate buffered saline (PBS)
8g sodium chloride
2.9g sodium hydrogen phosphate (anhydrous)
0.2g potassium chloride
0.2g potassium hydrogen phosphate 
-+ 1 litre H 20  [pH 7.4]
PBS & geletin & Tween (PBSGT)
PBS
lg  geletin
0.5ml Tween 20
-  1 litre H20  [pH 7.4]
Ortho-phenyldiamine substrate (OPD)
75ml citrate buffer 
30p\ H 20 2 (30%)
1 tablet OPD (30mg)
Tetm-methyl benzidine substrate (TMB)
40 ml citrate buffer 
16/tl H 20 2 (30%)
200/xl TMB stock (20mg/ml TMB in DM SO)
Tris buffer (TBS)
8.18g sodium chloride 
1.21 Tris HC1
0.5ml Tween 20
-  1 litre H 20  [pH 7.4]
